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The majority of the estimated 425 million people living with diabetes (PLWD) reside 
in low and middle-income countries. An estimated 35% of PLWD have diabetic 
retinopathy (DR) and 10% have vision threatening retinopathy (VTDR) requiring 
urgent treatment. There is a high unmet need for DR services in many of these 
countries, which highlights the need to strengthen health systems. The purpose of 
this PhD is to provide evidence on the factors and interventions for promoting access 
and utilisation of services for DR. The study setting is Kenya, which has adopted 
Universal Health Coverage (UHC) as a target for 2030. The specific objectives were: i) 
To synthesise the literature on the magnitude, needs and priorities for diabetic 
retinopathy services;  ii)To conduct an assessment of the health system for PLWD 
and diabetic retinopathy in Kenya;  iii) To use the evidence from the literature and 
evidence from the health system assessment as a platform for health system 
strengthening; and iv) To develop and  test an intervention through a randomized 
clinical trial  to improve uptake of eye care services for PLWD in Kenya.  
Methods 
The first objective was achieved through a literature review. For the second 
objective, a health system assessment for diabetes and DR was conducted, based on 
the World Health Organization’s framework for health systems building blocks and 
the tracer condition approach. For the third objective, as part of health system 
strengthening, national guidelines for DR and a short online course for health care 
workers were developed. For the fourth objective, using the evidence from the 
health system assessment, we designed and implemented a two arm (1:1) pragmatic 
12 
cluster randomized controlled trial to test whether a peer-supporter-led package of 
interventions can increase uptake of DR screening among members of diabetes 
support groups who have never had screening. The primary outcome measure was 
attendance at DR screening in the 14 clusters and 734 participants followed up over 
six months. 
Results 
A review of the literature on the epidemiology and interventions for diabetes and 
DR, identified that the key priorities of health systems in reducing the incidence of 
DR-related blindness are: (1) control of diabetes (2) early detection of DR and (3) 
appropriate treatment of DR. However, most of the available evidence is from high-
income countries. The health system assessment for diabetes and DR in Kenya 
identified a high unmet need for DR screening, and uptake of screening was the 
bottleneck to entry to DR services. The barriers were lack of referral and inadequate 
knowledge of diabetes eye health. The lack of clinical guidelines and inadequate 
opportunities for continuous professional development limit the availability of DR 
services. To address this barrier, national clinical guidelines were developed through 
a process of adaptation from generic guidelines. The scope of the guidelines is 
screening, diagnosis, treatment and follow-up for DR.  In addition, an online training 
course on the control of DR has been developed using the theories of adult learning 
and instructional design. The results of the cluster-randomized trial indicate that the 
peer-led interventions are acceptable and reach the population most vulnerable to 
DR. One in two of the participants in the intervention arm compared to one in ten in 
the control arm attended DR screening. We also found that most of the effect occurs 
early—within the first month of the intervention. 
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Conclusions
This thesis provides evidence about how national DR guidelines and online training 
programmes for health workers can be developed to strengthen health systems and 
improve eye services for PLWD. The thesis also provides evidence that the uptake of 
DR screening by PLWD can be significantly increased through a community based 
intervention utilising diabetes support groups and peer-supporters. This can lead to 
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Chapter 1- Introduction 
1.0 Overview 
This chapter presents an overview of the research described in this thesis through a 
brief description of: definition of key terms; research domain; purpose; impetus; 
rationale; aims and objectives; structure of the thesis and the role of the candidate in 
the research. 
1.1 Definition of key terms  
Diabetes  
Diabetes mellitus (herein referred to as diabetes) is a group of metabolic diseases 
characterized by chronic hyperglycaemia resulting from defects in insulin secretion, 
insulin action, or both.1 The World Health Organization (WHO) diagnostic criteria for 
diabetes is based on any of the following parameters: fasting plasma glucose of ≥ 126 
mg/dl (7.0 mmol/L); plasma glucose after 2-h oral glucose tolerance test (OGTT) ≥ 
200 mg/dl (11.1 mmol/L); glycated haemoglobin (HbA1c) ≥ 6.5% (48 mmol/mol Hb) 
or a random plasma glucose of ≥ 200 mg/dl (11.1 mmol/L) along with symptoms of 
hyperglycaemia.2
Diabetic retinopathy 
Diabetic retinopathy (DR), a common ocular complication of diabetes, refers to 
progressive pathology of the retinal microvasculature (capillaries, arterioles and 
venules) with subsequent leakage or occlusion of the vessels, and retinal ischaemia.3
The Early Treatment Diabetic Retinopathy Study (ETDRS) described the vascular 
lesions in DR, of which the microaneurysm is the hallmark.4 DR is a key cause of 
visual impairment and blindness in the working age population.5
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Screening for diabetic retinopathy 
Screening refers to the application of tests for detection of DR in persons with 
diabetes who have no symptoms of DR. The methods for screening include dilated 
fundus examination and retinal photography.  
Health system and health system strengthening 
A health system comprises all the activities, institutions, organizations and resources 
whose primary purpose is to promote, restore or maintain health.6, 7 It includes 
broad categories such as formal health care services (public or private), informal care 
(home care, herbal and alternative medicine), screening programs, disease control 
campaigns, health policies, and organizations involved in health insurance, research, 
training and service delivery organizations. 
Health system strengthening (HSS) refers to ‘purposeful and significant efforts or 
actions to improve the performance of the health system’.7  HSS is often needed to 
facilitate progress towards desired targets, for example universal health coverage 
(UHC) and better population health. 
Universal Health Coverage 
The WHO defines UHC as “access to key promotive, preventive, curative and 
rehabilitative health interventions for all at an affordable cost, thereby achieving 
equity in access.”8 UHC is a multi-dimensional concept, operationalized in terms of 
population coverage, financial protection, and access to quality health care according 
to need, pursued within the framework of legal right to health.9
Visual impairment  
The International Classification of Diseases 11 (2018) defines visual impairment (VI) 
as reduction in visual acuity and classifies it as follows: (A) distance VI can be mild 
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(presenting visual acuity worse than 6/12), moderate (presenting visual acuity worse 
than 6/18), severe (presenting visual acuity worse than 6/60) and blindness 
(presenting visual acuity worse than 3/60). (B) Near VI is defined as presenting near 
visual acuity worse than N6 or M.08 with existing correction.10
1.2 Research domain 
Epidemiologic evidence indicates that the prevalence of diabetes has increased 
internationally over the last four decades, with a more pronounced rise in low and 
middle-income countries (LMICs).11-13 In 2017, the global prevalence was estimated 
at 8.8%, affecting 415 million people aged 20-79 years.12, 14 The majority of people 
living with diabetes (PLWD) live in LMICs and are predominantly below the age of 65 
(88%).12, 14-16
Diabetic retinopathy is the most common ocular complication of diabetes and a 
major cause of visual impairment in PLWD, especially when there are no screening 
programs.17-20 Poor vision is associated with reduced quality of life, increased risk of 
fall-related injuries, cognitive decline, poor mental health, decreased independence, 
difficulties in managing comorbidities, and increased health expenditure.21
All persons living with any type of diabetes are at risk of DR. Poor control and 
increasing duration of diabetes are key risk factors for DR. Good management of 
diabetes is therefore important for the prevention of DR-related vision loss. Yau and 
colleagues in 2012 in a global review of the literature reported that 34.6% of PLWD 
at any given time have DR, while 10.2% have vision-threatening DR.22 Over the past 
few decades, major advances have been made in the management of DR to reduce 
associated vision loss. There is evidence that screening, early detection and prompt 
treatment of vision-threatening DR (VTDR) prevents or delays diabetes-related VI.23-
25 However, evidence on how to make these interventions work in different income, 
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geography or health system contexts is lacking.26 Resource constraints,27 differences 
in prevalence of DR,19 and health system barriers28 contribute to the increasing 
importance of DR as a cause of avoidable VI. 
In LMICs, there are more PLWD, often at a younger age, who are at risk of visual 
impairment. To address this public health challenge, health systems need to be ready 
to deliver an increasing volume and quality of services, commensurate to the 
predicted increase in need. Universal health coverage has become a central theme of 
global health efforts to provide health care for all people that is effective and 
sustainable. To achieve this, there is a need to strengthen health systems to address 
the public health needs of specific populations and specific disease conditions. How 
can LMICs ensure that all PLWD receive all the services that they need, e.g. eye care 
services for DR?  As LMICs face many health system barriers, it is important to 
understand how relevant innovations to address DR can be effectively introduced. 
The work in this thesis focuses on assessing and improving services for DR in Kenya. 
1.3 Impetus for the research 
The PhD was inspired by observation of the Kenyan health system, where I work at 
the intersection of ophthalmology, public health and health systems. The research 
questions have been generated from looking at Kenya’s health system through that 
lens. This research is bidirectional because the health system provided the research 
questions, and in turn the research has provided ways to strengthen the health 
system, some of which are already being implemented.  During my practice, I have 
noted that PLWD often fall through the care net. The typical patient with DR presents 
to the eye clinic with advanced disease already causing VI or blindness, despite 
having been in contact with the health system often for many years for routine 
diabetes management. The results of treatment at this stage are less than optimal 
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and the cost of treatment is often high with most patients not having health 
insurance. The aspirations of universal eye health, (as part of UHC, which Kenya has 
adopted) cannot be achieved with this status quo. There is a need to find the right 
policies and interventions for PLWD to prevent visual loss from DR.  
An important window of opportunity to implement change at scale in Kenya is 
presented by the upcoming development of a new national eye health plan. 
However, eye health plans need to be informed by evidence regarding interventions 
that can improve eye health services for PLWD.29 Towards this, it is important to 
synthesize evidence from the literature, test hypotheses, and provide local evidence. 
Given that interventions require considerable investment, it is also essential to 
understand the context and consider the practical ways in which the health system 
might work differently. Drawing on the literature review in section A and the health 
system assessment in section B, I present the need for knowledge translation, which 
underpins the interventions in section C, in addition to the strategic use of existing 
resources and the empowerment of PLWD, which underpin the interventions 
described in section D. 
Perhaps because of my medical background, or because the late presentation of 
PLWD with DR was the most visible gap, I originally thought the main need was to 
improve treatment services. Therefore, at entry to the PhD my intention was to 
develop interventions to improve treatment. However, after assessing the health 
system I found that the main bottleneck was the lack of access of PLWD to regular 
eye screening.  A cluster randomized controlled trial has therefore tested an 
intervention to improve access to screening, and I present the evidence for its 
effectiveness in chapters 9 and 10. 
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Reflecting on what I have learnt through the PhD, at the end of chapter 11, I revisit 
the question of the priority challenges facing the health system. I conclude that the 
main challenge to preventing visual loss from DR in PLWD in Kenya (and any LMIC) is 
broader than either screening or treatment, but that access to screening supported 
by good treatment services is a starting point. Given that there are no simple 
solutions to address the diabetes epidemic and its effects,13 evidence -based health 
system strengthening (HSS) has a critical role in the pursuit of UHC for PLWD.29-32
Such HSS requires the engagement of multiple actors and actions in the health 
system. The work described in this thesis has provided an opportunity to consider 
the unique contribution that researchers can bring to this agenda.  
1.4 Purpose of the research 
The purpose of the research is to contribute to improvement of DR services and 
prevention of vision loss in PLWD. In order to inform practice in the real world 
settings, a pragmatic approach is adopted.  
1.5 Rationale  
The number of people affected by VI and blindness from DR increased worldwide 
between 1990 and 2015.33 This is avoidable vision loss because DR can be prevented 
and treated.  Of the 415 million PLWD (20-79 years) in 2017, it is estimated that 145 
million have DR and 45million have vision-threatening DR (VTDR).34 Predictions 
suggest that by 2040, 642 million adults will be living with diabetes, 224 million will 
have some form of DR and 70 million will have VTDR.34 There is evidence that 
appropriate treatment can delay the onset and slow the progression of DR.35, 36  Thus 
eye health services for PLWD are important in reducing the incidence of vision loss 
from DR.  
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In sub-Saharan Africa (SSA) in particular, investments in health system strengthening 
may forestall the increase in vision loss from DR.30, 34, 37 This region is at the beginning 
of the diabetes and DR epidemic, and although data is limited, there is evidence that 
health systems can be strengthened to make control of diabetes and DR accessible, 
affordable and sustainable.38 SSA can apply existing tools for planning DR services, 
and learn from DR screening programs in other countries.39
Although PLWD have frequent contact with health services, eye care for PLWD is not 
routinely provided in many situations.40  This contributes to the risk of vision loss 
from DR, and increases the cost of care, since patients with DR are often identified in 
advanced stages. Investing resources on effective eye health services for PLWD can 
reduce the extra morbidity of vision loss in PLWD. As a starting point, there is a need 
to identify the current gaps in DR services and provide evidence on well-defined 
interventions to address these gaps. 
1.6 Aim and objectives 
1.6.1 Aim 
To provide evidence to improve eye care services for PLWD in Kenya in order to 
reduce vision loss in PLWD. 
1.6.2 Specific objectives 
1. To synthesise the literature on the magnitude, needs and priorities for 
diabetic retinopathy services (Chapter 2) 
2. To conduct an assessment of the health system for PLWD and diabetic 
retinopathy in Kenya (Chapter 3 and 4) 
3. To use the evidence from the literature and evidence from the health system 
assessment as a platform for health system strengthening (Chapter 5 and 6) 
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4. To develop and  test an intervention through a randomized clinical trial  to 
improve eye care services for PLWD in Kenya (Chapter 7-10) 
1.7 Thesis structure 
The thesis is organised in five sections (A, B, C, D and E), each of which has two or 
more chapters, Figure 1-1.  
Section A is the general introduction and consists of two chapters. Chapter 1 gives 
the background and general direction of the thesis. It provides an overview of the 
research area, how the research ideas developed and the purpose of the research. 
Chapter 2 is a synthesis of the published evidence.  As diabetes and DR are the 
subject of independent literature, the literature is analysed to identify the priorities 
and challenges in global health for eye care for PLWD, particularly in LMICs.  
Section B is the health system assessment. In Chapter 3, I discuss the different 
frameworks for health system assessment and describe the approach for assessing 
the health system for PLWD and DR in Kenya. This assessment is of interest on its 
own, because it provided useful evidence on the strengths and weaknesses of the 
system. This evidence will be useful to policy-makers and implementers. In addition, 
it provided evidence for developing interventions to improve eye services for PLWD, 
which were tested in the randomized trial.  Chapter 4 consists of two research 
papers discussing results from the health system assessment —the predictors of 
uptake of retinal screening and the rationale for integration of diabetes and DR 
services.  
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Figure 1-1: Schema of the thesis 
Evidence on Diabetes and Diabetic 
retinopathy (DR) in Kenya 
(Chapter 2)
Evidence on Diabetes and Diabetic 
Retinopathy (DR) globally 
(Chapter 2) 
Health System Assessment 
for diabetes and DR in Kenya 
(Chapter 3) 
Demand-side predictors of 
uptake of DR screening 
(Chapter 3 and 4) 
Supply-side barriers and 
enablers to DR screening 
(Chapter 3 and 4)  







 (Chapter 9 and 
10) 
Evidence on gaps 
in DR screening 
(Chapter 3 and 4)
Synthesis of the 
evidence (Chapter 11) 
Health System Strengthening
(Chapter 5 and 6) 
Literature review 
34 
Section C provides a discussion on health system strengthening – its importance in 
this study and how we applied it. The content includes technical and methodological 
contributions on developing clinical guidelines and a training course about DR, which 
might be useful to other LMICs wanting to undertake these activities. Chapter 5 
consists of two papers on guidelines development process and outputs. Chapter 6 
describes the development of an open online course on control of DR. 
Section D describes the DURE (uptake of retinal examination in diabetes) 
intervention to improve access to DR services, developed in accordance to the four 
phases of the Medical Research Council’s (MRC) framework for developing complex 
interventions. Chapter 7 describes the intervention development and includes the 
published trial protocol. Chapter 8 describes the pilot and feasibility trial, in a 
research paper. Chapter 9 describes the process evaluation of the full trial while 
chapter 10 describes the outcome evaluation of the trial. The four chapters provide 
evidence for the application of the MRC framework in DR research in a LMIC setting.   
Section E comprises Chapter 11, which is the thesis summary consisting of the 
discussion, conclusions and next steps. It ends with a personal reflection on my 
learning from the PhD. 
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The content of the research papers in each section are outlined below: 
Section Paper What the paper describes
Section B Paper 1
(published) 
Results of health system assessment (Predictors of 
uptake of retinal examination) 
Paper 2
(submitted) 
Results of health system assessment (Rationale for 
integration of diabetes and DR services) 
Section C Paper 3
(published) 
Process of adapting clinical guidelines for DR in 
Kenya (process and outputs) 
Paper 4
(published) 
A summary of the recommendations in the clinical 
guidelines 
Section D Paper 5
(published) 






Results: Process evaluation of the trial
Paper 8
(submitted) 
Results: Outcome evaluation of the trial
1.8 Roles of the candidate in the research 
I have carried out the work described in all the sections of this thesis, guided by my 








Taking the necessary courses (Listed in Appendix 1)
Managing the grant
Engaging stakeholders to determine priorities, plan and 
implement the study 
Section A Conducting the literature review








Section C Conducting literature review specific to guideline 
development 
Coordinating the guideline development team
Writing the outputs
Dissemination 
Developing the training program through mentorship
Section D Obtaining ethics approval
Developing protocol
Developing peer training materials
Developing questionnaires
Training research team
Coordinating field work 
Mixed methods process evaluation
Data analysis
Dissemination
Section E Interpreting the evidence from the PhD
After the research Synthesis, writing up, Identifying next steps
1.9 Study timelines  
The timeframe for the study activities are shown in Appendix 2. 
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Chapter Two: Diabetes, Diabetic retinopathy and Visual 
Impairment – A synthesis of the literature 
2.0. Overview 
This chapter addresses the first objective of the thesis and follows a narrative 
structure. Section 2.1 describes the epidemiology of diabetes. Section 2.2 describes 
the care model for diabetes. Section 2.3 discusses peer support for diabetes. Section 
2.4 discusses diabetic retinopathy (DR), visual impairment from DR, including the 
epidemiology, the impact, and the control measures. The concluding section (2.5) 
summarizes the priority needs in DR control within a non-communicable disease 
(NCD), Universal Health Coverage (UHC) and health systems agenda. 
2.1 The epidemiology of diabetes 
2.1.1 Diabetes globally 
The prevalence of diabetes and the number of people living with diabetes (PLWD) has 
been rising steadily over the past four decades1.The International Diabetes Federation 
(IDF) estimates that among adults aged 20–79 years in 2017 there was an estimated 
415 million PLWD with a global prevalence of diabetes of 8.8%. This is about a 
fourfold increase from the number of PLWD in 1980, which the World Health 
Organization (WHO) estimated to be 108 million, with a global prevalence of 4.7%. 2, 3
There are regional disparities in the prevalence: in 2017, North America and the 
Caribbean region had the highest prevalence (11%) while Africa had the lowest 
prevalence (4.2%), as shown in Figure 2-1. We can expect the number of PLWD to 
continue to increase in the next two decades. There is also a high level of undiagnosed 
diabetes in all regions, at 37.6% in North America and the Caribbean and 69.2% in 
Africa in 2017.4
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Figure 2-1: Prevalence of diabetes in different regions in 2017 and 2015 (data from the IDF Diabetes Atlas 
8th edition) 
There are three main types of diabetes (Type 1, 2 and gestational diabetes), all of 
which are treatable, with the goal of achieving normal levels of glucose. Type 2 
diabetes is largely preventable but it accounts for 90% of the diabetes prevalence, and 
the majority of undiagnosed diabetes. 4, 5  People with impaired glucose tolerance are 
at high risk of developing Type 2 diabetes and are classified as pre-diabetes. For PLWD 
in the different regions, whether diagnosed or not, access to diabetes services is a 
priority.  This includes health education, self-management, treatment and 
interventions for diabetes complications. In order to reduce the prevalence of 
diabetes it is also crucial to reduce the risk factors for diabetes in the general 
population.   
Given the escalating number of PLWD, diabetes is not only a global health concern, 
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systems and countries face a large, growing and long-term economic burden. This 
includes indirect costs due to disability, loss of productivity and premature mortality, 
besides the direct costs, particularly treatment costs. The loss in workplace 
productivity due to diabetes and its complications is considerable because 72% PLWD 
worldwide are within the working age bracket (20-64 years).4 This reduction in 
productivity has an adverse impact in all regions.6
The direct annual cost of diabetes in the world is estimated at Intl$ 825 billion, and a 
significant proportion of these costs are paid out-of-pocket, especially in LMICs, where 
out of pocket payment accounts for 25-80 % of this health expenditure.2, 6, 7 The 
presence of diabetes complications such as visual impairment and blindness from DR 
significantly increases the direct costs. PLWD and governments struggle to meet these 
costs, and the protection offered by health insurance is often incomplete.4 As an 
example, the health care costs of people with diabetes in the United States (US) are 
nearly two and a half times of those without diabetes within the same 
sociodemographic bracket.8 Jaspers and colleagues in their systematic review on the 
global impact of non-communicable diseases (NCDs) on households found that 
financial catastrophe due to NCDs, including diabetes, was seen in all countries and at 
all income levels, but with a higher proportion of households affected in lower income 
areas.9 When the costs of diabetes treatment lead to financial hardship, they are 
drivers for impoverishment. In turn, poverty is a driver for poor compliance with 
treatment, poor control of diabetes and the development of complications of 
diabetes.  
The rising magnitude and the high cost of diabetes point to the need for cost-effective 
control measures. The WHO has identified proven, priority cost-effective 
interventions ‘best buys’ for diabetes that can be implemented in all regions. These 
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are effective glycaemic control, preventive foot care for PLWD, DR screening for all 
PLWD and laser photocoagulation for prevention of blindness. 10  These ‘best buys’ 
may result in social, health and economic benefits by delaying complications and 
hence preserving health, quality of life and productivity. They are also potentially cost- 
saving on the treatment costs for these complications. Failure to implement proven 
interventions will increase health care costs and is therefore counterproductive. 
The recognition of the global impact of diabetes has led to several global 
commitments to catalyse action.  In 2011, the Political Declaration on the Prevention 
and Control of NCDs at the 66th General Assembly of the United Nations (UN) 
identified diabetes as one of four priority NCDs that constitute the largest NCD burden 
and are largely preventable.11 To generate global, regional and national momentum 
for action on these NCDs, the World Health Assembly in 2013 adopted the WHO 
Global Action Plan for the prevention and control of NCDs, which included targets for 
the control of diabetes and its risk factors.3, 12  Further, in 2015, all UN member states 
committed to the 2030 Sustainable Development Goals agenda which includes targets 
to reduce NCD-related premature mortality, achieve UHC and increase access to 
affordable treatment for these conditions.13 These commitments have been 
instrumental in raising awareness of the urgent need to place NCDs on the agenda of 
governments.7 Diabetes can be used as a tracer condition for examining the progress 
towards UHC 14, 15 and also for assessing health systems.16
What does UHC mean for PLWD globally? With UHC, all PLWD should obtain the 
services they need without suffering financial hardship. Many high-income countries 
such as those of Western Europe, and some middle-income countries such as 
Thailand, Brazil and Mexico have some form of UHC. For example, in Thailand, a 
country that has had UHC since 2002, PLWD can access a comprehensive package of 
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services with financial protection.17 We highlight some of the lessons the country has 
to offer to other countries below. One lesson is that not only does Thailand have UHC, 
but also importantly, the UHC package includes the diabetes services.  In many 
countries, UHC packages exclude even basic diabetes care components, such as 
HbA1c testing or DR screening, because they are perceived as expensive. Thus having 
UHC does not necessarily guarantee universal access to diabetes services. Without 
UHC, PLWD often receive inadequate services. Many undiagnosed PLWD are 
uninsured, yet health insurance is significantly associated with the likelihood of timely 
diagnoses, improved diagnosis and control of diabetes.18 For these reasons, although 
health-financing schemes cannot cover all possible interventions, it is of utmost 
importance to ensure that UHC packages address the needs of PLWD. 
Many PLWD, especially among poor, rural, less educated and other vulnerable or 
disadvantaged populations have been ‘left behind’, and do not access health services. 
Applying an equity lens to UHC can help to address this modifiable gap, by developing 
UHC packages that target these people without excluding the rest of the population.19
This approach has been useful in some Latin American countries, such as Costa Rica.20
Reaching the disadvantaged populations may be facilitated through investment in 
primary care, and the use of community volunteers as in the case of Thailand— 
another lesson from this country.17 Rwanda, an LMIC that has made significant 
progress to UHC, has also strengthened primary care through community health 
volunteers.21 In addition, Costa Rica and the National Health Service (NHS) in England 
have implemented UHC through strengthening primary care, where regular 
assessment of body mass index (BMI), HbA1c and foot examinations are provided to 
PLWD.20, 22
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Health system strengthening (HSS), such as better trained health workforce and 
improved infrastructure as well as addressing the other health system building blocks 
is critical if PLWD are to access good health services.17, 22 Ong and colleagues in their 
systematic review identified several health system factors that influence the response 
to the diabetes epidemic.23 They found removal of out of pocket payments and 
integrated diabetes models enabled the health system to address diabetes. Additional 
HSS interventions that have been found useful for diabetes services in the literature 
include:  training multidisciplinary health professionals in primary care about diabetes 
and its complications; avoiding stock-out of supplies; providing essential technologies, 
such as blood glucose measurement and engaging pharmacists in diabetes care 4, 23-25. 
The adoption of national guidelines for care of patients with diabetes, hypertension, 
and dyslipidaemia in Costa Rica 20 and incentive schemes for primary care providers in 
the NHS22 are further examples. 
2.1.2 Diabetes in LMICs  
The prevalence of diabetes is increasing disproportionately faster in resource-poor 
regions.26-28 As in other parts of the world, the rise is mainly for Type 2 diabetes. The 
risk factors for diabetes, such as sedentary lifestyle, high BMI and impaired glucose 
tolerance often go unrecognized, leading to a huge unmet need for prevention.29 The 
surge in incidence and prevalence of diabetes is driven by increasing population 
growth and life expectancy, industrialization, urbanisation, lifestyle changes such as 
the nutrition transition (shift in dietary patterns) and physical inactivity.1, 2, 4, 25, 30 An 
estimated 79% of PLWD live in LMICs, and these countries also have the highest 
proportion of undiagnosed diabetes in the world.4, 28 Notably, PLWD in LMICs are 
predominantly below the age of 65 years, experience a large unmet need for 
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treatment and have inadequate glycaemic control.24, 31 These are important risk 
factors for the development of complications such as retinopathy.  
In sub-Saharan Africa (SSA), where many of the LMICS are located,  public health 
strategies to manage the diabetes epidemic are known to be inadequate.32, 33 The 
priorities for health systems have hitherto been maternal and child health, and 
communicable diseases that require acute care. In contrast, PLWD require regular and 
lifelong engagement with the health system, which should mainly be at the primary 
care level. This is challenging for health systems that are oriented to acute care 
instead of overall health system development, and which are also fragile particularly 
at primary care.34 As an example, large losses to care for PLWD occur at each stage of 
the diabetes care cascade (testing, diagnosis, treatment, glycaemic control).24 Only an 
estimated 11% of PLWD (range 7-33%) are retained throughout the care cascade.35 In 
addition, in LMICs, younger PLWD are more likely to fall off the diabetes cascade than 
the older PLWD.24 As noted earlier, PLWD in LMICs are on average younger than 
PLWD in other regions. As they are ‘left behind’ in access to care, they are at greater 
risk of complications, with a high social and economic impact. 
The ongoing epidemiological transition between communicable diseases and non-
communicable diseases (NCDs) presents an opportunity to orient health systems to 
NCD-relevant responses. This includes health system changes at community level, 
primary care and secondary care, including referral systems (such as for DR screening) 
and follow-up mechanisms. As described earlier, effective interventions such as the 
best buys for diabetes proposed by the WHO exist. Cost-effectiveness analysis (CEA)  
for these best buys has shown that the cost of implementation is approximately 1$ 
per disability-adjusted life year (DALY) averted in LMICs.10 This suggests that with a 
modest increase in investment, the best buys are feasible for implementation even in 
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low-resource settings where resources are limited. Despite this evidence, there is very 
low coverage of these interventions in most LMICs. Given the scarcity of evidence 
about the best ways to improve coverage of these interventions within health 
systems, there is a need for robust implementation research that can inform 
strategies to improve coverage. 
The majority of diabetes-related premature mortality, disability and loss of 
productivity occurs in LMICs, leading to very high indirect costs of diabetes 2, 31. The 
direct costs of diabetes treatment are largely borne by PLWD and their families, rather 
than governments or insurance schemes.35, 36 This is likely to be a driver for disparities 
in access. In addition, those who fall out of care are likely to present with 
complications whose treatment will incur much higher costs. Although countries in 
the African region spend an average 6% of the national health budget on diabetes, the 
mean expenditure per PLWD per year is only Intl$ 444 (compared to 3132 and 8396 
Intl$ in Europe and North America respectively), and is inadequate to provide the 
required interventions.4, 31 The only option available, therefore, is to prioritize a core 
set of evidence-based interventions, particularly those that can reduce the cost of 
treating complications. The implementation of the best buys described above should 
therefore be a priority. 
2.1.3 Diabetes in Kenya 
The population of Kenya (Fig 2-2) in 2019 is estimated at 52.6 million, with a 2.3% 
annual rate of population increase, life expectancy at birth of 66 years and 60% of the 
population being under 25 years.37 This is a relatively young population, of whom 73% 
reside in rural areas. Responsibilities for health care in Kenya are shared between the 
national government and the 47 semi-autonomous county governments.  The county 
level is responsible for essential health service delivery while the national level is 
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responsible for health policy and regulation, technical assistance to counties and 
management of national referral hospitals.  Achoki and colleagues have recently 
discussed the gradual escalation in the relative contribution of NCDs to the disease 
burden at subnational level (epidemiological transition), and the challenge it poses to 
UHC.38
Figure 2-2: Kenya on the world map 
Both public and private sectors provide service delivery, with the private sector 
providing about 49% of services. 39 Health insurance coverage for the population is 
low, at about 19%.40 Within this, the national health insurance fund (NHIF), a public 
corporation, is the largest provider of health insurance, covering 16% of Kenyans. In 
addition, the NHIF’s contracted facility network is only 40% of the health care facilities 
in the country; hence, services obtained outside this network are not covered. Though 
NHIF has a comprehensive benefit package, covering the costs of many medicines, 
laboratory and radiologic tests in the public sector, some of these services are not 
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available in these facilities. 40 Not all costs in the private sector are covered, therefore 
even patients who are covered still incur out of pocket expenses.41
The Kenya Health Policy 2014-2030 elaborates the commitment to achieve UHC by 
scaling up health services to populations in need.42 The policy defines four levels of 
care within public health services: community level, primary care, county level and 
national level.  The primary care level is the first contact with the health system, 
which comprises dispensaries, health centres, maternity units and nursing homes. In 
practice, primary care level often concentrates on acute episodic care and defers 
chronic disease to county hospitals.  
The county level consists of hospitals that complement the primary level and provide 
secondary and tertiary care. Diabetes clinics and general medical clinics at county 
level provide the diabetes services. The national level consists of highly specialized 
tertiary hospitals.  Services for diabetes testing, diagnosis and treatment should be 
available at all the four levels, though not all the laboratory tests and medication are 
available at all the facilities.43 Specialist clinics at county and national hospitals provide 
screening for complications. As there is no gate-keeping mechanism, PLWD are 
allowed frequent engagement with any level of the services.  
At the community level, under the community health strategy, health services are 
organized around community units of about 5000 people.44  Each unit has 50 
community health volunteers (CHVs, also called community health workers), each 
responsible for 20 households.45 The strategy specifies the roles of the CHVs, which 
include visiting households on a door-to-door basis to identify health problems, 
provide some interventions related to disease prevention, maternal and newborn 
care, home-based care, observe treatment and some curative tasks. They are also 
responsible for community mobilisation and linking the community to the primary 
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health facility.  The CHVs receive an initial 10 days training with regular refreshers and 
have a kit of supplies. A community health extension worker (CHEW), who is a trained 
government health worker, provides support and supervision to the CHV. Two CHEWS 
are responsible for each community unit. A community health committee, consisting 
of community members, participates in the governance of this level. 44, 45
The success of implementation of the community level of health care varies at 
subnational levels. Some of the challenges faced are high attrition of CHVs and conflict 
of workload for CHEWs.45, 46 Diabetes services are generally not available at this level, 
but health promotion around the NCD risk factors may be provided. There is potential 
to leverage CHVs and CHEWs to deliver NCD interventions with diabetes as an entry 
point, such as regular BMI measurement or blood sugar testing for adults on a door-
to-door basis.  
At the community level, there are diabetes support groups (DSGs) for PLWD in many 
of the counties.47 The Kenya Defeat Diabetes Association, a civil organization, is the 
umbrella body for these groups. The groups have monthly meetings where they 
engage in peer-to-peer support, group education, monitoring BMI and metabolic 
control. They also engage in advocacy with the government and NGOs, and conduct 
community diabetes screening camps. These groups have links with the CVs and the 
primary health facilities. As this peer support resource is known to be useful in the 
management of diabetes,48, 49 its role is discussed in detail in subsequent sections.  
Evidence from the Global Burden of Disease Study and country-level evidence shows 
an increase in NCDs over time,38, 50, 51with disparities across counties.38 Kenya has an 
NCD division within the Ministry of Health, and an NCD strategy to halt and reverse 
this rising burden of NCDs.42 However, the NCD program faces challenges due to 
workforce shortages, frequent stock-outs of medicines in public-sector pharmacies, 
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and problems guaranteeing the quality of medicines.52, 53 The Kenya Service 
Availability and Readiness Assessment Mapping (SARAM) in 2014 showed that only 
5% of all facilities offered all NCD services defined in the Kenya Essential Package of 
Health (KEPH) and only 25% of health facilities had different tracer commodities for 
NCDs with huge regional variation.54 The most available services related to health 
promotion, while the least available services were screening and rehabilitation.54
Many people obtain the NCD diagnosis in the public sector but buy their drugs in the 
private sector, and these out-of-pocket payments can be high.53, 55
The Lancet Diabetes and Endocrinology Commission on diabetes in sub-Saharan Africa 
underscored the need for locally derived epidemiologic evidence on diabetes at 
country level.35 Such evidence is important because it allows for contextual analysis, 
identifies opportunities for improving outcomes at country level and can reliably 
inform subsequent policy, practice and research. A nationally representative STEPwise 
approach to surveillance (STEPS) survey for NCD risk factors in 2015 reported the 
prevalence of diabetes to be 2% among the age group 18-64 years.56 The estimates 
from the IDF were very similar, at 2.2%.28 This availability of data from a national 
survey is a significant starting point that allows consideration of some of the public 
health implications of the findings in the STEPS survey, which are discussed below. 
The age-adjusted prevalence of pre-diabetes and diabetes was 3.1% and 2.4% 
respectively.57 As the prevalence of pre-diabetes exceeded that of diabetes, the 
prevalence of diabetes is likely to increase in the medium-term rather than stabilise, 
through conversion from the large pool of individuals with pre-diabetes. As 
complications such as DR can occur even in pre-diabetes,58 there is need for an 
integrated response that includes prevention, diagnosis, treatment, and regular 
screening for complications.  
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The age adjusted prevalence of diabetes was highest among urban (3.4%) compared 
to rural (1.9%) residents. Similarly, the prevalence was highest in the richest wealth 
quintiles (5.2%) compared to the poorest wealth quintile (1.6%). Previous population 
based studies had also identified the urban-rural variation.59 That diabetes is still more 
prevalent in the urban and more affluent segments of the population suggests that 
the epidemic is still in the early stages. However, given that the majority of the 
population is rural, even a small increase in the prevalence in the rural areas 
(especially from conversion from the pre-diabetes pool) would have a significant 
impact. A cohort study of people age 50+ years in Nakuru Kenya found the six-year 
cumulative incidence of diabetes to be 61 per 1000, equating to about 10 new cases 
of diabetes per 1000 per year.60  Assuming 10% of the 53 million is aged 50+, 
(5.3million) this would be 53,000 additional PLWD every year, excluding the new cases 
aged <50 years. A large scale up of service provision in the diabetes care cascade will 
be required.  
The odds for diabetes increased with age and the prevalence was highest in 45–59 age 
category.57  Given that diabetes affects working-age people, the consequences of 
diabetes extend beyond the treatment costs.  Besides disability and death, other 
productivity effects have been described, including:  absenteeism, presenteeism (the 
practice of being present at one's place of work for more hours than is required, 
especially among workers with reduced productivity due to health issues, as a 
manifestation of insecurity about one's job), unemployment and premature 
retirement, leading to reduced income and savings, low self-esteem and low quality of 
life.61-63 This suggests the need for effective targeted intervention to help workers 
better manage their disease. Employers need to be engaged as pertinent stakeholders 
in diabetes control. 
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The proportion of undiagnosed diabetes in the STEPs survey was 52.8%, which 
although not surprising, has far-reaching implications for health-care providers in the 
country, as many currently undiagnosed PLWD carry the risk of advanced diabetic 
microvascular complications being present by the time they are diagnosed, resulting 
in kidney failure, retinopathy, neuropathies and diabetic foot. For patients diagnosed 
at a late stage, the complications are likely to be progressive. 
Among the 47% of PLWD who were aware of their diagnosis, only 41% were on 
treatment, and among those on treatment only 33% had achieved glycaemic 
control.57 This means that out of every 100 PLWD, 47 are aware of the diagnosis, 19 
are on treatment and only six have glycaemic control; the other 93 do not achieve 
glycaemic control.  In the poorest households, none of the PLWD were on treatment 
and as expected, none of them had achieved glycaemic control.57 This combination 
points to low awareness, poor access, low treatment coverage, inadequate 
management of diabetes, and loss of PLWD along the diabetes care cascade. People 
with uncontrolled diabetes are likely to present with complications, especially the 
microvascular complications. This means that interventions are required at all the four 
levels of health care, rather than only primary care. Access to treatment should be a 
priority in order to prevent the development of complications. Interventions targeting 
the poor are required.  
As expected, the direct cost of managing diabetes and its complications is much 
higher in private than public facilities. The largest costs are medication, clinical tests, 
inpatient costs and treatment of microvascular complications, which can result in 
catastrophic expenditure even in the public sector.7, 55, 64 The indirect cost is similarly 
high given that a high number of disability-adjusted life years (DALYS) lost are 
attributable to diabetes-related illnesses (364 per 100,000 person years of 
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observation).64, 65 Seeing that diabetes is a costly disease in Kenya,55 and that the 
complications are the largest source of the overall costs, there is a need for programs 
that can control these complications. Possible interventions include removing out-of-
pocket payments, which will require more effective engagement of insurers and other 
funders of health care. 
Based on the epidemiological data from the STEPS survey, to reduce the burden of 
diabetes at the population level, there is need to ensure all people with diabetes get 
tested, diagnosed and enter the continuum of care and are retained without dropping 
out. Successes in access to and retention in the diabetes care cascade can lead to 
better diabetes outcomes, and reduction in the health, social and economic burden of 
diabetes. This is likely to be achieved through a chronic care model, which is discussed 
below. 
2.2 Chronic care model for diabetes care 
 The Chronic Care Model (CCM), developed by Wagner and colleagues in the 1990s, 66, 
67 has been proposed as a suitable model for managing diabetes, Fig 3-3. The CCM 
envisions linking actively engaged patients with proactive health care providers.68
Studies have shown that CCM is beneficial to chronic care especially at primary care, 
even in SSA.69-71 Some CCM-related interventions in Kenya have been reported, 72, 73
and some aspects are routinely implemented in the country, but not as a 
systematically defined package. 
The CCM model enumerates six essential elements that encourage high-quality 
chronic disease care.  These elements are self-management support, delivery system 
design, decision support and clinical information systems, the health system, and 
community resources. Cost-effective interventions within each of these components 
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can be implemented as a package.68 Complex interventions that incorporate several of 
these elements have been shown to be more effective than single interventions, but 
none of them has been found to be the dominant driver of success in diabetes care.68
The actual interventions within each component also show heterogeneity in most 
studies. The next section provides a description of how these components might be 
operationalized. 
Figure 2-3: Chronic Care Model 
Diabetes Self-management support should focus on patient/family empowerment, 
and development of skills such as self-monitoring/home-based monitoring, 
administering insulin injections, action-planning and problem-solving.74, 75 A clinician 
or trained diabetes educator may provide diabetes education through different 
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channels such as face-to-face individual education, group education, education 
materials, online modules or mobile applications for the promotion of healthy 
lifestyle.75
Delivery system support is about strengthening the coordination of patient-centred 
services for PLWD, both during hospital visits and follow-up. This includes giving 
standing orders for annual screening tests, automated reminders, and developing a 
multidisciplinary team (nurses, clinicians, physicians, pharmacists, nutritionists, 
diabetes educators and other specialists). Team roles are specified (for example who 
takes care of foot examinations or DR screening), teams are trained, and they meet 
regularly to review progress.74, 75
Decision support helps to ensure that health workers attending to PLWD have the 
expertise that they need. Typical activities include training of multidisciplinary health 
care providers on the use of evidence-based guidelines or protocols, and providing 
these guidelines.70, 74 This can promote diabetes care by strengthening the workforce 
to provide quality care, and ensuring timely referral of PLWD who need additional 
care.  
Electronic records, a diabetes registry and reminder or recall systems are important 
aspects of the clinical information systems for diabetes.74, 75 This can help track 
referrals, clinical and public health outcomes, and strengthen engagement of PLWD 
along the care cascade to reduce the potential for dropout.  A call and recall 
mechanism can also ensure that patients are reminded of their screening schedule.   
The leadership provided by the health system determines how interventions for 
diabetes are implemented.70, 76 Providing sufficient resources (space, workforce, 
standards, information systems, funds); retraining health workers to give them a 
chronic disease orientation; removing barriers to care; integration of diabetes care 
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across different health care providers; increasing collaboration between specialists 
that attend to PLWD; implementing quality assurance measures and removing health 
system barriers can ensure that PLWD get all the services they require.70, 74
Community resources may help patients acquire self-management skills, such as 
achieving lifestyle modifications that positively influence chronic disease control. For 
example, community health volunteers (CHVs) and peer supporters are a flexible and 
cost-effective strategy in the control of diabetes in multiple settings.77-87 Local gyms, 
exercise programs and weight loss programs are also useful for lifestyle goals.  
Diabetes programs and PLWD should be encouraged to engage with these resources 
to fill gaps in care. As diabetes support groups (DSGs) are an existing community 
resource external to the formal health system in Kenya, and since the peer supporters 
are PLWD themselves, the next section explores their unique contribution.  
2.3 Peer support interventions  
2.3.1 Peer support in health care 
Peer support as a health intervention has been defined as ‘the provision of emotional, 
appraisal, and informational assistance by a created social network member who 
possesses experiential knowledge of a specific behaviour’. 8889, 90 The peer supporter 
has similar characteristics as the target population and the relationship relies on the 
following factors: non-hierarchical, flexible and reciprocal relationships,79, 88, 89 sharing 
similar life experiences, mastery of self-care behaviours and reduced social distance 
between peers.78, 87
There are diverse modes of peer support interaction (individual or group sessions, 
face-to-face, telephone or online interaction), which occur in diverse settings such as 
homes, health facilities, schools, prisons. Support can be structured as an informal or 
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a formal interaction (for example through training peer supporters). There are varied 
types of peer supporter training and peer group composition (homogenous or mixed, 
disease type) 78, 91. 
There are multiple applications of peer support in health care. It has been used as a 
health promotion approach to encourage behaviour change interventions such as for 
exclusive breastfeeding, prevention of Human Immunodeficiency Virus (HIV) and 
Sexually Transmitted Infections (STI), smoking cessation, mental health and cancer 
screening among other areas. In Kenya, peer support has been used to help patients 
with HIV transition between inpatient and outpatient care, for continuity of follow-
up.92
A systematic review of peer support for breastfeeding found the role of peer support 
to be most important during the early postnatal period.90, 93 Individual peer support 
for exclusive breastfeeding in Uganda was reported to be acceptable to  women.94 In 
Bangladesh, women’s groups with high population coverage reduced neonatal 
mortality.95 In Malawi, women’s groups and health education by peer counsellors 
were similarly found to have positive effects on childhood mortality, maternal 
mortality and breastfeeding rates.93 88, 90, 96 In China, community-based peer support 
for patients with severe mental illness has been found to be acceptable.97
2.3.2 Peer support in diabetes 
There is evidence that peer support can promote the implementation of diabetes 
care.80, 82, 85, 98 Peer supporters can assist people with their daily diabetes self-
management activities, provide emotional and social support, assist and encourage 
clinical care and be available when needed. 99, 100 A needs assessment in the 
Kilimanjaro Diabetic Program in Tanzania found that living with diabetes is not 
associated with stigma, and PLWD have a desire to raise community awareness of 
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diabetes and support others to live with the disease and secure social support to 
access hospital services.101
Peer approaches in other settings have been found to promote physical activity, 
healthy eating, glycaemic control and reduce hospitalisation of PLWD.80, 99, 102-104 A 
peer intervention led to significant reduction in the combined prevalence of type 2 
diabetes and intermediate hyperglycaemia as well as a 2-year incidence of type 2 
diabetes among an intermediate hyperglycaemia cohort of adults in Bangladesh.105
Several systematic reviews on the effectiveness of peer support have been published. 
Qi and colleagues in 2015 found that peer support had a significant impact on 
improving HbA1c levels in patients with poor glycaemic control.78 Dale et al in 2012 
found that peer support improved clinical and behavioural outcomes in some adults 
with diabetes.106 Fisher et al in 2017 found that peer support could reduce HbA1c 
levels. 48 Gatlin et al in 2017 found that peer led self-management education can 
increase diabetes knowledge and reduce HbA1c.107The studies included in these 
reviews were mostly from high-income settings and the models of peer support were 
heterogeneous. Having found no literature on the role of peer support specific to the 
long-term complications of diabetes, research in this area would help to expand 
knowledge and expand the application of the chronic care model in diabetes care. 
Although peer support is a scalable and potentially low cost intervention that would 
be particularly useful in low resource settings, 79, 100, 108some literature cautions 
against over-optimism in its potential to influence health outcomes. 81, 109 Local 
evidence, especially mixed-methods implementation research would be needed as 
peer support interventions are developed and evaluated, in order to identify what 
types of peer support work, where, how and why.  
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Peer support is not a monolithic ‘one-size fits all’ concept, and these studies have 
used different types of peer support. There are community based, home-based and 
facility-based approaches. Peer support can be peer-led or health worker-led.  It can 
be individual or groups peer support, and can be implemented through face-to-face, 
telephone, internet or other strategies.  Brownson and Heisler summarized six 
essential contributions of peer supporters to diabetes care in any of these models, 
which are listed below.87 These points outline the utility of peer support. 
1. Improving access to regular, safe, high-quality clinical care: Peer supporters 
conduct outreach and case finding; make referrals; help PLWD navigate the 
healthcare system; serve as liaisons between PLWD and healthcare settings; 
coordinate care/services (case management); provide language translation; 
assist with applications and paperwork for insurance or other 
services/programs. 
2. Individualized assessment and tailored management: Assess needs of PLWD; 
assess readiness to change, level of literacy, and other life influences on their 
ability to self-manage; individualize education and support; and provide 
services in non-traditional settings (e.g. home visits). 
3. Collaborative behavioural goal setting and problem solving: Help patients set 
and reach specific behavioural goals; help in problem solving to overcome 
barriers. 
4. Education and skills for managing diabetes: Conduct outreach and 
recruitment for educational services, lead (or assist with) culturally 
appropriate and accessible self-management training and education; and 
teach/reinforce self-management skills. 
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5. Ongoing follow-up and support: Provide non-judgmental follow-up, informal 
counselling, social support and encouragement; and provide instrumental 
support. 
6. Linkage to community resources:  Identify needed resources; develop 
relationships with community organizations; provide information and support 
to PLWD regarding available community resources; advocate for needed 
services; develop capacity within communities to support healthy behaviours 
These points provide us with an understanding of the utility of peer support. Looking 
at these roles, we can construe that the goal of peer support is to empower the 
individual PLWD and to ensure regular access to diabetes services.  
Turning to diabetic retinopathy, can peer support strengthen prevention, screening, 
diagnosis, treatment or rehabilitation for DR? We did not find any published evidence 
on peer support for DR. We suggest that this is an important area for investigation.  
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 2.4 Diabetic retinopathy 
Normal retina
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Mild non-proliferative DR
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Moderate non-proliferative DR
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Severe non-proliferative DR
© David Yorston CC-BY-NC-2.0  
Proliferative DR
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Macula oedema
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Figure 2-4: Retinal images showing Classification of Diabetic Retinopathy 
Source: Community Eye Health Journal https://creativecommons.org/licenses/by-
nc/2.0/legalcode 
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The long-term sequelae of diabetes, including diabetic eye disease (DED), make 
diabetes a complex comorbidity. DEDs include cataract, glaucoma, rubeosis iridis, 
optic neuropathy, ocular muscle dysfunction and retinopathy. The increase in 
prevalence of type 2 diabetes in LMICs will occasion proportionate increases in the 
rates of these complications.110 Cataract and glaucoma may occur in the absence of 
diabetes, but DR is a specific ocular manifestation of end-organ damage from diabetes 
(Fig 2-4). These conditions are potentially blinding and PLWD are 25 times more likely 
to go blind than the general population.111
2.4.1 Epidemiology of diabetic retinopathy 
Diabetic retinopathy is a progressive disease of retinal microvasculature and the most 
frequent microvascular complication of diabetes.112 All PLWD are at risk of developing 
DR; the risk increases with the duration of diabetes as Fig 2-5 illustrates.  After 20 
years of living with diabetes,  80% of PLWD will have some form of DR.113, 114 At any 
point in time, 35% of PLWD have DR, and about 10% of PLWD (or about a third of 
those who have DR) have vision threatening DR (VTDR) with a high risk of severe 
visual impairment from DR.115 The early stages of DR are asymptomatic, but with 
progression over time, the main vision-threatening sequelae are diabetic macular 
oedema (DMO) and proliferative diabetic retinopathy (PDR), both of which are part of 
VTDR, Figure 4. These complications make DR a leading cause of acquired vision loss 
particularly in the working age population.112, 113, 116
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Figure 2-5: Association of prevalence of DR with duration of diabetes 
The 2017 report of the Vision Loss Expert Group shows that the crude prevalence of 
blindness due to all causes except DR reduced between 1990 and 2015 globally.117
During these 25 years, the number of people with DR-related blindness and visual 
impairment (VI) increased, and the overall causal contribution of DR to blindness 
increased by 7.7%.117 This trend suggests that DR has potential to become one of the 
leading causes of VI globally in the future.  At present, the prevalence of DR-related VI 
in Asia and SSA is much lower than in high-income countries.117 This also has potential 
to reverse, based on the evidence of the escalating prevalence of diabetes and the 
increasing life expectancy in these regions. An increased focus on the control of DR is 
thus appropriate. Although large population-based studies on DR in SSA are lacking, 
posterior-segment eye diseases (PSEDs), grouped together, are the second leading 
cause of blindness in the region, accounting for 13 to 37% of blindness.118
A recent systematic review has shown the annual incidence of DR globally ranges from 
2·2% to 12·7% and progression from 3·4% to 12·3% among adult PLWD.119 In the 
Malawi Diabetic Retinopathy cohort study, progression from no retinopathy and 
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background retinopathy to VTDR over five years was approximately 5 and 3 times that 
reported in the Liverpool Diabetic Eye Study.120 The 5-year incidence of any DR in 
Malawi was 48.4%. Poor glycaemic control and HIV infection were predictors of 
progression.121, 122 This was the first report of an association between HIV infection 
and progression of retinopathy. It is a pointer that infectious diseases and other 
variables in LMICs may affect the epidemiology of DR. The 6-year incidence of DR 
among PLWD age 50+ in the Nakuru cohort study in Kenya was 225 cases per 1000.60
The other available incidence data for LMIC is from Bangladesh, where the cumulative 
incidence of DR over a 15-year period was 50.6%.123 It is difficult to compare these 
findings because of different study designs, follow-up rates and insufficient 
stratification of data by age and other parameters. It is still uncertain whether DR 
occurs earlier or progresses faster in African populations as compared to PLWD of a 
similar age in other populations. However, the data is useful for conceptualisation of 
the need for services such as screening programmes for early detection of these 
cases. 
The prevalence range for any DR among PLWD in SSA, as reported in individual studies 
(Table 2-1), is 7.0 to 62.4%.124 This wide variation may result from: the variation in the 
mean duration of diabetes among the participants in the different studies; differences 
in study methods and changes in the prevalence of DR over time.  
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Table 2-1: Prevalence of diabetic retinopathy in sub-Sahara Africa 




Botswana Mengesha et al125 2006 Clinic-based 401 9.2
Cameroon Jingi et al126 2015 Clinic-based 407 17.4
Ethiopia Seyoum and 
Mengistu127
2001 Clinic-based 302 37.8
Ethiopia Teshome and 
Melaku128
2004 Clinic-based 1390 28.7
Ethiopia Gill et al129 2008 Clinic-based 105 21
Kenya Mwendwa et al130 2005 Clinic-based 100 7.0
Kenya Mwale et al131 2007 Clinic-based 96 22.6
Malawi Glover et al132 2012 Clinic-based 249 32.5 
Nigeria Omolase et al133 2010 Clinic-based 100 15





2002 Clinic-based 253 40.43
Southern 
Africa 
Carmichael et al136 2005 Clinic-based 1517 26.5
Southern 
Africa 
Mash et al137 2007 Clinic based 400 62.4
Southern 
Africa 
Reed and Cook138 2007 Clinic-based 248 32.3
Tanzania Mumba et al139 2007 Clinic-based 86 20.9
Tanzania Cleland et al140 2016 18 diabetes 
clinics 
3187 27.9
Zambia Lewis et al141 2018 Clinic-based 2153 52
Malawi Burgess et al142 2014 Cohort study 357 50.1
Kenya Mathenge et al143 2014 Population 
based survey  
4414 35.9






In Kenya, a Nakuru study reported PSED to account for 30.4% of blindness, of which 
DR accounted for 2%.144, 145 The Nakuru cohort study found the prevalence of any DR 
among PLWD to be 35.9%.143 115 This data can be used for planning services in Kenya, 
although more studies would help to consolidate the evidence. The Rapid Assessment 
of Avoidable Blindness (RAAB + DR) is a potential method to collect more local 
prevalence estimates.146, 147  Table 2-2 shows how the data on incidence and 
prevalence can be used for planning DR programs. We propose that interventions to 
increase access to screening among PLWD are vital in preventing vision loss.  
Table 2-2: Planning for DR services in Kenya 
NEED FOR DR SERVICES IN KENYA
Population at risk
Total Population 53million
Population to be covered (consider age- above 20yrs = 45%) 24million
Diabetes Mellitus (PLWD)
Prevalence of diabetes (number DM / 100 pop)  2%
Number of people with diabetes  480,000
Diabetic Retinopathy
Proportion (%) of PLWD with DR  35%
Number of people with DR 168,000
Vision threatening diabetic retinopathy (VTDR)
Proportion of PLWD with VTDR 10%




2.4.2 Risk factors for onset and progression of DR  
The major risk factors leading to development and progression of DR have been 
elucidated, Table 2-3. Key factors that are consistently associated with DR include 
longer duration of diabetes, prolonged hyperglycemia, and systemic hypertension.112, 
115 These factors apply to all types and stages of DR.115 Dyslipidaemia is associated 
with DMO, but its role in other types and stages of DR is the subject of debate.115, 148
The duration of diabetes is considered the strongest independent predictor for DR,114
but in Kenya where  >50% of PLWD are undiagnosed, DR may be the first presentation 
of diabetes.57 This raises the need to increase early detection of both diabetes and DR. 
The Diabetes Control and Complications Trial (DCCT) and the United Kingdom 
Prospective Diabetic Retinopathy Study (UKPDS) showed the protective effect of good 
glycaemic control (HbA1c < 7%) in reducing the risk and progression of DR in type 1 
and 2 diabetes respectively.114 This effect has been quantified, such that a 1% 
decrease in HbA1c corresponds to a reduced risk of retinopathy by 40%, progression 
of DR to VTDR by 25%, need for laser therapy by 25%, and blindness by 15%.113 On the 
other hand, tight glycaemic control carries the risk of hypoglycaemia, and requires a 
strong compliance from both PLWD and physicians. High levels of undiagnosed 
diabetes, low treatment coverage for diabetes, and non-adherence to medication, 
which have been already highlighted in Kenya, are likely to be a challenge for 
achieving good glycaemic control.51, 57
The UKPDS showed the positive influence of tight blood pressure control. Every 
10mmHg reduction in systolic blood pressure results in a decreased risk of retinopathy 
progression by 35%, need for laser therapy by 35%, and visual loss 
by 50%.113 Crucial to note, the STEPS survey in Kenya found that 56% of the 
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population 18-64 years had never checked their blood pressure and 22% of those who 
were already diagnosed with hypertension were not on treatment.50, 51 This is another 
challenge for DR control programs. 
Given these risk factors, prevention of DR-related vision loss will require close 
collaboration between diabetes and eye care services.149 At present, such 
collaboration is minimal.150 The landmark trials mentioned above, along with the Early 
Treatment Diabetic Retinopathy Study (ETDRS) have shown that blindness from DR is 
almost entirely preventable with early detection of DR, timely treatment and effective 
diabetes control.151 To prevent vision loss, metabolic control and yearly retinal 
examinations are recommended for PLWD, beginning at the time of diagnosis of type 
2 diabetes or 5 years after diagnosis of type 1 diabetes, with increasing frequency 
once DR is identified.152, 153 At present, although PLWD in LMICs have some awareness 
of DR as a possible diabetes complication, specific knowledge about DR is rare, and 
many PLWD do not have an eye examination before they experience vision loss.147
One study reported that the mean time between diabetes diagnosis and DR screening 
for PLWD in different parts of LMICs  ranged from 8.0 (±7.0) to 14.4 (±10.8) years.154
Screening programs must therefore have a strong health education and advocacy 
component.  
As can be seen from Table 2-3, three priority risk factors for NCDs (physical inactivity, 
tobacco use, unhealthy diet) have been associated with onset and progression of DR. 
There is therefore optimism that the proposed interventions for NCDs will be useful to 
prevent and control DR. The association of DR with alcohol intake, another priority 
risk factor for NCDs, is the subject of debate, and the evidence is inconclusive at 
present, an area for further research.155, 156 There is no published evidence on the 
association of DR with the fifth priority risk factor for NCD, air pollution. Crucially, 
69 
there is a need for more evidence on other risk factors that are of special interest to 
Africa, such as co-pathology with HIV, malaria, tuberculosis, malnutrition, 
micronutrient deficiencies and anaemia.33, 142
Table 2-3: Risk factors for onset and progression of Diabetic Retinopathy 
Patient factors
Non-modifiable: increasing duration of diabetes, 157, 158 increasing age,159-161 African, 
South Asian and Latin American ethnicity,159, 162 male gender159-161, 163 metabolic 
hormones (leptin and adiponectin)164
Modifiable: hyperglycaemia 158, 165, high blood pressure 158, 165, dyslipidaemia158, 166, 
physical inactivity157, smoking,167  obesity,164 pregnancy,164 lack of awareness,168 lack 
of access to services169 inflammation and oxidative stress164
Health worker factors
Lack of knowledge, lack of education in diabetes care, poor communication with 
patients, failure to individually recommend patients for diabetes screening168 lack 
of collaboration between providers of diabetes and eye services169 ambivalence 
towards referral of patients, non-adherence to practice guidelines170
Health system factors
Limited and irregular anti-diabetes drug supplies168, high cost of treatment and 
tests168, lack of glucometers, strips and syringes168, lack of screening programs168, 
lack of diabetes registries168, lack of coordination of care168, stigma associated with 
diabetes in the society,168 lack of clinical guidelines,170  lack of endocrinologists168
and ophthalmologists168
2.4.3 Impact of DR-related vision loss 
The early stages of DR are asymptomatic but the development of severe non-
proliferative DR, proliferative DR and diabetic macular oedema causes irreversible 
vision loss.113, 171, 172 In the early stages of DR, vision specific functions are maintained 
at a similar level with those with no DR.  However, persons with VTDR are up to 6 
times more likely to have a low overall vision-specific functioning (participation in 
vision-dependent activities such as reading, watching television or driving) compared 
with those with less severe stages of DR, independent of their presenting visual 
acuity.173 Activities requiring fine visual acuity such as reading small print are 
70 
particularly affected. Loss of contrast sensitivity also occurs, especially with 
maculopathy. Laser photocoagulation is destructive to the retina and causes loss of 
visual field. Further, PLWD who have DR are at an increased risk of falls.174 As a result 
of vision loss, physical mobility is reduced, PLWD become socially isolated and often 
dependent on others.175 Thus, it is important to bring in interventions that can 
preserve vision. 
PLWD have difficulties in managing diabetes once they are visually impaired. For 
example, they have difficulty measuring their blood glucose or measuring the dose of 
insulin. This can lead to poor glycaemic control, deterioration in DR, frequent need for 
hospitalization and increased mortality. Furthermore, patients with DR are at greater 
risk of other systemic vascular complications, including stroke, coronary heart disease, 
and congestive heart failure.173 Physicians and ophthalmologists should therefore 
ascertain that patients with DR are receiving appropriate assessment and treatment 
for these comorbidities.164 Diabetes, DR and vision loss are independently associated 
with mental health problems such as emotional distress, depression and reduced 
psychosocial functioning.176-178 Fear and anxiety relating to potential visual loss as well 
as fear of laser photocoagulation treatment for DR has been reported.175
There is clear evidence of the heavy economic burden caused by diabetes, DR and 
vision loss. 4, 64, 179 DR incurs substantial treatment costs, often necessitates increased 
health care utilization and significantly reduces health-related quality of life, once VI 
occurs. 55 Further, diabetes and DR are associated with loss of productivity, in terms of 
loss of employment and lost workdays. In a US population, the presence of diabetes 
itself reduced employment of PLWD by 3.5%, and the presence of complications 
reduced employment by 12% as compared to similar population without 
diabetes.180  Given the economic impact of diabetes and DR to the PLWD, their 
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families and society, and given that vision loss worsens this burden and the quality of 
life, prevention of visual impairment is crucial. Early detection and timely treatment 
are essential.  
2.4.4 The role of health systems in the control of DR 
To reduce the incidence of blindness due to DR, a health system should: (1) ensure 
appropriate metabolic control of diabetes, as previously described; (2) enable early 
detection of DR through regular retinal screening; and (3) provide appropriate 
treatment and follow-up for patients with DR.181  As both diabetes and DR are 
increasing, and DR awareness remains patchy and low in many populations, there is a 
need to increase the awareness in PLWD and in health workers regarding these 
services. 182
 Retinal Screening 
The first screening tests for DR were conducted in 1980 in Iceland. 183 Wilson and 
Jungner (1968) established the criteria for screening in medicine, which was adopted 
by the WHO (Table 2-4). 184 Subsequent debate on the criteria has led to additional 
specifications of these criteria (Table 2-5). The St Vincent Declaration of 1989 was the 
first international commitment to apply screening to DR, targeting the reduction of 
DR-related blindness by a third over the next 5 years. Three decades since then, the 
application of these criteria continues.  In 2005, the Liverpool Declaration sought to 
reduce DR-related blindness through systematic screening with a coverage of at least 
80 % of PLWD by 2010, using trained personnel and access to the proper therapy. 
Since then many developed countries have initiated screening programs that use 
ophthalmoscopy, retinal photography and telemedicine.185 Understanding how the 
screening criteria can be translated into practice in LMICs where there is no 
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established systematic screening programmes is crucial. The implications of these 
screening criteria in the context of LMICs need to be considered. Although there is an 
assumption that these criteria apply universally, successful DR screening (DRS) 
programs should be suited to the context, and context influences the translation of 
the criteria into practice.147, 186
Table 2-4:Wilson and Jungner classic screening criteria184
1. The condition sought should be an important health problem
2. The natural history should be adequately understood
3. There should be a detectable early/latent/asymptomatic stage
4. There should be a suitable test for the early stage
5. The test should be acceptable
6. Treatment at an early stage should be of more benefit that at a later stage
7. There should be an agreed policy on whom to treat as patients
8. There should be adequate health service provision for the extra clinical 
workload resulting from the screen 
9. The costs of diagnosis and treatment should be balanced against benefits
10. Case finding should be a continuing process and not a “once and for all” 
project 
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Table 2-5: Emerging screening criteria proposed since 1968 187
1. The screening programme should respond to a recognized need
2. The objectives of screening should be defined at the outset
3. There should be a defined target population 
4. There should be scientific evidence of screening programme effectiveness 
5. The programme should integrate education, testing, clinical services and 
programme management 
6. There should be quality assurance, with mechanisms to minimize potential 
risks of screening  
7. The programme should ensure informed choice, confidentiality and respect 
for autonomy  
8. The programme should promote equity and access to screening for the 
entire target population 
9. Programme evaluation should be planned from the outset 
10. The overall benefits of screening should outweigh the harm 
In the previous sections the concept of DR as a chronic public health problem with a 
known natural history has been explored.152, 188 The previous sections have presented 
evidence that the increasing prevalence, and the adverse health, social and economic 
impact are significant factors for PLWD, heath care providers and policy-makers. The 
goal of DR screening is to identify PLWD with asymptomatic DR and provide timely 
treatment for those with VTDR.189 The target population for screening is well defined, 
since all PLWD are at risk, and will develop some DR if they live long enough. There is 
consensus that screening is required. However, the evidence base so far is from high 
income settings. While it is known that DR is generally progressive, the rate of 
progression in different settings is uncertain. It is also unknown whether the 
probability of adverse visual outcomes for PLWD in LMIC corresponds to the evidence 
from developed countries. Yet this is a learning point for LMICs – local evidence 
collected from screening programs would help identify the optimal screening intervals 
and methods for LMIC with more certainty.  
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As DR has a latent asymptomatic stage and effective treatment is available, annual 
examination of the retina is recommended.152, 190 However, screening all patients with 
diabetes for retinopathy has remained an elusive target in most countries.191 Lack of 
appropriate screening is a risk factor for VTDR and vision loss. The determinants of 
uptake of an eye examination are context-specific and can be categorised as personal, 
provider and health system factors.171, 192, 193 Evidence on the barriers from different 
LMIC settings have been collated,194 but screening programs will need to continually 
collect and use the evidence from their own settings. 
Retinal examination can detect the latent, asymptomatic phase of DR.189 International 
classifications of DR gives the specific parameters to be used for classifying DR and the 
subsequent clinical pathways to pursue.195 All stages of DR (as specified in these 
classifications) are detectable with the same screening test. Recognition of early DR is 
helpful as it provides evidence of early disease, and appropriate metabolic control can 
prevent or delay further deterioration. There is considerable evidence that prompt 
treatment of VTDR can prevent vision loss.113, 196 The challenge in LMICs is to ensure 
that all PLWD found to have VTDR get appropriate referral for treatment and access 
the treatment on time. Therefore, it is important that treatment services are available 
before establishing a systematic screening programme. 
Retinal examination is considered safe, non-invasive and relatively quick. One of the 
requirements that can be challenging is mydriasis (pupil dilatation). Mydriasis is 
considered safe in SSA, as acute angle closure is not common; in Asia angle-closure is 
common hence non-mydriatic modes of retinal examination may be preferable.147
Temporary blurring of near vision after pupil dilatation can discourage PLWD from 
uptake of retinal examination, especially if adequate explanation is not provided.186
Further challenges that can discourage uptake of screening include the cost of travel 
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and time away from work. False positives may raise alarm, while false negatives may 
raise false security. It is therefore important to consider the diagnostic test accuracy 
(DTA) of different screening methods in comparison to the gold standard, which for 
routine practice is clinical examination of the retina by an eye specialist.197 The 
recommended threshold for tests used in systematic population-based screening is 
over 80% sensitivity, over 95% specificity and less than 5% technical failure rate for 
satisfactory images or examination. 189, 198, 199
Dilated slit lamp bio-microscopy and ophthalmoscopy (direct or indirect) are the main 
modes of screening in LMICs.186 The sensitivity of direct ophthalmoscopy for detection 
of VTDR is only 65%, which is below the 80% threshold. However it is still useful for 
opportunistic case-detection.189  Indirect ophthalmoscopy has the limitation of 
requiring extensive training, but it’s accuracy is high and it is considered an alternative 
to direct ophthalmoscopy.200, 201  Slit lamp bio-microscopy through a dilated pupil has 
a high sensitivity and specificity of  89% and 94% respectively, but is time consuming 
and requires a slit lamp.202 The main disadvantages of these clinical examination 
methods is that the findings cannot be captured and stored for quality assurance. 
Fundus fluorescein angiography is expensive, time consuming, invasive, requires 
specific expertise, has a small risk of anaphylaxis and is not readily available in LMICs, 
hence it is not used as a screening tool. A combined colour camera and Optical 
Coherence Tomography (OCT) is useful for detection of diabetic maculopathy, 
however it not widely available or cost-effective for population-based screening. 189
 Screening programs in LMICs are gradually adopting mydriatic or non-mydriatic 
retinal photography. The limitation is the need for investment, as a single camera may 
cost $20,000, although low-cost fundus cameras are becoming more available.201  A 
recent systematic review reports that single field views of both mydriatic and non-
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mydriatic digital imaging methods generate a satisfactory level of sensitivity, i.e. 86%  
for the detection of any DR, once ungradable images are excluded from analysis.202
The specificity is 91% (non-mydriatic camera) and 87% (mydriatic camera), which is 
below the 95% recommended threshold, but this improves to meet the threshold if 
two or more fields are taken. For the detection of VTDR, the sensitivity and specificity 
also increases with the number of fields of view, providing evidence that the number 
of fields taken is an important consideration in photography-based screening. In one 
study the use of mydriasis reduced the number of ungradable images from 27.1% to 
8.3%, using a single‐field strategy.186 This is important because cataract and corneal 
opacities can be a source of ungradable images.183 However, non-mydriatic imaging 
reduces the screening time and inconvenience of pupil dilatation, and may thus be 
more efficient and acceptable to both PLWD and health care providers. 
Bragge and colleagues in their meta-analysis that included 20 studies found that 
screening involving non-medical photographers yielded lower specificity as compared 
to screening involving photographers with specialist medical or eye qualification, 
particularly with non-mydriatic imaging.203 Low specificity has potential to increase 
the false positives and unnecessary referrals. It may be attributable to imaging 
difficulties or poorer image quality in their photographs. However in a more recent 
analysis that included 26 studies, Piyasena and colleagues found that non-medical 
retinal image graders could achieve the threshold level of sensitivity and specificity in 
both mydriatic and non-mydriatic strategies.186 As screening is not an efficient use of 
ophthalmologists’ time, task-shifting to trained retinal graders is a useful option, as 
already exemplified by the English DR Screening program.204 While recommending this 
option, we emphasise the pre-requisite for training, certification and quality 
assurance mechanisms for the graders.  
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Screening at scale is cost-effective but can be expensive and labour intensive 
particularly for rural communities. One tool to address this is telemedicine. The 
diagnostic accuracy of telemedicine using digital imaging in DR is overall high (95% 
sensitivity and 86% specificity for detection of any DR). 116, 205 Considering the high 
sensitivity in the detection of any clinical level of DR, telemedicine can be used widely 
for DR screening. It has the potential to deliver cost‐effective screening to rural, 
remote and hard‐to‐reach PLWD. On the downside, it still requires a fundus camera, 
which is expensive. Secondly, noncompliance with follow-up appointments has been 
reported in telemedicine programs, leading to low take-up of the screening results 
and hospital referrals.147 One study in Kenya found that only 58% of PLWD return to a 
tele-ophthalmology site to receive screening results.206 This illustrates that the 
telemedicine programs must extend efforts beyond capturing the images, to keep 
PLWD engaged. Other essential components for the use of telemedicine are robust 
technology, clear referral pathways and quality assurance.  The retinal imaging 
devices must be validated and meet the specifications for image resolution which 
some programs have recommended as 20 pixels per degree with a resolution of at 
least 10–15 mm.201
Another tool is automated image analysis. A systematic review found that automated 
screening has high sensitivity (87-95%) but low specificity (49.6-68.8%). In this review, 
false negatives were likely to be mild DR with low risk of progression within one year. 
However, several studies in this review also reported missed cases of DME, which is a 
concern.207 The use of cloud-based image analysis software is an additional emerging 
trend. There is need for more evidence on the diagnostic accuracy of the analytic 
software especially in the African population. There are only two studies that have 
tested the use of artificial intelligence (AI) in imaging African eyes, which are usually 
more pigmented than other ethnic groups, and the results have been positive.208, 209
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There is also need for research on the ethical considerations, given the data security 
concerns. 
A third tool for which there is growing interest is smart-phone based retinal screening. 
Validation studies are ongoing for different prototypes that use the principles of direct 
or indirect ophthalmoscopy. Bilong et al have reported the findings for a study where 
retinal images were taken through a dilated pupil, using a smartphone attached to an 
adaptable camera. Indirect ophthalmoscopy was also performed. The retinal images 
were sent via internet to a retinal specialist for interpretation. Sensitivity and 
specificity for the detection of any DR, was 73.3% and 90.5%. For DME it was 78% and 
95%. However, for severe NPDR and PDR the sensitivity increased above the standard 
threshold.210 At present, there is insufficient evidence to make any recommendations 
regarding this modality in screening. 
The cost-effectiveness of DR screening compares well with other screening 
programs.199 Data from the Liverpool Diabetic Eye Study showed that photography-
based systematic screening is also more cost-effective than opportunistic screening or 
examination by a human screener, even if the screener has a sensitivity of 95%.191
Systematic screening is also cost‐effective in terms of sight years preserved compared 
with no screening.211 Early diagnosis and early treatment of diabetic retinopathy is 
cost-effective, and even cost-saving212 if the cost of VTDR is considered and if there is 
at least 80% compliance to screening.213 Coverage is an important driver for cost-
effectiveness.  
Achieving the desired coverage may be challenging especially in rural and remote 
areas. Outreach DR screening is one way of improving screening coverage  and can 
reduce overall health care costs, although quality assurance should be maintained.203
The highest DTA (sensitivity 90% and specificity 95%) is observed when screening is 
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delivered at secondary/tertiary level clinics. 186 However DTA is not the sole factor 
that needs consideration. Context, resources, costs and coverage vary widely and the 
success of screening programs depends on understanding the ‘best fit’ within the 
existing system.  
The appropriate timing and frequency of screening is an important consideration. DR-
associated vision loss has been found to increase as the screening interval is extended 
from one to five years.214 Annual screening is widely recommended, although some 
programs are moving to examination every two years if the initial examination is 
normal.191, 195, 215 The evidence to-date is that screening every two years is cost-
effective, but annual screening is outside the cost-effectiveness range,  defined as less 
than three times the gross domestic product (GDP), or <US$3183 per quality-adjusted 
life year (QALY) gained.147, 201, 216 On the other hand, long screening intervals may be a 
disincentive for PLWD, due to the potential for loss of contact and the interpretation 
that vision loss is unlikely and therefore not a concern.217 Therefore yearly intervals 
for those with no DR are generally preferred, unless individual risk of progression 
(glycaemic and blood pressure control) can be assessed with certainty.217 For those 
with DR, screening intervals depend on the severity of the DR. 
There is consensus that VTDR should be treated, and the goal of treatment is to halt 
progression and prevent vision loss; restoration of lost vision is uncommon.113
Because treatment is aimed at preventing vision loss and retinopathy can be 
asymptomatic, it is important to identify and treat patients early in the disease. Early 
laser treatment for diabetic retinopathy is safe, effective and universally agreed.190, 218
The DRS and ETDRS studies showed that timely laser decreases the risk of severe 
vision loss (15 letters) by 52%; early treatment of clinically significant macula oedema 
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(CSME) reduces the risk of severe vision loss by 50% at five years and reduces the 
need for treatment to only 8% at two years.196, 199, 219
Anti-vascular endothelial growth factor (anti-VEGF) therapy is increasingly being used 
for DMO and has been shown to maintain visual acuity if used early and frequently in 
the course of the disease.196 While both laser and anti VEGF injections are available 
treatment options for DMO, there is ongoing debate regarding which is the best 
treatment in LMICs, given the logistical and cost implications for each method.  
The realities in LMICs provide important considerations about what policies should be 
prioritized. Based on the discussion above, it is clear that DR screening as applied to 
LMICs meets the screening criteria. However, in an environment where there are 
operational or implementation complexities, screening tends to be neglected. These 
complexities include infrastructural capacity (equipment, technology), trained human 
resources, program coordination and evaluation, logistics (reaching hard to reach 
groups), social considerations (e.g. compliance, informed consent, confidentiality and 
autonomy) and sparsity of local evidence. Given these uncertainties, innovative and 
context-specific solutions to improve screening services are required.  
Photography-based systematic screening strategies are recommended, as they offer 
patient convenience, efficient use of skills, quality assurance and ability to detect 
other eye conditions. Retinal imaging devices must meet the minimum acceptable 
standard for screen resolution. The standards used in the English program is a vertical 
resolution of 1080 (1920 9 1080) with an achievable and recommended standard of a 
minimum of 1200 (1920 9 1200 or higher). It is recommended that a minimum of 60% 
of the image should be viewable on the grading screen to avoid too much scrolling to 
see the full image.204 Opportunistic screening programs can use the tools available. 
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A potential leverage spot for screening programs is program management. To make 
the most of resources, and cause ripple effect in the capacity, volume, quality and 
cost-effectiveness, it is necessary to strengthen capacity to manage screening 
programs. For example, a program manager may help to bring endocrinologists, 
physicians, ophthalmologists, epidemiologists, economists, funders and policy-makers 
together on one page, for a coordinated and concerted response. There is no 
published literature specifically investigating approaches to sustain and coordinate 
program management in DR programs. This is an important area for future research. 
Table 2-6 summarizes the interventions for control of DR-related vision loss.  In LMICs 
barriers to the access and utilization of these interventions abound, including lack of 
diagnostic equipment and treatment infrastructure (lasers, laser maintenance, anti-
VEGF, vitrectomy machines).33 International clinical practice guidelines (CPGs) on the 
use of these interventions have been developed,190 but locally adapted CPGs are often 
lacking.33, 150In SSA where the mean ophthalmologist density is 3.7 per million 
population,220 there is need to invest in developing sufficient workforce as well as task 
shifting.221
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Table 2-6: Interventions for control of vision loss from DR
1 Prevention of diabetes 
Lifestyle measures, especially healthy diet, regular exercise and weight vigilance.58, 
170, 222
2 Prevention of DR in PLWD
Good blood glucose control, BP control, control of hyperlipidaemia; avoid 
smoking113, 114, 222, 223
3 Prevention of visual loss from DR
Annual retinal screening examination, timely identification, referral and treatment 
of VTDR (laser for PDR, and laser or anti-VEGF or intravitreal steroids for DMO), 
with regular follow-up.191, 212, 224-227
Restoration of vision in severe PDR with vision loss from vitreous haemorrhage
Good tertiary eye care services, including vitreo-retinal surgery113, 195, 223, 228
5 Improving functioning in PLWD with visual loss
Visual rehabilitation services164, 195, 228
2.5 Control of DR within an NCD, UHC and the health systems agenda 
The previous sections have presented evidence from the literature that the health, 
economic and social burden of both diabetes and DR is likely to increase, and that 
LMICs carry a disproportionately high burden. It is clear that diabetes is a global 
health priority along with other NCDs.  The NCD agenda recognizes diabetes not as a 
single disease, but as a complex comorbidity.5 To this extent, NCD ‘best buy’ 
interventions that are relevant to DR have been recommended in the agenda. What is 
less clear is why relevant targets and indicators for DR, or any other long-term 
complication of diabetes, are not included in the global NCD targets and indicators.229
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The NCD targets focus on preventing mortality from diabetes. As we have described, 
DR causes morbidity and other social and economic effects, but it is not in itself fatal. 
Including targets relevant to DR, such as the number of people going blind or the loss 
in productivity from DR, might increase its visibility and attract investment in DR 
control at country level. 
Many PLWD in LMICs who would benefit from the interventions for diabetes and DR 
do not use them. For example many are undiagnosed and untreated, or fall off the 
diabetes care cascade.4, 5 Addressing DR at the individual PLWD level is therefore a 
priority need for PLWD. However, interventions that only have effect at the individual 
level are insufficient for control of DR, as there is need for system level impact. This 
chapter has made a case about the relevance of interventions based on the 
multifaceted chronic care model.  
To reduce the burden with NCD interventions, there is also need to prioritize 
surveillance and research, strengthening services and equity. These are some of the 
strategies that have contributed to the success of UHC and DR programs, for example 
in the United Kingdom.22, 198 Although LMICs cannot directly copy strategies used in 
high-income countries, they can learn from them. The Diabetic Retinopathy Network 
(DR-NET) provides an important learning opportunity in which existing VISION 2020 
LINKS between UK and overseas eye departments share learning on DR screening and 
treatment.171, 230 At present there are 22 DR LINKS in the network representing 18 
countries in Africa, the Caribbean and the Pacific.230 The DR-NET helps LMICs to 
develop collaboration between diabetes and eye services, set up diabetes registries, 
acquire screening and treatment infrastructure, develop clinical guidelines and plan 
for DR services using the DR-NET toolkit.228
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Although three in four of PLWD reside in LMICs, there is a dearth of data from these 
countries, which makes it challenging to define needs and priorities.231 National 
governments are making effort to address this; for example, the Ministry of Health 
Kenya has carried out a STEPS survey on the risk factors of NCDs.51 The data has 
helped to understand the epidemiological profile of diabetes, as discussed in this 
chapter. Local evidence about DR is required for planning DR services. In Kenya, the 
DR prevalence data so far has come from three observational studies (Table 1) and 
one longitudinal cohort study that provided the incidence data.60  While using this 
data to plan for services, we need solution-based research to identify feasible 
approaches to engage PLWD and prevent non-adherence along the care cascade. We 
also need surveillance data for both process and clinical outcomes, such as the 
number of PLWD screened for DR and the number that progress to vision-threatening 
DR. This evidence might then serve to attract investment in services. 
Like other NCDs, the control of DR has strategic links with health systems and UHC. 
The services required for control of DR are the interventions for prevention, 
screening, diagnosis, treatment and rehabilitation. These services have to be provided 
within a health system that is responsive to the changing epidemiology.232, 233 There is 
need to build a health system that will help people live in a way that prevents 
diabetes, achieve good control of their diabetes, provide regular retinal screening to 
detect DR in its early stages, and provide accessible and affordable laser or anti-VEGF 
treatment for those with VTDR to prevent blindness.171 As countries aspire to attain 
UHC, these health systems need these services to be comprehensive, have sufficient 
coverage, high quality and be at an optimal cost.22  Heath systems therefore play a 
crucial role in the response to the burden of both diabetes and DR. The WHO’s global 
report on diabetes in 2016 reported variation in the capacity of health systems to 
deliver diabetes services.233 For example some LMICs countries did not have national 
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policies or guidelines, basic technology for diagnosis of diabetes, or sufficient supplies 
of insulin in primary care. Planning services for DR also requires an assessment of the 
health system capacity.149 There is value in periodic health system assessment, 
specific to diabetes and DR, as it helps to identify the needs, and facilitate subsequent 
health system strengthening to address priority gaps. 
As NCDs become the leading disease category in developing countries, the provision 
of NCD-related services will increasingly form the backbone of health systems. Given 
the pluralistic needs of PLWD, there is need for investment in systems that make DR 
control programmes accessible, affordable, and sustainable. Weak health systems are 
an obstacle to access services, as well as to equity.15 At present, in many African 
health systems, laser photocoagulation and anti-VEGF drugs for DR are either 
unavailable or unaffordable, while the health workforce is insufficient, especially in 
rural areas. 149, 234. Without equitable coverage, for example with the ‘best buy’ 
interventions, the poor / rural PLWD will continue to be left behind and jeopardize the 
attainment of the  2030 SDG agenda. Populations of PLWD that are disadvantaged 
should be prioritized, not necessarily by interventions that target them exclusively, 
but those interventions that bring them most benefit. As health systems differ, the 
interventions to improve equity are likely to be context specific. 
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‘An epidemic is the wrong time to discover our preparations have not been sufficient, or 
that we have overlooked crucial components of the response.’ 
Dr Tedros Adhanom Ghebreyesus, 2018 
Director General, World Health Organization 
‘The pathway to UHC is not something you reach by investing in something called UHC. 
You make that pathway by building parts of the health systems, addressing the health 
care needs of a specific population and by addressing specific conditions. It will inevitably 
involve a mix of focusing on specific segments of populations, specific diseases and 
functional components of the system.’ 
                              Peter Sands, Executive Director, 2019 
The Global Fund to Fight AIDS, Tuberculosis and Malaria 
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Chapter 3: Health system assessment for diabetes and 
diabetic retinopathy 
3.0 Overview 
Health systems play an integral role in the response to the diabetes and DR epidemic, as 
described in chapter two. The concept of health system assessment (HSA) has gained 
significant emphasis in research and policy, because it can identify important areas of 
action to influence the achievement of health outcomes.1 Chapter three reports on the 
health system assessment for diabetes and diabetic retinopathy in Kenya.  This includes 
a summary of the purpose and research questions (3.1), the conceptual framework 
(3.2), an overview of theoretical frameworks for HSA (3.3), adaptation of a framework 
for this study (3.4), and a summary of study methods (3.5).  Section 3.6 outlines the 
results, culminating in the identification of priority interventions. A detailed description 
of study methods and additional results are provided in Research Papers 1 and 2 in the 
next chapter.  
3.1 Purpose of the health system assessment 
Building on the WHO definition of a health system,2  the system for diabetes and DR can 
be defined as ‘all resources, institutions and activities whose purpose is to promote, 
restore or maintain health for PLWD, including eye health’. The assessment of the 
strengths and weaknesses of the system in its ability to respond to the rising burden of 
these conditions is a lever that countries can use to strengthen the health system.1, 3
There is broad commitment at the global level to strengthen health systems as an 
approach to addressing emerging health needs,4 but there is no consensus on the 
optimal combination of strategies to improve the response of health systems to 
diabetes and DR.  Examples of interventions that have been applied to ensure that 
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effective diabetes and DR services are available include diabetes registers, task shifting, 
telemedicine, mobile screening clinics, integrated models of care, photographic retinal 
screening and artificial intelligence.5-7  However, it is uncertain whether any of those 
interventions would be feasible and appropriate in the context of Kenya. Therefore, 
there is a need to identify the local needs and resources, suitable interventions to 
address the needs, and suitable methods to test these interventions. This HSA is 
designed to identify the gaps and strengths in the health system, as a first step towards 
addressing the gaps.  
A general HSA,8 and an Eye Health System Assessment (EHSA) were conducted in 2010 
and 2017 respectively.9 Both HSAs showed that the health system is highly pluralistic, 
with formal and informal public and private sectors. However, the two HSAs did not 
provide evidence of an interaction between the two systems, or the specific issues 
relating to diabetes and DR services. Given that these conditions are a priority, the need 
for such evidence to inform the next eye health plan for Kenya has been articulated.10
This chapter describes a HSA for diabetes and DR, which sought to answer the following 
research questions: 
1. What are the strengths and weaknesses in the health system for diabetes and 
diabetic retinopathy? 
2. What priority intervention(s) can address the key gaps in the services for 
diabetic retinopathy? 
3.2 Conceptual Framework of the health system 
The conceptual framework of the health system for diabetes and DR, Figure 3-1, 
corresponds to the typical care pathway that a PLWD in Kenya would follow. In the 
community, there are health promotion activities and screening camps for diabetes. 
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Persons who do not access screening in the community are encouraged to visit a health 
facility for testing. Those diagnosed with diabetes are linked to the nearest diabetes 
clinic for metabolic control, follow-up and screening for complications. Assessment for 
metabolic control, through HbA1c, is a key service indicator for all PLWD.  Diabetes 
services should also refer all PLWD for screening for DR, which is available at the eye 
clinics. Attendance at DR screening is another key service indicator. The eye clinic also 
provides treatment for VTDR. Strengths and weaknesses can exist at any or all of the 
three levels (the community, diabetes clinic or eye clinic), which has impact on the 
burden of visual impairment from DR. 








Screening for complications 
Referral 
Screening for DR
Treatment of VTDR 
% PLWD assessed for 
glycaemic control (HbA1c) 
% PLWD screened  for 
DR 
% PLWD with VTDR 
receiving treatment 
Figure 3-1: Conceptual Framework for health system assessment 
PLWD care pathway
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3.3 Health system frameworks 
The purpose of a HSA is to take stock of a specific health system.1 There are several 
frameworks for health system assessment in the literature. Hoffman and colleagues 
identified 41 different health systems frameworks.11 The volume and diversity of 
existing frameworks highlights several things. First, the variation in the way different 
people or institutions conceptualize health systems. Second, the high interest around 
the concept of health systems. Third, the difficulty in capturing all the attributes of 
health systems in one framework, since health systems are complex. Fourth, the 
evolution of the understanding of health systems over time. Surprisingly, although many 
frameworks have been described in the literature, examples of how they have been 
applied in health system assessments are relatively few, with some of the frameworks 
being dominant.12
In 2007 the WHO described the health systems building blocks framework, which is 
ubiquitous and highly influential in the literature.13 In this framework, the health system 
is composed of six interacting building blocks, and each of them is relevant to diabetes 
and DR: – a) service delivery, b) health workers, c) health information, d) medical 
products, technology and vaccines, e) health finance, and f) governance and leadership. 
The framework has been used in studies relating to DR, vaccines, measles, polio, HIV 
and malaria, although it was originally designed for resource mobilization, not for 
research.4, 14The widespread use of the framework for assessing health systems fosters a 
shared understanding among researchers and the users of research evidence.15  Kenya 
has adopted this framework, and in 2010 used it for a general HSA.8 Subsequently Kenya 
added two building blocks to the framework (infrastructure and research), to make 
eight blocks, Figure 3-2. 16
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The limitations of using the building blocks framework in research have previously been 
described.4, 17 In particular, it does not capture the experiences of PLWD along the care 
pathway, a parameter of interest in this study. Additionally, there is need to capture 
evidence on the strengths and weaknesses on both the supply-side and the demand-
side of the health system. As the framework is predominantly a supply-side model 17 it is 
necessary to complement it with other approaches that take into account the demand-
side. 
In 2015 the WHO developed a specific tool for the assessment of diabetic retinopathy 
and diabetes management systems (TADDS).18 This tool is based on the WHO building 
blocks framework. Its stated focus is to assess the collaboration between diabetes and 
DR services. It has seven elements a) service delivery, b) health workers, c) health 
information, d) health technology, e) health finance, and f) policies, priorities and 
programs g) health promotion for diabetes and DR. It has the advantage of focusing the 
HSA on the condition of interest, but it narrows the scope of the “leadership and 
governance” building block to ‘policies, priorities and program’ and the medicines and 
other products building block to health technology. At the time of this study, this tool 
was new and had not yet applied in practice.  Figure 3-2 compares the building blocks in 
these frameworks. 
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WHO health systems 
building blocks 
Health systems building 
blocks (Kenya’s 
modification)






Priorities, policies and 
programs 
Service delivery Service delivery Service delivery
Health workforce Health workforce Health workforce
Medical products and 
technologies 









Health financing Health financing Health financing
Infrastructure Health promotion for 
diabetes and DR 
Research
Figure 3-2: Comparison of building block focused frameworks 
Another approach to HSA is the use of tracer conditions. Kessner and colleagues in 1973 
were the first persons to describe the use of tracer conditions to assess health 
systems.19 A tracer condition is a carefully selected health problem that makes it 
possible to capture differences in the performance of a health system.20 There are six 
criteria for a tracer condition.21, 22 Table 3-1 shows how the criteria apply to diabetes 
and DR.  The combination of the two conditions is suitable as a tracer for the 
responsiveness of a health system to chronic diseases in general and NCDs in particular, 
for three reasons. First, they occur in association with other chronic comorbidities, such 
as hypertension.23, 24 Second, for people with NCDs and other chronic diseases, 
preventing complications is an important aim of the health system.25 As DR is a specific 
complication of diabetes, the two conditions can mirror the subtleties of the 
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progression of disease. Thirdly, chronic diseases require an integrated health system,25
which can be exemplified by the level of integration between services for diabetes and 
DR.  A HSA using this approach therefore provides useful evidence for the health system 
for chronic diseases, including NCDs.  Diabetes has been used as a tracer condition for 
health systems in several studies.20, 22, 26-28 This is the first study to consider the 
combination of diabetes and DR as a tracer condition.  
Table 3-1: The suitability of diabetes and DR as tracer conditions 
Criteria How diabetes and DR fit the criteria
Disease has a known epidemiology The epidemiology of both conditions globally, 
in SSA and in Kenya has been described in 
chapter 2 
Disease is well defined and easy to 
diagnose 
The definition and criteria for diagnosis are 
provided in chapter 1 (diabetes) and chapter 2 
(DR) 
Its prevalence in the population is 
large enough to enable adequate 
data to be collected 
Both population-based and clinic-based 
surveys have shown that that the prevalence 
is sufficient to enable collection of data that 
can be used for planning (chapter 2) 
Its natural history is known, and it 
varies with the utilization and 
effectiveness of health care 
The predictors of the development of 
complications in both conditions, which 
include metabolic control, have been 
described in chapter 2 
It requires specific treatment, in the 
absence of which functional 
impairment results 
Hypoglycaemic drugs and lifestyle measures 
are required for glycaemic control, and the 
treatments for DR have been described in 
Chapter 2, without which visual impairment 
results 
Available and well-defined 
techniques of medical management 
exist for at least one of the 
following: prevention, diagnosis, 
treatment or rehabilitation 
Prevention, diagnosis and treatment apply to 
both diabetes and DR. Rehabilitation is 
provided for those who develop severe visual 
impairment and blindness 
Nolte and colleagues assessed the performance of health systems using diabetes type 1 
as a tracer condition in 29 countries.20 Using routine data, they demonstrated a 
remarkable variation in case-fatality across these countries, suggesting differences in 
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the ability of the various health systems to respond to diabetes. In this study, it is 
envisaged that using diabetes as a tracer will provide a broad understanding of the 
health system response to the needs identified along the care continuum. We did not 
use mortality as an indicator due to lack of suitable registers for diabetes and death in 
Kenya.  
Diabetes type 1 has also been used as a tracer condition to investigate the capacity of 
the health system in Mozambique, Zambia and Mali, using a rapid assessment protocol 
for insulin access (RAPIA).20, 29 The RAPIA method is a rapid and low cost method of 
situation analysis, centred on access to insulin. The RAPIA study was conducted in three 
areas; the capital city, a large urban centre and a rural area, to provide a picture of the 
national health system. It involved studying the path of insulin from its arrival in the 
country to the point of the end-user, including identifying determinants along the 
pathway. In Kenya a RAPIA study to assess insulin access in two counties of Kenya (Meru 
and Trans-Nzoia) found that a public-private partnership (the Base of the pyramid
project) helped to stabilize the cost of insulin but was not sufficient to improve access to 
diabetes care.27
3.4 Adaptation of the WHO health system framework for this study 
Each of the frameworks provides conceptual contributions and a general direction for 
health system assessment. However they do not serve all purposes and require 
adaptation for use in different settings.4, 30 This study is anchored on the WHO 
framework as the main assessment framework, since all the building blocks are relevant 
to diabetes and DR. Since the study is in Kenya, the eight building blocks model was 
considered appropriate for facilitating shared understanding with Kenyan policy-makers 
and for future comparison with other local studies. The tracer approach, used in 
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combination, helped to illuminate how the various building blocks of the health system 
are responsible for health system performance along the care pathway. This 
combination has the benefit of focusing the study on issues pertinent to diabetes and 
DR whilst retaining the benefits of a common framework. It is important to note, for 
replication of this approach in other studies, that familiarity with the typical patient 
pathway is a key prerequisite for adapting the framework for this purpose. 
3.5 A summary of study methods 
Bennett and Peters have proposed a set of three key principles to guide HSAs: 
relevance, coherence and trustworthiness.1 These principles were operationalized by 
consulting local stakeholders and obtaining consensus on: the purpose of HSA and the 
choice of the appropriate study counties (relevance), the fitness of the HSA framework 
for the purpose (coherence), and the choice of study procedures (trustworthiness). The 
stakeholders included the NCD division and the Ophthalmic Services Unit at the Ministry 
of Health, the national DR working group and the national eye care coordinating 
committee.  
Three counties were purposively selected for the study, based on geographic context 
(rural/urban), location within the diabetes belt (Figure 3-3) and other unique 
characteristics highlighted below. The ‘diabetes belt’ is an area that stretches from the 
coast to the Lake Victoria region, corresponding to the area along the railway (marked 
red). However, there are also additional pockets outside this belt that also have high 
prevalence (also marked red). It was named the ‘diabetes belt’ based on a historical 
perception of high prevalence as reported from some screening camps in this region. 
Nairobi (population 3.6 million, 100% urban) is a cosmopolitan city with a unique social 
structure compared to the rest of the country (high population, heterogeneous social 
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strata including the affluent, the middle class and the urban poor) and a unique health 
system structure (a large number of both private and public health facilities, including 
primary, secondary and tertiary centres). Nakuru (population 1.8 million, 46% urban) 
has been the focus of previous DR prevalence and incidence studies reported in chapter 
two, and it is of interest to relate these research efforts to the national health system.31
Kirinyaga (population 0.6 million, 16% urban) is considered to have a relatively high 
prevalence of diabetes compared to other counties within the ‘diabetes belt’.  
Through simple random sampling from a sampling frame of clinics, three diabetes clinics 
were identified in each county (public, private-for-profit and private-not-for-profit 
facilities), giving nine diabetes clinics. Eye clinics were also identified using the same 
procedure. Data for this mixed-methods analytical cross-sectional study was collected 
through:  
a) Patient interviews at the diabetes clinic (n=270) 
b) Interviews with service providers for diabetes (n=18) and eye care (n=9)  
c) Interviews with key informants who were familiar with the organization and 
delivery of healthcare at the national or at county level, with particular 
reference to diabetes and eye care (n=18)  
d) Review of documents provided by key informants  
The data collection tools were designed to collect information on the eight building 
blocks, with reference to the community, diabetes and eye clinic settings. This data was 
then triangulated.  Research papers 1 and 2 provide additional details on the methods. 
The London School of Hygiene and Tropical Medicine (LSHTM) and the African Medical 
Research Foundation (AMREF) granted ethics approval.  
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Figure 3-3: Study counties and the diabetes belt 
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3.6 Results 
Based on the data from all the interviews and the document review, the findings for 
each building block are discussed concisely below. Additional results are presented in 
the research papers in chapter 4. 
Service delivery 
Community  
Strengths: Local radio and television programs have health programs that include 
diabetes education for the public. This reflects recognition that before people become 
patients, they need to be empowered to protect their health.32 Testing for diabetes is 
available at outreach screening camps. Community health volunteers (CHVs) link those 
diagnosed with diabetes to primary care clinics and diabetes support groups (DSGs) in 
the community. These DSGs and CHVs are important examples of linkage between 
patients and community resources, one of the elements of the chronic care model 
(CCM).25, 33 At the DSGs, PLWD receive self-management education, glucose-monitoring 
services and peer support.  DSGs value disclosure and PLWD discuss their illness and 
treatment freely. There is no stigma associated with diabetes in adults in the community 
and in the DSGs. This is important because it influences the capacity of PLWD to take on 
self-care tasks, including attending appointments and adhering to treatment.34
Weakness: Public education through mass media is inadequate and mainly concentrated 
around advocacy events such as the World Diabetes Day, World Health Day and World 
Sight Day. This portrays a lack of emphasis on prevention of both diabetes and DR. A 
high proportion of adults have not been tested for diabetes, therefore many PLWD 
remain undiagnosed. The first point of care for the community is local clinics and 
pharmacies, many of which do not offer routine blood glucose testing, causing delay in 
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diagnosis. Children with Type 1 diabetes often avoid disclosure of their condition to the 
school community for fear of stigmatization. This may reduce their capacity to enact 
self-care within the school context, and hence undermine health outcomes.35 Similarly, 
formal and informal places of employment do not offer any type of diabetes services, 
and employees may not disclose their illness to the employer since they do not perceive 
this as beneficial. Work sites and schools therefore require strategic engagement.36
Although DSGs exist in the three counties, they are not uniformly active. For example, 
DSGs are very active in Kirinyaga and Nairobi, and less active in Nakuru, which is 
attributed to variation in DSG leadership capacity at county level.   
Diabetes clinic 
Strengths: There are dedicated diabetes clinics in all the counties, where PLWD are 
booked to attend appointments for follow-up. All the clinics in Kirinyaga and Nakuru run 
twice a week. In Nairobi, some clinics run five days a week but most run two days. On 
the day of appointment, PLWD are seen on a ‘first in first out’ basis. PLWD are free to 
switch clinics or use multiple clinics. This aspect of autonomy is valued by PLWD, but its 
effect on quality of care in LMICs has not been investigated. Diabetes clinics work 
closely with DSGs, which ensures that PLWD in the community are linked with diabetes 
clinics. DSGs also mobilize communities for screening camps organized by diabetic 
clinics. 
Weaknesses: Most of the diabetes clinics run only two days a week, rather than the five 
working days. This results in a high volume of patients and long waiting queues at the 
clinics.  The result is short consultation interactions that focus on the immediate 
complaint, and comorbidities such as depression and hypertension may be missed. This 
differs from the productive patient-provider interactions envisaged in the CCM.37
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Outpatient and inpatient services are delinked, such that it is not possible to track the 
frequency of hospitalizations of PLWD attending the clinic. Other supply side barriers to 
services are: inefficiencies such loss of patient files, lack of facilities for HbA1c testing, 
stock out of insulin, oral drugs and glucose test strips. PLWD receive care from multiple 
diabetes clinics which is likely to deter continuity of care.5, 38
Demand side barriers include long distances to diabetes clinics, with its associated 
transport costs and travel inconveniences. Some of the PLWD have to connect two or 
three routes to reach the health facilities, and they are typically required to arrive by 
8am in order to be attended that day. The cost of tests and medication, the opportunity 
cost of waiting time at the clinic and lack of permission from employers to attend clinic 
appointments are additional problems, similar to the experience in other settings.38
Barriers to accessing HbA1c services 
Only 27% of PLWD have had an HbA1c test in the preceding 12 months, and only 40% 
have ever had the test, with Kirinyaga county having the lowest indices, Figure 3-4. 
HbA1c testing is often not available in diabetes clinics due to malfunctioning equipment 
or lack of reagents. Therefore PLWD have to get HbA1c done privately, incurring high 
costs. In addition, health workers often use fasting blood sugar to monitor glycaemic 
control, rather than send PLWD for HbA1c test outside the health facility. Considering 
that HbA1c measures the glycaemic control over three months, is a proxy for the quality 
of care and a predictor for complications, it is a more suitable test for chronic care.39-41
This reflects that resource challenges in the health system are hindering adoption of 
chronic care.42
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Figure 3-4: Access to HbA1c testing by county in 270 PLWD (90 in each county) 
Barriers to accessing DR screening services among PLWD attending diabetes clinics   
DR screening rates are low among PLWD attending diabetes clinics in all counties, with 
the lowest indices being in Kirinyaga, Figure 3-5 and 3-6. The predictors of DR screening 
are discussed in research paper 1. Supply side barriers include failure to refer PLWD for 
screening.43  Service providers attribute this to forgetting, heavy clinic workload, 
diabetes being a complex disease that requires too many tests, more pressing concerns 
such as renal failure, lack of guidelines on DR screening and lack of point of use 
materials such as checklists to ensure screening is not forgotten. Further, they cite the 
lack of coordinated links with eye care services. The diabetes and eye clinics are located 
in different buildings in most of the facilities and sometimes PLWD who are referred for 
DR screening are “lost” along the facility corridors, and do not arrive at the eye clinic. 
Diabetes clinics do not have a formal way of following up PLWD to monitor uptake of 
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Demand side barriers include low levels of awareness of PLWD on the need for DR 
screening and failing to take up the appointment, especially if they did not have 
symptoms.43  This delay or refusal to take up screening services even when they are 
available has been noted in the literature on diabetes care in LMICs.38 It points to a level 
of screening hesitancy (delay in acceptance or refusal of a service despite its 
availability), mostly associated with lack of awareness, low perceived risk of DR or 
perceived inconveniences of screening services or undervaluing of the services.  This 
suggests a need for PLWD education about DR and its treatment as well as research on 
effective strategies for risk communication. 
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Figure 3-6: DR screening rate in different categories of diabetes clinics                            
Eye clinic 
Strengths: There are written information brochures on DR, which are provided for PLWD 
and general health care providers. Opportunistic screening services and case finding for 
symptomatic PLWD are available at the static eye clinics and outreach eye care camps 
on a walk-in basis. Tertiary eye clinics have a retina clinic at least once a week. There is 
no waiting list for screening in any of the eye clinics. There are waiting lists for laser 
photocoagulation in some clinics, but the waiting time is only one week.  
Weaknesses: Eye care services are underutilized by asymptomatic PLWD. This is 
paradoxical, since screening services provide significant benefit for early detection of 
DR.44 Most of the PLWD attending diabetes services do not attend the eye clinic for 
screening, because of the demand side and supply-side barriers highlighted above. 
There are missed opportunities for screening at the eye clinics as well, mainly attributed 
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countries, patients with DR present late when they have advanced DR and vision loss.45
The eye clinics do not engage with the DSGs. 
Opportunities  
Service provider and key informants suggested the need to integrate diabetes and DR 
services to improve service coordination on the long-term. The rationale for this 
integration is discussed in research paper 2. Previous studies have identified a positive 
association between different integrated models of care and diabetes outcomes.5
Progress with such integration will require time and capacity development across the 
system.  
National DR Guidelines are needed to ensure services are available to PLWD, and that all 
actors in eye health services for PLWD speak from a common guideline. There are 
opportunities for peer-led education on diabetes eye health in the community and for 
engaging DSGs to link PLWD with eye clinics for DR screening. These interventions will 
be discussed in subsequent chapters of this thesis.  
Health workforce 
Community 
Strength: Community health volunteers (CHVs) link community members with primary 
care facilities, for instance for testing for diabetes. Peer supporters in DSGs carry out 
health education and link PLWD with diabetes clinics, which is a form of task shifting. 
Previous studies have identified task shifting as a successful intervention in some parts 
of SSA, which has potential to influence diabetes care.5, 45
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Weakness: The peer supporters and the CHVs are not trained to provide education on 
the component of diabetes eye health, resulting in low heath literacy on this aspect. 
Diabetes clinic
Strengths: All clinics have a multidisciplinary team available, including a physician, 
diabetes educator, pharmacist, nurses, nutritionists, records clerks, medical officers, 
clinical officers and social workers. PLWD are referred to additional specialists such as 
surgeons based on need. Most of the team is trained locally, though some have foreign 
training. This is important because multidisciplinary care is a facilitator for effective 
diabetes care within a chronic care model.5, 46 The extent to which the different cadres 
provide care as a coordinated team rather than separately is uncertain. This is an 
important area for research — as diabetes care by uncoordinated specialists may 
overwhelm both health workers and PLWD, given its effect of increasing workload.34
Weaknesses: The number of health workers is inadequate for the population, and the 
distribution is generally skewed in favour of Nairobi. Table 3-2 provides an example of 
the distribution of physicians and diabetes educators. Service providers identify limited 
training as a major hindrance to providing services, coupled with frequent transfers of 
trained workers. This points to the need for effective and constantly available training 
opportunities.38, 45
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Strengths: The eye care workforce includes ophthalmologists, ophthalmic clinical 
officers and ophthalmic nurses, mostly trained in two training institutions in the 
country. These cadres provide service delivery but also have roles as educators, 
administrators and researchers. 
Weaknesses: There are no optometrists, patient counsellors, equipment maintenance 
technicians or records clerks in most of the public service eye clinics. There is only one 
equipment technician at the Ophthalmic Services Unit, and another at one tertiary 
hospital, which leads to delays in equipment repairs. The eye care workforce is 
insufficient in number and distribution, as in other LMICs.47, 48 Table 3-3 shows the cadre 
to population ratio. The training capacity of the training institutions is insufficient to 
meet the needs. Although the pre-service training is perceived as high quality, the lack 
of opportunities for continuous professional development especially regarding eye care 
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for PLWD is a major hindrance to service delivery. Thus the capacity of both individuals 
and institutions influence the service delivery.42
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Empowering peer supporters in DSGs to deliver education on eye health to PLWD may 
be a useful form of task shifting, given the workforce shortage. An integrated open-
access training program for diabetes and eye heath workers may address the need for a 
training program that is flexibly available.   
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Health Management Information Systems (HMIS) 
Community
Strengths: DSGs keep paper-based records of PLWD, recording sociodemographic 
details, comorbidity with hypertension and the measurements taken at every DSG 
meeting: blood sugar, blood pressure and weight or body mass index (BMI). PLWD keep 
a copy of this data (patient-held records). 
Weaknesses: The data collected is not shared or used to inform services beyond the 
DSG. There is no system of risk factor surveillance, which is an important target for 
countries looking to improve their health system performance for diabetes.49
Diabetes clinic 
Strengths: There is a gradual shift from paper-based records to electronic records, 
though currently both forms are used. Aggregate facility data (such as numbers 
attended) is transmitted to the national HMIS system.  
Weaknesses:  Individual PLWD do not have access to the comprehensive medical record 
from the diabetes clinics. There is no diabetes registry with call and recall mechanism 
and there is no way of tracking the movement of PLWD along the care pathway. The 
Chronic Care Model recommends that HMIS systems foster the formation and use of 
diabetes registries, to enhance access to clinical data, patient engagement and 
generation of evidence.46, 50, 51 The facility and county data is not used for decision-
making at the local level. Without complete electronic medical records (EMR), it is 
difficult to use the HMIS to track inputs and outputs such as medicines used, to avoid 
stock-outs.45, 46 The data transmitted to the national HMIS is mainly workload data, and 
some facilities do not submit this data, which limits the use of the data. 
Eye clinic 
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Strengths: Sociodemographic and clinical data is collected at the eye unit mainly using 
paper-based systems.  
Weaknesses: Individual PLWD do not have patient-held records. Indicators for DR, such 
as number screened for DR are not reported. There is no mechanism for tracking PLWD 
who have been screened, referred or treated, and most clinics do not have 
infrastructure for capturing and storing retinal images.  There is no surveillance system 
for DR. The data collected also has missing/incomplete information, as most eye clinics 
do not have a trained and dedicated records officer. Training the people entering data 
to also analyse it and present it can improve the performance.52
Opportunities:  
There is a need to develop a diabetes database to provide longitudinal information on 
individual PLWD. The HMIS system should alert the provider to the needed tests and 
provide tracking. Given the mobile phone penetration of about 77% in Kenya, mhealth 
interventions such as patient reminders through short message service (SMS) would be 
useful for scheduling follow-ups or educating PLWD.53
Health Financing 
Community:  
Strengths: In some counties, public-private partnerships (PPPs), such as the ‘base of the 
pyramid program’ by Novo Nordisk have helped to stabilize the cost of insulin at about 
$5 per vial of Mixtard insulin, compared to $18 in other counties. This is because they 
supply the insulin at subsidized cost to some facilities, introducing competition among 
retail suppliers, and hence prices come down. 27
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Weaknesses: Less than 20% of the population has any form of insurance coverage, 
which implies that a correspondingly small proportion of PLWD have insurance.54 DSGs 
have not been adequately sensitized on the need for PLWD to register with the national 
hospital insurance fund (NHIF), the largest provider of health insurance. Comorbidity 
with hypertension or depression increases the financial burden on PLWD.55 In addition, 
the transport burden is high for patients in rural areas, which may impede access to 
services.27, 56 The other weakness is that peer supporters and CHVs work on a volunteer-
basis, but the community is responsible for keeping them incentivized. This often 
involves a form of payment in kind, but this is largely invisible and unaccounted for in 
the health financing indicators. The sustainability of PPPs, as mentioned above, is in 
doubt, since they are not integrated within national plans.27
Diabetes clinic:  
Strengths: NHIF covers some of the costs for laboratory tests and treatments for 
diabetes, within the chronic disease package of care.57 Some commodities and services 
are available at subsidized cost, due to PPPs mentioned earlier.27 There is a centralized 
payment system at each health facility for financial accountability. 
Weaknesses: Most of the services have to be paid for at the point of care (out of pocket 
payment) as only a small proportion of PLWD have NHIF, mainly those in formal 
employment. This means that the unemployed PLWD are more likely to suffer financial 
barriers to access, leading to inequity. In addition, some of the services are not available 
at the diabetes clinics, and have to be sourced from external pharmacies and 
laboratories, at a high cost.57 Further, only 40% of health facilities in the country are 
covered by NHIF, hence PLWD attending facilities outside this network have to pay for 
services out of pocket.54
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Eye clinic 
Strengths: The cost of screening is included in the consultation fee at the eye clinic, 
hence there is no extra cost to the patient requiring DR screening. NHIF has recently 
expanded coverage to include treatments for DR: laser, anti-VEGF and vitrectomy. This 
incremental coverage has resulted from lobbying by interest groups especially the 
Ophthalmologic Society of Kenya, as has been the experience of other countries.58 Some 
of the outreach screening programs provide transport for PLWD so that they can obtain 
treatment at static eye clinics. This innovation to reduce the transport burden is in 
keeping with the delivery support element of CCM.34
Weaknesses: A consultation fee is paid out-of-pocket for each clinic visit, with PLWD 
attending both diabetes and eye clinics having to pay a double fee. Most PLWD present 
to the eye clinic late, when DR is advanced, yet the cost of treatment would be lower if 
DR is detected and treated early.7, 59 Without NHIF cover, PLWD have to pay for 
treatment out of pocket. The financial burden for DR treatments is considerable, 
reflecting that universal health coverage has not yet been achieved.57, 60 On the other 
hand the sustainability of financing UHC through NHIF is doubtful, given that the current 
premium rates are quite low (averaging 2.4% of gross pay for formal sector workers) 
and yet the benefit package is very generous.61 The country is currently facing these 
sustainability concerns. 
Opportunities 
CHVs and DSGs can be instrumental in ensuring that their members are registered with 
NHIF, if they are adequately sensitized. 
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Medicines and health technologies 
Community 
Strengths: DSGs have glucometers and blood pressure machines and sometimes they 
have some drugs at subsidized cost. There are some mobile phone applications for 
health promotion, such as Afya Pap, but their use among PLWD has been limited to a 
pilot project in Nairobi, perhaps because the highest coverage with mobile phones is in 
urban areas.53, 62
Weaknesses: Technology to aid lifestyle modification such as wearable devices are not 
commonly available. Most PLWD do not have devices for home glucose monitoring. 
DSGs have the devices for group use but often run out of strips for testing blood 
glucose. PLWD have difficulty obtaining insulin syringes, as they sometimes have to buy 
them in private pharmacies. This is of concern because it limits glycaemic monitoring 
and increases the risk of complications.  
Diabetes clinic 
Strengths: Access to diabetes medicines is facilitated by two main factors. Firstly, the 
Essential Drugs List for county hospitals includes key medications, such as insulin and 
metformin. Secondly, some clinics have insulin at subsidized cost, through arrangements 
with stakeholders in the supply chain management, such as Novo Nordisk, the 
International Diabetes Federation, the Changing Diabetes in Children program, Medicins 
Sans Frontieres, and distributors of drugs. 
Weaknesses: Clinics experience shortages of drugs at different points in the year, mostly 
due to procurement delays.  As the cost of diabetes medicines is unaffordable to many 
PLWD, non-adherence is likely to result.45, 57 Clinics sometimes run out of glucose test 
strips, and most of them do not offer HbA1c testing.  
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Eye clinic 
Strengths: Treatment services (laser photocoagulation) for DR are available in at least 
one facility in most counties. 
Weaknesses: Eye clinics sometimes run out of supply of mydriatic drugs. Anti-VEGF is 
not routinely available in government clinics, hence PLWD are asked to buy it and bring 
it for injection. This negatively affects compliance with anti-VEGF treatment. The multi-
dose vial of anti-VEGF is expensive, and can lead to drug wastage. 
Opportunities: The use of artificial intelligence and telemedicine in DR screening has 
been tested in research settings, but is not yet applied in routine use.63 There is 
potential for automated AI-based grading systems to improve efficiency in DR screening. 
Governance 
Stewardship for diabetes care is under the auspices of the Division of Non-
Communicable Diseases (NCDS) of the Ministry of Health. There is a comprehensive 
national strategy for the control of NCDs 2015-2020 which is actively used.64
Community 
Strengths: The Kenya Defeat Diabetes Association, a civil society organization 
responsible for the DSGs, is strongly engaged in advocacy with the government and 
other stakeholders at national level, such as the Diabetes Management and Information 
Centre, Diabetes Kenya Association, World Diabetes Federation, and International 
Diabetes Federation. These stakeholders, coordinated by the Division of NCDs, mobilize 
communities and schools for events such as annual diabetes walks, community 
screening and health promotion activities especially around annual advocacy weeks. At 
facility level, local health committees provide a forum for community participation in 
governance. 
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The national strategy for control of NCDs includes a strategic objective on implementing 
legislation regarding the content of processed foods and drinks (refined sugar, salt, 
saturated and trans fats), as well as the labelling and marketing of these products.64
Another strategic objective in the strategy relates to implementing economic incentives 
for encouraging consumption of healthy foods, such as taxes and subsidies.64
Weaknesses: The component of eye health is often missing in the health promotion 
program. Action on the social and economic determinants of health, such as 
engagement with the agriculture, food industry and urban planning sectors has been 
challenging, as has been enacting legislation on processed food products, because these 
require lengthy political processes. 
Diabetes clinic 
Strengths: There is a national diabetes strategy, albeit it requires updating.36  The 
Ministry of Health has a focal person for NCDs in each county who provides leadership. 
The NCD division is in the process of establishing some diabetes clinics as centres of 
excellence for diabetes care in children. Diabetes services actively engage DSGs, non-
governmental organizations (NGOs), and pharmaceuticals as stakeholders. 
Weaknesses: The NCD and diabetes strategies do not include eye health. The strategies 
are not available in some of the diabetes clinics outside Nairobi, which hinders their use, 
though they have potential to improve diabetes care.46, 65 The diabetes strategy does 
not provide guidance on managing prediabetes, and most of the people with 
prediabetes do not attend diabetes clinics. Although there is a focal NCD lead, 
coordination between public, private-for-profit and private-not-for-profit actors is 
challenging as they have different lines of accountability. In addition, the role of the 
focal NCD lead in fostering implementation of the chronic care model is not explicit. 
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Eye clinic 
Strengths: The national level has strong links with professional associations, academia, 
NGOs and other sectors besides the Ministry of Health. Decentralisation of governance 
to county level has increased efficiency, for instance in procurement of supplies. Each 
county has a focal eye care person who provides leadership. Some non-governmental 
organizations such as the Fred Hollows Foundation and Operation Eyesight Universal 
support DR services in some counties. 
Weaknesses: There is no long-term strategy for control of DR, and no national guidelines 
for DR. There have been several attempts to develop the guidelines in the past, but the 
process was not completed. A recent systematic review identified clinical guidelines as 
one of the interventions that have improved diabetes care in SSA.38, 45 This might be 
because guidelines articulate a consistent set of priorities and attract stakeholder 
support.42
Opportunities 
The upcoming updating of the diabetes strategy is an important window of opportunity 
to include eye health in the strategy and to implement CCM in diabetes care. Leveraging 
on the stakeholder support can facilitate the development of clinical guidelines for DR. 
Infrastructure 
Community 
Strengths: DSGs can use public facilities, such as bus parks, churches or schools for 
outreach screening camps.   
Weaknesses: There is no infrastructure and equipment for screening for DR at the 
community level.  
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Diabetes clinic 
Strengths: In a few facilities, diabetes clinics and eye care clinics are located within the 
same building. This proximity is advantageous for linking PLWD to the two services. One 
diabetes clinic in Nairobi has a retinal camera for DR screening, facilitating screening at 
the point of diabetes care.14
Weaknesses: Often the clinics are in separate buildings and do not have sufficient space 
hence they are over-crowded. Equipment inventories are not regularly done. Most 
clinics reported that the equipment was insufficient, reflecting suboptimal infrastructure 
for diabetes.40, 41
Eye clinic 
Strengths: Some of the eye clinics have renovated buildings and vehicles provided by 
partners, especially NGOs. 
Weaknesses: The equipment for screening is insufficient, and most eye clinics do not 
have retinal cameras. There are not enough treatment facilities including space and 
equipment for laser, as well as theatre for vitrectomy or administration of anti-VEGF. 
Some of the equipment such as lasers and vitrectomy machines are broken down and 
not functional. Spare parts are often unavailable locally.  
Research 
Community 
Strengths: Previous population-based research includes epidemiologic studies such as 
the STEPS survey66 and the Nakuru cohort study.63, 67-70 Some studies have investigated 
access to medicines.27, 71 Kenya has adopted risk factor surveillance based on the 
STEPwise approach. 
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Weaknesses: Public engagement and dissemination of research to rural communities is 
insufficient. 
Diabetes clinic 
Strengths: There are strong national research partnerships, such as the Kenya Diabetes 
Research Group. The types of research that have been done include operational 
research and epidemiological studies. A recent study has examined the cost of diabetes 
care to the patient.57
Weaknesses: Most of the research is quantitative, and there is a need for more 
qualitative research, for example on patient-related outcomes such as quality of life and 
treatment burden. Appraising the evidence is not systematically performed, and it is 
unclear how much this research has been used to inform policy and practice. 
Eye clinic 
Strengths: There is a national DR working group coordinated by the Ministry of Health, 
which is interested in collating all the research on DR and conducting collaborative 
research. There is a strong link between the national level and research institutions, 
both local and international. Some studies have investigated the effectiveness of a DR 
screening program,72the use of telemedicine,73 and the use of AI in DR screening.63 The 
most recent Kenya Demographic and Health Survey (KDHS) has included data on visual 
impairment.74
Weaknesses: The research conducted does not include patient-related outcomes. There 
is a shortage of skills in implementation research.  
Opportunities 
The research endeavours should contribute to developing local research capacity as 
robust research can provide evidence to improve DR services.  
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There is a need for research that focuses on the experience of patients along the care 
pathway and patient-related outcomes, such as financial protection.  
3.7 Synthesis of gaps and strengths 
Although there are some differences between the counties, the findings revealed gaps 
in health systems in all the counties, suggesting the need for health system 
strengthening (HSS) in the country. Both supply-side and demand-side barriers lead to 
gaps in access and continuity of care.  There is low access to both HbA1c and DR 
screening. As DR is asymptomatic, without screening there are long delays before 
detection and treatment, with worse health and cost outcomes.  
Three key strengths of the health system should be harnessed. First, there are 
community resources such as DSGs whose task profile can be expanded to include 
educating PLWD on eye health and linking them to screening services. Second, there is 
high stakeholder support for strengthening services. Third, key informants and service 
providers recognize the need to foster collaboration between diabetes and DR services, 
and they could provide support for collaboration and integration.  
3.8 Priority-setting – health system strengthening  
The results of the health system assessment were shared with the national DR working 
group. Taking consideration of the main gaps, and the strengths, as well as the 
resources available, the DR working group prioritized two HSS actions:  
(a) the development of national clinical guidelines for diabetic retinopathy 
(b) the development of a flexible training program on eye health for DR  
Guidelines were considered a priority because they would influence multiple interacting 
factors to improve services, such as mobilise resources for DR, strengthen a referral 
system and provide a quality assurance mechanism for DR services. Guidelines would 
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also have long-term effects. Training was considered important because health workers 
identified it as a need. These HSS activities are discussed in chapter 5 and 6 of this 
thesis. 
3.9 Priority-setting- Intervention to improve access to DR screening  
DR screening is the entry point to DR services, and since attendance at screening is low, 
increasing the attendance at screening is a priority. The HSS action points above target 
the supply-side barriers to screening. It is unclear whether a peer supporter-led 
intervention within DSGs can help to address the demand side barriers and increase 
demand for screening. A clinical trial to test the effectiveness of this intervention was 
designed with input from stakeholders in diabetes and DR care. As Kirinyaga county has 
the lowest uptake of DR screening, and the most active DSGs among the three counties, 
it was selected for this intervention. Additional information on DSGs is provided below, 
while Chapter 7, 8 and 9 of this thesis describe this clinical trial. 
Diabetes Support Groups 
The Kenya Defeat Diabetes Association (KDDA) is a not-for-profit civil society 
organization that brings together the DSGs in the country. It has a national and county 
level governance structure and works in partnership with the Ministry of Health, 
particularly the Division of Non-Communicable Diseases. KDDA trains peer educators, 
mobilizes resources for DSGs (glucometers, glucose test strips, blood pressure machines, 
weighing scales, stationery), and organizes community diabetes screening camps. These 
activities are funded by partners such as Non-Governmental Organizations that work 
with the county health services. KDDA also engages in advocacy for improved access and 
quality of services at the facility, county and national level. 
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PLWD become aware of DSGs through community events such as health talks and 
announcements provided at various meetings – at village barazas (public meetings), 
places of worship, women’s groups, door to door visits by community health volunteers 
and community diabetes screening camps. Peer educators also give health talks at the 
diabetes and nutrition clinics in health facilities, and recruit PLWD to join DSGs. 
A DSG is established when at least 15-20 PLWD in a particular location have been 
recruited and two DSG leaders (1 male, 1 female) have been selected from among them. 
The target size of DSGs is 50-100 PLWD. Formal membership status is obtained by 
payment of a one-off requisite fee (Ksh 1500, $15), upon which one receives a KDDA 
membership card. However attendance and participation in DSG activities is open even 
to those who do not have formal membership status. DSGs meet once a month at a 
designated venue agreed on by the group e.g. at a church, school, market or health 
facility. The activities at the meeting include health talks by peer educators, 
measurement of weight, blood pressure and blood glucose. PLWD pay Ksh 100 ($1) at 
each meeting to support the purchase of resources such as glucose test strips. 
The role of the DSG leader is administrative – organizing the DSG meetings, stewardship 
of DSG resources and linking the DSG with county and national leadership of KDDA. The 
DSG leaders are volunteers and do not receive formal training for that role. Peer 
educators on the other hand are trained by KDDA to deliver health talks on self-
management, and to provide group/ individualized peer support; they also are 
volunteers.  In some DSGs, one individual has the dual role of leader and peer educator. 
Being volunteers, they do not receive formal remuneration for their work, and the DSG 
activities are not expected to interfere with their usual economic activities.  
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Chapter Four: Additional findings from health system assessment 
4.0 Overview 
This chapter includes two results papers. Research paper 1 is on the predictors of uptake of DR 
screening (DRS). This paper has been included since it describes the barriers and enablers for 
screening in the specific context of PLWD in Kenya. These results provide the basis of thinking for 
developing the interventions described throughout the rest of the thesis. 
Research paper 2 is on the rationale for integration of diabetes and DR services, as proposed by 
key informants and service providers who participated in the health system assessment. The 
health system context influences the nature, extent and success of integration. This paper has 
been included because it provides evidence on how integration might be implemented and 
includes a contextual framework that may be generalizable to similar settings.   
4.1 Research paper 1 
Preamble
The barriers and enablers that influence the access and uptake of screening for DR among people 
living with diabetes (PLWD) are poorly understood, and there is little evidence on how these 
factors vary by context. Understanding the predictors for attendance to DRS is essential to refine 
strategies to improve access to DRS. There are no known studies which have looked at the specific 
predictors to attendance at DRS in Kenya, and this study addresses this gap. The evidence from 
this study has been used to inform the development of interventions to increase attendance at 
DRS, which are discussed in subsequent chapters. This paper was published in the journal BMC 
Tropical Medicine and Health in December 2017 after peer review. 
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4.2 Research paper 2 
Preamble 
The lack of linkage between diabetes services and eye care services for PLWD is a challenge for 
the health system in Kenya. PLWD in diabetes clinics receive diabetes care, largely without an eye 
heath component e.g. eye health education, screening or referral for treatment. PLWD attending 
eye clinics for DR care may receive services to address this ocular complication but without 
adequate attention to other aspects of diabetes management.  This limits the continuity of care 
for PLWD, who also have difficulty navigating the health system.  
To strengthen health systems and to achieve continuity of high quality care, some integration 
between diabetes and DR services is important. Experts recommend tailoring integrated care 
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interventions to the local context, which highlights the potential value of this paper’s focus on 
understanding integration of care within Kenya’s health system. 
The evidence presented in this paper is part of the results of the health system assessment for 
diabetes and diabetic retinopathy.  Integration of DR into diabetes services emerged as a key 
theme during interviews with key informants and service providers, as they described the factors 
related to lack of integration, ways to remedy the lack of integration, and the priorities for 
integration. 
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work through a Creative Commons attribution license that clearly states how readers can copy, 
distribute, and use their attributed research, free of charge. All of which helps make articles 
available to the widest audience, and contributes to the furthering of research in ways that would 
have seemed impossible two decades ago.  
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Predictors of uptake of eye examination in
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three counties of Kenya
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Abstract
Background: Diabetic retinopathy (DR) is a significant public health concern that is potentially blinding. Clinical
practice guidelines recommend annual eye examination of patients with diabetes for early detection of DR. Our
aim was to identify the demand-side factors that influence uptake of eye examination among patients already
utilizing diabetes services in three counties of Kenya.
Methods: We designed a clinic based cross-sectional study and used three-stage sampling to select three counties,
nine diabetes clinics in these counties and 270 patients with diabetes attending these clinics. We interviewed the
participants using a structured questionnaire. The two outcomes of interest were ‘eye examination in the last 12
months’ and ‘eye examination ever’. The exposure variables were the characteristics of participants living with diabetes.
Results: The participants had a mean age of 53.3 years (SD 14.1) and an average interval of 4 months between visits to
the diabetes clinic. Only 25.6% of participants had ever had an eye examination in their lifetime, while 13.3% had it in
the preceding year. The independent predictors of uptake were referral by diabetes services, patient knowledge of
diabetes eye complications, comorbid hypertension and urban or semi-urban residence.
Conclusions: We conclude that access to retinal examination for DR is low in all three counties. An intervention that
increases the knowledge of patients with diabetes about eye complications and promotes referral of patients with
diabetes for eye examination may improve access to annual eye examination for DR.
Keywords: Diabetes, Diabetic retinopathy, Eye examination, Access, Screening, Kenya, Sub-Saharan Africa
Background
Diabetes mellitus (DM) causes visual impairment and
blindness through diabetic eye disease, which includes
cataract and diabetic retinopathy. Diabetic retinopathy
(DR) is a progressive microvascular complication of dia-
betes. Approximately one third (34.6%) of people living
with diabetes (PLWD) have DR and 10% have sight-
threatening DR (STDR) [1]. The increasing magnitude of
DM and DR is a significant public health challenge [2,
3]. There is strong evidence for the cost-effectiveness of
screening for DR in prevention of blindness [4, 5].
There are several reasons why access to eye examin-
ation for PLWD in Kenya is important. First, the preva-
lence and magnitude of DM and DR is increasing. An
estimated 14.2 million people in the African region had
diabetes in 2015 [6]. This number is expected to increase
by 140% between 2015 and 2040 [6]. The greatest in-
crease is predicted to be in countries transitioning from
low to middle income, like Kenya. The prevalence of dia-
betes in the Kenyan population aged 20–79 years was
2.2% in 2015 [7]. This translates into 484,000 adults with
diabetes, of whom approximately one third have DR
(150,000–170,000) and 10% (40,000–50,000) have STDR.
Second, both DR and STDR are asymptomatic and
STDR can progress to blindness if not treated early [8–
10]. An eye examination of the retina through a dilated
pupil, usually annual, can identify those with DR who
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are at risk of developing STDR and needing treatment
[10, 11]. Third, treatment of patients who have STDR re-
duces the risk of vision loss [12–14].
The determinants of access to retinal examination are
complex and include both supply and demand factors [9,
15]. Understanding the demand-side factors facilitates
the development of targeted demand-side interventions
that reduce the barriers and support the enablers to in-
crease the uptake of eye examination. Several studies
have examined the use of eye care among patients with
diabetes in America, Asia, Europe, and Oceania [16–21].
Many studies in Africa have focused on access to eye
care for cataract but not DR [22–30]. In this paper, we
report on factors influencing the uptake of eye examin-
ation for DR in PLWD. We define this test as a retinal
examination through a dilated pupil conducted by an
eye care worker using either an ophthalmoscope or ret-
inal camera.
Research in context panel
Evidence before this study
We searched Ovid MEDLINE, Cochrane Library, and
EMBASE (2000–2016) using the terms ‘diabetes’ and
‘diabetic retinopathy’ in combination with the following
terms: ‘access’, ‘screening’ and ‘eye examination’. We also
searched cited references in articles identified by this
search strategy. The evidence is that uptake of annual
retinal examination is low in resource-poor settings
(Table 1). However, the predictors of uptake of retinal
examination have not been documented.
Added value of this study
We found the uptake of retinal examination among pa-
tients utilising diabetes services in three counties of
Kenya to be even lower than documented in other stud-
ies. Predictors of uptake of retinal examination were (a)
referral from diabetes services, (b) knowledge of diabetes
eye complications and (c) comorbid hypertension. About
half of the patients had the perception that a retinal
examination was not necessary in the absence of ocular
symptoms. Using this evidence, we present a conceptual
model on how to improve uptake of retinal examination.
Implications of all the available evidence
An intervention to reverse low uptake of retinal examin-
ation should include both health education and referral
pathway interventions. From our findings, the education
component should prioritize two aspects of knowledge:
(1) information on diabetes eye complications and (2)
information on eye examinations (importance and fre-
quency). The referral intervention should address bar-
riers to uptake of examination. These interventions are
potentially cost-effective and may also strengthen inte-
gration of diabetic retinopathy screening into diabetes
services.
This study was conducted when Kenya has just com-
pleted a STEPwise survey on risk factors for non-
communicable diseases and determined the prevalence
of DM. It could form the baseline from which trends in
uptake of retinal examination can be compared as preva-
lence of DM increases in the next decade.
Methods
Study setting
This study was part of a cross-sectional health system
assessment for diabetes and diabetic retinopathy. A
three-stage sampling process was used. Three counties
were purposively selected to represent different environ-
ments and populations within the diabetes belt in Kenya:
Kirinyaga (predominantly rural), Nakuru (semi-urban)
and Nairobi (urban). Three diabetes outpatient clinics
were selected in each county. A list of public, private
and faith-based clinics in each country was obtained,
and 1 clinic was selected in each category through ran-
dom sampling. In each of these nine diabetes clinics, 30
patients were selected by random sampling from the
PLWD attending the clinic on the day of interview. The
list of male and female patients was used as the













GV Murthy et al.
[35]
Country Kenya Tanzania Nigeria Kenya Indoneshia China Delhi, India 11 cities, India


































Not reported 15.3% 33.3% 7.4% Not reported
Screening rate
(ever)
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sampling frame, with a random starting point and a
regular sampling interval of between three and five de-
pending on the volume of the patients attending each
clinic. This procedure made it possible to recruit an
equal number of men and women. A minimum sample
size of 73 per county (thereafter increased to 90) was de-
termined based on the estimate that 5% of the popula-
tion of PLWD attending diabetes clinics have an annual
dilated eye examination, with the desirable degree of ac-
curacy set at 0.05.
The study followed the tenets of the World Medical
Association’s Declaration of Helsinki. The London
School of Hygiene and Tropical Medicine and African
Medical Research Foundation granted ethical approval.
All participants gave written informed consent.
Participants
Eligible persons included those 18 years of age or older,
known to have diabetes, resident in the county, receiving
services at participating outpatient diabetes clinics, and
willing to participate in the study. Non-residents in the
county and acutely ill patients were excluded.
The primary investigator and research assistants inter-
viewed the participants in English or Kiswahili using a
pretested structured questionnaire. Prior to data collec-
tion, the questionnaire was reviewed by local diabetolog-
ists, ophthalmologists and statisticians. A pilot test with
diabetes patients was conducted in two different diabetes
clinics within the study area (which were not part of the
study sample).
Participation was voluntary and participants did not re-
ceive any financial incentives. The questionnaire had four
broad categories of questions for PLWD: (a) sociodemo-
graphic characteristics, (b) experience with diabetes ser-
vices, (c) knowledge of complications of diabetes and (d)
experience with examination for complications of diabetes
(including DR). All subjects reporting previous eye exami-
nations were questioned as to whether the eye care worker
instilled eye drops to dilate the pupils before the eye
examination. This differentiated a regular eye examination
and a dilated eye examination.
Statistical analysis
STATA version 14 was used for data analysis [31]. The
study had two outcomes of interest: ‘eye examination in
the last 12 months’ and ‘eye examination ever’. Both
were dichotomous ‘yes’ and ‘no’ variables. The exposure
variables were characteristics of participants in relation
to living with diabetes.
Descriptive statistics were shown as counts and percent-
ages for categorical variables, and means and standard de-
viations for continuous variables. For each of the two
outcomes of interest, tests of crude association were per-
formed using chi-square tests for categorical exposure
variables and t tests for continuous variables. Univariate
logistic regression was used to identify exposure variables
that were predictors of uptake of examination in the last
year, and in analysing the ever had an eye exam outcome,
all logistic regressions were adjusted for age. Multivariable
analysis was performed using forward stepwise selection
where exposure variables with the lowest p value were se-
quentially added to the regression model, using a cutoff
for inclusion in the model of p < 0.05.
Role of funding source
The funders did not participate in study design, data collec-
tion, analysis, writing of the paper or submission for
publication.
Results
Outcome variables: uptake of dilated eye examination
Ninety participants were interviewed in each county (n
= 270). None of the participants declined to participate,
and data for all variables was collected for all partici-
pants. Only 25.6% (n = 69) had ever had fundoscopy,
while only 13.3% (n = 36) had been examined in the pre-
ceding year. The uptake of eye examination in other
resource-poor settings is shown in Table 1.
Exposure variables: participant characteristics
The mean age of participants was 52.3 years (SD 14.1,
range 25–88 years). Approximately 47% were male,
23.7% had a family history of diabetes and 37.4% had co-
morbid hypertension. The mean duration of diabetes
was 7.3 years (SD 5.5), and participants attend the dia-
betes clinic every 4 months (SD 1.5) on average. The
main reason for that frequency is the physician’s recom-
mendation. The other variables are shown on the first
column of Table 2.
Determinants of eye examination
Table 2 also shows the patient-level determinants for
fundoscopy. Only 24.4% had been referred from the dia-
betes clinic for a retinal examination, and 13.3% had
taken this examination (fundoscopy) in the last
12 months. Variables that had the strongest evidence of
an association with having had the exam in the last
12 months were (a) referral for an eye examination (p <
0.001), (b) knowledge of diabetes eye complications (p =
0.002), (c) comorbid hypertension (p = 0.02) and (d)
county of residence (p = 0.07) (Table 3). Participants re-
ferred for an eye exam had almost eight times the odds
of having attended an eye exam in the last 12 months
compared to those who had not been referred (OR 7.9,
95% CI 3.7–16.4, p < 0.001). Participants who had a
knowledge of diabetes eye complications had four times
the odds (OR 3.9, CI 1.6–9.1) of attending as those who
had no knowledge of eye complications. Hypertensive
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Table 2 Patient characteristics and association with eye examination
Variable Summary of participants
characteristics












Number (%) in each category 270 36 (13.3%) 234 (86.3%) 69 (25.6) 201 (74.4)
Number (%) by county 0.07 0.002
Kirinyaga 90 6 (6.7%) 84 (93.3%) 11 (12.2) 79 (87.8)
Nairobi 89 14 (15.7%) 75 (84.3%) 29 (32.6) 60 (67.4)
Nakuru 91 16(17.6%) 75 (82.4%) 29 (31.9) 62 (68.1)
Age (mean years, SD) 53.3 (14.1) 57.1 (11.7) 52.7 (14.4) 0.08 60.5 (13.8) 50.8 (13.4) < 0.0001
Sex (no. %) 0.7 0.5
Men 127 (47%) 18 (14.2) 109 (85.8) 35 (27.6) 92 (72.4)
Women 144 (53%) 18 (12.5) 126 (87.5)
Literacy 0.3 0.05
Primary or below 88 (32.8%) 13 (14.8) 75 (85.2) 30 (34.1) 58 (65.9)
Secondary 111 (41.4%) 11 (9.9) 100 (90.1) 21 (18.9) 90 (81.1)
Post-secondary 69 (25.8%) 12 (17.4 57 (82.6) 18 (26.1) 51 (73.9)
Occupation 0.4 0.014
Unemployed 70 (25.9%) 6 (3.6) 64 (91.4) 19 (27.1) 51 (72.9)
Low skilled 70 (25.9%) 9 (12.9) 61 (87.1) 14 (20) 56 (80)
Professional 90 (33.3%) 13 (14.4) 77 (85.6) 18 (20) 72 (80)
Retired 40 (33.3%) 8 (20) 32 (80) 18 (45) 22 (55)
Duration of diabetes (mean years, SD) 7.3 (5.5) 8.9 (4.5) 7.1 (5.6) 0.06 9.4 (5.5) 6.6 (5.3) 0.0002
Interval of diabetes clinic visits (months) 4.0 (1.5) 4.3 (1.3) 4.0 (1.5) 0.4 4.3 (1.4) 3.9 (1.5) 0.08
Referred for eye examination < 0.001 < 0.001
Yes 66 (24.4%) 23 (34.9) 43 (65) 47 (68.1) 19 (28.8)
No 204 (75.6%) 13 (6.4) 191 (93.6) 22 (10.7)) 182 (89.2)
Perceived level of glucose control 0.02 0.4
Very good 10 (3.7%) 0 10 (100) 2 (20) 8 (80)
Well 73 (27%) 17 (23.3) 56 (76.7) 23 (31.5) 50 (68.5)
Adequate 107 (39.6%) 9 (8.4) 98 (91.6) 24 (22.4) 83 (77.6)
Poor 68 (25.2%) 10 (14.7) 58 (85.3) 19 (27.9) 49 (72.1)
Very poor 12 (4.4%) 0 12 (100) 1 (8.3) 11 (91.7)
Diabetes in family member 0.8 0.6
Yes 64 (23.7%) 8 (12.5) 56 (87.5) 18 (28.1) 46 (71.9)
No 206 (76.3%) 28 (13.6) 178 (86.4)
Information on diabetes given at health facility 0.3 0.8
Yes 205 (75.9%) 30 (14.6) 175 (85.4) 53 (25.9) 152 (74.2)
No 65 (24.1%) 6 (9.2) 59 (90.8) 16 (24.6) 49 (75.4)
Knowledge of diabetes complications 0.4 0.9
Yes 103 (38.1%) 16 (15.5) 87 (84.5) 26 (25.2) 77 (74.8)
No 167 (61.9%) 20 (12) 146 (88) 43 (25.8) 124 (74.3)
Knowledge of diabetes eye complications 0.001 0.001
Yes 150 (55.6%) 29 (19.3) 121 (80.7) 50 (33.3) 100 (66.7)
No 120 (44.4%) 7 (5.8) 113 (94.2) 19 (15.8) 101 (84.2)
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individuals had twice the odds of attendance, compared
to those with normal blood pressure (OR 2.3, CI 1.1–
4.7). The PLWD in Kirinyaga (rural) were the least likely
to have had an eye examination in the last 12 months,
with PLWD in Nairobi (urban) having 2.6 times the odds
(CI 1.1–7.1) and PLWD in Nakuru (semi-urban) having
three times the odds (CI 1.1–8.0).
The main predictors for having ever had fundoscopy
included (a) referral for eye examination (OR 20.5, CI
10.2–40.9, p < 0.001), (b) knowledge of diabetes eye
complications (OR 2.7, CI 1.5–4.8, p < 0.001), (c)
county (p = 0.02) and (d) comorbid hypertension (OR
1.8 CI 1.0–3.1 p = 0.02). The PLWD in Nakuru or
Nairobi had three times the odds of attendance as
compared in Kirinyaga (OR 3.4, CI 1.6–7.5 and OR
3.5, CI 1.6–7.5) (Table 3).
There was strong evidence of association of having a
dilated eye examination (ever) with both increasing age
and duration of diabetes (p < 0.0001), but the effect size
was quite small, with the odds increasing by 1.1 times
each year (thus, 2.6 times every decade), Table 3. In mul-
tivariable analysis, (a) referral, (b) knowledge of diabetes
eye complications and (c) county of residence remained
independent predictors for fundoscopy. Referral and
knowledge of diabetes eye complications had the stron-
gest relationship with uptake of eye examination and
thus were included in the final multivariable analysis
model. Interaction between referral and knowledge of
Table 2 Patient characteristics and association with eye examination (Continued)
Variable Summary of participants
characteristics












Comorbid hypertension 0.02 0.04
Yes 101 (37.4%) 20 (19.8) 81 (80.2) 33 (32.7) 68 (67.3)
No 169 (62.6%) 16 (9.5) 153 (90.5) 36 (21.3) 133 (78.7)
Opinion on need for an eye examination P < 0.001 P < 0.001
No need 51 (18.9%) 1 (2.0) 50 (98) 6 (11.8) 45 (88.2)
Only for ocular symptoms 115 (42.6%) 15 (13) 100 (87) 27 (23.5) 88 (76.5)
Acceptable 80 (29.6%) 13 (16.3) 67 (83.8) 25 (28.8) 57 (71.3)
Already doing it 9 (3.3%) 5 (55.6) 4 (44.4) 9 (100) 0
Other opinion 15 (5.6%) 13 (13.3) 2 (86.7) 4 (26.7) 11 (73.3)
Table 3 Predictors of eye examination last 12 months
Variable Eye exam last 12 months Eye exam ever
OR (95% CI) p value OR (95% CI) p value
Demographic factors
Increasing age (every year) 1.2 (1.1–1.6) 0.08 1.1 (1.0–1.1) < 0.001
Male gender 1.1 (0.6–2.3) 0.7 1.2 (0.7–2.1) 0.5
County of residence (compared to Kirinyaga)
Nakuru 3.0 (1.1–8.0) 0.03 3.4 (1.6–7.5) 0.02
Nairobi 2.6 (1.1–7.1) 0.06 3.5 (1.6–7.5) 0.02
Education
Post-secondary education 1.1 (0.5–2.8) 0.8 0.7 (0.3–1.4) 0.3
Occupation (as compared to the unemployed)
Professional 1.8 (0.6–5.0) 0.3 0.7(0.3–1.5) 0.3
Retired 2.7 (0.9–8.3) 0.09 2.2 (1.0–5.0) 0.06
Duration of diabetes 1.1 (1.0–1.1) 0.06 1.0 (1.0–1.1) < 0.001
Referral for eye examination 7.9 (3.7–16.4) < 0.001 20.5 (10.2–40.9) < 0.001
Knowledge of diabetes complications 3.9 (1.6–9.2) 0.002 2.7 (1.5–4.8) 0.001
Comorbid hypertension 2.3 (1.1–4.7) 0.02 1.8 (1.0–3.1) 0.04
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diabetes eye complications was tested, and these
remained significant independent predictors (p < 0.0001).
As referral for examination (ever) was the stron-
gest predictor of uptake of examination, the vari-
ables associated with referral were analysed. The
main exposure variables positively associated with
referral (Table 4) were (a) increasing age (p <
0.0001), (b) longer duration of diabetes (p = 0.0005),
(c) knowledge of diabetes eye complications (p =
0.003), (d) positive opinion on need for an eye
examination (p < 0.001), (e) retirement (p = 0.01) and
(f ) residence in Nairobi or Nakuru (p = 0.03).
For the 109 (40.4%) who had knowledge that diabetes
causes complications, the complications that were of
concern were losing a leg 34%, kidney failure 31.2%,
stroke 22% and blindness 9%. Although 150 (55. 6%)
knew that diabetes can affect the eye, 18.9% of the par-
ticipants felt that there was no need for an eye
examination and 42.6% would only go for an examin-
ation if they developed ocular symptoms.
Discussion
The results indicated that both initiation and mainten-
ance of annual fundoscopy is low. This may be due to
the lack of systematic DR screening programmes in the
country. Similar findings have been documented in other
resource-poor settings (Table 1) [19, 20, 32–36]. The
findings can be generalised to examination for DR in
adult PLWD populations in Kenya since the study in-
cluded any PLWD above 18 years in three geographical
locations representing the rural-urban continuum within
the diabetes belt. The lowest uptake was in Kirinyaga,
suggesting that the macro environment in which PLWD
live is a determinant of uptake [15]. Referral by the dia-
betic clinic for an eye examination, positive opinion on
need for an eye examination and knowledge of diabetes
Table 4 Variables associated with referral for eye examination
Variable Referred Not referred p value
Number (%) in each category 66 (24.4) 204 (75.6)
Number (%) by county 0.03
Kirinyaga 15 (16.7) 75 (83.3)
Nairobi 30 (33.8) 59 (66.3)
Nakuru 21 (23.1) 70 (76.9)
Age mean years, SD 59.8 (13.3) 51.2 (13.8) < 0.0001
Sex N (%) 0.09
Male 37 (29.1) 90 (70.9)
Female 29 (20.3) 114 (79.7)
Occupation N (%) 0.01
Unemployed 17 (24.3) 53 (75.7)
Low skilled 13 (18.6) 57 (81.4)
Professional 18 (20) 72 (80)
Retired 18 (45) 22 (55)
Literacy N (%) 0.6
Primary or below 24 (27.3) 64 (72.7)
Secondary education 24 (21.6) 87 (78.4)
Post-secondary education 18 (26.1) 51 (73.9)
Duration of diabetes years: mean, SD 9.3 (5.4) 6.6 (5.4) 0.0005
Diabetes in family member N (%)
Yes 16 (25) 48 (75) 0.9
No 50 (24.3) 156 (75.7)
Comorbid high BP N (%)
Yes 31 (30.7) 70 (69.3) 0.07
No 35 (20.7) 134 (79.3)
Knowledge of diabetes eye complications N (%) 0.003
Yes 47 (31.3) 133 (68.7)
No 19 (28.8) 101 (84.2)
Mwangi et al. Tropical Medicine and Health  (2017) 45:41 Page 6 of 10
eye complications are the modifiable factors that were
positively associated with uptake of examination.
Sociodemographic attributes of patients were found to
affect uptake of examination. The heterogeneity by
county reflects geographic, social, cultural and/or eco-
nomic influences. Rural populations are known to have
low access to screening services [20]. This could be re-
lated (in part) to a rural-urban gap in awareness, re-
sources or empowerment [37]. Paksin-Hall et al. [38]
found income level, education level and health insurance
status to be important determinants of annual dilated
eye examinations, but these were not significant inde-
pendent predictors in this study.
In previous studies, increasing age was a predictor for
having an eye examination [39, 40]. In our study, the evi-
dence for this association with strong for eye examin-
ation ever (p < 0.0001) and weak for an examination in
the last year (p = 0.08). Although the effect size was
small, the findings of an association are consistent with
an increased likelihood of examination with age. Given
that the risk of developing DR increases with age, older
adults, more than any other age group, need to have
regular eye examination, and as the population is aging,
an expanding need for retinal examination in the coun-
try is predictable. Duration of diabetes is an important
predictor for incidence and prevalence of DR, [40–42]
so as more people live longer with diabetes, the need for
an annual eye examination will increase.
Gender was not a predictor of uptake of examination,
although there was very weak evidence that male gender
was a predictor for referral (p = 0.09). A positive family
history of diabetes was similarly not a predictor of up-
take of examination, which suggests that barriers to ac-
cess are not just at the individual level but also within
households [15].
Hypertension in PLWD was a positive predictor of up-
take of eye examination in this study, as also reported in
another study [19]. Comorbidity is known to increase
health care utilization in diabetes, [43] and hypertension
is a common vascular comorbidity [11, 33, 35, 37, 40].
Uncontrolled hypertension is a risk factor for develop-
ment of DR. There was weak evidence that PLWD with
hypertension were more likely to be referred (p = 0.07)
than normotensive PLWD, perhaps because the diabetes
is considered more severe. This association strengthens
the case for integration of eye care into non-
communicable disease care.
There was very strong evidence that knowledge of any
diabetes eye complication increases the uptake of exam-
ination (Table 3). Other studies have also found that
knowledge is a predictor for uptake of screening [19, 20,
42]. However, in this study, only 9% listed blindness as a
complication that they were concerned about. Another
finding in this study is that PLWD need knowledge
about the necessity and the frequency of eye examina-
tions. Nearly half (42.6%) of the participants thought
that DR screening should be symptom-led, which is a
misconception that can lead to delay in getting an exam-
ination and treatment resulting in visual loss. Educa-
tional messages need to be tailored to an awareness of
eye complications from diabetes and the need for dia-
betics to have the eyes examined once a year. This tallies
with the finding that the most frequently reported sug-
gestion for improvement given by PLWD was the need
for more information/education. Thus, there exists a real
opportunity for demand-driven health education.
Although there was strong evidence that knowledge of
diabetes eye complications is a predictor of examination,
there exists a gap between possessing this knowledge and
the uptake of examination. About 56% of PLWD knew
that diabetes causes eye complications, but only 25% of all
PLWD had ever received an eye examination. Similarly,
although approximately 25% were given a referral, only
13% had actually gone for the examination in the last year.
This suggests that there are additional factors besides
knowledge and referral that influence uptake.
The health belief model (HBM) is a widely used theor-
etical framework for understanding health behaviours
within public health. Weiss et al. have previously shown
that behavioural interventions can improve uptake of
eye examination [44]. Taking the predictors found in this
study into consideration, and using HBM as a theoretical
framework, we conceptualise that self-efficacy is on the
pathway between knowledge, referral and uptake of
examination (Fig. 1). Research has shown that health be-
haviours such as taking an eye examination are associ-
ated with self-efficacy. In turn, self-efficacy can be
increased in four ways: performance accomplishment,
vicarious experience, verbal persuasion and psycho-
logical cues [45]. We postulate that interventions that
increase knowledge, referral and self-efficacy can in-
crease uptake of eye examination. Our conceptual model
captures these different aspects (Fig. 1).
Only a quarter of PLWD had received a referral for
DR screening. Similarly, in other studies in China and
India, less than a half had been referred [19, 20], al-
though in one study in India, over 60% had a referral
[35]. We found that the strongest predictor for having
an eye examination was referral from diabetes services.
Participants already attend the diabetes clinic every
4 months because of the recommendation of the dia-
betes services. As there is no systematic DR screening
programme, a referral to the eye clinic is a crucial
bridge. These three visits a year are missed opportunities
for referral for eye examination. Lack of a diabetes pro-
vider’s recommendation has been documented as a bar-
rier in Germany [9] and Paraguay [42], diabetes services
being gate keepers to other services required by PLWD.
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Written communication from the patient’s ophthalmolo-
gist to the primary care provider has also been found to
increase adherence to future dilated eye examination
[46]. Conversely, as entry to the eye clinic in Kenya does
not actually require a formal referral note from diabetes
services, an intervention that empowers patients for
‘self-referral’ might increase uptake of the examination.
There was strong evidence that older people with dia-
betes, those with longer duration of diabetes and those
with a knowledge of diabetes eye complications were
more likely to be referred. There was evidence that
PLWD in Kirinyaga were less likely to be referred than
those in Nakuru or Nairobi. Interventions to strengthen
the use of clinical guidelines can ensure that all PLWD
get a referral for an annual eye check.
Limitations
This study has several limitations. First, as this is a
cross-sectional study, a temporal relationship cannot be
established between the predictor factors and the uptake
of screening. In addition, the association between the
variables is still subject to residual confounding by un-
measured variables such as distance from home to the
eye clinic, medical conditions such as depression, dis-
ability and membership of diabetes support groups. Self-
reported data was used and is prone to recall bias and
social desirability bias. Under reporting of health behav-
iours, such as the duration since the participant had the
last eye examination, may introduce information bias.
This is a clinic-based study and did not include PLWD
not attending diabetes services; however, we presume
that they would have an even lower uptake of screening
for DR.
Conclusions
There is poor compliance with recommendations for an-
nual eye examination among PLWD who have access to
diabetes services. An intervention targeted at motivating
adherence is essential. Such an intervention should em-
power PLWD to request/demand an eye examination
and strengthen knowledge, referral and self-efficacy.
The opportunity to increase uptake of eye examination
is also a valuable avenue for integrating diabetes care
and eye care. Programmes to increase awareness regard-
ing the importance of eye examinations can be com-
bined with interventions to improve blood pressure
monitoring and other aspects of diabetes management.
Implications
Our study has demonstrated the low uptake of screening
for DR by PLWD and described the attributes associated
with uptake of eye examination. Low uptake has adverse
effects at individual level and at the health system level
because of the associated increased risk of blindness
from DR. The low uptake highlights barriers in the link
between diabetes services and eye care services. There is
need to integrate screening for DR within the routine
diabetes services and to implement interventions to in-
crease uptake of screening.
Fig. 1 A conceptual model on how interventions to strengthen knowledge of PLWD, referral and self-efficacy can improve uptake of
eye examination
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Future work
As the burden of diabetes grows over the next decade,
there is a need to investigate the trend in uptake of an-
nual eye examination and to examine sustainable inter-
ventions that can maximise increase uptake for eye
examination. There is also need to investigate why there
is a lack of attention to DR screening among diabetes
clinicians and to evaluate the effect of providing them
with clinical decision-making tools such DR guidelines.
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Additional notes on methods reported in Paper 1 
The study was conducted in three counties that vary in size and demographic characteristics. Disproportionate equal allocation was used in 
sampling, with an equal number of facilities and participants being recruited for the study in each of the counties. Proportionate sampling was not 
feasible as we do not have the county-level data on prevalence of diabetes and distribution of PLWD which would be required to calculate the 
sample size in each county. 
Additional information on Table 2* in Paper 1 
*Mwangi, N., Macleod, D., Gichuhi, S. et al. Predictors of uptake of eye examination in people living with diabetes mellitus in three counties 
of Kenya. Trop Med Health 45, 41 (2017). https://doi.org/10.1186/s41182-017-0080-7 
Table 2*: Participant characteristics and association with eye examination 
Variable Sample 
statistics 
Retinal exam (last 12 months) Retinal examination (ever)
Had eye exam No eye exam P value Had eye exam No eye exam P value
Number (%) in each category 270 (100%) 36(13.3%) 234 (86.3) 69(25.6) 201(74.4)
Number (%) by county 0.07 0.002
Kirinyaga 90 6 (6.7) 84 (93.3) 11(12.2) 79(87.8)
Nairobi 89 14 (15.7) 75 (84.3) 29(32.6) 60(67.4)
Nakuru 91 16(17.6) 75 (82.4) 29(31.9) 62(68.1)
Age (mean years, SD) 53.3 (14.1) 57.1(11.7) 52.7(14.4) 0.08 60.5(13.8) 50.8(13.4) <0.0001
Age (median, IQR) 52(43-65) 56.5(49-65.5) 50.5(41-65) 61(51-71) 48(41-62)
Sex (no, %) 0.7 0.5
Men 127(47%) 18(14.2) 109 (85.8) 35(27.6) 92(72.4)
155 
Women 144(53%) 18 (12.5) 126(87.5) 34(23.8) 109 (76.2)
Literacy 0.3 0.05
Primary or below 88(32.85) 13(14.8) 75(85.2) 30(34.1) 58(65.9)
Secondary 111(41.4%) 11(9.9) 100(90.1) 21(18.9) 90(81.1)
Post-secondary 69(25.8%) 12(17.4 57(82.6) 18(26.1) 51(73.9)
Occupation 0.4 0.014
unemployed 70(25.9%) 6(3.6) 64(91.4) 19(27.1) 51(72.9)
Low-skilled 70(25.9%) 9(12.9) 61(87.1) 14(20) 56(80)
Professional 90(33.3%) 13(14.4) 77(85.6) 18(20) 72(80)
Retired 40(14.8%) 8(20) 32(80) 18(45) 22(55)
Duration of diabetes (mean 
years, SD) 
7.3 (5.5) 8.9 (4.5) 7.1(5.6) 0.06 9.4(5.5) 6.6(5.3) 0.0002
Duration of diabetes (median, 
IQR) 
6(3-7) 8(5-12) 6(3-10) 9 (5-13) 5(3-9)
Interval of diabetes clinic visits 
(months) – mean (SD) 
4.0 (1.5) 4.3(1.3) 4.0(1.5) 0.4 4.3(1.4) 3.9(1.5) 0.08
Interval of diabetes clinic visits 
(months) -median and IQR 
4 (3-5) 4(3.5-5) 4 (3-5) 4 (3-5) 4 (3-5)
Referred for eye examination <0.001 <0.001
yes 66(24.4%) 23(34.9) 43(65) 47(68.1) 19(28.8)
no 204(75.6%) 13(6.4) 191(93.6) 22 (10.7)) 182 (89.2)
Perceived level of glucose 
control 
0.02 0.4
Very good 10(3.7%) 0 10(100) 2(20) 8(80)
well 73(27%) 17(23.3) 56(76.7) 23(31.5) 50(68.5)
adequate 107(39.6%) 9 (8.4) 98(91.6) 24(22.4) 83(77.6)
Poor 68(25.2%) 10(14.7) 58(85.3) 19(27.9) 49(72.1)
Very poor 12(4.4%) 0 12(100) 1(8.3) 11(91.7)
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Diabetes in family member 0.8 0.6
yes 64(23.7%) 8(12.5) 56(87.5) 18(28.1) 46(71.9)
no 206(76.3%) 28(13.6) 178(86.4) 51(24.8) 155(75.2)
Information on diabetes given at 
health facility 
0.3 0.8
Yes 205(75.9%) 30(14.6) 175(85.4) 53 (25.9) 152 (74.2)
No 65(24.1%) 6(9.2) 59(90.8) 16(24.6) 49(75.4)
Knowledge of diabetes 
complications 
0.4 0.9
Yes 103(38.1%) 16(15.5) 87(84.5) 26(25.2) 77(74.8)
No 167(61.9%) 20(12) 146(88) 43(25.8) 124(74.3)
Knowledge of diabetes eye 
complications 
0.001 0.001
yes 150(55.6%) 29(19.3) 121(80.7) 50(33.3) 100(66.7)
no 120(44.4%) 7(5.8) 113(94.2) 19(15.8) 101 (84.2)
Comorbid hypertension O.02 0.04
yes 101(37.4%) 20(19.8) 81(80.2) 33(32.7) 68(67.3)
no 169(62.6%) 16(9.5) 153(90.5) 36 (21.3) 133 (78.7)




No need 51(18.9%) 1 (2.0) 50 (98) 6(11.8) 45(88.2)
Only for ocular symptoms 115 (42.6%) 15(13) 100 (87) 27(23.5) 88(76.5)
Acceptable 89(29.6%) 13(16.3) 67(83.8) 25(28.8) 57(71.3)
Already doing it 9(3.3%) 2 (13.3) 13 (86.7) 9(100) 0
Other opinion 15(5.6%) 36(13.3) 234 (86.7) 4(26.7) 11(73.3)
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Abstract 
Background: Good diabetes mellitus (diabetes) and diabetic retinopathy (DR) management 
depends on the strength of the health system, prompting us to conduct a health system 
assessment for diabetes and DR in Kenya. We used diabetes and DR as tracer conditions to 
assess the strengths and weaknesses in the health system, and potential interventions to 
strengthen the health system. In this paper, we report on the need and relevance of 
integration to strengthen diabetes and DR care. 
Methods: Using a mixed methods study design, we collected data from service providers in 
diabetes clinics and eye clinics in three counties, from key informants and we reviewed 
documents. 
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Results: There is interest in integration of diabetes and DR services to address discontinuity of 
care. We report the findings describing the context of integration, why integration is a goal and 
how these services can be integrated. We use the results to develop a conceptual framework 
for implementation. 
Conclusions: The principal rationale for integrated service provision is to address service gaps 
and to prevent complications of diabetes and DR. The stakeholder interest and the existing 
infrastructure can be leveraged to improve these health outcomes. 
Key Words: diabetes mellitus, diabetic retinopathy, non-communicable diseases, screening, 
integration, health systems, service delivery, Kenya, Africa 
Abbreviations 
DR  Diabetic Retinopathy 
DR NET  Diabetic Retinopathy Network 
KI  Key Informant 
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PLWD  People Living With Diabetes 
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WHO  World Health Organization 
161 
Introduction 
Integration of services is a strategy for improving the performance of health systems and 
achieving clinical outcomes. The World Health Organization’s (WHO) working definition of 
“integrated service delivery” is: “the management and delivery of health services so that 
clients receive a continuum of preventive and curative services, according to their needs over 
time and across different levels of the health system.”[1] This definition posits integration as a 
composite construct with continuity and quality of care being essential components. The aim is 
to provide services that meet the needs of the user: services that are not disjointed, that are 
easy to navigate and that provide a smooth link to specialist services, if required.[1, 2]  Although 
there is consensus on the desirable outcomes of integration, and its importance for universal 
health coverage in every country, the rationale and the operational models remain 
contextual.[3, 4]
Diabetes Mellitus (hereafter referred to as ‘diabetes’) is associated with the development of 
organ damage, leading to multiple morbidity. Providing care for people living with diabetes 
(PLWD) thus requires balancing diabetes management with management of its chronic 
complications. Diabetic retinopathy (DR) is the major ocular morbidity in diabetes, and there is 
strong epidemiologic evidence that its prevalence is increasing.[5, 6]  In common with other 
chronic diseases, the management of both conditions requires: promotion of healthy lifestyle, 
early detection, compliance to treatment, regular monitoring of treatment outcomes, and 
active involvement of the patient and family in the care. An integrated approach is an efficient 
and effective method of addressing inter-related chronic diseases.[4, 7, 8]  At present, diabetes 
and DR care are provided in diabetes and eye clinics respectively, with minimal collaboration 
between them. Given that the patient with DR also requires diabetes services, and the 
similarities in the approach to management, it is appropriate to explore the extent to which 
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diabetes and DR services provided in a comprehensive or integrated manner.[9]  This provides 
an opportunity to consider how integration would intersect with the need for specialist 
services. 
The literature on integration of diabetes services has largely focused on integration with HIV, 
tuberculosis and hypertension.[8, 10-12] The paucity of literature on integration with services for 
diabetic retinopathy services might be based on the assumption that these services are 
automatically integrated, since they are intricately linked. However, the point of entry into 
integration is often unspecified. Further, the interventions that should be integrated, and in 
which ways and by whom, is not explicit even in clinical guidelines. The evidence on what 
diabetes practitioners and eye care practitioners think of the integration, or of their 
professional relationship is also sparse.[13]
Proactive prevention and early detection of DR is an important best practice that is often 
missing in the services for PLWD. As this population has regular contact with diabetes services, 
this platform is a good entry point to bring DR services to where the patient is, or to link the 
patient to the eye service, where the DR services are. Innovative approaches such as 
integration can augment access, quality and continuity of care for PLWD. In this paper, we 
explore the interface between diabetes services and eye care services in Kenya, as an 




Study design and theoretical approach 
A mixed methods cross-sectional health system assessment for diabetes and diabetic 
retinopathy was conducted in three counties of Kenya, guided by the WHO’s health system 
building blocks framework and the tracer condition approach.[14],[15] The aim of focusing the 
assessment on diabetes and DR was to provide evidence relevant to services for the two 
conditions that may be missed in a general health system assessment. Both conditions meet 
the criteria for a tracer condition, Table 4-1. In line with the WHO framework, we defined a 
good service as one which delivers effective, safe, quality, personal and non-personal health 
interventions to PLWD, when and where needed, with minimum waste of resources.[16] In this 
paper we report on integration as a theme that emerged from interviews with key informants 
and service providers.  
Table 4-1: Diabetes and diabetic retinopathy as tracer conditions 
Criteria How diabetes and DR fit the criteria
Disease has a known epidemiology The epidemiology of both conditions globally, 
in SSA and in Kenya has been described 
Disease is well defined and easy to 
diagnose 
The definition and criteria for diagnosis of 
each condition is well-established 
Its prevalence in the population is 
large enough to enable adequate 
data to be collected 
Both population-based and clinic-based 
surveys have shown that the prevalence is 
sufficient to enable collection of data that can 
be used for planning services 
Its natural history is known, and it 
varies with the utilization and 
effectiveness of health care 
The natural history of  diabetes and DR 
including the predictors of the development 
of complications is known  
It requires specific treatment, in the 
absence of which functional 
impairment results 
Hypoglycaemic drugs and lifestyle measures 
are required for glycaemic control, and the 
treatments for DR have been described, 
without which visual impairment results 
Available and well-defined 
techniques of medical management 
exist for at least one of the 
Prevention, diagnosis and treatment apply to 
both diabetes and DR. Rehabilitation is 
provided for those who develop severe visual 
impairment and blindness 
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following: prevention, diagnosis, 
treatment or rehabilitation 
Sampling and data collection 
Kirinyaga (predominantly rural), Nakuru (semi-urban) and Nairobi (urban) counties were 
selected through stratified purposive sampling to represent these different regions within the 
diabetes belt in Kenya. Three health facilities providing outpatient diabetes services in each 
county were identified by simple random sampling from a sampling frame of the clinics. Two 
clinicians who provide diabetes services were interviewed (n= 3 counties*2 clinicians*3 
facilities=18). Three eye care workers providing services in the county were also interviewed 
(n=3 workers*3 facilities=9).  The primary investigator and research assistants interviewed the 
27 service providers at the clinics using a structured questionnaire with both closed-ended and 
open-ended questions. 
 The key informants were representatives of stakeholders in these services, who were familiar 
with the organization and delivery of healthcare at the national or at county level, with 
particular reference to diabetes and eye care, but whose principal role in the health system is 
non-clinical. The key informants (n=18) were identified using an initial sampling frame and 
subsequently through snowballing from those interviewed. These included eight health service 
managers, four NGO program leaders, four policy makers and two members of the umbrella 
PLWD body that represents patients. The primary investigator interviewed the key informants 
at their work sites or preferred locations.  Interviews lasted 45-60 min, were audio-recorded 
and extensive field notes were taken.  We also conducted document review of health system 
documents provided by the key informants and service providers. 
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We collected data at national level (key informant interviews) and county level (interviews with 
service providers, key informant interviews). The structured questionnaire and the topic guide 
had questions on the strengths and weaknesses of the health system for diabetes and DR, and 
potential interventions to strengthen the health system.   
Ethics  
The study was conducted according to the tenets of the World Medical Association’s 
Declaration of Helsinki. The London School of Hygiene and Tropical Medicine and African 
Medical Research Foundation (AMREF) granted ethical approval. All participants gave written 
informed consent. Participation was voluntary and participants did not receive any financial 
incentives.  
Data analysis 
Audio records were transcribed verbatim. All qualitative data (from interviews and documents) 
were analysed using thematic content analysis, guided by the theoretical frameworks.[17]  The 
primary investigator and a second independent coder read and coded the transcripts 
independently section by section, after agreeing on a coding structure. Where clarifications 
with participants were required, they were contacted by telephone.  The codes were then 
grouped together into subthemes. These were later collapsed into themes within the six 
building blocks of the health system, as well as within the areas of prevention, diagnosis, 
treatment, and rehabilitation. We reviewed themes repeatedly across all transcripts. 
Quantitative data and data from document review was summarized using descriptive statistics 
and summary tables respectively. Triangulation of different types and sources of data was 
useful for elaboration and providing complementary insights. 
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Results 
Characteristics of participants  
We interviewed 18 key informants and 27 service providers from diabetes services (n=18) and 
eye care (n=9). None of the participants invited declined to participate. Of the 45 participants, 
25 (56%) were male, the median age and duration of employment being 41 years and 15 years 
respectively. We examined 22 documents, which were strategies and strategic plans, reports, 
policies, published literature and meeting presentations related to diabetes and DR in Kenya. 
Integration as an emerging theme in participant interviews 
When the participants were prompted to discuss potential interventions to strengthen the 
health system for diabetes and DR, integration emerged as a dominant theme. Table 4-2 shows 
sample quotes within the integration theme.  
Table 4-2: Integration as a theme in the different building blocks
Leadership and Governance
We have been working very closely (with ophthalmic services) at national level…the 
next step is integration of diabetes eye care services into comprehensive diabetes 
services (Key informant, diabetes care) 
Our policies, which include DR care, fit into the NCD policies…but in practice they do 
not seem to work in an integrated way (Key informant, eye care)
Service delivery
We offer a wide range of services in the diabetes outpatient clinics…but there is a 
missing link with the eye services…you know, for the annual eye examination (Key 
informant, diabetes care) 
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Eye care services for DR are part of the wider community of diabetes services, and 
also part of  the wider community of eye care services (Key informant, eye care)
Human resources for health
We need integration of the training on comprehensive diabetes management…we 
have to integrate the eye component into it, and we have to integrate this training in 
the preservice curriculum of colleges and universities…this is actually a low-hanging 
fruit (Key informant, diabetes care) 
Nurses in the diabetes clinic and in the eye clinic should also be trained as trainers of 
trainers in diabetes eye care…they need to be part of the team (Service provider, eye 
care)
Medicines and health technologies
NHIF [National Hospital Insurance Fund] caters for the costs of inpatient care for 
both diabetes and diabetic retinopathy, now we need to include all tests and 
medicines for both conditions in this cover (Key informant, eye care) 
We value integration of  services,…it may help to ensure we don’t lose PLWD to 
informal services… we would not integrate herbal medicine into our services, but this 
is a cultural and social issue that cannot be addressed by us alone (Key informant, 
diabetes services)
Health Management Information System
Surveillance of chronic illnesses like diabetes and diabetic retinopathy is difficult. The 
solution is an integrated electronic medical records system (Key informant, diabetes 
care) 
Even though we do not use the same reporting system or software, it should still be 
possible for us to have access to relevant data from the diabetes system, and vice 
versa….we are not talking of a merger (Key informant, eye care)
Health financing
I would suggest that an integrated implementation framework be developed at the 
county level, and it should have a dedicated budget (Service provider, diabetes care) 
DR being principally a diabetes issue, we need to present the case for financing for 
DR by NHIF as part of diabetes services (Key informant, eye care) 
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Integration as envisaged in government policies and plans 
Integration is a key policy objective as reflected in a sample of the documents, Table 4-3. 
Possible integration with HIV, Tuberculosis and Malaria programs is envisaged, though how it 
should be done is not explicit. Integration of diabetes and DR is not mentioned.  
Table 4-3: Examples of concepts of integration in a sample of health system plans and 
strategies 
Kenya Health Sector Strategic and Investment Plan 2013-2017
The health sector will focus on:  
• Integrating health service provision tools, mechanisms and processes for 
responding to NCDs  
• Establishing screening programs at community level and in health facilities for 
major NCDs (Page 25) 
Kenya Essential Package for Health
Institutional screening for NCDs is one of the KEPH interventions for reversing the 
rising burden of NCDs. The services targeted are routine BP, routine BMI and blood 
sugar testing. 
Kenya National Strategy for the Prevention and Control of Non-Communicable Diseases 
2015-2020 
Several bottlenecks of NCD prevention and control have been identified and 
addressed in this strategy, including:  “Silo” nature of the health system with minimal 
opportunities of integrating NCDs in well-established public health care platforms 
like HIV, TB, family planning, maternal and child health. (Page 31 and 32) 
Strategic Objective 1 of the strategy: To establish mechanisms to raise the priority 
accorded to NCDs at national and county level…The interventions for this objective 
include integrating NCD prevention and control into policies across all government 
sectors.
Kenya National Diabetes Strategy (2010-2015)
The objectives of the Kenya diabetes strategy include: 
• To improve early detection for diabetes and its complications through screening 
• To network and integrate diabetes care with other national programs e.g. 
HIV/AIDS, TB and malaria     (Page 9) 
One of the activities in the resource mobilization strategy is: 
• Integrate diabetes prevention and control into the national and district health 
plans (Page 11)
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Kenya Service Availability and Readiness Assessment Mapping (SARAM) Report 2013
• General service readiness for provision of NCD services is 34% (for the KEPH defined 
NCD services) 
• There is an overall limitation on the availability of KEPH services contributing to 
reversing the burden of non-communicable diseases (Page 112-126)
Norms and Standards for Health Service Delivery 2006
Integration of care: Every contact with individuals, households and communities is 
used to ensure that a comprehensive set of defined services is made available. This is 
different from using “every opportunity to do everything”. (Page 4) 
How integration of diabetes and eye care services can be implemented 
Participants described a positive existing relationship between diabetes and eye care services 
in the context of DR, and envisioned a closer and newer way of ‘mutual accommodation’:  
In the DR NET [Diabetic Retinopathy network] program, we have worked very well as 
physicians and ophthalmologists (Key informant, diabetes service) 
Diabetes services need to accommodate us more, it seems that DR gets forgotten 
(Service provider, DR) 
We identified three points of emphasis regarding how the integration of the two services 
should be implemented. Firstly, is that DR should be integrated into diabetes services. This is 
because of the pre-requisite for a functional service, such as the diabetes services, to which the 
DR service can be integrated. Policy documents recognize that services should be integrated 
into existing well-established health services or programs, Table 4-3.   
Sometimes we forget the eye, because there are too many different things that have to 
be done for the patient… but we need to make sure it is not” (Service provider, 
diabetes) 
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We would like DR to be seen as a diabetes issue, not an eye care issue (Key informant, 
eye care) 
When we review the diabetes guidelines, DR will take centre stage (Key informant, 
diabetes service) 
Of the 18 key informants, 17 (94.4%) believed that DR services should be integrated with 
diabetes care. 61.1% of key informants (n=11) reported that diabetes services should lead in 
the integrated service because they have a stronger infrastructure and accessibility to PLWD. 
However, 33% of key informants (n=6) indicated that eye care infrastructure in some hospitals 
is stronger than the diabetes infrastructure, but diabetes services should lead the integration 
because they have a stronger reach to the PLWD. One key informant (5.5%) felt that the 
discourse on the relative merit of integration should not focus on the infrastructure but should 
strengthen links between the services. 
The second point of emphasis is that eye care workers have a role in enhancing care for 
diabetes care, as well as care for other non-communicable diseases:  
Using the eye examination, eye clinicians can monitor diabetes, and 
hypertension…because the finding of diabetic or hypertensive retinopathy is useful 
information (Key informant, diabetes service) 
Eye care workers should also ask patients about diabetes control (Service provider, 
diabetes)
Thirdly, both diabetes and eye care services need to work together: 
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I see that sometimes they {eye care services} will just examine the eye and not be 
interested in the medical management of the diabetes…we should all be seen to be 
involved with this (Service provider, diabetes) 
Those of us on the ground…we know that DR is being missed in diabetes services…I 
think we need to go to the diabetes clinic…get involved with diabetes and get to look 
into the eye (Service provider, DR) 
Key informants identified that referral and screening for DR might be strengthened through 
integration: 
Although we have links with diabetes services, there are unexploited opportunities to 
integrate DR, particularly screening, with routine diabetes services (Key informant, eye 
care) 
There is no follow up system so that even if a diabetes patient is referred to eye clinic 
and disappears, there is no system of follow up or feedback, as currently we work as 
separate services (Service provider, diabetes) 
Of the 18 diabetes clinicians, only one had received a patient referred from eye services in the 
preceding month, while four of the nine eye care clinicians had received a referral from 
diabetes services in the same period. This implies that cross-referral is ineffective; there are 
missed opportunities for referral or patients are lost in transit. Furthermore, none of the 
diabetes clinics had visual acuity charts or ophthalmoscopes, and none of the eye clinics had a 
functional glucometer, which shows there is a big role for referral. The lack of readiness of 
health facilities for provision of NCD services is also noted in the Service Availability and 
Readiness Mapping (SARAM) report, Table 4-3.  
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Benefits of integration 
We identified three main benefits of integration. First, integration can help to address service 
fragmentation, Table 4-3, as well as other gaps identified by participants, Table 4-4.  
Participants suggested that integration may provide opportunities for joint on-the-job training 
for staff, which is a priority because 12/18 diabetes clinicians and 4/9 eye care clinicians had 
not had a recent training update on DR and diabetes respectively. Secondly, participants 
suggested that integration might enhance continuity of care and increase awareness of DR 
among diabetes care providers.  Thirdly, participants also identified that integration can 
attenuate potential problems, such as conflicting clinical recommendations that confuse PLWD 
and staff. However, none of the participants suggested that integration would have an 
economic benefit. 
Table 4-4: Benefits of integration
Purpose of integration Why integration is required
1. To solve current gaps in care
Services are fragmented
Services are duplicated
Patients are lost between the diabetes clinic 
and eye clinic 
Patients do not get referred appropriately
No screening program for DR
Glycaemic control is not monitored
DR is not detected early enough
Staff in each service work in isolation
There are missed opportunities for adequate 
assessment 
Patients are not empowered for self-
management 
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2. To obtain benefits of 
integration 
To increase first contact of PLWD with eye 
examination 
To facilitate continuity of care
To increase staff awareness of DR
To provide follow up system for patients who 
are referred 
To increase the chances of timely detection 
rates of DR  
To increase coverage of DR screening
Eye care workers can monitor and report 
diabetes and comorbidities through an eye 
exam 
To emphasise health promotion
To improve equity by increasing access to 
services by the poor  
To avoid burdening the patient with multiple 
visits 
To have a platform for monitoring health 
outcomes 
To use the available resources for maximum 
benefit 
To have the two services ‘speak the same 
language’ 
To develop joint clinical guidelines and tools
To make the service user-friendly
3. To avoid potential problems
To avoid conflicting recommendations for 
patient care 
To avoid overloading the clinicians with 
different information 
Even patients who have a retinal image taken 
in the diabetes clinic will still need a 
comprehensive eye examination, this will be 
missed if there is no integration 
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To reduce the number of PLWD going blind 
from diabetes 
Steps towards implementing integration  
We found that the policy documents do not elaborate how integration should occur. However, 
the norms and standards document states that integration “does not mean ’doing 
everything’…”. This implies the need to establish the priorities. The participants identified four 
main priorities: referral (n=34), retinal screening for DR (n=23), patient monitoring (n=19) and 
patient education for self-management (n=16). Seven participants remarked that the 
interaction between diabetes and eye clinics must be continuous, particularly through 
bidirectional referral; otherwise, “integration will be ineffective”. Five participants indicated 
that the integration should be gradual, and preceded by a pilot. 
The inputs that will be needed to achieve integration were listed: joint planning, joint training 
of health workers on diabetes and DR, equipment for monitoring diabetes (glucometer, test 
strips), DR screening equipment, a database that includes both diabetes and DR, clinical 
checklists and guidelines. Key informants suggested that financing for the additional inputs and 
processes would be sourced from the government and partners. All diabetes clinicians 
indicated that they would be happy to have a retinal camera situated in their clinic, though 
they had space constraints. Six of the nine eye care service-providers were willing to hold 
regular outreach clinics to screen PLWD for DR. 
All participants concurred that they would have roles in the integration, which include; getting 
buy-in from all staff and administrators, facilitating or participating in joint planning, obtaining 
the resources and supporting implementation. Participants identified that integration should 
be led by the team leads in diabetes and eye clinics, and should prioritize strengthening 
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referral, metabolic control, self-management and screening for DR. Based on the findings in 
this study, we present a conceptual framework for integration, Figure 4-1, showing the inputs 
required to make integration feasible and the outcomes envisaged in successful integration. 
Discussion 
Integrated health systems have been promoted as a means to build a more effective, efficient 
and patient-focused health system that better meets the needs of the populations served.[4]
Integrated DR services can blur the boundary between diabetes services and eye care services, 
to create a shared repertoire and synergy for the investments made in these services. Such 
synergy is vital for strengthening the health system responsiveness to the rising burden of 
diabetes and DR.[7, 13] It can ensure equity by reducing the exclusion and difficulty in navigating 
the services by PLWD, since comprehensive diabetes care would include DR services. Further, it 
provides a unique opportunity to integrate primary, secondary (early detection) and tertiary 
prevention (treatment to prevent complications), Figure 1. This can lead to improved health 
outcomes and therefore more cost-effective use of health system resources by PLWD. For 
example, screening and detection of DR might improve adherence to self-management and 
optimal metabolic control, which would prevent additional complications of diabetes that 
require expensive treatment. 
The endorsement of integration in the health policies is relevant to its sustainability, because it 
implies long-term government commitment.[7] Integration of comprehensive diabetes care 
with HIV, tuberculosis and malaria services would entail investment at all levels of health care, 
as services for these communicable diseases are offered across the continuum of primary, 
secondary and tertiary care.  To ensure that comprehensive diabetes care includes DR, we 
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propose a service-level model of integration at the diabetes clinics and eye clinics, which are 
usually located at secondary and tertiary hospitals. This is expedient for three reasons. One, 
the resources for integration are already available at this level of the health system, where the 
two clinics are already functioning. This would avoid aggravating existing resource challenges, 
such as health workforce shortages.[18] Two, the integrated service removes the complexity 
that patients face while navigating the care pathway, and which often presents a barrier to 
access to DR services.[1, 19] Three, the integrated services includes specialist diabetes and eye 
care services, which shows that integration does not imply compromising specialist functions.[1, 
2] Such a fear can cause resistance by specialists, although this was not evident in our study.[1, 
19]
Furthermore, there was high level of interest on integration among all participants, which is 
likely to facilitate successful implementation of integration.  This is important because 
reluctance, opposition or lack of ownership by the service providers would lead to poor 
integration results.[20] In other studies, service providers have been concerned about the likely 
increase in workload.[11, 20] In this study, staff shortages, inadequacy of space for additional 
services, lack of equipment and weak referral linkages were identified as potential challenges 
but not as deterrent to the integration. Although we did not investigate the reasons for this 
enthusiasm, it might be because diabetes and eye care services target the same population 
(PLWD) and have a converging goal in relation to diabetic retinopathy (prevention of 
blindness).  It might also have resulted from several system antecedents:  (1) An ongoing pilot 
program of the DR NET hospital-twinning initiative, which is a link program involving both 
diabetes and eye care stakeholders, with the aim of strengthening DR services. (2) A recent 
national STEPwise survey for risk factors of non-communicable diseases, and (3) Sensitization 
of participants on DR as a potentially blinding condition. 
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The reasons for integration nominated by participants reflect the perceived differences 
between integrated and non-integrated care. The main impetus is local service gaps, such as 
fragmentation, and missed opportunities for early detection of DR or inefficiency and 
discontinuity of care, which concurs with the drivers cited in other literature.[2, 7, 10, 13, 20] These 
are typical  barriers to access to care that will be addressed through integration.[2] The 
necessity for integration has also been recognised in a previous study in Kenya.[13] Cost-control 
was not identified as the major driving force for integration in this study, unlike in other 
contexts.[19] However, integration is likely to reduce costs by reducing duplication of services 
and multiple client visits.[1, 12, 20] In addition, early detection or DR is a sound economic 
investment because timely treatment is cost-effective.[21, 22]This shows that the interest in 
integration among these participants was predicated on improved services outcomes and not 
as an end in itself. 
The conceptualisation of integration around screening is significant because Kenya does not 
have a systematic screening program for diabetes or DR.[13] It reveals an excellent opportunity 
to develop an effective screening program inclusive for all PLWD attending diabetes services. 
The bidirectional referral strategy shows the pertinence of organising integration as a process 
of mutual but not symmetric accommodation. It is not symmetric because the entry point is 
the diabetes services, which PLWD are already accessing even without integration; hence, it is 
the primary service. An excellent example of how synergy might be realised is that eye care 
workers can identify and monitor comorbidities. Ocular findings in hypertension, 
hyperlipidaemia, and other medical conditions may be the first sign of these diseases, and 
these can be identified during the screening examination. Medications used to treat these 
comorbidities might also have ocular adverse effects that can be identified upon ocular 
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examination. A comprehensive dilated eye examination can be a radar for detection or 
monitoring several comorbidities and medications. 
The integration could be operationalized through co-implementation of the key interventions, 
which are self-management, glycaemic control, DR screening and referral. This scope focuses 
on prevention of complications, rather than treatment.[23] Some integration models, such as 
sexual and reproductive health programs integrated into HIV programs, have focused on 
clinical services, such as testing or prescription of treatment, rather than lifestyle 
modification.[11, 24] Conversely, other integration models for diabetes, HIV and hypertension 
have emphasised adherence counselling for medication and lifestyle modification.[25] Still other 
models have included a mix of patient education and prescription of medications for PLWD.[10, 
26, 27]No method is inherently good or bad, the scope largely depends on the objectives of the 
two services.[1, 7, 8] Given the priority for diabetes and DR is to prevent progression or 
complications, bidirectional referral and health promotion approaches would be useful.[13, 21] In 
the event of future integration with HIV, Tuberculosis and Malaria programs, a treatment 
component may be added, since the main priority for these conditions is universal coverage to 
treatment for those eligible.[7, 27]
Several inputs are required: inter-professional collaboration, joint planning, clinical 
governance, training, clinical tools, database and equipment. This means that supply-side 
resources are required, and need to be allocated differently.[7, 13] Integration is not monolithic 
but encompasses all building blocks of the health system and hence requires resource 
mobilization. Given that integration cannot mitigate against lack of necessary resources or 
infrastructure, failure to invest in it would hamper the desired benefits .[1, 23] For example, the 
lack of a monitoring and evaluation component has been identified as a weakness in previous 
integration initiatives.[28] This being one of the first studies to discuss this context of 
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integration, we have proposed a conceptual framework for integration, which can be used by 
policy-makers for planning, Fig 4-1.    
What are the expected effects of integration? Investing in this integrated service delivery 
system creates distinct deliverables, such as increased demand for the specified services and 
reducing the unmet need for DR screening.[7], [12, 21]Integration should translate to prevention of 
complications of diabetes and DR, which is a widely agreed priority of health systems.[21] To 
monitor whether integration confers these benefits, an appropriate metric will need to be 
jointly determined. 
Our study has several strengths. Geographical variability (three counties) accentuated the 
external validity of the study. The inclusion of clinicians from both diabetes and eye care 
services, as well as patient representatives, enabled us to obtain unique perspectives of service 
providers. The data is subject to social desirability bias as the participants are directly involved 
in the services, however we used triangulation to mitigate this. This is the first study to 
document the interventions and the platforms for integration of these services in the region. 
The main limitation is the novelty of the concept of integration with respect to diabetes and DR 
but this shows that this health system is dynamic, and it may jumpstart the process of broader 
integration of diabetes services.  
Conclusion 
Integration, as envisaged in this paper, is relevant to the goals of the health system and 
congruent to the existing health system for diabetes and DR and to the broader health 
strategies in Kenya.  The purpose of integration is to address service gaps, ensure universal 
access to a range of services and prevent complications of diabetes and DR.  This is evidence 
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that the health system is not static in its response to NCDs, and integration may be applicable 
to other countries with similar health systems.  
Future research 
Further research is required to test and refine this empirical conceptual framework. The impact 
of integration on the following parameters will also need to be evaluated: performance of 
health workers, service utilization, patient satisfaction and cost of the services. The effect of 
integration on equity may be determined by disaggregating the health outcomes of PLWD by 
gender, social strata and other indices of vulnerability. 
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Health System Strengthening 
“Mosquito [...] had asked Ear to marry him, whereupon Ear fell on the floor in uncontrollable 
laughter. "How much longer do you think you will live?" she asked. "You are already a 
skeleton." Mosquito went away humiliated, and any time he passed her way he told Ear that he 
was still alive.” 
“You do not know me,’ said Tortoise. ‘I am a changed man. I have learned that a man who 
makes trouble for others makes trouble for himself.” 
“Eneke the bird says that since men have learned to shoot without missing, he has learned to fly 
without perching.” 
Prof Chinua Achebe 1930-2013 
Nigerian novelist, poet, professor of literature, and critic 
In his book ‘Things Fall Apart’ 
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Chapter Five 
Health system strengthening: Development of clinical guidelines 
for diabetic retinopathy in Kenya 
5.0 Overview 
Multiple supply and demand factors interact to influence health systems. These factors are 
responsible for low access to diabetic retinopathy (DR) services in Kenya (chapter 3).  Health 
system strengthening involves broad interventions designed to permanently make the health 
system function better in relation to the long-term goals for population health, including 
prevention of vision loss and blindness from DR.  
Chapter 5 and 6 address Objective 3 of the thesis: To use the evidence from the literature and 
evidence from the health system assessment as a platform for health system strengthening. 
This chapter focuses on this health system strengthening initiative and includes two papers.  
Evidence-based clinical guidelines for diabetic retinopathy define what services people living 
with diabetes (PLWD) should receive for prevention, screening, diagnosis and treatment of DR. 
The health system assessment identified that lack of national clinical guidelines for DR in Kenya 
leads to lack of standardization of services. Addressing this supply-side barrier can ensure that 
the required resources, tools and services for DR control are available and aligned to the local 
needs.  This aspect of health system strengthening was considered critical at national level. 
(Chapter 3). National clinical guidelines were therefore developed through a process of 
adaptation from generic guidelines.  
The adaptation process followed internationally defined good practice, which include defining 
the PICO framework (population, intervention, comparator and outcome), determining the 
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clinical questions, using a systematic approach for literature search, appraising the quality of 
generic guidelines using validated instruments, identifying contextual considerations and 
following established guideline adaptation frameworks. 
The adaptation process requires high-level skills in finding, appraising and interpreting 
evidence, in stakeholder engagement for a participatory process as well as in writing the 
guideline documents. The PhD provided opportunity to develop these skills, while guideline 
development provided opportunity to apply the skills in a real-life situation, and to participate 
in knowledge translation to close the gap between evidence and practice. 
5.1 Research Paper 3 
Research paper 3 is on the process and outputs of guideline development. This paper has been 
included since it describes the opportunities, challenges and lessons learnt that might need to 
be considered in future guideline development. Given that Information on guideline 
development in LMICs is sparse, the paper facilitates understanding of the feasibility and 
implications of this initiative in similar contexts. This paper was published in the journal BMC 
Implementation Science in December 2018 after peer review. 
BMC Implementation Science – Licences and Copyright 
The following terms apply to this publication 
“The sustainable open access model that BMC pioneered has become the industry standard. 
We make research free to access for everyone, everywhere. Our authors retain copyright of 
their work through a Creative Commons attribution license that clearly states how readers can 
copy, distribute, and use their attributed research, free of charge. All of which helps make 
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articles available to the widest audience, and contributes to the furthering of research in ways 
that would have seemed impossible two decades ago. All articles published by BMC 
Implementation Science are made freely and permanently accessible online immediately upon 
publication, without subscription charges or registration barriers. “ 
https://www.biomedcentral.com/about/open-access 
https://implementationscience.biomedcentral.com/about
5.2 Research Paper 4 
Research paper 4 provides a summary of the content of the guidelines. This paper has been 
included because it provides an understanding of the recommendations for DR care in Kenya, 
and because the guideline document is too large to include in this chapter. This paper was 
published in the Journal of Ophthalmology of Eastern, Central and Southern Africa in 
December 2017 after peer review. 
The following terms apply: 
“All articles published in Journal of Ophthalmology of Eastern, Central and Southern Africa are 
made freely and permanently accessible online on the JOECSA website immediately upon 
publication and without subscription charges. “ 
This journal provides immediate open access to its content on the principle that making 
research freely available to the public supports a greater global exchange of knowledge. 
http://joecsa.coecsa.org/index.php/JOECSA/about/editorialPolicies#openAccessPolicy
Nyawira                                                                                        17 SEPT 2019
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Adapting clinical practice guidelines for
diabetic retinopathy in Kenya: process and
outputs
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Abstract
Background: The use of clinical practice guidelines envisages augmenting quality and best practice in clinical
outcomes. Generic guidelines that are not adapted for local use often fail to produce these outcomes. Adaptation is a
systematic and rigorous process that should maintain the quality and validity of the guideline, while making it more
usable by the targeted users. Diverse skills are required for the task of adaptation. Although adapting a guideline is not
a guarantee that it will be implemented, adaptation may improve acceptance and adherence to its recommendations.
Methods: We describe the process used to adapt clinical guidelines for diabetic retinopathy in Kenya, using validated
tools and manuals. A technical working group consisting of volunteers provided leadership.
Results: The process was intensive and required more time than anticipated. Flexibility in the process and concurrent
health system activities contributed to the success of the adaptation. The outputs from the adaptation include the
guidelines in different formats, point of care instruments, as well as tools for training, monitoring, quality assurance and
patient education.
Conclusion: Guideline adaptation is applicable and feasible at the national level in Kenya. However, it is labor- and time
-intensive. It presents a valuable opportunity to develop several additional outputs that are useful at the point of care.
Keywords: Clinical practice guidelines, Diabetes mellitus, Diabetic retinopathy, Guideline development, Guideline
adaptation, Kenya
Background
The first definition of clinical practice guidelines (CPG),
hereafter referred to as “guidelines,” was provided by the
Institute of Medicine (IOM) in the USA in 1990: “systemat-
ically developed statements to assist practitioners and
patient decisions about appropriate healthcare for specific
circumstances” [1]. Guidelines-related initiatives have
subsequently increased globally since the 1990s. This defin-
ition was revised in 2011 to: “statements that include
recommendations to optimize patient care that are
informed by a systematic review of the evidence and an
assessment of the benefits and harms of alternative care
options” [2]. Guidelines constitute one tool for good
decision-making in clinical practice, which has potential to
reduce variations in health care and its cost. Although a
plethora of barriers may compromise their effectiveness,
guidelines are instruments to improve the quality of care.
Guideline adaptation is potentially an efficient alterna-
tive to de novo guideline development, particularly in
resource-constrained contexts [3]. Adapting guidelines to
suit a local context may also improve local uptake of the
guidelines [4, 5]. Adaptation requires an active, systematic,
and participatory process [4] that preserves the integrity
of the transferable evidence-based recommendations.
Although this adaptation process is context-specific and
may not be transferable or generalizable, it needs to be
systematic, explicit, transparent, rigorous, and reprodu-
cible. The ADAPTE and Practice Guideline Evaluation
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and Adaptation Cycle (PGEAC) framework of adaptation
are validated approaches to conduct and document this
process [4].
The Institute of Medicine [2] has described eight
attributes of good guideline development. These are (a)
validity, (b) reliability and reproducibility, (c) clinical ap-
plicability, (d) clinical flexibility, (e) clarity, (f) documenta-
tion, (g) development by a multidisciplinary process, and
(h) plans for review. Guidelines are likely to reflect these
attributes when they are developed via a transparent
process by a multidisciplinary team without potential bias
and conflicts of interest, and supported by a systematic re-
view of the evidence [2].
This paper describes the process involved in adapting
the diabetic retinopathy (DR) guidelines for Kenya, in
order to assist others undertaking a similar endeavor.
The STEPwise survey [6] for risk factors of
non-communicable diseases in 2015 reported that diabetes
mellitus (DM) affects an estimated 2% of the Kenyan popu-
lation aged 18–69 years, with the highest proportion (5%)
being in the 45–59 years age group. Every person living
with diabetes (PLWD) is at risk of potentially blinding dia-
betic retinopathy (DR). In turn, visual loss from DR is asso-
ciated with additional morbidity, such as falls, fractures,
and difficulties with taking medications. Both DM and DR
are associated with significant morbidity, mortality, and ex-
cess health care costs. The prevalence of DM is predicted
to rise steeply over the next decade [7], and consequently
DM and DR are important public health concerns.
Effective and quality service delivery in relation to
DR in Kenya is required within the existing health
system [8–10]. Currently, there are notable gaps in
DR screening, diagnosis, referral, treatment, and
follow-up. Although screening and laser treatment are
cost-effective interventions for prevention of blindness
from DR [11], there are inequities in access to them.
Some of the services are underutilized for a variety of
reasons, while some of the services delivered are of
insufficient quality. This disparity is linked to multiple
supply and demand factors, such as variation in refer-
ral practices of diabetes care providers, screening
practices of eye care providers, integration of services,
and level of awareness of patients [9, 12, 13].
Clinical guidelines offer recommendations to im-
prove service delivery, advocate for resources, leverage
existing resources, and improve outcomes. Imple-
menting evidence-based practice guidelines for DR is
thus vital to address the gaps and prevent blindness
from DR. International guidelines for this purpose
exist, but there are no published local guidelines. This
guideline adaptation aimed to address this lack of
national guidelines. We envisaged providing a
user-friendly guideline that describes appropriate care
based on the best available scientific evidence.
Methods
We relied on adaptation instead of de novo development
of the guideline in order to avoid duplication of effort, to
use the available resources cost-effectively, and to facilitate
customization of the guidelines prepared for other income
and health system settings to reflect local context.
The process of standardizing clinical practice recom-
mendations for DR in Kenya began over a decade ago.
Several guideline documents have been produced al-
though none has been formally published as a national
guideline. Our reflection was that opportunity costs, turn-
over of experts involved in the process, and other context-
ual factors might have slowed down further development
of the guidelines. The methodology discussed here is that
followed over the last 2 years leading to the production of
the published guideline. However, we expect that a similar
process was undertaken in the previous period.
The adaptation process has been systematic, consulta-
tive, and guided by a technical working group (TWG).
Several widely used toolkits and guidelines provided a
point of entry [14–20]. We followed the tasks of adapta-
tion, as applied within the ADAPTE framework, al-
though some of the tasks were synchronized and we
often had to return to previously completed steps. The
ADAPTE process is a well-known framework for guide-
line adaptation, which consists of 3 phases and 24 steps.
Seven core principles underpin this framework, and the
TWG adopted them for this adaptation [14]. Figure 1
provides a simplified schema of our methods.
The identification of the need for the DR guidelines by
stakeholders prompted the Ophthalmic Services Unit to
constitute a steering team of five members. This team
prepared terms of reference and a list of potential mem-
bers for the TWG. At the first few meetings of the
TWG, we discussed the following: the need for the
guidelines, the feasibility of guideline development, the
required expertise, funding, work plan, outputs, and role
definition of the members. In subsequent meetings, the
topic and clinical questions were defined.
We identified the methodological resources, the clin-
ical guidelines, and the evidence for effectiveness of vari-
ous DR interventions through a literature search on
various databases including Cochrane Library, ELDIS,
Embase, Global Health, and PubMed. We also searched
the websites of agencies that develop these resources.
The search strategy (Additional file 1) was limited to re-
ports published in English from 2000 up to date.
Two TWG members conducted the literature search
and recorded the characteristics and content of retrieved
guidelines. Guidelines that did not meet the predefined
inclusion and exclusion criteria were eliminated. Two re-
viewers assessed the quality of the retrieved guidelines
using the AGREE II instrument and presented the find-
ings in a TWG meeting. All TWG members participated
Mwangi et al. Implementation Science  (2018) 13:81 Page 2 of 9
in the assessment for currency, content, consistency, ac-
ceptability, and applicability of the recommendations.
Following consensus on the results of the assessment,
guidelines suitable for adaptation were selected.
The clinical guidelines that were selected for reference
were the American Diabetes Association (ADA) Stan-
dards for Medical Care in Diabetes [21], International
Council of Ophthalmology (ICO) guidelines for diabetic
eye care [22], the Royal College of Ophthalmologists’
diabetic retinopathy guidelines [23], and the Canadian
Diabetes Association’s retinopathy guidelines [24]. We
chose the ADA and ICO guidelines as the prototypes for
DM and DR guidelines respectively and collated evi-
dence from Cochrane systematic reviews relevant to dia-
betic retinopathy. None of the guidelines contained an
adaptation template for different contexts.
We utilized the AGREE II (Appraisal of Guidelines Re-
search and Evaluation II) instrument to assess the quality
of the clinical guidelines. This instrument consists of 23
items grouped into six domains: (a) scope and purpose,
(b) stakeholder involvement, (c) rigor of development, (d)
clarity and presentation, (e) applicability, and (f) editorial
independence.
The following additional guidelines were also
reviewed, so as to identify any potential conflict in rec-
ommendations for care of diabetes and other comorbidi-
ties: Kenya national guidelines for management of
diabetes [25], Kenya national strategy for the prevention
and control of non-communicable diseases [26], and
International Diabetes Federation’s diabetes eye health
guide for health professionals [27]. Similarly, we
reviewed previous drafts of local DR guidelines.
Draft guidelines were prepared by the TWG and circu-
lated via email to all members for review. Three drafts
were circulated, with the final draft also being circulated
to external reviewers to assess content validity, clarity,
and applicability. The TWG evaluated the final draft
guidelines for the quality requirements of the AGREE II
instrument prior to release. A consensus stakeholders
meeting approved the final draft.
Pilot testing was conducted in different health care
settings in purposively selected counties that differed in
characteristics that may influence applicability. We col-
lected feedback on the usability through interviews, re-
ports, and observation. Dissemination of guidelines was
done through county coordinators, conferences, training
institutions, professional associations, social media, and
distribution of print material.
Results
Table 1 shows the results of the adaptation process in
each of the steps of the ADAPTE framework. We ap-
plied the guiding principles as exhibited in Table 2. We
further applied the AGREE II instrument to ensure qual-
ity of our draft guideline as reported below.
Scope and purpose
The TWG’s first task was to define the scope. The main op-
tions were to include only DR or diabetic eye disease as a
whole. The consensus was to limit the scope to DR because
of its unique natural history and public health implications.
The overall objective of the guideline is to reduce the pro-
portion of PLWD who go blind due to diabetic retinopathy
in Kenya through interventions for prevention, early detec-
tion, and effective treatment of DR. The adaptation process
aimed to reduce inappropriate variation in screening and
treatment, to provide a rational guide for referral, and to
use the diabetes care and eye care resources efficiently to
meet these goals. The recommendations needed to be ger-
mane to the social context, the patient pathway, and the re-
ferral systems in addition to being capable of integration
into the routine workflow. The Population, Intervention,
Professions, Outcomes and Health care system (PIPOH)
summary (Table 3) defined the clinical questions addressed
in the guidelines.
Fig. 1 Schema for the methods used in guideline adaptation
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Table 1 Adapting the guidelines using the ADAPTE process
Step Activity Result
Phase I Set up
1. Establish a resource team The Ophthalmic Services Unit constituted a steering team of five members which
developed the terms of reference and prepared a list of 25 potential members for
the technical working group (TWG), who were subsequently invited to the group
2. Determine criteria for selection and select
a topic using criteria
DR was selected because it is a public health concern and there is variation in
standards of care
3. Check if adaptation is feasible Evidence-based guidelines were already in use internationally, and there was high
interest from the Ministry of Health, clinicians, and other users to develop guidelines
4. Identify necessary resources and skills There was high level of commitment by members of the TWG. The Fred Hollows
Foundation committed to provide funds, and the required expertise was available:
retinal specialists, public eye health specialists, endocrinologists, diabetes educators,
epidemiologists, search and retrieval of information, critical appraisal, research, policy,
guideline development, and eye health systems. A need for input from other professions
in the multidisciplinary care team for type 1, type 2, and gestational diabetes was identified
5. Complete tasks of the set-up phase Members of the group decided to function as a working group coordinated by the
Ophthalmic Services Unit. A set of guiding principles to foster development of the
guidelines was adopted (Table 2). Potential conflicts of interest were explored, and
there were none to declare
6. Write the plan for adaptation A timeline for completion, list of additional resource persons to be included, list of outputs
to be developed in conjunction with the guidelines and task allocation among the TWG
members were agreed upon
Phase II Adaptation
7. Determine and clarify the question A PIPOH summary was prepared (Table 3). The areas of interest for standards of care were
determined as screening, diagnosis and management of DR, and the management of DM
in relation to DR, within the existing care pathway for PLWD in the Kenyan health system
8. Search for guidelines and other relevant
documentation
The TWG searched for relevant DR guidelines and evidence on DR interventions in
systematic reviews
9. Screen the retrieved guidelines and record
their characteristics and content
The recommendations of the guidelines for screening, diagnosis and management of DR,
and the management of DM in relation to DR was reviewed, extracted, and compiled in
summary tables. Evidence from Cochrane systematic reviews was also reviewed
10. Eliminate a large number of the retrieved
guidelines using the AGREE instrument
The rigor dimension of the AGREE II tool was utilized to eliminate guidelines that did not
meet the stipulated criteria
11. Assess the quality of the guideline The AGREE II instrument was used to scrutinize the quality of the guidelines
12. Assess the currency of the guideline The guidelines retrieved were sufficiently current, and we did not identify any new evidence
13. Assess the content of the guideline Recommendations for screening, diagnosis, grading, referral and treatment were examined
and did not differ significantly between guidelines
14. Assess the consistency of the guideline There was clear consistency between the evidence from systematic reviews, the
interpretation of the evidence, and the recommendations in the guidelines in all
the areas of interest
15. Assess the acceptability and applicability
of the recommendations
Care was taken to ensure the recommendations are not in conflict with other local
guidelines and to appraise the implications of the guidelines on health service delivery
16. Review assessments The results of the assessment of the guidelines were discussed in meetings of the TWG
17. Select among guidelines and recommendations
to create an adapted guideline
The ICO guideline for DR was the main guideline used because the recommendations
compared well with the other high-quality DR guidelines and the practice-based
recommendations were well-stated
18. Prepare a draft of the adapted guideline The facilitators of the working group compiled the results of the deliberations and wrote
the draft guideline document
Phase III Finalization
19. Seek feedback on the draft guideline from
those who would be using it
Three revisions of the draft were circulated for comment to TWG members as well as
surgeons, pediatricians, ophthalmologists, Kenya Defeat Diabetes Association, vitreoretinal
surgeons, physicians, diabetes educators for agreement and identification of gaps
20. Consult with endorsement bodies The Ministry of Health adopted the guidelines
21. Consult with developers of guidelines
used as sources
No substantive changes were made to recommendations so this step was not undertaken
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Stakeholder involvement
The Ophthalmic Services Unit at the Ministry of Health
convened a steering group of five members. They
drafted the terms of reference for a task-oriented TWG,
which were to (1) determine the scope and focus of the
required guidelines, (2) appraise the evidence and rec-
ommendations in existing DR guidelines, (3) develop the
national guideline, and (4) craft messages to be used at
the point of care, to influence practice.
The steering group identified 25 potential members of
the TWG, based on the criteria of diverse expertise, ex-
perience, representation of multiple stakeholder groups,
and commitment to the process, all aimed at increasing
both internal and external validity of the guidelines.
These members received personal invitations to partici-
pate. An average of 15 were active members of the TWG
at any given time, but the others remained involved on
the periphery and received frequent reminders to
participate remotely. Participation was through attending
meetings, email and telephone correspondence,
face-to-face consultations, availing resource documents,
reviewing drafts, providing evidence, and informal con-
sultations. This proactive integrative and flexible ap-
proach was designed to ensure ownership, external
validity, and the involvement of end users of the
guideline.
The TWG members were all volunteers with other
clinical, educational, administrative, and policy roles re-
lated to DM and DR in public, private, or faith-based
health facilities, academia, ministry of health, and pro-
fessional organizations. Participation on a volunteer
basis inferred limitation of availability, though addition-
ally, it implied indirect institutional participation of the
employer. They had diverse expertise including clinical,
public health, research, epidemiology, literature search,
systematic reviews, and health systems. Differences in
opinion were encountered in the deliberation of some
recommendations, particularly regarding the role of dif-
ferent cadres in making DR treatment decisions and
delivering treatment. This was resolved through varied
strategies: expressing judgements about values and
risks, making reference to regulation, reviewing the
evidence for role specification, and adapting the role
definition prescribed by the source guidelines and
informal consensus techniques.
We did not employ a research assistant, because the
team had skills in literature review, recent systematic re-
views on interventions for DR were available and the
Table 1 Adapting the guidelines using the ADAPTE process (Continued)
Step Activity Result
22. Acknowledge source documents The key guideline documents and other resources used have been acknowledged through
attribution
23. Plan for aftercare of the adapted guideline A review date was planned for 5 years. Monitoring indicators were also identified. Pilot-
testing has been used to check for usability. Distribution will be through electronic and
print copies
24. Produce a final document of the guideline
and other outputs
The following additional outputs were produced (along with the guideline): posters and
brochures for patient information, posters, brochures and checklist to be used by clinicians,
workshop slides for training health workers, quality assurance guidelines
Table 2 Guiding principles for guideline adaptation
Guiding principle Indicator
1. Respect for evidence-based principles in the development
of guidelines
The evidence on which the recommendations are based is included in the
guidelines
2. Ensuring that the quality of guidelines is high Well-known frameworks for guideline development were used to guide and
assess the quality of the adaptation process
3. Participation of key stakeholders to foster acceptance and
ownership of the adapted guideline and ultimately promote
its use
The involvement of stakeholders was acknowledged in reports of the adaptation
process
4. Consideration of context during adaptation to ensure
relevance for local practice and policy
The context of application of the guidelines has been explicitly stated and the
content adapted for the Kenyan health system
5. Transparency to promote confidence in the guideline
development process
The methodology in the adaptation process has been documented so that it is
accessible and reproducible
6. Flexibility to accommodate specific needs and
circumstances in the health system
The guideline presents recommendations for diverse categories of PLWD (such as
those with different stages of DR or comorbidities) who receive service in different
clinical settings
7. Respect for and acknowledgement of guideline materials
used as sources
Citation and referencing have been used to acknowledge all source documents
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existing guidelines were current. The team did not have
a health economist and did not conduct an economic
appraisal. As the guidelines were in English, we did not
require expertise in foreign languages.
The TWG considered it is important to include pa-
tients’ values and perspectives in the guidelines. A pa-
tient group was invited and PLWD who are clinicians
were included, but despite our efforts, we did not suc-
ceed in having patients directly participate in the adapta-
tion. We also aspired to have the participation of large
groups of PLWD in a way that adequately represents the
diversity of perspectives of PLWD from different geo-
graphical locations, social strata, and stages of disease.
Since we do not have a comprehensive database of
PLWD in the country, this was not feasible.
Rigor of development
We obtained high quality and current international guide-
lines. We examined the methods and the quality of the
evidence used to formulate the recommendations for in-
terventions for DR. We also considered the implications
for resources and health service delivery in Kenya. Further,
we searched for any recent evidence from systematic re-
views and for relevant domestic research. In the absence
of this, and judging the recommendations current and
evidence-based, we incorporated them in our guidelines.
The draft guidelines were subsequently reviewed by exter-
nal multidisciplinary reviewers and pilot-tested in various
health facilities. The guideline will be updated in 5 years
to incorporate any new evidence that will have emerged.
Clarity and presentation of the guideline
We used the Conference for Guideline Standardization
(COGS) checklist [20] as a guide to the content that
needed documentation, although we excluded those
items on the list that we did not consider necessary. The
adapted guideline also includes additional information
that was not in the international guidelines, such as the
pattern of diabetes in Kenya, integrating DM and DR
services, dissemination, and review plans.
In writing the guidelines, we avoided vague, nonspe-
cific, or ambiguous terms and phrases. We aimed to
produce a user-friendly guideline in which the precise
recommendations are easily identifiable and clear, and
the formatting is appropriate.
Applicability
We recognized the facilitators and barriers to the appli-
cation of this guideline in the Kenyan health system. To
overcome the barriers, the guideline provides tools to fa-
cilitate its implementation at the point of use. These in-
clude workshop slides for training guideline
implementers. Flexible 1- day training programs have
been executed at implementing health facilities, confer-
ences and training institutions, in conjunction with
guidelines dissemination. The potential resource impli-
cations (equipment, staff, and training) and resultant
work burden of applying the recommendations were
considered. A monitoring and evaluation plan has also
been included to assess adherence to recommendations
and the outcomes of the implementation.
We required data on the costs of DR services in
Kenya, but we did not undertake this as the Division of
Non-Communicable Diseases had recently undertaken
costing for diabetes services, including DR services. We
lacked a costing model for guideline adaptation at the
start of the exercise, but in our experience, the largest
cost of the adaptation process was the production,
pilot-testing, dissemination, and implementation of the
print outputs. This may be reduced with progressive en-
hancement of digital literacy of the users and increased
utilization of the electronic resources.
Editorial independence
The basic logistic needs of the adaptation process (ad-
ministrative and meeting costs), as well as the imple-
mentation costs, were funded by The Fred Hollows
Foundation. The funders did not influence the content
of the guideline. There was a 100% consensus on the de-
sired outcome of the guidelines, which is prevention of
blindness from DR. Members and funders did not have
any conflict of interest with respect to this outcome.
Context-specific modifications
Unlike the reference guidelines, the Kenyan guideline is
designed for use by both diabetes and eye care clinicians,
as well as other stakeholders in eye care. The population
of interest is all PLWD aged 12 years and over, without
any exceptions. The guideline attempts to take care of
various complexities of service delivery. The role of dif-
ferent cadres in the screening, diagnosis, and treatment
Table 3 PIPOH summary of the clinical questions
Parameter Specification
P Population All patients with diabetes mellitus who are aged ≥ 12 years
I Intervention Screening, diagnosis, referral, and management of diabetic retinopathy
P Professions (target users) Primary care workers, diabetes care providers, eye care workers, administrators, policy-makers
O Outcomes All persons living with diabetes are screened for DR at least annually and blindness from DR is prevented
H Health care setting Community, Primary, Secondary, and Tertiary level health care settings
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of DR is highlighted. Noting the variability in access to
required equipment and skills, a referral mechanism has
been determined through mapping of the services avail-
able in different facilities in the country. We found it
practical to constantly relate the guideline to the patient
pathway. Additional specifications have been made on
linking diabetes care and eye care services, clinical gov-
ernance for the services, and using the health informa-
tion management systems (HIMS) to monitor the effect
of implementation of the guidelines.
Outputs
This process has led to several outputs: (i) the national
guidelines in various formats—print copies, electronic ver-
sion, and an executive summary of the recommenda-
tions. The guideline has a national coverage and applies to
persons with any type of diabetes.' (ii) quality assurance
guidelines; (iii) mapping of DR services in the country; (iv)
posters and leaflets for patients; (v) posters and checklists
for clinicians; (vi) workshop slides for training health
workers; and (vii) monitoring and evaluation tool. These
outputs are to be used at the point of care by diabetes and
eye care clinicians, as well as by administrators and policy
makers. They were chosen because they were perceived to
increase convenience of users and to intensify user adop-
tion of the guidelines. They are in English, but they can be
translated. An executive summary of the guidelines is
published in a separate paper [12].
Feedback from pilot-testing indicated that the guideline
is useful in various clinical and geographic settings in the
country. It served an educational role for clinicians and re-
duced missed opportunities for screening and referral.
The demand for the print outputs continued after
pilot-testing. The point-of-use outputs were reported to
boost user satisfaction because they contained simplified
key messages for different users. During prospective col-
lection of feedback, the lack of a tool to guide integration
of diabetes and eye care services has been identified as a
gap, and its development is being considered.
Discussion
The process of DR guideline development in Kenya has
taken several iterative episodes. This trajectory may reflect
the intensive work that guideline adaptation entails, as well
as the capacity building that has resulted over that process.
This experience is not unique to this initiative; long time-
lines have been reported in other guideline initiatives in the
same context [28]. Contextual factors such as transitions in
the guideline development team or critical leadership may
result in delays, repetition of effort, and modification of
approach.
We did not experience a shorter time scale for adapta-
tion compared to the 2–3 year period suggested for de
novo development or shorter timelines for adaptation
[29]. This could be because we did not conduct this
guideline development process continuously and the
team of experts had other primary engagements. How-
ever, it is evident that the adaptation approach also re-
quires a heavy time commitment. From our experience,
which concurs with the literature, it is an essential pre-
requisite to realistically determine the workload, re-
sources, access to expertise, and the need for dedicated
leadership [29].
The diverse expert skills and commitment of our multi-
disciplinary TWG are a recognizable success factor for
our initiative. This is pertinent for both the internal and
external validity (generalizability) of the guidelines [4, 17].
As adaptation requires significant investment from this
team, the selection of potential TWG members is a pivotal
priority step. Kenya being one of the countries with facing
health workforce crisis [30], the major drawback we faced
was availability of the TWG members to attend face to
face meetings, as they had competing clinical and man-
agerial responsibilities. This was predictable and inexor-
able, necessitating strategies to ensure group functioning
was not interrupted.
The integrative participation method, which allowed
both in-person participation and remote participation of
the working group, helped to mitigate this constraint.
This may have provided impetus to the process and
achievement of the outcome. The enabling factor was
that both electronic communication and face-to-face
meetings were feasible, allowing for flexible engagement.
Involving patients in the process of guideline develop-
ment is recommended [1, 29], because their opinions
about the process of investigation and treatment and
their outcomes are often quite contrary to the views of
professionals. The lack of practical methods for engage-
ment of PLWD precluded it. Although there are re-
sources to guide this, such as the toolkit from Guideline
International Network [16], local literature or prece-
dence to guide such a process is lacking. Despite invita-
tion of patient representatives to attend meetings and to
review the drafts, we did not get this direct input. This
may be because this type of involvement is not instinct-
ively consistent with patient expectations or felt needs in
our setup. Recruiting diverse groups of PLWD in a rep-
resentative manner in a setting without comprehensive
databases also requires contextual strategies. These limi-
tations call for further local research.
We found that the guideline adaptation had the pat-
tern of back and forth interlinked steps. We did not fol-
low the ADAPTE steps sequentially as a stringently
linear progressive and prescriptive tool. Further, even
with the use of methodological tools, we found that there
is need to maintain focus so that the process is not stag-
gered. Clarity of the scope and significance to the patient
pathway helped to maintain focus and continuity. Focus
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helped to avoid attrition, considering that universal com-
pletion of guideline development is not the norm [1].
Similar to de novo development, adaptation requires a
review of the evidence and explicit use of valid evidence
[15]. It would have enriched the process if we had add-
itional domestic evidence. There is need for local re-
search to fill gaps in scientific knowledge regarding
interventions for DR in this population and health sys-
tem. Local evidence on economic analysis such as
cost-minimization and cost-utility evidence of the inter-
ventions is also necessary.
Adaptation itself has cost implications, and although
we did not have a large dedicated budget for the
process, we found it important to have a budget for
the variable costs. In the absence of funding for fixed
costs, we cannot provide an estimate of the funding
required. Such estimates would help to calculate the
cost-effectiveness of the process, considering the op-
portunity costs, and comparison with the cost of de
novo development. The interventions described in the
guidelines are clinically effective, but we need to in-
vestigate whether these interventions and the process
of guideline development are also cost-effective in our
setting. At present, we assume that guidelines aug-
ment the efficiency of DR services and optimize value
for every shilling invested in the health system. In
order to balance cost and accessibility of services, the
guidelines promote the use of existing resources while
aspiring to progressively mobilize the range of re-
sources that are recommended.
National guidelines for various conditions may contain
conflicting recommendations, which can be confusing for
clinicians. This is especially the case for PLWD, as they
often have comorbidities. We avoided such discrepancies
by reviewing the other diabetes-related guidelines, and we
recommend this as an important step in adaptation.
The output from the adaptation process is a guide-
line that is different from the generic guidelines (or
source guidelines) and contains additional information
that will be useful for the target user. An additional
benefit is the production of additional tools for use at
the point of care. This shows that the role of guide-
line adaptation is not limited to endorsing generic
recommendations.
This initiative has coincided with other DR activities,
such as the initial steps towards implementing regular ret-
inal screening for PLWD attending diabetes services. This
may have contributed to its success, and we can further
leverage on this to market the guidelines. Given that
countries in the African region, particularly the Eastern,
Central, and Sothern African region may face similar
needs to develop guidelines, a network or collaboration of
sharing and learning may be an efficient approach to de-
velop them.
Conclusions
Guideline adaptation is a structured investment -inten-
sive process that is feasible at the country level. Rigor
and focus are important in this process. The ADAPTE
process and AGREE II instrument are valuable tools for
this process, though it would be helpful for the generic
guidelines to have an adaptation template for other
contexts.
Multiple informational, technological, economic, so-
cial, and professional variables influence the effectiveness
of guideline adaptation. Beyond the utility of this process
in producing the outputs we required, it could also be
useful to inform the development of other guidelines in
similar contexts. Our experience has helped to provide
insights on the use of the adaptation methodology in the
African context. We have also identified guideline devel-
opment as a potential area for collaboration.
Involvement of the end user of the guidelines (diabetes
and eye health clinicians) in this adaptation process aims
to increase adherence to the guidelines. We expect that
DR services that were not routinely available to PLWD
in Kenya will now become accessible as a response to
the guidelines.
Implications for practice
Availability of a national guideline is a necessary but not
sufficient impetus to standardize patient care. The extent
to which the prevention of blindness from DR is realized
will depend on the effectiveness of guideline dissemination
and implementation, in tandem with other interventions.
Future research
An economic analysis is required to determine whether
guideline adaptation is cost-effective. Research evidence
is also required to determine the effective methods of in-
volving patients, such as DR patients, in the adaptation
process. In addition, the effectiveness of the guidelines
in reducing DR blindness will need evaluation.
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ABSTRACT
All persons living with Diabetes Mellitus (DM) have a lifetime risk of developing Diabetic Retinopathy (DR), a 
potentially blinding microvascular complication of DM. The risk increases with the duration of diabetes. The 
onset and progression of DR can be delayed through optimization of control of blood glucose, blood pressure 
and lipids. The risk of blindness from DR can be reduced through cost-effective interventions such as screening 
for DR and treatment of sight-threatening DR with laser photocoagulation and anti-VEGF medications.
 Several factors make it important to provide guidance to clinicians who provide services for diabetes and 
diabetic retinopathy in Kenya. First, the magnitude of both DM and DR is expected to increase over the next 
decade. Secondly, as the retina is easily accessible for examination, the early signs of retinopathy may provide 
clinicians with the first evidence of microvascular damage from diabetes. This information can be used to guide 
subsequent management of both DM and DR. Thirdly, there are notable gaps in service delivery for the detection, 
treatment and follow-up of patients with DR, and the services are inequitable. Strengthening of service delivery 
will require close collaboration between diabetes services and eye care services.
 Following a systematic and collaborative process of guideline development, the first published national 
guidelines for the management of diabetic retinopathy have been developed. The purpose of this paper is to 
highlight the recommendations in the guidelines, and to facilitate their adoption and implementation.
Key words:  Clinical practice guidelines, Diabetic retinopathy, Kenya
INTRODUCTION
Diabetes Mellitus (DM) is a priority non-communicable 
disease that requires multidisciplinary care and continuity 
of care. Its prevalence and incidence is increasing in 
every country. According to the STEPwise survey1 for 
risk factors of non-communicable diseases in 2015, DM 
affects an estimated 2% of the Kenyan population aged 
18-69 years with the highest proportion (5%) being in 
the 45-59 years age group. Every patient with diabetes 
is at risk of potentially blinding ocular complications, 
particularly Diabetic Retinopathy (DR). In turn, visual 
loss from diabetic retinopathy is associated with additional 
morbidity, such as falls, fractures and difficulties with 
seeing and taking medications. Both DM and DR are 
silent diseases that patients may be unaware of until they 
cause complications. Clinicians attending to patients 
with these conditions have a role to reduce the associated 
morbidity, disability and mortality.           
Diabetic Retinopathy (DR) is the leading cause of 
blindness in diabetes, and for this reason it warrants 
specific attention. It is estimated that a third of the 
people with diabetes have diabetic retinopathy, and one 
third of the latter (or 10% of those with diabetes) have 
vision threatening DR2.  Early signs of retinopathy 
or maculopathy in a patient with diabetes, identified 
on retinal examination, may be the first evidence of 
generalised microvascular damage from poor control 
of diabetes. This information would be very useful in 
planning subsequent holistic management of the patient. 
There is therefore need to strengthen links between eye 
care services and diabetes services.          
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The risk factors for DR include both modifiable and 
non-modifiable factors.  Epidemiologic studies have 
identified the non-modifiable risk factors to include 
increasing duration of diabetes and genetic factors2,3. 
The leading modifiable risk factors include poor 
control of blood sugar, poor control of blood pressure 
and dyslipidaemia2,4-6. Service providers need to pay 
attention to these factors, as well as to other lifestyle 
factors associated with diabetes in order to delay onset or 
progression of DR. These are interventions for primary 
prevention of blindness from DR.
Stronger service delivery for DR is required within the 
existing health system7-9. Currently there are notable gaps 
in the screening, diagnosis, referral, treatment and follow-
up. Although screening for DR and laser treatment are 
cost-effective interventions for prevention of blindness 
from DR10, there are inequities in access to them. Some 
of the services are underutilised and of insufficient 
quality. DR guidelines and use of clinical guidelines is 
an important step towards ensuring that all people with 
diabetes have access to quality DR services.
The purpose of these clinical practice guidelines is 
to give guidance regarding screening and diagnosis of 
DR, management of diabetes as it pertains specifically to 
DR, and treatment of DR. These guidelines apply to all 
patients with type 1 or type 2 diabetes who are at least 12 
years old, who receive care at the primary, secondary or 
tertiary level of the health system. They should be used by 
health workers providing diabetes services and eye care 
services, as well as by administrators and policy-makers 
who plan for the resources for these services.
METHODOLOGY FOR GUIDELINES 
DEVELOPMENT
The development of these guidelines was a systematic, 
widely consultative process guided by an expert 
technical group over a lengthy period and involving 
many stakeholders. The process was guided by the use of 
several toolkits and guidelines which include: ADAPTE 
toolkit11, PGEAC framework12, AGREE 11 instrument13 
and WHO handbook for guidelines development14.  
The guidelines were adapted from existing relevant 
standards and guidelines, particularly the American 
Diabetes Association standards for medical care in 
diabetes15 International Council of Ophthalmology 
guidelines for diabetic eye care16 Canadian Diabetes 
Association’s retinopathy guidelines17 and the Royal 
College of Ophthalmologists’ diabetic retinopathy 
guidelines18. The following guidelines were also 
reviewed, and the recommendations are in line with their 
provisions: Kenya national guidelines for management 
of diabetes19, Kenya national strategy for the prevention 
and control of non-communicable diseases20, and 
International Diabetes Federation’s diabetes eye health 
guide for health professionals21. The adaptation strategy 
was chosen instead of de novo development in order to 
avoid duplication of effort, to use the available resources 
cost-effectively and to facilitate customization of the 
guidelines to reflect local context. These guidelines 
were identified through a literature search followed by 
application of the AGREE 11 instrument to evaluate the 
quality of the guidelines. Previous drafts of local DR 
guidelines were also reviewed. Care was taken to ensure 
that the guidelines are evidence-based, locally applicable, 
of high quality, and that the process of adaptation was 
consultative. The guidelines were subjected to  external 
review by a multidisciplinary team as well as pilot-testing 
in various health facilities.
The process of guideline development is discussed in 
detail in a separate paper.
Key messages
1. Stronger service delivery is needed for People 
Living with Diabetes (PLWD) in Kenya in relation 
to DR. There is need to develop strong links between 
diabetes services and eye care services within the 
existing health system.
2. Blindness from DR is avoidable, but only if diabetes 
care givers and eye health professionals perform 
their roles in ensuring early detection and treatment 
of DR.
3. Screening is important for early detection of treatable 
diabetic retinopathy. It is also a cost-effective 
intervention for reducing blindness from DR. All 
patients with diabetes aged 12 years and above 
should have a retinal examination (usually a dilated 
eye examination or a retinal photograph) once a 
year or more frequently if recommended by the eye 
specialist.
4. Consistent and appropriate metabolic control reduces 
the onset and progression of sight-threatening 
diabetic retinopathy.
5. Laser photocoagulation therapy, local intraocular 
pharmacological therapy and surgery reduce the risk 
of significant visual loss.
Recommendations
Domain: Strengthening links between diabetes services 
and eye care services at primary, secondary and tertiary 
level of care
1. All health workers providing diabetes services should 
raise awareness of PLWD on diabetic retinopathy and 
support them to access eye examination (Panel 1). 
2. The health worker attending to a PLWD at any health 
care level should use a checklist (Panel 2) to identify 
whether the patient has had a retinal examination in 
the preceding 12 months. Any patient who has not 
should be referred to the nearest facility for screening 
for DR.
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3. The screening examination for DR should be 
performed by trained personnel (health care worker, 
eye care workers or technicians) and should consist 
of a minimum of:
a. A retinal examination appropriate for DR, 
which would include dilated direct or indirect 
ophthalmoscopy, slit lamp bio-microscopic 
examination of the retina or retinal photography.
b. Visual acuity test using distant and near charts. 
If the visual acuity is reduced, then pin hole test 
is also performed.”
4. All PLWD require follow up, therefore service 
providers in both eye clinics and diabetes clinics 
should encourage compliance with follow-up.
5. A service charter for diabetes services and eye care 
services should be available in all clinics offering 
these services to inform PLWD of the minimum care 
they should expect and to highlight the importance 
of yearly comprehensive risk assessment including 
dilated eye examination.
6. The ophthalmologist and the physician/diabetologist/
endocrinologist will provide clinical governance as 
the team leads for diabetes services and eye care 
services. The clinical governance team would also 
include: (a) liaison diabetes nurse (from the diabetes 
clinic), (b) liaison ophthalmic nurse (from the eye 
clinic), (c) designated medical records officer and (d) 
a biomedical / equipment maintenance technician. 
7. The physician/diabetologist/endocrinologist and the 
ophthalmologist would be responsible for oversight 
on the screening for DR, training of health workers 
and data management. 
8. The Ophthalmic Services Unit would be responsible 
for clinical governance for DR services at national 
level.
9. Data would be systematically collected in both 
diabetes clinics and eye clinics. The liaison nurse in 
the diabetic clinic and eye clinic would forward the 
captured data to the designated records officer for 
reporting.
10. The Ophthalmic Services Unit would coordinate 
the use of this data to inform decisions on service 
improvement strategies.
Panel 1: Key messages for health workers attending to 
PLWD
1 in 3 of patients with diabetes has diabetic retinopathy. 
Act to save their vision today!
1 Send all newly diagnosed patients with diabetes 
for a baseline retinal examination.
2 Ensure all patients with diabetes have an annual 
retinal examination.
3 Refer any patient with diabetes who has poor 
vision to an eye specialist urgently.
4 Do not wait for visual loss to refer patients with 
diabetes to an eye specialist- ‘prevention is better 
than cure.’
5 Glycated hemoglobin (HbA1c) is a good indicator 
for long-term sugar control and should be done 
at least annually for all patients. Good glycemic 
control prevents or delays diabetic retinopathy.
6 Assess for other end organ damage- oral 
examination, diabetic foot review, renal and 
cardiac function, tests for neuropathy at least 
annually
7 Assess for hypertension, hyperlipidemia and other 
co-morbidities as these may impact negatively on 
diabetes and diabetic retinopathy.
8 Send all pregnant patients with diabetes for a 
retinal examination at least each trimester and 
post-delivery, or more frequently if recommended 
by the eye specialist.
Panel 2: Checklist for screening for DR
Patients name: …………………………………………
Date of birth:  …………………………………………
Date of screening:  ……………………………………
Duration of diabetes:  …………………………………
Have you ever had an examination of the back of the eye 
(either a photograph was taken or drops were instilled 
into the eye before examination)?      
a. YES    b. NO
How long ago was the last examination of the back of the 
eye?
a. < 12 months   b. ≥ 12 months
Where was the eye examination done? ........................... 
facility
Recommendation:  ……………………………………
Have an eye check: as soon as possible / in the next 
………………. months at………………. health facility
Domain: Eye examination for DR
Annual dilated and comprehensive eye examination is 
recommended for all patients with diabetes, aged 12 years 
and above, starting at the time of diagnosis of diabetes 
mellitus, unless the eye specialist recommends a different 
frequency. For type 1 diabetes, an eye exam should be 
done at diagnosis, at 5 years of diagnosis and annually 
thereafter.
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Domain: Patient-centred care
1. Health workers should provide verbal and written 
information on diabetes, diabetic retinopathy, and 
on the health care that is needed, including self-
management.
2. All PLWD should receive regular and individualised 
self-management support on healthy diet, appropriate 
physical activity and weight reduction if they are 
overweight. All smokers should be encouraged to 
quit smoking.
3. Patient education materials such as posters, leaflets, 
booklets and flyers on DR should be available (Panel 
3) to patients and to peer support groups.
4. Diabetes support and structured self-management 
education should also be provided to family members 
of PLWD.
5. PLWD should be treated with dignity and involved 
in decision-making for their care. The results of 
their examination and the implications should be 
explained to them, and they should be encouraged to 
ask questions. The presence of co-morbidities should 
be taken into consideration in the care of each patient.
Panel 3: Key messages for patients
DID YOU KNOW THAT DIABETES AFFECTS THE 
EYES?
What can you do to prevent blindness?
1 Diabetes mellitus is marked by high sugar levels 
in blood. High blood sugar destroys small blood 
vessels in the body including those at the back 
of the eyes, leading to a condition called diabetic 
retinopathy.
2 Damage to the eyes is slow, painless, gets worse 
with time and finally leads to blindness if not 
treated in good time.
3 The damage to the eyes needs to be detected early, 
before permanent damage occurs.
4 An eye check by an eye specialist can detect 
damage to the eyes before symptoms develop. 
During the examination, the eye specialist will 
check vision, and instil an eye drop to assess the 
damage in the eye. Both eyes need to be examined.
5 For prevention and treatment of diabetic 
retinopathy, the eye specialist may advise on sugar, 
blood pressure, and lipid control.
6 For treatment of diabetic retinopathy, the eye 
specialist may perform laser or administer 
injections in the eye or perform eye surgery. 
7 All persons with diabetes should have their eyes 
checked once every year by an eye specialist, even 
before any symptoms or poor vision develop or as 
frequently as recommended by the eye specialist.
8 A child with diabetes should have the eyes checked 
annually from the age of 12 years, or more 
frequently if recommended by the specialist. 
9 A pregnant mother with diabetes should undergo an 
eye check by an eye specialist at least once every 
trimester, and soon after delivery, or as frequently 
as recommended by the eye specialist.
10 If the eyes are found to be normal at your eye 
check by an eye specialist, please continue with an 
eye check annually.  If you notice any abnormality 
with your eyes, visit the eye specialist as soon as 
possible.
Domain: Metabolic control 
1. All PLWD should be asked about the level of control 
of glucose, blood pressure and lipids.
2. To prevent the onset and delay the progression of 
diabetic retinopathy, people with diabetes should be 
treated to achieve optimal control of blood glucose.
3. Regular monitoring of blood sugar at home should be 
encouraged. 
4. Regular monitoring of blood pressure in a health 
care setting or at home should be encouraged. Target 
blood pressure is 140/90 mmHg. Drugs blocking 
the Renin-Angiotensin System (RAS) may have 
benefits, particularly for mild retinopathy, but should 
be discontinued during pregnancy.
5. A comprehensive biochemical profile (risk 
assessment) should be done at least annually, 
and include fasting lipid profile, HbA1c, urine 
microalbumin among other tests. 
6. Aim for a target glycosylated haemoglobin (HbA1c) 
of <7%. 
7. Serum fasting lipid profile should be assessed at 
diagnosis and annually. Consider statins in primary 
and secondary prevention of DR but discontinue 
statins in pregnancy.
Domain: Pregnancy
1. All female PLWD of reproductive age should be 
asked if they are pregnant.
2. Patients should be assessed for diabetic retinopathy 
before pregnancy, at least once every trimester of 
pregnancy, as well as within 6 months after delivery 
or more frequently if recommended by the eye 
specialist. 
3. Statins and angiotensin inhibitors should be 
discontinued in patients who are planning for 
pregnancy.
4. All women of child-bearing age who have diabetes 
should be educated that pregnancies should be 
planned.
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Domain: Screening programs for DR
1. All PLWD should be screened for DR at least once 
a year, irrespective of whether they have ocular 
symptoms or not.
2. Screening programs can utilise whatever screening 
method is available (ophthalmoscopy, slit-lamp bio-
microscopy and retinal photography), and should be 
conducted by a suitably trained person. Pupil dilation 
is recommended. Visual acuity should be assessed 
before pupil dilation. 
3. Photography based screening
a. Where a fundus camera is available, ideally the 
fundus camera should be located in the diabetes 
clinic.
b. Fundus photographers should be trained to 
identify cataract, other causes of media haziness 
and glaucoma on the images. Patients who 
have these pathologies should be referred to 
an ophthalmologist. Ultrasonography may be 
useful in assessing the posterior segment in the 
presence of cataract or vitreous haemorrhage. 
c. Regular retraining in form of short courses 
(either online courses or standard contact 
courses) should be provided for screeners.
4. The following patients should be referred to an 
ophthalmologist:
a. Where the screening examination is unsuccessful, 
or the results of the visual acuity test or retinal 
examination are unclear
b. Where the retinal examination is unsuccessful, 
for example due to additional pathologies
c. Any grade of retinopathy, except mild non-
proliferative retinopathy
d. Visual acuity worse than 6/12 and all patients 
with ocular symptoms
5. Screening should identify true positives (patients 
with DR). For this to be achieved, it is important to 
use the correct equipment, adhere to the standards of 
practice, make correct diagnosis and have a quality 
assurance mechanism. The guidelines for quality 
assurance are provided as an addendum to the 
guidelines.
6. All health workers have a role in ensuring patients 
undergo screening. All health workers should also 
document and collect data on screening activities, 
as the data is useful for planning and monitoring 
services. Health workers at each health facility 
will collect this data using standard monthly data 
collection forms. The Ophthalmic Services Unit in 
the Ministry of Health will coordinate the collection 
of data.
Domain: Diagnostic evaluation of patients at the eye 
clinic
Once the person with diabetes has been referred to 
an eye specialist, he or she should undergo a complete 
ophthalmic assessment. Ophthalmic evaluation by an 
eye care worker is available at the secondary level of the 
health system. This should include taking medical history, 
assessing visual acuity, and identifying and grading DR 
or Diabetic Macula Oedema (DME), using standard 
procedures described in the guidelines.
Domain: Referral pathway
Once a decision for referral for evaluation or treatment has 
been made, it should be carried out as soon as possible. 
The nearest health facility offering DR services will be 
identified (mapping of services has been conducted, 
and this information is provided as an addendum to the 
guidelines), and patients will be referred to reach the 
facility on the designated days that the services can be 
provided.
Domain: Treatment interventions
The ophthalmologist will make the final diagnosis and 
the decision on the treatment that the patient should 
receive. There is evidence from Cochrane systematic 
reviews included in Panel 4 to support the use of laser 
photocoagulation in proliferative diabetic retinopathy22 
anti-VEGF injections in diabetic macula oedema23 and 
intravitreal steroids in refractory diabetic macula oedema24. 
Laser or intravitreal injections can be administered by the 
ophthalmologist at secondary level. Surgical interventions 
for DR will be provided by the vitreo-retinal surgeon at 
tertiary level. Practical information on these procedures is 
provided in the guidelines.
Panel 4. Evidence from Cochrane systematic reviews for 
Interventions used to treat diabetic retinopathy.
Laser photocoagulation is beneficial in reducing the 
risk of severe visual loss and the risk of progression 
12 months after treatment in patients with proliferative 
diabetic retinopathy compared to no treatment or deferred 
treatment. However most trials here are old and the 
quality of evidence is judged as low22.
There is very low or low quality evidence from randomized 
controlled trials that anti-VEGF injections are effective in 
patients with proliferative diabetic retinopathy but they 
prevent intraocular bleeding25.
There is high quality evidence that anti-VEGF injections 
are effective in preserving and improving vision in 
patients with diabetic macula oedema compared to grid 
laser23.
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Intravitreal steroids delivered either by injection or 
implants may improve visual outcomes in patients with 
persistent or refractory diabetic macula oedema but it 
is unclear whether they are beneficial in other earlier 
stages24.
Domain: Follow up
All PLWD screened for DR will require follow up. The 
frequency of follow-up depends on the clinical findings, 
and the grading/severity of DR, as described in the 
guidelines.
Domain: Patients with low vision
Refer the patient with low vision (best corrected visual 
acuity of <6/18) for rehabilitation. PLWD who would 
benefit from counselling and social services should be 
referred as appropriate.
Domain: Monitoring DR services
Specific process and outcome indicators will be used 
to monitor services on a quarterly basis at each level of 
service delivery, using the hospital health management 
and information system. Health workers at each health 
facility will therefore collect this data using standard 
monthly data collection forms. The Ophthalmic Services 
Unit will coordinate the collection of data. The indicators 
of interest are listed in the guidelines.
CONCLUSIONS
Patients with diabetes require specific care relevant to 
diabetic retinopathy, which includes patient education, 
screening, referral, treatment and follow-up. These are 
the first published national clinical practice guidelines for 
the screening and management of diabetic retinopathy. 
Their goal is to ensure best practice throughout the 
whole pathway from primary care to tertiary care. 
Implementation of the guidelines has potential to reduce 
blindness from DR. 
The Working Group welcomes feedback from all users 
of these guidelines. In particular, data on the enablers and 
challenges experienced in the use of the guidelines would 
be very useful in informing revisions on the guidelines. 
Please email feedback to the Ophthalmic Services Unit, 
Ministry of Health, through ophthalmicserviceske@
gmail.com.
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Chapter Six  
Health system strengthening: The development of an open online 
training course on control of DR 
6.0 Overview
The unavailability of educational opportunities for health workers providing care to people 
living with diabetes (PLWD) hampers the capacity of the workforce for control of DR (chapter 
three). Health systems strengthening through health workforce capacity building is therefore a 
critical factor for expanding availability of comprehensive DR services. Online courses provide a 
useful model allowing flexible access to training for health workers providing services in 
different institutions while minimizing work-place disruption.  Although much attention has 
been given to the number and distribution of health workers, little focus has been directed at 
developing models of training that address these real-life workplace needs.   
This chapter describes the experience and lessons learnt from developing an online course to 
strengthen capacity of health workers in Kenya to deliver services for DR.  Section 6.1 
highlights how online learning may address the needs for continuing education for health 
workers. Section 6.2 describes the role of mentorship in the development of the course.  
Section 6.3 and 6.4 describe the systematic process of course development following the 
theories of instructional design and adult learning. The course will be launched in late 2019 and 
the implications are discussed. 
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6.1 Online learning for continuous professional development of health workers 
Continuous professional development (CPD) is required because preservice training alone is 
not sufficient to keep health workers equipped to respond to the rapidly evolving changes in 
health care.1-3 Importantly, CPD has been linked to professional competence, health worker 
motivation and job satisfaction.4, 5Traditional forms of CPD include educational meetings with 
face-to-face contact, such as conferences, symposia and workshops, but the literature points 
out numerous challenges. These include difficulties juggling clinical workload and time-off for 
CPD, especially with inflexible CPD sessions that do not consider work commitments.1, 6, 7 In 
low-resource settings, where the need for training and CPD may be highest, the limited CPD 
sessions available often occur off-site, in urban areas, at tertiary training institutions or central 
teaching hospitals. For those living remotely, the expenses in terms of registration fees, 
accommodation and transport are often prohibitive.  
Online learning can enhance education experience, support professional development, ease 
time constraints, overcome geographic limitations and offer greater flexibility in CPD.8 Online 
platforms for CPD may enable care providers to remain at their place of employment while 
continuing their education.7 Richmond et al in their systematic review found that online 
methods may be as effective as alternative methods for training health workers.9 Such 
platforms are gaining in popularity because of their relatively low costs, high flexibility, and 
reduced dependence on geographical or site boundaries.10 Studies have shown that online CPD 
opportunities are acceptable across a diverse group of health care workers in sub-Saharan 
Africa.6, 11
Despite these benefits, there are also barriers to the use of online CPD such as cost of 
developing programmes, possible technology problems, lack of computers, lack of continuous 
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internet and data costs.  Sub-Saharan Africa has a lower level of internet use than other 
regions, but this is rapidly changing in East Africa.12 Kenya is one of the countries with the 
highest smart phone penetration and mobile adoption.13, 14 This presents an opportunity for 
online CPD learning to take place. However investment in developing CPD courses is a complex 
undertaking, this is likely to remain a significant barrier.15 Documenting experiences related to 
course development would therefore be of interest to policy makers, medical educators, 
regulators and front line workers involved in designing or supporting implementation of CPD 
interventions.  
Developing CPD courses is particularly pertinent in the subject of diabetes eye health because 
of the dynamic epidemiology of diabetes-related vision loss, and the technology and 
competencies required for addressing it. 16-18 Studies from Africa have reported insufficient 
training about diabetes, on specific procedures such as examination of the retina (fundoscopy) 
and on the management of DR.17 In addition, the recent advances in knowledge and 
technology in the field of diabetes eye health will only offer benefits to PLWD if health workers 
remain up to date in the field. At present, there is a paucity of local online CPD courses on this 
subject. However, there is evidence from a free online course ‘Global Blindness: Planning and 
managing eye care services’ that appropriately designed online courses can deliver training at 
scale, support educational capacity building and impact health practice in LMICs.19  Another 
major weakness is the insufficient information on how the few courses available were 
developed, the contextual factors considered and the instructional design methodology used.9, 
15, 20For that reason, the existing literature does not adequately advance an understanding of 
how courses can be developed, hence failing to promote interpretation and replicability. To 
address this gap, the process of developing this open online course on control of DR, and the 
lessons learnt from this process are described in this chapter. 
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6.2 Adult learning theory 
In order for knowledge transfer to translate into effective CPD for health workers, there is a 
need to leverage adult learning theories, because they provide the conceptual frameworks for 
the acquisition of knowledge, skills, and attitudes to achieve behaviour change.21 Adult learning 
theories hold a set of assumptions about how adults learn and emphasize the value of the 
process of learning. They postulate that adults are independent and self-directing, have prior 
knowledge and experience, apply learning to real life, are interested in problem solving and 
have internal motivation for learning.15, 22, 23 Although the theories were developed for 
traditional classroom education, the basic principles effectively transfer to the online learning 
environment. Online CPD programmes take into account these principles through integrating 
the following factors: - voluntary participation, autonomy of learning, self-pacing, mutual 
respect, reflection, collaboration and responding to emergent learning.7, 24 Examples of how 
these approaches were applied in the development of the course are provided in the sections 
below. 
6.3 The ADDIE instructional design framework 
The use of an instructional design framework in course design helps to ensure that the process 
is credible and transparent, and that the course is likely to be relevant and effective in 
professional improvement.25, 26 A literature search for evidence on effective models of online 
course development identified at least 30 models, but the ADDIE (acronym for Analysis, Design, 
Development, Implementation, and Evaluation) model is the most ubiquitous, with good 
evidence of its effectiveness.27, 28 The framework was first used during the World War II when 
the United States military developed strategies for rapidly training people to perform complex 
technical tasks.29 It has remained the most influential instructional design framework in the 
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literature.30, 31 It involves analysis of learning needs, the design and development of a 
curriculum, and the implementation and initial evaluation of the training programme. 
The ADDIE framework has previously been used to design high quality educational 
programmes, both print-based and online.32 It is particularly useful where the focus of the 
programme is targeted toward changing participant behaviour.33  It takes into account learning 
theories, the learner’s needs and context, and can be applied to teach knowledge, skills, or 
attitudes.28, 30 In health and medicine, it has been used to design training interventions to 
change practice behaviours in the management of various medical conditions.26, 28, 33-35
6.4 Mentorship for course development 
Improving clinical care rapidly, comprehensively, at large scale, and sustainably is a 
fundamental challenge for health systems.36 Mentorship is an effective approach for 
developing knowledge and skills, and it could potentially be used to enhance knowledge 
transfer between researchers, educators and clinicians.37 For example, mentoring can build the 
expertise and self-efficacy of mentees from LMICs to develop online courses.38 However, little 
empirical research in healthcare settings has specifically described the application of 
mentorship for this purpose.36, 37
Insights from mentoring initiatives can inform the conduct of future mentoring initiatives to 
optimize chances of success. An overview of mentorship to develop this course within the 
UNESCO Open Education for a Better World (OE4BW) is documented and discussed below, so 
that future efforts towards developing similar mentoring programmes could draw from this 
learning and experience.39 This is an international online mentoring programme run by the 
United Nations Educational, Scientific and Cultural Organization (UNESCO) to unlock the 
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potential of open education in achieving the United Nations’ 2030 Sustainable Development 
Goals (SDGs).40 Mentees develop course materials that address one or more SDGs, finding 
a solution with impact on society and ensuring quality of the course materials. The mentor’s 
role is to advise on the design of the course, and to ensure that the course is supportively but 
critically reviewed. At the end of the six-month mentoring period, the mentees and mentors 
attend a face-to-face workshop organized by UNESCO to present the outputs and lessons 
learnt. The formal mentoring structure provided by UNESCO ends at six months, but mentoring 
may extend post-programme, given that courses often take a long time to develop. Some 
mentoring programmes have reported difficulty maintaining the mentoring relationship during 
this transition period, but I did not experience this.41 UNESCO provides a website to host 
information on the course and mentorship.40 This is particularly helpful because it helps to 
form a community of practice for professional networking.  
6.5 Developing the online course on control of DR using the ADDIE framework 
Figure 6-1 depicts the conceptual model of the five phases of the ADDIE framework as 
operationalized in the development of this course. The analysis, design, development and 
implementation phases are cyclical and iterative. Each phase depends upon the successful 
completion of the preceding phase.26 Formative evaluation provides feedback specific for each 
phase, facilitating refinement of the outputs.25 Table 6-1 shows the tasks and outputs in each 
phase. Experts on diabetes, ophthalmology and medical education reviewed the outputs from 
each of the phases for quality assurance. 
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Figure 6-1: Conceptual model of the ADDIE framework as applied in the development if this 
course 
Table 6-1:  Tasks and outputs within the ADDIE framework in this course 
Phase Sample tasks Sample outputs
Analysis 
Defining what is to be learnt 
• Identification of target 
learners 
• Identification of needs 
and problems of target 
learners 
• Analyse subject field 
• Work with content 
experts to determine 
the content 
• Search for evidence 
• Search for materials 
• Target learners 
identified 
• Description of current 
constraints 
• Current environment 
described 








• Identify optimal 
methods of content 
delivery 
Design
Determine the learning 
objectives and strategies 
• Identify the learning 
theory 
• Identify the media for 
course delivery 
• Consult with subject 
experts  
• Identify the creative 
commons licence 
• Write objectives  
• Plan instruction 
• Identify resources 
• Identify course site 
• Vetting of design 
document by key 
stakeholders 
• Measurable objectives 
• Instructional strategy 




Prepare course materials 
• Work with multimedia 
team, content experts 
and instructional 
designers  
• Develop learning 
materials 
• Peer review 









• Upload content on the 
course site 
• Testing the prototype 
• Official launch 
• Course advertisement 
• Support learners 
• Course link  
• User feedback 
Evaluation
Formative and summative 
evaluation of the course 
• Pre-course user survey 
• Post-course user 
survey 
• Monitoring course 
analytics 
• Course analytics 
• Course evaluation 
reports 
• Revised prototype 




The first step in course development is to analyse the need and context of the learners. The 
health system assessment (chapter three) provided the evidence on the need for the course. 
The literature provides evidence of other courses developed as a result of needs identified 
from health system assessment.33 The health system assessment also identified the population 
(P) of interest for the training, the intervention (I), which is the development of the course, the 
comparator (C), which is the current situation with few educational opportunities. The 
expected outcome (O) of the course development endeavour is the availability of the online 
course and the achievement of the learning outcomes. This analysis phase also involved 
searching for the relevant published evidence (E) and setting a timeframe (T). The EPICOT 
format42 provided the context for the course development, Table 6-2.   
Table 6-2: EPICOT description for the Control of Diabetic Retinopathy course 
Evidence Online courses are acceptable and feasible in this setting, as described within 
this chapter 
Population Heath workers providing care for PLWD
Intervention Development of a flexible course on eye health for PLWD, which will enable 
learners to understand eye health complications in diabetes, especially DR, 
holistic care for PLWD, the role of the health care provider in the care 
pathway and how to strengthen health systems 
Comparator The current situation, where training opportunities are few, for both service 
providers and trainers  
Outcome Availability of a free online course that can be used on mobile devices or 
computers 
Timeliness Course should be ready for launching by World Diabetes Day, 2019
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The target population is the heterogeneous and multidisciplinary group of health care 
providers who provide services along the care pathway described in chapter three. The topic of 
focus was chosen to address the training needs identified in the health system assessment. The 
needs of the target learners, including the working environment, technological and economic 
needs were identified. Analysing these factors helps to ensure the relevance of the course 
within the realities of the health system.12, 43  Over the long term, the course is expected to 
improve provision of DR services. Accreditation is an anticipated need, and this is expected to  
be provided through local training institutions in the future.43 This is not easy to achieve, but 
experts from the two institutions that currently offer ophthalmology-related training in the 
country have reviewed the course materials, as a starting point for further engagement.  In this 
way, health system strengthening (HSS) through development of an online course has potential 
to influence education services and health services, and support local institutions.44, 45 It also 
shows the need for sustainability and evolution of HSS interventions over time, in response to 
local needs.44, 46 However, this long-term impact of the course will need to be evaluated. 
Although the course was developed for the local context, it was also intended to have an 
appeal to an international audience. As other researchers have documented, developing an 
online course from a LMIC is challenging because the audience might undervalue the quality of 
the course content, since the MOOC originated from an LMIC.47, 48 To address this potential 
challenge, quality assurance through peer review from experts from a mix of income settings 
was planned. It is significant that institutions in LMICs offer only 3% of the health and 
medicine-related online courses, and this is partially attributable to this barrier to entry into 
knowledge production and curation.49, 50  Another factor might be challenges related to weak 
health systems, where health workers are few and there is lack of time and incentives to 
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engage in knowledge production.45 What is critical is that the unequal production and 
accumulation of knowledge is as worrying as the inequitable distribution of wealth and 
health.48, 51  Academic and professional communities in LMICs may be missing opportunities to 
address this gap. 
Subject matter analysis is essential to defining the content of a course. Experts 
(ophthalmologists and physicians) who are active in both clinical and training services were 
consulted and clinical guidelines on diabetes eye care were reviewed.52-55 Based on this 
consultation, the literature review on the subject (chapter two), the gaps identified in the 
health system assessment as well as the standards set in clinical guidelines, there was 
consensus that the course should be organized in four units (Box 1). In consideration of the 
principles of adult learning, the course will be available throughout the year, to provide flexible 
access to learners. 
A search for existing online resources identified a few courses relevant to diabetes eye heath, 
such as from the International Centre for Eye Health56 and the International Diabetes 
Federation.57 However these courses are only available during two or three runs in a year to 
participants who register, which is a limitation to access for the target population.58 Using best 
practices to design, develop, implement, and evaluate courses designed locally can provide 
creative solutions to this accessibility gap.43 At the same time, the local courses can include 
links to the external online courses, thus maximising access to all the available learning 
opportunities. The strategic linking of the course to other online courses offers an opportunity 
to expand the educational scope of this HSS initiative. This might also trigger the development 
of partnerships to offer additional courses. 
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Table 6-3 Course Units
Unit 1 Understanding the disease
Unit 2 Understanding the patient
Unit 3 Understanding the health care provider
Unit 4 Understanding the health system
6.5.2 Course Design  
The contextual realities of the target learners were considered as design decisions were made. 
English was chosen as the preferred language because it is the language used in educational 
programmes in Kenya. Language appropriateness and tailoring materials to reflect country-
specific health care realities in LMICs are crucial to successful CPD.12 In addition, the use of 
English will reduce barriers to access by an international audience.49, 58 The technological 
requirements for this course are access to a computer or a smart phone and internet 
connection. The course is designed to be compatible with all internet browsers at no cost to 
the learner, in order to promote access. In line with the principle of autonomy, participation is 
voluntary, self-paced, and without rigid deadlines, which allows learners to revisit the materials 
whenever they need to. Learners from LMICs are known to favour these attributes. 6, 47
The instructional materials include different media elements such as text, graphics, images, 
research papers, and short .mp4 videos that are downloadable for offline use. Simplicity in 
course design and low technological demand are imperative given the uneven technological 
resources of learners.15, 58 All videos are captioned and text description is provided for non-text 
visuals, to create engaging learning experiences for adult learners with different skill-sets, 
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interests or disabilities. Adult learners also learn better where they can see the immediate 
value and application of content, hence real world case scenarios are included. Useful 
hyperlinks to relevant external resources are also provided to facilitate autonomous 
exploration and curation, without overwhelming the learner with too many of them.15 To allow 
the learners to reuse the materials, all the course materials are published under a creative 
commons licence.59
Social media use is integrated in the course design, since learners are likely to have used this 
strategy to accumulate experience in digital literacy, and this can stimulate active engagement 
of adult learners.24 The course uses Google Drive and Dropbox to manage documents, Flickr for 
photographs, and Youtube for videos. Twitter and LinkedIn are used to connect with the course 
instructor. Pre- and post-course surveys will further enhance learner-instructor 
communication.  
Open-source online platforms for hosting the course were investigated, and the free version of 
WordPress was chosen for the course website.  WordPress has also been used before for 
educational purposes.60 Some of the attributes of the platform are popularity with users, free 
access to learners, user-friendly content editing options, ease of administration, large variety of 
plugins, allowance to export content to other online platforms and opportunity for use on 
computers, tablets or smartphones. The setup of the website requires technical expertise, 
therefore it is recommended that a website designer be included in the course development 
team.24
Storyboarding is the systematic and iterative process where all the elements to be included in 
each unit are mapped.30 Storyboarding is helpful for pointing out steps that might be 
overlooked in instructional sequence, and allows for modification of the course structure.30, 32
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Storyboards shared with collaborators, such as mentors and web designers, enhance shared 
understanding. The storyboard was prepared on a Microsoft Word template, since it is 
predominantly text-based. Each of the four units is designed to take a maximum of 1 week if 
learners allocate 3-4 hours per week, which can be spread within the week. The course 
duration is four weeks. This is important because the most prevalent point of dropout from 
online learning occurs after week 4, which suggests that a four-week duration is more 
convenient for learners than longer courses.58 Each unit is composed of several topics, which 
are chunked into short sections. This signposting makes it easier to navigate the course.31 The 
stakeholders reviewed the outputs from the design phase (Table 1) for quality assurance. 
6.5.3 Developing course content 
The storyboards created in the design phase were used to develop learning materials. This 
process required thinking through each step of the storyboard, with an unexpectedly high 
investment in time and labour. Preparing content for each week took several weeks, and as 
other researchers have found, the time required and the opportunity cost are often 
underestimated.50, 61 This challenge was overcome by dedicating blocks of time to content 
development, and working with mentors, in addition to utilizing the evidence synthesis and 
writing skills developed over the PhD. It is advisable not to underestimate the amount of 
workload involved, especially for course developers with other responsibilities.47 Collaborative 
creation of course materials by a team of experts may alleviate this challenge, as the heavy 
workload can be shared.12 However feasibility may be constrained by existing health workforce 
challenges in LMICs and course development may divert time from other activities such as 
service delivery, research, teaching or administration.50 On the other hand, online courses may 
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enhance the effectiveness of the limited faculty.12 This raises the question as to how best to 
calibrate participation such that LMICs contribute and gain from online learning. 
Preparing instructional audio-visual content was challenging because it required access to 
studios, compressing the content into short lectures, recording in front of cameras and editing 
the multimedia materials. Like in other LMICs, access to resources and expertise for digital 
capture was limited at local level.47 Once the slides and scripts were ready, the multimedia 
team at LSHTM filmed the narration and provided video editing services.  Access to these 
institutional resources was an opportunity provided by being a student at the school and by 
linkage from the mentors. Building on such educational presence and networks is therefore 
pivotal to successful completion. Recording was challenging because speaking in front of a 
camera with no audience did not feel natural. In addition, listening to playback of my own 
voice was quite disconcerting, as the voice did not sound authentic. The literature reports 
similar experiences with digital production and these can potentially slow progress.61 However 
mentorship helped to manage expectations and acclimatize to the experience, hence 
increasing efficiency.37
Developing course materials requires balancing the use of multiple formats to enhance 
usability and ensuring scientific accuracy and clarity.15 Metadata such as an overview of the 
course and strategic instructions that have been provided at the start of the course help to 
enhance navigation. To facilitate comprehensibility, precise language has been used. Sentences 
have been formulated in a way that is not too abstract or scientific.   The webpages are not 
text-heavy, as this often has an adverse effect on readability. Medical educators and subject 
experts have reviewed the materials and their suggestions for improvement, such as including 
definitions of important concepts, have been incorporated. 
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Adult learners are self-directed, so although the four course units are arranged in sequence, 
learners can complete the units in any order. Further, adult learners are goal and relevancy-
oriented, so the practical application to the care of PLWD is emphasised. In order to provide for 
personalized learning, which is important for adult learners, ‘to do’ prompts, questions for 
reflection and links to optional resources are provided for those interested in deeper study of 
particular concepts. This enables learners to apply autonomy and personally select from a 
diverse array of actions. Other online courses have attempted to personalize learning through 
weekly course announcements and emails that may make learners feel more personally 
connected.15, 60, 61 However, such a high level of personalization was beyond the scope and 
feasibility of this course, since it would require extensive instructor support all year round.  
6.5.4 Implementation  
The course content was uploaded to the WordPress course site: 
https://oerdiabeticretinopathy.wordpress.com/. The course instructor, the mentors, and a 
learning designer have done usability testing of the site on a variety of browsers and devices. 
Feedback from this usability testing helped to fix errors (duplicate pages and inactive 
hyperlinks) in navigation and improve user experience.  
For the course to have acceptability among learners, it should be user-friendly and meet the 
expectations of the users. Pilot testing with users can be helpful to establish the content 
validity (the utility of the course for training on the different components of control of DR) and 
face validity (the appropriateness and relevance to real life needs of the users of the course).62
For that reason, after testing usability the course was piloted by ten potential learners and ten 
potential instructors. They were asked to run through the course slowly, identifying unforeseen 
practical difficulties and providing feedback. Most of the feedback related to the format of the 
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website, and not to the content. In addition, users recommended accreditation and 
certification by an academic institution, which is not currently available but is planned for the 
future, as already discussed.  Instructors recommended that such certification should be based 
on a pre-test and post- test scores so that educational effectiveness can be measured.  
6.5.5 Evaluation 
In each stage of the ADDIE framework, formative evaluation was constantly applied to identify 
limitations in course outputs (Table 6-1), and to modify them appropriately. Once the course is 
launched, learning analytics from the course site will be used to track learner engagement. In 
addition, Kirkpatrick’s framework for evaluating training will be used to evaluate the 
effectiveness of learning on the course. This framework focuses on evaluation at four levels: 
immediate reaction to the training, learning obtained from the training, behaviour change and 
results (effect on the initial training gap).63 The first two levels (reaction and learning) will be 
assessed using the post-course survey as well as pre-test and post-test scores. To evaluate the 
extent to which the course supports behaviour change in clinical practice, a questionnaire will 
be emailed to learners three months after the course. The effect on training needs and 
performance will be assessed in a subsequent needs assessment.  
6.6 Potential challenges in running the online course 
The literature reports a variety of barriers to implementation of online courses.45, 47, 49, 50  These 
include existing norms and behaviours, the lack of appreciation of investment in online 
learning by the academic and health community, and lack of corresponding alignment of 
resources. The official launch of the course as part of the activities organized by the Ministry of 
Health for the World Diabetes Day 2019, and course advertisement through the mailing lists of 
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professional groups will promote engagement with learners and educators. This integration 
into local structures and processes is expected to facilitate local ownership and 
implementation of the course at scale in Kenya.45
An educational website needs to be maintained over time and content updated, if it is to be a  
sustainable solution.15 The instructor will update content annually, and collaboration with 
institutions and the Ministry of Health will help to overcome the funding and opportunity 
costs. Other researchers have found that support for the long-term implication of maintaining, 
updating and upgrading the site is often overlooked, yet it is vital to the quality of the online 
courses.12, 15, 50 Institutional and country-level support will be critical for sustainability.36
Adapting to the online environment can be a challenge for both learners and facilitators.45 The 
WordPress interface used in this course is simple to use, therefore users are unlikely to 
experience technical problems with the site, however this will be monitored and technical 
support provided.60 The popularity of WordPress increases the risk of academic fraud, viruses 
or breaches of data protection, but this is not considered a major concern as all the materials 
are open access.60, 64
Other researchers have reported the inherent challenges in the evaluation of online courses.  
For example, high dropout rates and the need to adjust for contextual factors affect the validity 
and complexity of assessment of online learners.61, 65 These are challenges that the online 
course community must learn to overcome. Although there are no easy solutions, the use of 
diverse methods of evaluation in this course will provide evidence on the effectiveness of 
learning.65 The long-term impact of these evaluation strategies will need to be evaluated. 
As mentioned earlier, certification is an important motivator for learners in online courses in 
health and medicine in LMICs.6, 49, 61 Assessments for accreditation will not be provided on the 
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platform, but through institutional websites once the course is accredited. Educational 
institutions accredit courses through a rigorous quality assurance, which will provide further 
quality assurance, in addition to the peer review already mentioned. The accreditation process 
is likely to be a time-consuming and complex process, which is a major challenge. However, the 
engagement of stakeholder institutions may provide an enabling environment.  
6.7 Lessons learnt during course development 
The learning gained from the PhD research was a significant starting point in terms of subject 
domain knowledge. Reflecting on the principles of control of DR gained from the PhD was a 
useful prompt for knowledge transfer within the health system. The potential impact of public 
health training on health system strengthening in LMICs has previously been examined.66, 67
Given that health workers in Kenya also often work as educators in training institutions 
(chapter three), health service delivery and education are closely connected. Considering the 
unique demands of this dual role, it is important to understand how learning from a PhD might 
interact with the health system and the education context, thereby enhancing capacity for 
health system strengthening. This is of interest because success of training researchers for 
Africa should not only be measured by research outputs, but also by the ability to execute 
other programmes that will advance population health in Africa.67
Being a mentee from Kenya (LMIC) and my mentors being from other income settings provided 
rich diversity within the mentorship process. The diversity fostered access to learning from 
contrasting perspectives and led to a concrete conception of the detailed task of course 
development in the early stages of course development. This was useful because at the 
beginning I was unfamiliar with the online course design process, leading to underestimating 
the complexity of the design task. Mentorship illuminated the strategic opportunities, for 
226 
example, the digital technologies for online courses. It also allowed the recognition of 
contextual complexities that needed to be overcome, such as how to make a business case for 
free online courses, which is a nascent concept in LMIC training institutions.47 In addition, 
mentoring helped to contextually apply theories of learning and theories of course design, 
either explicitly or implicitly, to the designing of the course.68 The literature reports that 
interactions between foreign mentors and local researchers may create tension or conflicts 
due to variations in mentoring culture, but this was not experienced.41, 69
6.8 Conclusion  
Reflecting on the synergy between the academic skills important in both PhD and course 
development can provide an understanding of the value that can be leveraged from a doctoral 
programme. The academic discourse around the potential contribution of PhD studies in 
African health systems is ongoing.67 There is growing recognition that such training should 
provide the skills to apply theories to inter-relationships between health and other factors, 
such as education.51, 70 In particular, doctoral researchers need to be agents of change and seek 
solutions to the challenges in education, research and health caused by scarce resources and 
other contextual factors. This is because they have the advantage of familiarity with local 
challenges, context-specific determinants, and the expertise to apply relevant global concepts 
to local problems.  As an example, effective course development requires a facilitator who is 
familiar with the subject field and possesses the requisite expertise, which a PhD provides.12, 62
There is potential for doctoral programmes to contribute to capacity building for the health 
workforce. This model can be replicated in other settings in sub-Saharan Africa with similar 
health workforce challenges.  
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Section D 
DURE Cluster randomized 
controlled trial 
“I stand before you and the world humbled by this recognition and uplifted by the honor of 
being the 2004 Nobel Peace Laureate. As the first African woman to receive this prize, I accept 
it on behalf of the people of Kenya and Africa, and indeed the world. I am especially mindful of 
women and the girl child. I hope it will encourage them to raise their voices and take more 
space for leadership.” 
 Prof Wangari Muta Maathai (1940-2011) 











      The DURE trial 
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Chapter Seven 
Effectiveness of peer support to increase attendance at DR 
screening - a pragmatic cluster randomized clinical trial 
Study protocol 
7.0 Overview 
A prospective cluster randomised clinical trial (RCT) was conducted to investigate  
whether a peer support can increase attendance to diabetic retinopathy screening (DRS). 
Members of diabetes support groups who have never had DRS were recruited into the study. 
Diabetes support groups were randomised on a 1:1 basis to one of the following arms: 1) 
Intervention arm, to receive a peer led health education intervention, in addition to usual care 
provided in support groups 2) Control arm, to receive usual care alone. The proportion of 
participants attending DRS was evaluated over a six months period. 
7.1 Intervention development 
The intervention was developed following the guidance provided by the United Kingdom 
Medical Research Council’s (MRC) guidelines on developing and evaluation complex 
interventions.1
1. Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M. Developing and 
evaluating complex interventions: the new Medical Research Council guidance. BMJ. 
2008;337:a1655. https://doi.org/10.1136/bmj.a1655. 
The MRC recommends that interventions are developed systematically, using the best available 
evidence and appropriate theory to understand the likely process of change. Interventions 
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should then be tested in a pilot phase targeted at feasibility objectives before full-scale 
implementation. A clear description of the intervention and a detailed report of both process 
and outcome evaluations of the trial are important to enable replication and synthesis of 




• Identifying the 
evidence 
• Developing theory 





effectiveness of peer 
support to increase 
attendance to DRS 
• Understanding the 
change process: what 
worked, for whom and 
why 











up of clusters and 
participants 
Figure 7-1: Development, piloting, implementation and evaluation of the clinical trial 
Research paper 5 gives a detailed description of the methods for this clinical trial in Kirinyaga, 
Kenya. This paper was published in the journal BMC Implementation Science in December 2018 
after peer review. 
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Subsequent chapters provide the results for the pilot trial (chapter 8), process evaluation 
(chapter 9) and outcome evaluation (chapter 10). 
7.2 Research Paper 5 
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Abstract
Background: All patients with diabetes are at risk of developing diabetic retinopathy (DR), a progressive and
potentially blinding condition. Early treatment of DR prevents visual impairment and blindness. The natural history of
DR is that it is asymptomatic until the advanced stages, thus annual retinal examination is recommended for early
detection. Previous studies show that the uptake of regular retinal examination among people living with diabetes
(PLWD) is low. In the Uptake of Retinal Examination in Diabetes (DURE) study, we will investigate the effectiveness of a
complex intervention delivered within diabetes support groups to increase uptake of retinal examination.
Methods: The DURE study will be a two-arm pragmatic cluster randomized clinical trial in Kirinyaga County, Kenya.
Diabetes support groups will be randomly assigned to either the intervention or usual care conditions in a 1:1 ratio.
The participants will be 700 PLWD who are members of support groups in Kirinyaga. To reduce contamination, the
unit of randomization will be the support group. Peer supporters in the intervention arm will receive training to deliver
the intervention. The intervention will include monthly group education on DR and individual member reminders to
take the eye examination. The effectiveness of this intervention plus usual care will be compared to usual care
practices alone. Participant data will be collected at baseline. The primary outcome is the proportion of PLWD who
take up the eye examination at six months. Secondary outcomes include the characteristics of participants and peer
supporters associated with uptake of eye examination for DR. Intention-to-treat analysis will be used to evaluate the
primary and secondary outcomes.
Discussion: Eye care programs need evidence of the effectiveness of peer supporter-led health education to improve
attendance to retinal screening for the early detection of DR in an African setting. Given that the intervention
combines standardization and flexibility, it has the potential to be adopted in other settings and to inform policies to
promote DR screening.
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Background
The global prevalence of diabetes has escalated in recent
decades, with important implications on the health system.
In 2015 the International Diabetes Federation estimated
that there were 415 million people with diabetes aged 20–
79 years (global prevalence of 8.8%), and this is predicted to
increase to 642 million by 2040 (global prevalence of
10.4%). [1] The incidence and prevalence of diabetes is in-
creasing disproportionately faster in resource-poor regions
and 75% of people living with diabetes currently reside in
low- and middle-income countries. [1–3] This dramatic in-
crease in incidence is occurring in both rural and urban
areas. [4] The regional prevalence for Africa was 3.8% in
2015, and the number of people with diabetes in this con-
tinent is expected to increase by 140% between 2015 and
2040. [1] In Kenya, the STEPwise survey for risk factors of
non-communicable diseases in 2015 found a diabetes
prevalence of 2% in the population 18–69 years, and 5.4%
in the population 45–59 years. [5]
All patients with diabetes are at risk of developing dia-
betic retinopathy (DR), the most severe and progressive
ocular complication of diabetes. One third of patients
with Type 2 diabetes have DR while 10% of them have
sight-threatening DR, which represents a significant
public health concern. [6, 7]. A population-based study
in Nakuru county, Kenya found that 35.9% of people liv-
ing with diabetes (PLWD) have DR [8]. Visual impair-
ment and blindness from DR is preventable mainly
through early detection and timely treatment. Since DR
is asymptomatic until the advanced stages, regular ret-
inal screening is of paramount importance. DR meets
the Wilson and Jungner (1968) criteria for screening,
and current clinical guidelines support annual screening
[9–12]. Participation of PLWD in regular retinal screen-
ing, has been shown to be clinically effective in prevent-
ing blindness and is also cost-effective. [13, 14]
In developed countries, health systems have formal sur-
veillance programmes for detection of DR. Kenya does not
have a national population-based DR screening service
where PLWD are systematically invited for screening, but
opportunistic screening is available in various hospitals.
Importantly, participation and re-participation rates in
screening for DR are sub-optimal in Kenya and other re-
source poor settings. [15–22]. The determinants of the at-
tendance to retinal examination are complex and include
both supply and demand factors. [23, 24] For instance, a
Tanzanian study found that PLWD also have limited
awareness on diabetic retinopathy, particularly on the
need for annual eye examination [25]. This is a barrier
that appropriate demand side interventions could address.
A health system assessment conducted before this study
has shown that 87% of PLWD in Kenya have an unmet
need for annual retinal screening. [22] One of the gaps as-
sociated with this is the lack of strong links between
diabetes services and eye care services. There is need for
context-specific pragmatic solutions to address this gap.
A systematic review of interventions to increase diabetic
retinopathy screening attendance reported that several
strategies are effective, including those targeting the pa-
tient (e.g. increasing patient awareness), the health care
practitioner (e.g. improving adherence to recommenda-
tions) or the organization (e.g. improving patient records)
[26]. Members of diabetes support groups (DSGs) are a
population subgroup that might benefit from additional
support to initiate screening, and adhere to re-screening.
Targeting screening interventions towards PLWD in DSGs
provides a timely opportunity for three reasons. Firstly this
is a community resource that is already available in the
community setting. Secondly this population is likely to
consider health as an important rationale for behaviour
change and the health seeking behaviour of members is
potentially malleable to change through peer support. Peer
support refers to the provision of emotional and informa-
tional support from a created social network member who
is considered an equal and who has characteristics similar
to the target population. [27] Thirdly it is an economical,
culturally-sensitive and flexible intervention for improving
diabetes care and outcomes. [28, 29]
Self-efficacy is a direct predictor of health behaviour, ac-
cording to the social cognitive theory and the self-efficacy
theory [30] [31]. Self-efficacy is a predictor of uptake of
screening for DR among PLWD. [32] Interventions that
improve patients’ self-efficacy decrease perceived barriers
and improve the likelihood of initiating the desired health
behaviour. There are four main sources of self-efficacy [31]:
(i) Successful performance accomplishments (e.g. having
attended a previous eye examination) (ii) vicarious experi-
ence (e.g. learning that peers have successfully attended an
eye examination) (iii) verbal persuasion (e.g. encouragement
and recommendation to go for an eye examination by a
trusted person, such as a peer or a health care worker) and
(iv) psychological cues (decreased sense of isolation of
PLWD interacting with a peer, or increased awareness of
the risk of DR after receiving educational messages on DR).
Fig. 1 shows how self-efficacy for taking a retinal examin-
ation might improve through peer support in the Uptake of
Retinal Examination in Diabetes (DURE) study.
Rationale
Although there is evidence that peer support improves
glycaemic control and quality of life among adult PLWD,
and that peer support is both cost-effective and flexible
[33], evidence on whether or not it would increase uptake
of eye examination in an agrarian African population is
lacking. DURE study aims to provide this evidence.
The development of the intervention has been in-
formed by the following:
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i. A review of the literature on peer support in diabetes
[34–42] and other chronic conditions in resource
poor settings. [43–51] There is evidence that peer
approach is widely used in the management of
diabetes, to promote physical activity, healthy eating
and improvemt in glycaemic control.
ii. The results of a recent published meta-analysis of
randomized clinical trials on effectiveness of
peer-support for glycaemic control in Type 2
diabetes [52] which concluded that peer support
had a significant impact on improving HbA1c
levels in patients with poor glycaemic control.
iii. A health system assessment in three counties of
Kenya conducted before this study showed that
services for DR are underutilised: 74% of PLWD
have never had a retinal examination in their
lifetime, and 76% have never had a recommendation
for an eye examination by their diabetes care
provider [22].
iv. Evidence that improving health literacy, provider
patient interaction and linking patients to health
care improves patients’ self-efficacy and glycaemic
control. [42, 53, 54]
Aim
To evaluate, by means of a pragmatic cluster randomized
controlled trial, the effectiveness of a peer supporter- led
community education programme in Kirinyaga county,
Kenya.
Research questions
1. To what extent can health education delivered by
peer supporters increase the demand for annual
retinal examination among PLWD?
2. What are the contextual factors that determine the
effectiveness of the intervention?
Hypothesis
The hypothesis is that the proportion of PLWD having a
retinal examination for DR is higher in diabetes support
groups (DSGs) allocated to the peer supporter-led edu-




This is a two-arm pragmatic cluster randomized con-
trolled trial with additional process evaluation. It is a
complex intervention to empower patients to undergo
an annual eye examination. It is complex because those
delivering and receiving the intervention require to dem-
onstrate different behaviours and to engage in multiple
interactions. [55] Its design is guided by the Medical Re-
search Council framework for complex interventions,
Fig. 1 Peer support and self-efficacy for retinal examination
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available at https://mrc.ukri.org/documents/pdf/com-
plex-interventions-guidance/ [55].
The study will be conducted in accordance with the
Consolidated Standards of Reporting Trials (CONSORT)
2010 statement and its extension to cluster randomized
clinical trials (cRCTs). [56, 57] The cRCT design is
adopted for the following reasons: (i) to reduce the effect
of intervention contamination, as compared to an indi-
vidually randomised trial, as patients in the same DSG
often interact with one another (ii)to make it feasible to
study the effect of the intervention at the individual level
and the cluster level.
Definition of eye examination for DR
We define this test as: measurement of visual acuity and a
retinal examination through a dilated pupil conducted by
an eye care worker (using either an ophthalmoscope, a slit
lamp or a retinal camera). Retinal examination for DR and
DR screening in this protocol are used interchangeably.
Study setting
This trial will be conducted among the DSGs in Kiri-
nyaga county, Kenya. The target population is members
of the 16 support groups and volunteer peer supporters
within these groups. Eye examination will be conducted
at Kerugoya County Referral Hospital.
Sample size calculation
We aim to randomize seven diabetes patient support
groups (clusters) with an average membership of 50 each
to each arm. The study thus has two arms of equal size
(350 participants in each arm).This sample size has been
calculated using standard formula for sample size for
cRCTs and taking into consideration the primary outcome
of interest [58, 59]. A 15% loss to follow-up contingency
has been built into the sample size calculation. This sam-
ple size would have 80% power to detect a two-fold differ-
ence in the proportion of PLWD who take up eye exam,
with a 5% level of significance. Member registers of the
DSGs will be obtained from the team lead. These registers
will be the frame for identification of participants for the
study.
Pilot study
A pilot study will be conducted in two clusters with 50
PLWD in each arm (intervention arm and control arm), se-
lected through convenience sampling. The pilot will be
conducted for 3 months and will involve: Testing study op-
erational procedures; Implementation of the intervention in
the intervention clusters; Testing study instruments for
quantitative and qualitative data collection (questionnaires,
observation sheets and topic guides); Outcomes evaluation.
The primary outcome will be the proportion of participants
in each arm that take up eye examination.
Inclusion and exclusion criteria
Participants will be included if they are PLWD aged 18+
years, will reside in Kirinyaga for the next 12 months,
are members of DSGs in Kirinyaga, have a mobile phone
and are willing to participate in the study. In addition to
these criteria, peer supporters will be selected from
those willing to participate as peer supporters, willing to
commit two days for training and many hours of peer
support, fluent in Kikuyu or Kiswahili, and have had a
retinal examination for DR before the start of the study.
PLWD who will be excluded are those already attending
annual retinal screening, have a severe debilitating med-
ical condition, are already on treatment for DR or do
not meet the inclusion criteria.
Recruitment
Eligible participants will be recruited into the study by the
research nurse, who will also obtain informed consent at
the cluster level using the consent form approved for the
study. Participants will be asked for consent to receive the
intervent ion and for follow up. If the patient does not
consent, reasons will be sought and recorded. After re-
cruitment, a unique identifier number will be issued. All
those recruited will be given an identification card which
contains the name and a unique study number. They will
be required to present this card at the eye clinic when they
go for retinal examination. The flow diagram for the study
is presented in Fig. 2.
Randomization
Randomization will be done after recruitment. The
randomization will be through computer generated random
numbers prepared by a statistician (DM) using STATA ver-
sion 15 (StataCorp 2017), away from the project site. The
allocation sequence will be concealed from the other trial
personnel. Block randomization with block sizes of two or
four will be used to ensure that the two arms are balanced
over time, and to maintain unpredictability of allocation.
Masking will not be possible but only the research team will
have formal knowledge of the allocation.
Intervention
Two peer supporters will be recruited from each cluster in
the intervention arm (one male and one female). These
peer supporters will be selected from volunteers who meet
the specified criteria. They will receive structured training
in a two-day workshop. The content of the training ses-
sions includes: an introduction to the project, the role of
the peer supporter, diabetic eye disease and DR, retinal
examination for DR, communication skills, managing
groups, confidentiality and behaviour change. The training
team will include a certified diabetes educator.
They will receive support to retain them in the study
(airtime vouchers for delivering the telephone reminders).
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Fig. 2 Flow diagram for the trial
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They will also receive a weekly telephone call from the
principal investigator for support. The intervention group
will receive the usual care, a monthly group talk and a
monthly individual telephone reminder to attend retinal
examination. The key messages to be delivered in the
group talk are shown in Table 1. The control group will
receive the usual standard of care, which consists of ad
hoc diabetes educational talks, blood sugar and blood
pressure measurements during support group meetings.
Data collection
Standardized operating procedures will be used to col-
lect data at baseline, using approved tools in the study
proposal. Demographic and anthropometric (height,
weight, waist circumference) as well as blood pressure,
blood sugar and visual acuity will be recorded at base-
line. Study participants will be given their body mass
index and blood pressure measurements in the field, at
the point of data collection; where these results are ab-
normal, participants will be referred to a health worker.
Completed questionnaires will be monitored and data
entry staff will be trained to minimize errors in data
entry into computerized databases. Identifiers will be re-
moved from participant data, and all paper data will be
stored in locked cabinets. Electronic data will be pass-
word protected for confidentiality. A detailed data man-
agement plan is included in the study proposal.
Follow up
Participants in both arms will be followed up for six
months to assess attendance to retinal examination. Par-
ticipants who are lost to follow up will be identified at
the monthly contact points with peer supporters. Three
home visits will be made to trace participants who are
lost to follow up. Characteristics of those lost to
follow-up and reasons for loss will be evaluated.
At the end of six months two separate focus group dis-
cussions will be held with two participants from each
intervention cluster in each arm (n = 14 for each focus
group discussion) to explore the experience of the support
groups with the intervention. A focus group discussion
will also be held with peer supporters to explore the im-
pact of ‘peer supporting’ on the management of their own
diabetes, and their role in the health care team.
Process evaluation
A process evaluation will be conducted using qualitative
interviews and non-participant observation (Table 2).
The findings of the process evaluation will be evidence
Table 1 Key messages to be delivered to participants
Messages on diabetic eye disease
1 Diabetes causes several complications in the eye, including DR
2 DR is a progressive condition that leads to blindness if treatment is not provided in good time
3 DR has no symptoms until the advance stages
4 An eye check by an eye specialist can detect damage to the eyes before symptoms develop
5 All persons with diabetes should have their eyes checked once every year by an eye specialist, even before any symptom or
poor vision develops
6 Do not wait for your vision to get worse or for any other symptom to occur before you see an eye specialist
7 If eyes are found to be normal at your eye check by an eye specialist, please continue with an eye check annually
8 If you notice any abnormality with your eyes between your clinic appointments, visit the eye specialist as soon as possible.
It may not mean that you have diabetic eye disease, it may be a simple problem that requires treatment.
9 The eye check may help to determine if your sugar, blood pressure, and lipid control needs to be re-assessed.
Good control of your blood sugar levels, blood pressure and cholesterol reduces the risk of diabetes-related sight loss.
10 If you are found to have DR the eye specialist will inform you about the diagnosis, and how it will be treated.
Messages on retinal examination for DR
1. Ensure you have a dilated eye examination at the eye clinic at least once a year.
2. You do not need to have a referral note to go to the clinic. However we will give you a card to present at the clinic.
3. At the eye clinic, your vision will be checked first.
4. A examination for DR is different from any other type of eye examination. It is called a dilated eye examination.
5. In this examination, the doctor puts eye drops into your eyes to dilate (widen) your pupils. This allows the doctor to
have a good view of the back of the eye. Both eyes need to be examined.
6. The examination is not painful. When the eye drops are first instilled, there may be a slight stinging sensation but
this only lasts about a minute. You may feel uncomfortable because of light sensitivity and blurred vision once the pupils are dilated.
7. Do not be afraid to ask the doctor questions about the examination or about diabetic eye disease.
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on why and how the intervention worked. The following
domains of the intervention will be evaluated:
1) Whether the intervention activities are
implemented as planned (fidelity).
2) The extent to which the intervention reaches the
PLWD (reach).
3) The degree to which PLWD are exposed to the
intervention package (dose).
4) The extent to which the intervention is acceptable
to PLWD and to eye care workers (acceptability).
5) The contextual factors that may have an influence
on the theory of change (context).
Assessment of outcome
Primary outcome
Rates of eye examination in each arm will be assessed in
each arm at the end of six months. This outcome will be
assessed by an independent and masked research nurse
who will review the eye clinic records of all participants.
The outcome will be recorded on the outcome evalu-
ation form for each participant. The form contains iden-
tification details of each participant recruited into the
study (name, residence, telephone number) and will thus
differentiate them from other patients who are examined
in the eye clinic. The form does not contain information
on the intervention arm to which the patient is allo-
cated. The project manager will receive the completed
outcome evaluation forms and link the data to the par-
ticipant database for each arm.
Secondary outcomes
These outcomes will be assessed at six months:
1. Contextual factors that affect the effectiveness of
the intervention
2. Characteristics of peer supporters associated with
uptake of eye examination
3. Barriers to uptake of eye examination among
PLWD.
These outcomes will be evaluated using the database
for participants and peer supporters, as well as data from
focus group discussions with peer supporters and
in-depth interviews with eye care workers at six months.
Statistical analysis
Baseline comparability of the two groups will be assessed
to check that the important confounders and baseline
characteristics that would affect uptake of eye examin-
ation are balanced between the two arms through ran-
domisation. If the arms are found to be substantially
Table 2 Domains and methods for process evaluation
Source Domain Data collection method Stage of the trial






2 Focus group discussions at
6 months
At recruitment (n = 700)
Three months: n = 10% pf participants
in each intervention cluster(35)









PI Field notes N = 2 group meetings per intervention
cluster during the trial (14)






PS Diary for telephone calls
PS Group session report form
Focus group discussion at 6 months
After training (n = 14)
Through the trial (n = 14)
Throughout the study (1 report form




Context In-depth interviews At 6 months
N = 3
N = 7
Research project manager Reach
Fidelity
Dose delivered
Reports At recruitment of PS
At training the PS
At 3 and 6 months
Research nurse Outcome evaluation
procedures
Report At 3 months and 6 months
Study steering committee Context Spreadsheet of external events that
may have affected study outcomes
At 6 months
PI Principal Investigator, PS Peer supporter
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imbalanced an appropriately adjusted logistic regression
model will be used.
Study-wide pooled analysis will be conducted for the
primary outcome. Missing data will be reported using
standard flow charts. Repeated measures mixed models
regression with adjustment for age, sex, and baseline an-
thropometric measures will be used to compare the two
groups for the primary outcome.
Analysis will be conducted on intention-to-treat basis.
Regression analysis will be used to determine the extent to
which individual and support group characteristics are as-
sociated with the primary outcome. Models for comparing
continuous outcomes will use linear regression while
models for categorical outcomes will use logistic regression.
Kaplan-Meier analysis will be used to plot the survival
curves for both treatment arms. Cox regression will be used
to assess the impact of the intervention on time to first eye
examination. The hazard ratio will be estimated with Cox
regression, adjusting for substantial baseline imbalances if
appropriate. Interim analysis is not planned.
Data monitoring
The principal investigator will coordinate and monitor
all recruitment, intervention and follow up procedures.
A data monitoring committee will not be required.
There is no reason to expect significant adverse effects
and there are no stopping rules. The principal investiga-
tor will have access to all the trial data sets.
Harms
Neither arm of the trial has serious anticipated harms. The
retinal examination involves the use of mydriatic eye drops.
This may cause temporary blurring of vision, but this is
only expected to last for a few minutes or hours. In this trial
the drugs will be instilled by highly experienced clinicians,
and patients will be made aware of this effect beforehand.
Any unexpected effects of the trial will be documented and
reported to the sponsor and ethics committees.
Dissemination
The dissemination strategy will include a summary of
the findings for support groups, a report to Kerugoya
County government and the Ministry of Health Kenya,
publications in peer-reviewed journals and presentations
at national and international conferences.
Post-trial care
It is recommended that all PLWD have an annual retinal
examination for DR, and more frequent examinations
are required for those found to have any stage of DR.
This is best practice that is recommended by the na-
tional guidelines for screening and management of DR
in Kenya. [12] The service will continue to be available
as routine care to PLWD at the Kerugoya County Refer-
ral Hospital beyond the study.
Discussion
This study is pragmatic in that it tests the effectiveness
of this intervention in the real-world situation of the
community and the health system in Kirinyaga. There is
a strong need to develop interventions that can reach
PLWD populations in real world settings to ensure that
any effect found is generalizable.
Public health strategies to manage the diabetes and DR
in sub-Saharan Africa (SSA) are known to be inadequate
or non-existent. [60, 61] Given that we are at the emer-
gence of the epidemic, this is an appropriate time to de-
velop contextual interventions that will enable our health
system to cope with this challenge. To our knowledge, this
is the first study that has targeted the DSG population in
DR research. The use of peer support in DR is a relatively
new field and little has yet been published on the topic.
The trial is important for a number of reasons. For the
individuals with diabetes, this trial is in line with the
growing global focus on patient empowerment. The
PLWD will be empowered to demand for retinal exam-
ination, thus reducing demand side barriers to uptake of
the examination. These actively engaged PLWD will be
linked to eye care providers by the peer supporters. The
Chronic Care Model, which has been proposed as a suit-
able model for managing diabetes, emphasises on the
need to implement such links between patients and the
health system using community resources. [62] [47] As
all PLWD are at risk of DR, empowerment to initiate
and maintain screening will be beneficial to all.
For the support groups, if this intervention positively in-
fluences uptake of retinal examination, this could in turn
influence how the DSGs define their role. It has potential
to instigate a new agenda, making the groups key sites for
preventive public health initiatives that are adaptable, feas-
ible and embedded within support group culture. The
peer supporters will remain a valuable resource in the
DSG, which enhances sustainability of effect.
For Kirinyaga county, our study findings might help
the county (formerly district) health services to develop
initiatives to promote early detection of DR, by involving
DSGs, empowering patients and developing effective re-
ferral systems for DR services. The role the support
groups can play in strengthening the health system for
diabetic retinopathy in the county will become explicit.
The intervention will be provided by trained peer sup-
porters, which is a form of task-shifting. Task shifting is com-
monly applied in both diabetes and eye care services in our
setting. It helps to address the severe shortage of human re-
sources for health. The peer supporters will refer patients to
the eye clinic, thus linking diabetes patients with eye clinics
and strengthening the referral system in the county.
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In national context, Kenya aims to achieve universal
eye health, which includes care for DR. This study pro-
vides a framework for the promotion of retinal screening
in the population with the risk of developing DR. If ef-
fective, the intervention would be a sustainable and scal-
able to other countries.
In the international contexts, the DURE study has the po-
tential to extend current evidence and inform the scientific
debate as to whether embedding retinal screening into
DSGs is an effective next step toward meeting health goals.
The explicit use of a theoretical construct (self-efficacy
theory) to conceptualise the potential determinants that
would influence attendance to DR screening is a key
strength of the study. It enhances the understanding of
the plausibility of the intervention. The intervention pack-
age combines both standardization and flexibility, which
allows for scalability in diverse settings. A further strength
of this study is the inclusion of process evaluation, which
will assist in the interpretation of how and why the inter-
vention did, or did not, bring about the predicted effects.
The study has potential limitations. There are only 16
support groups in the county, which limits the possibil-
ity of increasing the number of clusters to further en-
hance statistical power. Delayed recruitment of the
required sample size and loss to follow-up during the
trial may be a challenge. In mitigation, a 15% loss to
follow-up contingency has been built into the sample
size calculation. Sample attrition can result from any in-
accuracies in the data collection, such as incorrect ad-
dress and telephone number information. Other diabetes
studies have documented that patients were unable or
unwilling to participate due to transportation issues and
lack of time or interest [63]. However this is not antici-
pated because: alternative contact information of partici-
pants will be documented, only one visit to the eye
clinic is required of participants, and the intervention is
expected to build participants’ self-efficacy. Attrition bias
may occur if whole clusters drop out, however this is
not anticipated as the study period is short.
Despite these limitations, DURE study illustrates the tre-
mendous potential of implementing pragmatic cluster
RCTs in the diabetes support group setting. Implementing
the trial in this at-risk population will be an invaluable
learning opportunity. Many of the lessons learned from
this experience could be useful to other research projects.
Trial status
At the time of submission, the trial is at the stage of
enrolment.
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Sample size calculation for DURE study 
The formula for calculation of sample size for cluster-randomized trials whose primary 
outcome is a proportion is 
                                                                                                                 (Hayes and Bennett, 1999) 
Based on this formula: 
Parameter Value Notes
Zα/2=the normal distribution value 
corresponding to risk for Type 1 error (at 95% 
confidence level) 
1.96
Zβ = the normal distribution value corresponding 
to β for statistical power at 80% 
0.84
pi0 = true population proportion in control group 0.12 (using data from the health 
system assessment – 12.2% of 
PLWD in Kirinyaga had ever 
had a screening eye 
examination 
pi1 = true population proportion in the 
intervention group 
0.24 Reflecting an expected two-
fold increase in the 
proportion that has ever had 
a screening eye examination 
n = number of individuals in each cluster 45 Increased to 50 to account for 
potential loss to follow-up 
k = coefficient of variation of the true 
proportions between clusters within each arm 
0.25 Estimate gained from 
assessment of pattern of 







c = number of clusters 6.9344 =7 clusters in each arm
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Chapter Eight 
Effectiveness of peer support to increase attendance at DR 
screening - a pragmatic cluster randomized clinical trial 
Pilot of the DURE trial  
8.0 Overview 
The previous chapter of this thesis (chapter 7) described the trial methods to addresses 
objective 4 in chapter 1 of the thesis: To develop and test an intervention through a 
randomized clinical trial (RCT) to improve eye care services for PLWD in Kenya. 
This chapter consists of a research paper that describes the randomised pilot and feasibility 
study conducted in advance of the definitive RCT (Uptake of Retinal Examination in Diabetes, 
DURE trial), with the primary aim of assessing feasibility. The RCT is reported in adherence to 
the Consolidated Standards of Reporting Trials (CONSORT) 2010 statement and its extension to 
randomised pilot and feasibility trials (www.consort-statement.org).  
Research paper 6 (submitted to BMC Pilot and Feasibility Studies) includes data on baseline 
characteristics of participants, feasibility outcomes as well as an interim measure of the 
effectiveness of the intervention. Publishing these results contributes to maximising the 
benefits of this research to other organisations or researchers seeking to understand the value 
of pilot and feasibility studies to the progression to full RCTs. 
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8.1 Research Paper 6 
BMC Pilot and Feasibility Studies – Licences and Copyright 
The following terms apply to this publication 
“The sustainable open access model that BMC pioneered has become the industry standard. 
We make research free to access for everyone, everywhere. Our authors retain copyright of 
their work through a Creative Commons attribution license that clearly states how readers can 
copy, distribute, and use their attributed research, free of charge. All of which helps make 
articles available to the widest audience, and contributes to the furthering of research in ways 
that would have seemed impossible two decades ago.  
All articles published by BMC Pilot and Feasibility Studies are made freely and permanently 
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 People living with diabetes can reduce their risk of vision loss from diabetic retinopathy by 
attending screening, which enables early detection and timely treatment.  The aim of this pilot 
trial was to assess the feasibility of a full-scale cluster randomized controlled trial of an 
intervention to increase uptake of retinal examination in this population, as delivered within 
existing community-based diabetes support groups (DSGs). 
Methods
 All 16 DSGs in Kirinyaga county were invited to participate in the study. The first two groups 
recruited took part in the pilot trial.  DSG members who met the eligibility criteria were recruited 
before the groups were randomized to the two arms. In the intervention group, two peer-
supporters were trained to deliver monthly DSG-based eye health education and individual 
telephone reminders to attend screening.  The control group continued with usual DSG practice, 
which is monthly meetings without eye health education. The recruitment team and outcome 
assessors were masked to the allocation. We documented the study processes to ascertain the 
feasibility, acceptability and potential effectiveness of the intervention. Feasibility was assessed in 
terms of clarity of study procedures, recruitment and retention rates, level of acceptability and 
rates of uptake of eye examination. We set the target feasibility criteria for continuation to the 
main study to be recruitment of 50 participants in the trial, 80% monthly follow-up rates for 
individuals and no attrition of clusters. 
Results
Of the 122 DSG members who were assessed for eligibility, 104 were recruited and followed up; 
51 (intervention) and 53 (control) arm. The study procedures were well understood and easy to 
apply. We learnt the DSG meeting days were the best opportunities for recruitment. The study 
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had a high acceptance rate (100% for clusters, 95% for participants) and high follow up and 
retention rate (100 % of those recruited). All clusters and participants were analysed. We 
observed that the rate of incidence of eye exam was about 6 times higher in the intervention arm 
as compared to the control arm. No adverse unexpected events were reported in either arm. 
Conclusions 
 The study is feasible and acceptable in the study population. The results support the 
development of a full-scale cluster RCT, as the success criteria for the pilot were met. 
Trial registration
Pan African Clinical Trials Registry PACTR201707002430195  Registered 25 July 2017  
Keywords
Diabetes, Diabetic retinopathy, peer-support, Kenya, pilot, cluster randomised controlled trial 
Background  
The long-term complications of diabetes, such as diabetic retinopathy (DR), are a threat to health 
among people living with diabetes (PLWD). DR is a growing concern in global epidemiology due to 
the high proportion of DR that remains undetected. Vision loss from DR can be prevented through 
regular retinal screening (hereafter referred to as ‘screening’) and timely treatment.1-3 There is 
notable geographic variation in the incidence and visual impairment burden of DR, both within 
and between countries, reflecting variation in access to health care.4-8 Services for DR prioritize 
early detection, metabolic control, regular monitoring and timely treatment. Access to these 
services is a significant challenge due to demand side barriers (such as low awareness of the need 
for services among PLWD) and supply side barriers (such as availability of clinical guidelines or 
screening services).9  There is a need for better evidence and patient empowerment to address 
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the demand side barriers, as well as health system strengthening to address supply-side barriers.9-
11
In the Global action plan for the prevention and control of non-communicable diseases(NCDs) 
2013-2020, the World Health Organization (WHO) highlighted the need to empower people with 
NCDs to seek early detection, and to provide them with appropriate education, incentives and 
tools for self-management.12 The peer-support model has been used in diabetes and other 
chronic conditions to improve social support and self-management, with positive outcomes in 
other countries.13-17 In contrast, peer-support has not been used in diabetes eye health services, 
and subsequently there is a knowledge gap regarding its effectiveness to reduce vision loss from 
diabetic retinopathy. Leveraging on peer-support in a clinical or community setting might be a 
potential enabler for the adoption of healthy behaviours, such as screening. 
Clinical guidelines target to have a 100% attendance to regular screening.18 Our health system 
assessment reported that PLWD in three counties of Kenya have low attendance to annual 
screening, which is the frequency recommended in this setting.19 This is consistent with findings 
that uptake of DR screening is low in many parts of the world, but more so where access to health 
care is generally limited.9 To address this deficit, the Uptake of Retinal Examination in Diabetes 
(DURE) trial20 aims to test the effectiveness of peer-support in increasing the uptake of retinal 
examination among members of diabetes support groups (DSGs). Diabetes support groups are 
volunteer social groups of PLWD in which peers provide mutual support for improving diabetes 
care. The support may include information and skills for self-management, as well as emotional 
support.   Given this objective, DSG members are likely to be health conscious and interested in 
adopting healthy behaviours. The intervention in this study is based on the self-efficacy 
theory21and is targeted to PLWD who are already members of support groups and have not had 
screening in the previous 12 months or longer. Screening in this setting involves a visual acuity 
test and a retinal examination through a dilated pupil.18, 22
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The study setting is a rural county whose inhabitants are mainly small-scale farmers. The DSGs are 
spread over the 1200km2 area of the county.  Undertaking the DURE study raises important 
practical concerns. In this pilot study, our aim was to gain experience in delivering the 
intervention, and to assess if the DURE cluster randomized clinical trial (cRCT) is feasible by: (1) 
Testing clarity and ease of study procedures for enrolment and data collection. (2) Determining 
the potential for participant recruitment and retention. (3) Assessing the acceptability of the 
intervention, by considering the level of adoption of the study interventions by different actors. 
(4) Documenting an interim measure of the effectiveness of the intervention on the primary 
outcome.  Our hypothesis was that it is feasible to conduct the DURE study.  We set the target 
feasibility criteria for continuation to the main study to be recruitment of 50 participants in each 
cluster, at least 80% follow-up rate of participants in each month of the trial and no attrition of 
clusters. The 90 - day duration of the pilot trial was considered sufficient for these feasibility 
objectives, while the main trial will take six months. 
Methods 
Study setting  
The demographic and health statistics of Kirinyaga county are highlighted in Table 8-1. The study 
intervention was developed following a health system assessment for diabetes and DR in three 
counties of Kenya, which identified gaps in access to services for DR, as well as the need for health 
system strengthening. We found that only 7% of PLWD in this county had a DR screening exam in 
the preceding 12 months. The main barriers to access are lack of referral from diabetes services, 
lack of knowledge of diabetes eye complications among PLWD and the belief that a screening 
exam is only necessary once ocular symptoms develop. 
An estimated 25-30% of the PLWD in the county are regular members of DSGs (with a registration 
number) while another 20% of PLWD attend some DSG meetings even though they are not 
members. Peer group leaders and community health volunteers recruit members as they give 
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group health talks at community meetings, churches, outreach camps, and diabetes clinics in 
health facilities. As membership is voluntary, the distribution of members by demographic 
parameters in different groups varies. All groups are under the Kenya Defeat Diabetes 
Association, which provides them with equipment for use within the group (such as a glucometer 
and a blood pressure machines). The association also trains peer-supporters and DSG leaders.  




Total population ( estimates based 
on 2009 census)  
595,379 48.5million
Females 50% 50%
Age > 18 years 409,995 22,005,235
Urban population 16% 29.9%
No of people with diabetes (2%)23 8,185 440,104
No of people needing an annual eye 
exam 
8,185 440,104
No of eye care facilities 1 112
No of ophthalmologists 1 115
No of ophthalmic clinical officers 3 300
No of ophthalmic nurses 0 200
DSGs hold routine monthly meetings at a dedicated time and location in the community. An 
estimated 80% of the members attend at least two thirds of the meetings annually. The meetings 
are held in the morning, starting between 8 and 9am and last 2-3 hours. Each member’s fasting 
blood sugar, blood pressure and weight are recorded. The group then shares a light meal. The 
cost of the blood sugar test strips and meal are met by a contribution of Kenya shillings 100 (the 
equivalent of 1$ dollar) per PLWD attending the meeting.  The other activities in the meeting 
include: group health talks delivered by peer-supporters; informal discussions among PLWD; 
planning for advocacy and awareness-raising activities. A record of these activities are captured in 
attendance registers and minutes of the meeting. 
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Sampling 
All 16 DSGs in Kirinyaga were eligible for inclusion. We invited the DSG leaders to a meeting 
where we explained the objectives of the DURE study and invited all the groups to participate. 
The leaders then took time to discuss the study with their members before giving approval 
through signing consent forms. The first two DSGs to confirm willingness to participate were 
included in the pilot study, for simplicity, transparency and visibility to the DSG leaders. All sixteen 
DSGs consented to participate hence the remaining 14 will participate in the main study.  
We aimed to recruit at least 50 members who met the eligibility criteria (Table 8-2) in each DSG 
(size of DSGs is 80-100 members). This is the same cluster size calculated for the main study, using 
the formula for sample size calculation provided by Hayes and Bennett.24 A statistician not 
involved with the fieldwork conducted the sample size calculation. We also recruited two peer-
supporters (1 male and 1 female) who met the eligibility criteria to deliver the intervention in the 
intervention cluster. 
Design 
The pilot study design mimics the design of the main study, being a two-arm cRCT with a 1:1 ratio.  
A research nurse who is a local health worker recruited participants who met the eligibility criteria 
during a DSG meeting. The list of existing DSG members was provided by the DSG lead. 
Participants were recruited through random selection. The research nurse assessed each 
potential participant for eligibility using the criteria in Table 8-2. Verbal consent for recruitment 
and follow-up was obtained at the time of recruitment, from individual participants who met the 
eligibility criteria (DSG leaders provided cluster-level consent). For those who did not consent, the 
reasons for non-consent were recorded. Baseline demographic, anthropometric and metabolic 
data was collected at the time of recruitment using standard operating procedures (appendix 3). 
All participants were given a study identifier card to present at the eye clinic at the time of eye 
exam. 
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Two members of the research team observed the recruitment process to identify any difficulties 
with participant recruitment, eligibility criteria or completing the data collection tool. The 
recruitment nurse provided additional feedback on these critical components in a debriefing 
session after each recruitment session.  
Table 8-2: Eligibility criteria for participants and peer-supporters
Criterion Participants Peer-supporters
Age > 18 years
Member of a diabetes support group
Will reside in the county for the next 12 months
Has a mobile phone
Willing to participate in the study
Had not had a screening exam in the last 12 months
Has had a screening exam in the preceding 12 months
Willing to be a peer-supporter
Willing to commit two days for training
Willing to commit many hours to peer-support work
Fluent in Kikuyu or Kiswahili
Already attending DR screening
Already receiving treatment for DR
Has a debilitating illness
KEY Include Exclude Not applicable
Following participant recruitment within each of the DSGs, random allocation of the intervention 
was through drawing of lots.  A lay person not participating in the study picked one of four sealed 
and opaque envelopes from a container, in the presence of two members of the research team. 
Each envelope contained a card bearing the name of one DSG and either ‘intervention’ or 
‘control’. Opening the envelope revealed the arm allocation for one group, and by inference the 
allocation of the other group.  This allocation was copied on the envelope and stored to provide a 
reference trail. The remaining envelopes were destroyed. A research assistant (not involved in 
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recruitment or outcome assessment) followed up the participants in each group at monthly 
intervals for 90 days from the first group education session, to check retention rates.  
The primary outcome was the feasibility of recruiting 50 participants in each cluster, and 
achieving at least 80% follow-up rate of participants in each month of the trial. The records at 
Kerugoya County Hospital eye clinic were monitored daily and the identifier cards of participants 
that attended screening were deposited in a specific container by the eye care team. These cards 
were then collected and given to the outcome assessment nurse (not involved in recruitment or 
follow-up). During the study, we also found that some eye care teams external to the county 
health services held outreach camps in the county and provided screening for some of the 
participants. As our team was alerted ahead of the outreach camps, we liaised with these teams 
and monitored the attendance of any study participants. As they used the same screening 
guidelines, any participant screened at the outreach site was taken to have the outcome of 
interest. 
The recruitment nurse, research assistants and the outcome assessors had no training in eye care, 
and were masked to the cluster and participant allocation, to avoid contamination and bias. The 
eye care providers were also masked to the intervention allocation. It was not possible to mask 
the study participants or peer-supporters in the intervention arm, because the peer-supporters’ 
activities within the DSG were overt. As the primary outcome was assessed from hospital records, 
we concluded that the lack of masking could not incentivise over-reporting or under-reporting in 
either arm.  
Intervention 
The DSGs in the intervention arm received the study intervention combined with usual care for 90 
days, while the control group received the usual standard of care alone (Table 8-3).  The 
intervention was a monthly group health talk and individual monthly telephone reminders to 
attend eye exam, delivered by two peer-supporters (1 male, 1 female) collaboratively. The 
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intended mechanism of the intervention and the key messages to be delivered in the health talk 
are described in the trial protocol.20 Fidelity to the intervention and the influence of peer-
supporter characteristics will be assessed in the process evaluation of the main trial. 
We trained the peer-supporters for two days to deliver the intervention. They had already 
received previous training as peer-educators (training provided by the Kenya Defeat Diabetes 
Association), and had about four years’ experience with providing peer education. We also 
supported them during the implementation phase in the following ways. (1) Telephone calls were 
made by the team before and after each group session to discuss the sessions and any challenges 
faced by the peer leaders. (2) Practical support was provided to help organize the logistics for 
local program delivery, such as provision of telephone airtime and reimbursement for transport 
costs for peer-supporters. (3) The research team attended two of the three DSG meetings. Peer-
supporters kept logs of the DSG attendance during group sessions and the individual reminders. 
Table 8-3: Trial Interventions
Domain Intervention group Control group 
Usual care Monthly group meetings with 
general diabetes education 
talks, blood sugar and blood 
pressure measurements 
Monthly group meetings with 
general diabetes education 





Two days training following a 
structured curriculum 
regarding diabetes eye 
disease,  retinal screening, 
role of peer-supporters, 
communication and other 
aspects specified in the 
protocol20
Group education Monthly group education
provided by trained peer-
supporters, with structured 
content on diabetic eye 
disease and retinal screening 
as specified in the protocol20
Individual participant 
reminders 
Monthly individual telephone 
reminder by peer-supporters 
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to participants to take a 
screening exam as specified in 
the protocol20
Reporting and analysis 
This study is reported in accordance with the Consolidated Standards of Reporting Trials 
(CONSORT) guidelines for pilot studies.25 The CONSORT flow chart and the checklist are included 
as appendices. We documented recruitment procedures and rates, reasons for ineligibility and 
non-participation, and follow-up rates.  We calculated descriptive statistics for each study arm at 
baseline. We also summarized survival outcomes at arm level as per intention-to-treat analysis 
and estimated hazard ratio for any differences. All data analysis was carried out using Stata 
version 15 (StataCorp, Texas, USA). 
Results 
The results are reported under four headings corresponding to the specific objectives of the pilot 
trial:  
Study procedures for enrolment and data collection 
We found that the enrolment rate was high during the DSG meetings. The peer group leaders 
could predict which meetings would be well attended, considering other concurrent community 
activities, and they mobilised members to attend. We found it helpful to liaise with these leaders 
in planning for the recruitment. 
The study materials were easy to carry around and work with. We did not identify any practical, 
ethical or interpretation difficulties in the use of the eligibility criteria and the completion of the 
data collection tools. The eligibility criteria were therefore found to be appropriate and the data 
collection tools were well understood. We collected baseline data for all participants, before 
randomization.  
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The time taken to complete the data collection processes per participant exceeded the planned 
time.  Some of the participants had difficulty finding some of the data that we needed for the 
purpose of follow-up, such as the telephone numbers of the next of kin, but with assistance they 
were able to retrieve this from their phones or to contact other people who had the data. 
However, this added about 10 minutes per participant over the initial estimates for the 
recruitment process. This resulted in increased waiting time for the other persons awaiting 
recruitment. Learning from this, we trained three additional research nurses for the recruitment 
team, so that at least two of them could attend each recruitment meeting. 
A research assistant checked the data collection tools for completeness at the recruitment site.  
All the data forms were also checked by the team lead for quality assurance after each 
recruitment meeting.  Thereafter the forms were sent to the data entry assistant where further 
quality checks were carried out as data was entered into a database.  
We used standardised protocols for all measurements, and the descriptive data is provided in 
Table 8-4. The two arms were balanced for most characteristics except age and gender. Females 
and older people were over-represented in the intervention arm. This difference reflects the 
variation in the existing composition of the DSGs. 
Potential for recruitment and retention 
The response rate of clusters was good (both accepted to participate). All 122 participants 
assessed for eligibility were willing to participate, but 6 (4.9%) withdrew during the recruitment 
process because of long waiting time.  Of the 122 assessed for eligibility, 12 (9.8%) were ineligible 
as they were temporary visitors (non-resident) or were going to be absent from support groups 
during the study period (school and employment commitments).  
By conducting recruitment at well-attended routine DSG meetings, all or most of the regular DSG 
members had an equal chance to be recruited in the study. We were able to recruit within the 
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anticipated time such that all the participants entered the study at time 0, and we had similar 
recruitment levels in both clusters. Follow-up rates were high in both arms. Both DSGs remained 
in the study and received the intended intervention (Fig 1). One peer-supporter fell sick over part 
of the period, but by this time most of participants in intervention arm already had the outcome 
of interest, and the other peer-supporter was able to carry on with the intervention. All 
participants were followed up for 90 days, and there was zero loss to follow up. 







Median (IQR) 69 (60-72) 57 (57-62) 63 (54.5-70) P=0.002
Sex
Female (%) 41 (80.4) 30 (56.6) 71 (68.3) P=0.009
Duration of diabetes 
(years) 
Median(IQR) 5.0 (2-10) 5.0 (2-8) 5.0 (2-10)
Duration of support group 
membership (years) 
Median(IQR) 3.0 (1-3.5) 2.0 (1-4) 2.0 (1-4)
Anthropometric measures
Body Mass Index (kg/m2)
Male 25.0 (2) 25.3 (4.4) 25.2 (3.8)
Female 25.4 (3.9) 26.4 (3.4) 25.8 (3.7)
Waist circumference (cm)
Male 96.5 (7.3) 96.0 (11.1) 96.1 (10)
Female 97.0 (8.9) 100.0 (8.4) 98.3 (8.8)
Metabolic measures
Fasting blood sugar ( g/dl) 7.4 (2.7) 9.1 (4.5) 8.3 (3.8)
Systolic blood pressure  
(mmHg) 
139.0 (20) 142.0 (26) 141.0 (23)
Diastolic blood pressure  
(mmHg) 
81.0 (7.6) 78.0 (13) 80.0 (11)
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Acceptability of the intervention 
Before the start of the study, we had initial meetings with the Ophthalmic Services Unit at the 
national level, the Kirinyaga county director of health, eye care providers in the county, and the 
national officials of Kenya Defeat Diabetes Association (KDDA) that is the umbrella body for DSGs. 
We obtained their buy-in for the study, and they linked us with the DSGs.  
Given the recruitment rates, the follow up rates and the attrition rates (Figure 8-1, Flow chart at 
the end of the paper), the study and the intervention were acceptable to participants and 
clusters. The peer-supporters attended all the sessions of the two-day training and gave the group 
talks as planned. For the individual telephone reminders, we found that peer-supporters 
supplemented this with face-to-face discussions with the individuals who were yet to take a 
retinal exam (in addition to the telephone reminders). This flexibility reflects a sense of ownership 
of the intervention by the peer-supporters.  
We did not record any adverse event related to the intervention. Temporary blurring of vision 
after dilatation of the pupils during retinal examination (the outcome of interest) is a common 
undesirable effect but this was explained to the participants before examination and none of 
them declined to have the examination.  
The ‘drop-in’ referral mode of patients from the DSGs for screening for DR was acceptable to both 
patients (who adopted it) and eye care providers (as they screened all who dropped in). The 
attendance to the eye clinic showed some peaks, and during these peaks the workload in the eye 
clinic was significantly increased, however all who turned up were screened. None of the 
participants who presented at the eye clinic had lost or forgotten the identifier card, which would 
suggest that the card was highly valued. Such participants would still have received screening and 
this would be captured in the eye clinic records.
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Estimating the effectiveness of intervention 
We estimated the tentative effectiveness of the intervention in both arms, although the study 
was not powered for hypothesis testing. Participation rates are presented without adjustment for 
clustering.  
The intervention arm had a substantially higher uptake of eye exam during the trial (Fig. 8-1). Of 
the 104 participants, 31(29.8%) attended screening during the trial: 25/51 (49%) in the 
intervention arm, as compared to 6/53 (11.3%) in the control arm.  
In the intervention arm, the rate at which participants attended an eye exam was high 
immediately after the start of the intervention and then it decreased (Figure 8-1). The highest 
rates were observed between day 10 and 20 following the first group education session, even 
though the education sessions continued on a monthly basis. The pattern suggests that most of 
the benefit of the intervention occurs early in the intervention. In the control arm, the rate of eye 
exam was nearly constant. Although it increased around day 50 (without any intervention) it 
didn’t reach the rate in the intervention group. 
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Figure 8-2: Time to screening among PLWD in intervention and control arms 
Discussion 
We are the first to report a pilot cluster RCT on the feasibility of a full-scale RCT to assess the 
effectiveness of a community-based DSG intervention to increase uptake of DR screening among 
PLWD. Other studies have examined the effectiveness of such community-based groups on health 
outcomes such as maternal, neonatal and childhood survival.26-29
The study has several strengths. Firstly, a mixed methods health system assessment30 preceded 
the trial. This helped to identify DSGs as a community resource that was a potential channel for 
increasing uptake of screening.  Secondly, this study targets PLWD in a rural setting who have not 
had screening in the last 12 months. However, we found that our participants had never had 
screening, meaning the people who are the most vulnerable to DR-related blindness and who 
need the intervention most were included. It is known that screening programs are more cost-
effective in people who derive more benefit from screening.2, 7
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Thirdly, it is known that demand-side behaviour changes alone may be insufficient to change the 
health outcomes being addressed, therefore health system strengthening is important before or 
within a trial.26, 27, 31. Before this study, we developed and implemented national clinical guidelines 
for DR, and our training program for peer-supporters is currently being embedded in the Kenya 
Defeat Diabetes Association peer-support manual. Therefore, a further strength of the study is 
that we tested the intervention within a bigger health system strengthening context.32, 33 Fourth, 
the study setting, eligibility criteria, study design and amount of data collected in the pilot is by 
design, similar to what will be collected in the main study. This makes it easy to transfer the 
learning from the pilot to the main study. 
Our findings show that the potential for recruitment and the feasibility of data collection, study 
implementation and follow-up is high. There was high acceptability of the study in general and the 
intervention by participants. This might be because the DSG members are already health 
conscious, or because of the community entry process that we followed.  The top leadership of 
KDDA and the county director of health introduced us to the county support group leader, who in 
turn introduced us to the DSGs. We had strong liaison with these stakeholders and with local 
health care workers, which helped successful study implementation. We considered this to be 
important because the feasibility of the implementation and future scalability of the intervention 
depends on acceptability not only among the participants but also among these stakeholders in 
health care.34 Further, the intervention itself requires constant engagement with the DSGs and 
the participants, which may have aided the acceptability and retention of participants in the 
study. Of note, we did not pay the participants— they participated voluntarily.  
The recruitment process was embedded in DSG meetings, which was a critical factor for efficiency 
in recruitment. We learnt that recruitment required more time and more research nurses than 
initially planned, and this will be taken into account in the main study.  The pilot findings suggest 
that the trial should achieve high recruitment and retention. We excluded PLWD who were 
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temporary visitors to the DSGs, as they were not likely to stay long enough to receive the 
intervention. Other studies have used a similar approach to avoid contamination between 
clusters.33 We monitored support groups attendance and did not have evidence of inter-cluster 
migration in our study. We also learnt the necessity of liaison with mobile eye care providers from 
other counties who visit Kirinyaga county on eye camps, as they provided screening to this 
population (besides the static eye clinic at Kerugoya county referral hospital).  
When interventions are implemented in real-world settings, some degree of flexible adaptation of 
program components occurs.34-36 Although mobile phone interventions are useful due to their 
ubiquity even in this population37, we found that face-to-face contact is valued and that peer-
supporters still supplemented individual telephone reminders (prescribed in the protocol) with 
additional face-to-face reminders to persons who had not yet taken a retinal examination. This is 
perhaps because of the close residential proximity of the members and the existing personal 
relationships between them. It also reflects that in the ‘real world’ setting peer-support is not 
provided in tightly sequential or discrete categories. These flexible interactions may have 
contributed to the success of the intervention.  The peer-supporters in this study were highly 
experienced with peer-support, having been peer-supporters for a long time and having had other 
trainings. This may have contributed to the success of the study, and it is not known whether if 
we have less experienced peer-supporters in the main study we will have different findings. 
In the pilot study, we observed a much greater proportion of individuals attending retinal 
screenings in the intervention arm than in the control arm. Given only one cluster was 
randomised to each arm we cannot draw inferences from this, but it does suggest that the 
intervention has potential and is worth bringing forward to the full trial. Among those in the 
intervention arm who had an eye exam, there was a striking uptake of the exam in the first two 
weeks of the intervention. This means the benefit of the intervention was visible within a short 
period. Conversely, it also means that there is risk of eye care provider fatigue if the same pattern 
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of uptake is seen in the larger full trial. Kwaku et al31 have noted that such negative effects can be 
experienced in a clinical trial. We did not experience this in the pilot. In the full trial, we will 
stagger the intervention over time hence this challenge is unlikely to occur. As most of the PLWD 
only need one screening examination annually, we do not expect this to be a significant problem 
beyond the study. 
Although the participants were aware of the risk of temporary blurring of vision during dilated eye 
exam, this was not a barrier to uptake of eye exam. However, since this is the first screening 
examination for the participants, we do not know whether it would be a barrier to future 
screening. 
It is good practice to consider the attributes that contribute to the scalability of interventions, 
even at the stage of pilot trials.38This pilot trial represents a step towards developing a scalable 
intervention because of its acceptability to participants.  Acceptance by PLWD is necessary but 
not sufficient for scalability, since it also needs the support of service providers, administrators 
and policy-makers. Based on the evidence from the pilot trial, scalability might also be feasible 
because of (1) the acceptability and involvement of state and non-state stakeholders who run the 
support groups and health services (2) the trial is implemented within routine (pragmatic) 
conditions (3) we documented the processes involved in the trial.   
The pilot study had some limitations. We only involved two DSGS in the study (out of the 16 DSGs 
in the county) but we considered this to be sufficient to address the issues of uncertainty in the 
feasibility of the study. For the main trial, we have recruited the other fourteen support groups 
(seven in each arm).  
The first two DSGs that accepted to participate in the study were recruited in the pilot study. This 
convenience sample might mean that these initial findings are not generalizable to all DSGs. 
However, we considered that this method was helpful to demonstrate transparency to the DSG 
leaders and to meet the feasibility objectives. As women and older people were over-represented 
274 
in the intervention arm, the extent to which the interim results of the primary outcome can be 
extended to men is not clear. This over-representation is a reflection of the composition of the 
two DSGs - it is a reflection of the participants that would receive this intervention if it became 
the usual standard of care. This composition was previously undocumented, therefore it is an 
important contribution of this pragmatic trial. With the larger sample size of the main trial (700 
participants), we expect more balance, but if this is not the case we will conduct subgroup 
analysis.  
Given that this is pragmatic trial20, we anticipate that co-interventions may occur in the ‘real-
world’ setting of the study. We found that there were external outreach eye camps in the county 
during the trial period. These camps have potential to introduce co-intervention bias, particularly 
if they include eye health promotion activities. However, the exposure to this co-intervention was 
likely balanced between the two arms, since the camps were widely publicised through 
community meetings and held at diverse locations across the county. In the main trial, we will 
identify any pre-specified or unplanned co-interventions, assess the risk of co-intervention bias 
and estimate its effect on the trial outcomes. 
We did not perform a process evaluation at this stage, however this is planned as part of the main 
study,20 when we will have data on the primary and secondary outcomes. The process evaluation 
will help us understand the way the intervention worked to lead to these outcomes. 
Conclusion 
The pilot study met our success criteria for the feasibility objectives. We conclude that a full trial 
of the intervention is feasible, and the results of this pilot will inform this full trial. The findings of 
this study may be relevant to other countries with a similar model of DSGs. Given the paucity of 
literature on implementing community-based interventions, the results of this pilot may be of 
interest to other researchers interested in addressing feasibility challenges in cRCT interventions 
targeting community groups. 
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Enrolment We invited all
16 clusters to 
participate 
The other 14 clusters will 
participate in the main study 
Cluster 
recruitment 
into pilot trial 
First 2 clusters to accept 





12 did not meet eligibility criteria
6 declined (citing long waiting 






Intervention arm: 1 cluster,  
51 participants, 2 peer-
supporters  
Control arm: 1 cluster, 53
participants, 2 peer-supporters 
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Intervention Peer-supporters received a 
2 day training 
All participants received 
the intervention (monthly 
group talk) and those who 
had not attended eye exam 
received a weekly 
individual reminder plus 
usual care 
All received usual care
Follow-up All 51 participants and 2 
peer-supporters were 
retained over 90 day  
follow-up period 
1 peer supporter fell ill and 
did not participate day 69 - 
90 
All 53 participants were retained 






0 participants excluded 
Intention-to-treat analysis 
54 participants included
0 participants excluded 
Intention-to-treat analysis  
Figure 8-1: Flow diagram for pilot study 
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Chapter Nine 
Effectiveness of peer support to increase attendance at DR 
screening - a pragmatic cluster randomized clinical trial 
Process Evaluation of the DURE trial  
9.0 Overview 
The effectiveness of complex interventions is estimated through outcome evaluation of 
randomized clinical trials (RCTs). Chapter 10 will provide information on the effectiveness of 
the DURE trial in increasing attendance to DRS. There is also a need to understand the factors 
shaping implementation and outcomes of the trial in order to provide possible explanations for 
the effect of the intervention. Process evaluation of clinical trials provides evidence about what 
and how interventions are implemented, how interventions generate change in outcomes 
(mechanism of impact) and how the context affects the outcomes.1 
This chapter consists of a research paper that describes a mixed method process evaluation of 
the DURE full trial, guided by the Consolidated Framework for Implementation Research 
(CFIR).2  This framework is an implementation science tool that is used to investigate the 
influence of the characteristics of the intervention, the individuals involved, the inner and 
outer setting of the intervention, and the implementation processes. 
1. Moore GF, Audrey S, Barker M, et al. Process evaluation of complex interventions: 
Medical Research Council guidance. BMJ 2015;350:h1258.doi:10.1136/bmj.h1258 
2. Damschroder LJ, Aron DC, Keith RE, et al. Fostering implementation of health services 
research findings into practice: a consolidated framework for advancing 
implementation science. Implementation Science 2009;4:50.doi:10.1186/1748-5908-4-
50 
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Research paper 7 (submitted to BMC Tropical Medicine and Health) includes our analysis of the 
quantity and quality of what was delivered, the role of context, why the intervention did or did 
not work, what elements appear to be the ‘most essential components’ of the intervention, 
barriers and facilitators, and implications for scale-up of the intervention. These findings can 
inform stakeholders on how to change or improve implementation of this intervention in the 
current settings or replication of the intervention in different settings.  
9.1 Research Paper 7 
BMC Tropical Medicine and Health – Licences and Copyright 
The following terms will apply to this publication once it is published in this journal: 
“The sustainable open access model that BMC pioneered has become the industry standard. 
We make research free to access for everyone, everywhere. Our authors retain copyright of 
their work through a Creative Commons attribution license that clearly states how readers can 
copy, distribute, and use their attributed research, free of charge. All of which helps make 
articles available to the widest audience, and contributes to the furthering of research in ways 
that would have seemed impossible two decades ago.  
All articles published by BMC Tropical Medicine and Health are made freely and permanently 
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Abstract
Background: There is limited evidence on how implementation of peer support interventions influences
effectiveness, particularly for individuals with diabetes. We conducted a cluster randomized controlled trial to
compare the effectiveness of a peer-led health education package versus usual care to increase uptake of screening
for diabetic retinopathy (DR).
Methods: Our process evaluation used a mixed-method design to investigate the recruitment and retention, reach,
dose, fidelity, acceptability, and context of implementation, and was guided by the Consolidated Framework for
Implementation Research (CFIR). We reviewed trial documents, conducted semi-structured interviews with key
informants (n = 10) and conducted four focus group discussions with participants in both arms of the trial. Three
analysts undertook CFIR theory-driven content analysis of the qualitative data. Quantitative data was analyzed to
provide descriptive statistics relevant to the objectives of the process evaluation.
Results: The trial had positive implementation outcomes, 100% retention of clusters and 96% retention for
participants, 83% adherence to delivery of content of group talks (fidelity), and 78% attendance (reach) to at least
50% (3/6) of the group talks (dose). The data revealed that intervention characteristics, outer setting, inner setting,
individual characteristics, and process (all the constructs of CFIR) influenced the implementation. There were more
facilitators than barriers to the implementation. Facilitators included the relative advantage of the intervention
compared with current practice (intervention characteristics); awareness of the growing prioritization of diabetes in
the national health policy framework (outer setting); tension for change due to the realization of the vulnerability to
vision loss from DR (inner setting); a strong collective sense of accountability of peer supporters to implement the
intervention (individual characteristics); and regular feedback on the progress with implementation (process).
Potential barriers included the need to queue at the eye clinic (intervention characteristic), travel inconveniences
(inner setting), and socio-political disruption (outer setting).
Conclusions: The intervention was implemented with high retention, reach, fidelity, and dose. The CFIR provided a
valuable framework for evaluating contextual factors that influenced implementation and helped to understand
what adaptations may be needed during scale up.
Trial registration: Pan African Clinical Trials Registry: PACTR201707002430195 registered 15 July 2017
Keywords: Diabetes, Diabetic retinopathy, Peer support, Cluster-randomized clinical trial, Consolidated Framework
of Implementation Research (CFIR), Process evaluation
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Background
Early detection of diabetic retinopathy (DR) poses a sig-
nificant medical and public health challenge, particularly
because DR is asymptomatic until the advanced stages.
The benefits of regular screening have been documented
[1], but uptake remains low for people living with dia-
betes (PLWD) in settings without systematic DR screen-
ing programs [2]. Diabetes Support Groups (DSGs)
provide an opportunity for demand-side interventions to
increase attendance at screening and confront this in-
equity [3]. However, there is need for evidence on the
factors that influence implementation and outcomes of
DR interventions involving DSGs.
The DURE (Uptake of Retinal Examination in Diabetes
mellitus) trial was a 6-month pragmatic cluster random-
ized controlled trial (cRCT) to evaluate the effectiveness
of a complex intervention to promote screening for dia-
betic retinopathy among members of DSGs in Kirinyaga
County, Kenya. The DURE trial interventions have been
described in detail [3]. Briefly, the trial compared the
proportion of PLWD who attended screening in seven
DSGs that received the intervention with seven “usual
care” DSGs that did not receive the intervention. The
intervention consisted of (i) training of peer supporters;
(ii) monthly group talks at the DSGs by peer supporters
and referral of PLWD to the eye clinic; (iii) monthly in-
dividual reminders to PLWD (by peer supporters) to at-
tend screening the eye clinic; and (iv) weekly telephone
support to peer supporters from the research team.
The intervention was developed in accordance with
the guidelines of the Medical Research Council (MRC)
framework for complex interventions [4]. These guide-
lines recommend using appropriate theory to develop in-
terventions that address the barriers to behavior change.
Our formative research identified several barriers to up-
take of DR screening [2]. Self efficacy is a strong precur-
sor to behavior change [5, 6] including attendance to
screening [7]. Based on the self-efficacy theory, we
hypothesized that an intervention that increases self-
efficacy can decrease the perceived barriers to attend-
ance to screening. The theory proposes four methods of
changing self-efficacy in order to change behavior: pro-
viding mastery experiences (e.g., recalling previous
screening for other diabetes complications); vicarious
learning (e.g., from hearing experiences of peers who
have had DR screening); verbal persuasion (of the need
for screening); and addressing psychological and
affective states (such as anxiety about taking a screening
exam) [6]. The theory-driven conceptual framework of
intervention effect is illustrated in the protocol [3].
The MRC framework [4] emphasizes four key phases
of interventions: intervention development; feasibility
and piloting; implementation; and the evaluation of both
outcomes and process. In this paper, we describe the
results of the process evaluation. Process evaluation is a
study which aims to understand the functioning of an
intervention, by examining implementation, mechanisms
of impact, and contextual factors [8]. The conduct of
process evaluations alongside RCTs has been recom-
mended, because they give insight into the “black box”
of health care interventions; facilitate the interpretation
of the findings; explain why, for whom and how a com-
plex intervention had a particular impact; and determine
whether a complex intervention should be scaled up or
modified for other contexts [9, 10]. Process evaluations
are particularly important in cRCTs, because of the po-
tential for between-cluster differences that need to be
understood [10, 11].
Theory-driven process evaluation necessitates that the
designers make the theory explicit and then use it to
identify how the intervention leads to the outcomes [12].
The Consolidated Framework for Implementation Re-
search (CFIR) is a is a meta-theoretical framework that
synthesizes constructs from multiple theories on imple-
mentation of interventions, in order to explain what
works and why across multiple contexts [13]. The CFIR
outlines five major factors that influence implementation
of interventions: the characteristics of the intervention,
the inner setting, the outer setting, the individuals in-
volved, and the process of implementation (Table 1). By
applying this framework to the process evaluation for
this cRCT (Fig. 1), we aimed to (1) understand the deter-
minants for the outcomes of the DURE intervention in
Kirinyaga and (2) examine the context of implementa-
tion in terms of the intervention’s recruitment and re-
tention, reach, fidelity, dose, and acceptability (Table 2).
Methods
Ethics
The DURE trial and its process evaluation has ethics ap-
proval from the research ethics committees of the
London School of Hygiene and Tropical Medicine in
London and the African Medical Research Foundation
in Nairobi. Trial registration: Pan African Clinical Trials
Registry: PACTR201707002430195.
Setting
The setting of the study is described elsewhere [3]. Briefly,
Kirinyaga county is a rural agrarian county in Central Kenya.
The prevalence of diabetes in Kenya is estimated to be 2% in
the population 18–64 years [14]. An estimated 40% of the
PLWD in Kirinyaga are members of DSGs, and a health sys-
tem assessment by our research group found that only 7% of
them have had an annual DR screening exam as recom-
mended. DSGs have monthly meetings in the community led
by peer supporters, where they measure the weight, blood
sugar, and blood pressure of attenders. They also engage in
other activities relevant to health promotion and advocacy. At
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the time of the DURE study, there were 16 DSGs active in
Kirinyaga. Two of them participated in the pilot trial, while
the other 14 were recruited into the main trial.
Two peer supporters were recruited in each DSG (1
male, 1 female), as per the eligibility criteria in Table 3,
and none of them had previously delivered an eye health
intervention. They received two days of training using a
curriculum developed through the process described in
Additional file 1. The content of the training and the key
messages that the peer supporters delivered to partici-
pants are described in the protocol [3]. An allowance
was provided to peer supporters for telephone commu-
nication with participants, but no other financial incen-
tives were given. Weekly telephone calls between the
principal investigator and peer supporters were carried
out to share progress, build a sense of belonging, and ad-
dress any challenges emerging during the program.
The county has a well-equipped eye clinic at the Keru-
goya county referral hospital. Patients at the clinic are
attended on a walk-in basis. There were four eye health
workers (one ophthalmologist, three ophthalmic clinical
officers) in the county during the study period. Guide-
lines for screening and management of diabetic retinop-
athy were launched at the national level 3 months before
the start of the main trial, and were also being imple-
mented in Kirinyaga county [15].
Design
This is a mixed-methods process evaluation of a cRCT.
We used the CFIR to guide the process because it is
comprehensive and can be used to develop the evalu-
ation tools, guide the content analysis, and aid interpret-
ation of findings [16].
Table 1 Constructs of the Consolidated Framework for Implementation Research
Construct How the construct relates to the DURE trial
Characteristics of the intervention—core components
and adaptable components
Intervention characteristics (adaptability complexity,
relative advantage) can influence whether the
intervention is adopted
Inner setting—structural, political, and cultural context
that directly affects the implementation
The context of the DSGs and the eye health system
in Kirinyaga can influence how participants
experience the intervention
Outer setting—broader economic, political and social context Broader political, economic, health policies, priorities,
resources, incentives, and governance may
impact trial activities
Characteristics of individuals—people responsible for delivering
the intervention (peer supporters)
Training, knowledge, perceptions, motivation, and
leadership of peer supporters can influence extent
of implementation of the intervention
Implementation process—the activities involved in planning,
engaging, execution, and evaluation of implementation process
The involvement of stakeholders in the planning,
execution, and evaluation of progress of the trial
may influence the acceptability of delivery and
reception of the intervention
DSG Diabetes Support Group, DURE Uptake of Retinal Examination in Diabetes study
Fig. 1 Consolidated Framework for Implementation Research as it relates to this trial (adapted from Dramschroder et al, 2009 [13])
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Table 2 Measures for the level of implementation
Implementation measure Questions related to DURE study Quantitative indicator(s)—
compared with target
Recruitment and retention How successful were the recruitment
and retention procedures?
-Proportion of DSGs that agreed
to participate (%)
-Proportion of participants invited
who agreed to participate (%)
-Peer educators recruited, trained
and retained (n)
-Retention rate of clusters and
participants in the study (%)
Reach What proportion of the intended audience
was exposed to the intervention?
-People who were referred (n)
-People who received individual
reminders (n)
-People who attended group
meetings (n)
Dosage delivered What percentage of interventions was delivered
most/least successfully by implementers?
-Group talks delivered (n)
-Referrals made (n)
-Individual reminders given(n)
Dose received What percentage of the intervention was received
most/least successfully by the target audience?
-Proportion of group sessions
attended by each participant (%)
-Referrals given (n)
Fidelity How much of the intervention was delivered
as intended (adherence)? What parts were
not delivered?
-Adherence to content of group talks
-Adherence to frequency of group talks
Acceptability How acceptable is the intervention for current
and future implementation?
Acceptance of the intervention by peer
supporters and participants
Willingness of stakeholders to scale up
the intervention in future
DSG Diabetes Support Group, DURE Uptake of Retinal Examination in Diabetes study
Table 3 Eligibility criteria for participants and peer-supporters
Criterion Participants Peer-supporters
Age > 18 years √ √
Member of a diabetes support group √ √
Will reside in the county for the next 12 months √ √
Has a mobile phone √ √
Willing to participate in the study √ √
Had not had a screening exam in the last 12 months √ ×
Has had a screening exam in the preceding 12months × √
Willing to be a peer-supporter N/A √
Willing to commit 2 days for training N/A √
Willing to commit many hours to peer-support work N/A √
Fluent in Kikuyu or Kiswahili N/A √
Already attending DR screening × √
Already receiving treatment for DR × ×
Has a debilitating illness × ×
“√” indicates participants or peer-supporters included in the study
“×”indicates participants or peer-supporters excluded in the study
N/A Not applicable
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Data collection
Data on recruitment and retention, fidelity, reach, and dose
were collected routinely during the trial activities and col-
lated through document review. Peer supporter training re-
cords provided information on attendance and content of
training. Trial registers provided data on recruitment, while
DSG meeting attendance registers captured participants at-
tendance and retention, as they provided the date of the
meeting and the list of attendees. DSG meeting minutes,
peer supporter diaries, and the research team’s activity logs,
and field notes contained detailed information on the inter-
vention activities, personnel involved, duration, frequency,
and resources used.
We studied the sample interview questions available
on http://cfirguide.org/ and tailored our data collection
tools to gather information relevant to the DURE study.
These questions related to the stakeholders’ perception
of the intervention and how it worked/did not work.
Ten interviews were conducted with purposively se-
lected key informants to represent recipients, implemen-
ters, administrators, and policy-makers. Key informants
were recruited until data saturation was reached. Face to
face interviews were conducted by the first author in
English at locations convenient to the key informant,
using a semi-structured interview schedule. Interviews
lasted 30–60 min and were captured through field notes.
We conducted four focus group discussions in com-
munity settings with 7 participants in the intervention
arm who did not take up screening; 7 participants in the
intervention arm who took up screening; 8 participants
from the control arm; and 7 peer supporters. Focus
group discussions were conducted in the Kikuyu lan-
guage by the first author and two research assistants
who were considered culturally appropriate but not in-
volved in the trial implementation. Discussions were
audio-recorded, transcribed, and translated into English.
Data analysis
Quantitative data on recruitment and retention, reach,
fidelity, and dose were analysed for descriptive summary
statistics.
A thematic content analysis of qualitative data was
undertaken based on the different constructs and sub-
constructs of the CFIR: (1) Intervention characteristics
(e.g., acceptability of the intervention, compatibility with
existing DSG programs, relative advantages, or disadvan-
tages of the intervention, and suggested adaptations); (2)
Outer setting (e.g., perceived role of the Ministry of Health
(MoH) policies and guidelines in driving which services
were implemented); (3) Inner setting (e.g., perceptions
about organizational factors within DSGs and the eye
clinic, that might have affected the implementation); (4)
Individual characteristics of peer supporters who delivered
the intervention (e.g., knowledge, attitudes, self-efficacy
about their role); and (5) Implementation processes (e.g.,
planning, engagement, and execution factors that may
have affected the delivery and reception of the DURE
intervention). Using the CFIR as a template framework,
the principal investigator and two other analysts (1 male,
1 female) read the transcripts, coded the data independ-
ently, and grouped the codes into themes. Analysis began
as soon as the first interview was completed, and then
proceeded concurrently with data collection until data sat-
uration was reached. The analysts reviewed the codes it-
eratively to check for potential biases, and to verify the
emerging themes. Discrepancies between coders were re-
solved through discussion and review of the original
transcripts.
Data (qualitative and quantitative) from all sources were
organized under the respective constructs and sub-
constructs to facilitate triangulation and to identify which
factors affected the acceptability, recruitment, retention,
reach, fidelity, and dose of implementation.
The first author had undertaken training on imple-
mentation research and clinical trials, and had expertise
on the technical content of the intervention. All the ana-
lysts had skills in quantitative and qualitative research
methods.
Results
How was the intervention implemented?
Recruitment and retention
All the 16 DSGs in the county accepted to participate in
the trial (2 in the pilot trial and 14 in the main trial). All
clusters were retained throughout the study. Of 837
members of DSGs approached to participate the main
trial, 86 did not meet eligibility criteria (Fig. 2), and 17
did not consent, thus 734 participants were recruited
and participated in the trial. Of these, 31 (4.2%) were
lost to follow-up during the trial (95.8% follow-up rate
rate). The 14 peer supporters (age range was 29–58
years) received the training program. All had at least
secondary education, with three having achieved a ter-
tiary level qualification, although this was not a require-
ment. One peer supporter was absent from day 72 as
another DSG project that was being implemented a dif-
ferent county contracted him for their team. The
remaining 13 actively participated in the DURE trial
until the end of the trial. The research team maintained
weekly contact with peer supporters and attended some
of the DSG meetings, which minimized the likelihood of
loss to follow-up or missing data. Recruitment proce-
dures had already been tested in the pilot trial [17].
Reach
Out of 369 PLWD recruited into the intervention
arm, 92% attended the first group talk, while 72%
attended all six talks. Seventy-eight percent attended
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three or more talks (50%), and this ranged from 68%
in the most rural DSG to 88% in urban DSGs. One
hundred percent of the participants were referred for
the screening examination and were issued with a re-
ferral card. Peer supporters also gave monthly tele-
phone reminders to those who had not yet taken the
screening exam. Seventy-four percent of participants
received at least one telephone reminder to attend
screening.
Dose delivered and dose received
The 14 peer supporters attended the training. During
the 6 months of the study, peer supporters in the seven
DSGs in the intervention arm delivered a group talk
Fig. 2 Flow diagram for the trial
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each month (total 42 talks, 100% of planned talks were
delivered). We found that 34/42 (81%) meetings had an
attendance of ≥ 80% of the trial participants.
Of the targeted 369 telephone reminders in the first
month, 273 (74%) telephone reminders were made as
some of the participants took the screening exam imme-
diately after the first group talk and before the telephone
reminders. Forty-eight percent of participants received a
reminder each month (six reminders in total) over the 6
months trial period. There were frequent reports of par-
ticipants being unreachable on phone, as the phones
were switched off, or they had changed the number. In
such cases, the peer supporter arranged a personal visit
to the participant to give a face-to-face reminder (this
was a local adaptation of the intervention). During the
first two months of implementation, peer supporters
from two different DSGs made weekly calls to the prin-
cipal investigator to seek feedback (in addition to the
weekly calls that all peer supporters received from the
principal investigator). This was a further form of inter-
vention adaptation; these two DSGs had the highest
rates of implementation fidelity.
Fidelity
There was 100% adherence to the frequency of the group
talks (one group talk every month). However there were oc-
casional changes on the actual date of the group talk each
month (due to other communal activities), such that the in-
tervals between the group talks were not constant. Adher-
ence to content of group talks met the required threshold
in 83% of the group talks. Some 43 participants could not
be reached on telephone at least once during the trial, and
the peer supporters gave them a reminder through a face-
to-face communication as mentioned above. We monitored
adaptations, which we interpreted as evidence of ownership
and adaptation to meet contextual needs.
Acceptability
The acceptance of the intervention in the study popu-
lation was high, given the high retention in the study.
The intervention was perceived as beneficial and ac-
ceptable to participants because it was bridging infor-
mation gaps.
I am happy you people are coming here to us, because
we are benefiting. Although I have not yet gone [for
screening], I now know that I should not wait to have
problems with my vision and I know where I should go
[for screening] (FGD participant)
There was satisfaction with the study procedures among
the participants. This was not surprising as we had tested
these with a pilot study [17]. We had anticipated partici-
pants to be uncomfortable with temporary blurring of
vision due to dilating drops, but it was not perceived to be
a significant problem because they were forewarned about
it.
The difficult seeing after the medicine in the eye…it
was not as serious as I expected,… it was not like you
could not see at all…, and by the time I was going
home I could see very well (FDG participant)
All 10 key informants were willing to scale up the
intervention to other counties in future, using the DURE
tools such as the PS training curriculum and the com-
munity entry mechanism.
The DURE curriculum for the peer supporter training
is very comprehensive and easy to follow, and we want
to formally adopt it in our peer supporter manual, so
that we can use it in our routine training of peer
supporters (KDDA national representative)
Eye care workers accepted to conduct the screening
for DR, even though at first they were concerned about
a sudden increase in the screening workload.
Initially we had concern that this might increase the
workload, but we found that this was only a
temporary effect as many participants came at the
same time for the screening, which is unlikely to
happen in the repeat screening visits. It is good to see
the participants asking for the screening… they already
have the information about it (eye health worker)
How was the intervention experienced?
Table 4 shows the five CFIR constructs, the sub-constructs
identified within them and examples of the related quotes.
DURE intervention characteristics
Stakeholders considered the peer-supporter-led intervention
to have relative advantage, as it was not feasible to have
health workers go to the community to give the same inter-
vention. All PLWD also perceived the DURE intervention as
a relative advantage compared with the usual practice where
they were not offered screening. In particular, participants
found the referral card highly valuable as it represented per-
sonalized care and was perceived to make it easier to navi-
gate interaction with eye care providers. Peer supporters
valued the training and task shifting which gave them confi-
dence and recognition that they did not have before.
The intervention components were easy to implement
along with the usual duties of peer supporters, and were
adaptable to suit local needs (such as additional face-to-
face reminders for participants who could not be
reached by phone). Although research assistants
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Table 4 Quotes on CFIR constructs
CFIR construct/sub-construct Sample quotes
Intervention characteristics
Relative advantage This is more effective than leaving it to health
workers from the hospital to go to the
community to educate the PLWD, for that is
not always feasible (MoH national representative)
The training we received was very good. People
appreciate my work when I give them talks…
(Peer supporter)
The referral card…have a look (showing the
card)…it has my name, and the date of my
next clinic … at the clinic I just showed it
(to the staff) and I was attended (FGD
participant who attended clinic)
I still have my referral card … I never leave it
behind…so I know that the day I go to the eye
clinic I will show it and get checked (FGD
participant who did not attend clinic)
Complexity Training the peer supporters was not difficult,
the training slides are easy to use (trainer)
We are not doing things that are very different
from what is usually done …[in DSGs]…we
were already familiar with group talks, what
we have not been doing was the telephone
reminders...and giving referrals, but that is not
burdensome (peer supporter)
When I learnt the reason for the test, and was
given the referral card…all I needed was to
present myself at the clinic. You could go even
the following day, anytime…and you only
needed to go once. We went together several
of us. Can anyone say that it is difficult? (FGD
participant who had screening)
Adaptability and flexibility I wanted the PLWD to go to the eye clinic as
soon as possible…so if I could not reach them
on phone because they had put off the phone,
I took it upon myself to go to their homes
(peer supporter)
We carry out the DURE activities because they
fit well with our other activities…I go on with
my usual work on the farm except for the DSG
meetings (peer supporters)
During recruitment, we realized that we needed
additional personnel in the recruitment team,
so we expanded the team (member of
research team)
Cost The intervention uses existing resources in the
community and in the hospital…this is the biggest
advantage because it can scaled up without cost
limitations…(MoH county representative)
People’s pockets are different…when I went there
I had only 100 shillings … I paid 50 for registration.
They asked me to pay another 50 for eye
examination.
I paid it because I had to get the screening. But
someone else will just say they will come next
week. (FGD participant who attended screening)
Relative disadvantage The only problem is that at both the diabetes clinic
and the eye clinic they make you wait… queuing
two times…then in the eye clinic they put some
medicine in your eyes and ask you to wait again
…you can end of wasting a lot of time waiting.
Why should I que twice? (FGD participant who
attended screening)
But why don’t you focus on preventing the
complications, rather than just screening? For me
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Table 4 Quotes on CFIR constructs (Continued)
CFIR construct/sub-construct Sample quotes
I have begun with doing exercises, but later I will
go for the screening. [names peer supporter] will
take me there… (FGD participant who did not
attend screening)
Outer setting
Diabetes as a health priority We are keen on sustainable interventions for
NCDs and we have to go to where the patients
are found…We should not wait for patients to
come but go to them. This is sustainable
because the trained peer educators will remain
in the DSG to educate more people. We will
work with them more. (MoH representative
at national level)
Clinical guidelines for DR are used as a national governance tool that is also useful for
resource mobilization
The clinical guidelines have been very helpful.
Earlier on I did not routinely screen those who
have good vision. Now I dilate and screen all
those that come here. We also order more
dilating drops (eye health worker)
Peer supporters mitigated potential implementation challenges such as political events The presidential elections were nullified,
everyone left the (DSG) meeting to go and
watch the news… and had I not been
passionate to mobilise members there would
have been very poor attendance at the next
meeting… (peer supporter)
Intervention fits within the norms of the health care system The county health services, including eye care
and diabetes care services supported this
innovative involvement of peer supporters
because we all want to improve quality of life
for PLWD (MoH representative at county level)
External outreach camps There were two external mobile outreach camps
organized at a church by a private care provider
…some of the people preferred to go for the
screening here because it was nearer
(DSG county lead)
With the mobile outreach clinic, you know it is
only for one day, so you don’t want to miss the
opportunity. For the hospital, some of the people,
even if they live near, do not attend… They keep
on postponing because the eye clinic will always
be here… (Peer supporter)
Inner setting
Tension for change I know someone who doesn’t go out of his home
now, because he can’t see…that is why we have
been told not to wait till we have eye problems
(FGD participant who took screening)
I have never had my eyes checked…. Can you
check me today? Or give us the referral cards
so we can go [to the eye clinic] tomorrow (FGD
participant from control arm)
We have to find a way of easily identifying those
any diabetes patient who has not been screened.
May be label their files so that they can easily
identified (eye health worker)
We have seen people going blind…nobody will
come from outside to stop it… we have to do
something ourselves (KDDA county representative)
Compatibility We give the group talks as part of the monthly
DSG meetings (peer supporter)
We want to have all PLWD screened for DR, thus
this intervention is contributing to that mandate
(eye care worker)
DSG Organisational Culture For us we are always open to new things that
can help us who live with diabetes, so we are
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Table 4 Quotes on CFIR constructs (Continued)
CFIR construct/sub-construct Sample quotes
happy to work with you on this…it empowers
us to not just to go for screening, but to engage
in advocacy for diabetes eye health (KDDA local
representative)
In DSGs, we know about volunteering … and
for the good of our people, we all have to work
together to ensure everyone goes for the eye
check… I do not mind giving my time to do
this, though of course it requires extra time …
I am happy people got tested
(peer supporter)
At the DSG I tell them my experience with
screening…we don’t hide things from one
another…(PLWD who has taken screening)
In some of the DSGs, participants came
together…we would have a large group
turn up at one go…they would tell me
they all agreed to come together (eye
health worker)
Here we like to share about ourselves openly,
we don’t hide things, we are not afraid to
open up or keep reminding one another
about attending screening (FGD participant
who attended screening)
Incentives and rewards We do not get paid for this work, it is about
volunteer work, people who do not want to
volunteer their time cannot do this work
(peer supporter)
But since we are doing good work, and
we spend a lot of time on it, if we were
paid we could do even more (peer supporter)
Readiness for implementation We are planning a peer supporter training in
[names county]…we want you to come and
train them so that they start doing the same
in [names county]… (KDDA national
representative)
Now that you have done this with some
groups, you also have to come to our groups
and give us the intervention, … you should
not leave us out (PLWD from control group)
Adjustments in the eye health system Sometimes, people did not screen for diabetic
retinopathy if the patient’s vision was good.
But now we have been reminded to screen
all PLWD annually and we have started
doing that
(eye health worker)
The eye clinic has recently been renovated,
we saw the governor launch it and we heard
that it has all the equipment, so we are now
happy to go there. (FGD participant who
attended screening)
Community volunteers (CVs) reinforced key messages Community volunteers really support us…
because they reinforce what we say. In our
DSG, we have a member who is a community
volunteer… I usually call her to speak after
I given the group talk...it is better when the
message comes from two people. (peer supporter)
Geographical barriers hinder uptake of screening Getting to the eye clinic is a problem because
the easiest way is to take a boda boda (motorbike
taxi) to the main road and then wait for a matatu
(public van). I avoid boda boda because I have a
back problem, so I just wait for the outreach camp.
(FGD participant who has not attended screening)
From this experience, the cost of mobility must
be borne by the provider, not the PLWD. We
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Table 4 Quotes on CFIR constructs (Continued)
CFIR construct/sub-construct Sample quotes
must find a way of going to the DSG for
screening, rather than asking them to come.
(member of the steering team)
For me, I haven’t gone to the eye clinic. I am
looking for the fare. Why can’t you come to
do the test here? (FGD participant who has
not attended screening)
Peer supporter characteristics
Knowledge and beliefs about the intervention The peer supporter at [DSG] informed me
that they have started a WhatsApp group
for peer supporters…to discuss how they
can do more to prevent diabetes complications
in general…they feel the work they are doing
with DURE can be expanded (PI field notes)
I observed that the peer supporters enjoyed
giving the group talks, and the key messages
were easy to explain and it was a social activity,
unlike the paper work which was more of an
individual task. They still did the documentation
since they were trained to do it. (research
assistant)
Individual identification with the role of PS In our support group, most people have gone
to the eye clinic, because [names peer supporter]
is very active, and he makes us laugh when he
is giving the talk…you cannot get tired…and
every time he meets you he will remind you,
even at church… (FGD participant who
attended clinic)
I always see [name] here in the diabetes clinic,
bringing his DSG members. Then he also takes
them to the eye clinic. Sometimes they tell him
they do not have the money for the hospital
fee but he insists and they pay (diabetes
care worker)
Individual stage of change All the peer supporters had already taken
screening so they must have been good role
models (KDDA national representative)
None of the peer supporters had any previous
training on delivering a diabetes eye health
intervention, you could tell that they liked
it…the novelty of the information seems
to have been a motivator… (Trainer)
Personal attributes “I did not do as much work as [name], though
he and I are the supporters in our group. But
he did very well…you know he is younger,
‘sharp sharp’ (slang for exuberance) and
men can do this work more easily…
” (Female peer supporter)
[Name] is ever punctual so we know (DSG)
meetings will run on time. She is a teacher
so she explains very well. That is why many
people don’t miss the meetings, and most
of us got tested the very first month (FGD
participant who attended screening)
What I have seen, is that he [peer supporter]
is self-sacrificing…from the heart … he
closes his business of selling clothes to
bring PLWD to both the diabetes clinic
and the eye clinic (diabetes clinician)
We did not know whether keeping the
peer supporters engaged over six months
would be challenging…I would say selection
of peer supporters is important as they have
to be highly motivated and committed
(member of steering team)
Mwangi et al. Tropical Medicine and Health            (2020) 48:1 Page 11 of 17
observed that documentation tasks were time-
consuming for peer supporters, these peer supporters
did not perceive it as difficult. Given that the pilot trial
had provided an opportunity to test-drive the interven-
tion, all stakeholders recognized the intervention as “fit
for trial”.
Stakeholders noted that the intervention utilized exist-
ing resources, rather than requiring additional resources,
which pointed to the advantage of cost-efficiency and pos-
sibility for scaling up. At the individual level, some PLWD
indicated an inability or unwillingness to pay the hospital
consultation fee at the eye clinic might be a financial
Table 4 Quotes on CFIR constructs (Continued)
CFIR construct/sub-construct Sample quotes
Self-efficacy of peer supporters He took me to the eye clinic, together with
others… he did not feel bothered about
waiting in the queue with us… (FGD
participant who attended screening)
When I saw that the first five members
had gone for screening right after I
gave the first talk, I knew I was doing
it right, I felt motivated me to continue
with the work (peer supporter)
When I observed [names peer supporters
giving the talk], they performed so well,
they answered all the questions. I think
it is because they were trained well…
(research assistant)
Process of implementation
Planning We were very happy to be involved from
the beginning…we have always insisted
on being involved as equal partners in
things that concern us, so we participated
(KDDA national representative)
I remember the meeting we had at the
beginning…when our chairman of KDDA
came and introduced the project…we
agreed to support… (peer supporter)
Engaging The research team was really committed
…they were always available and we
worked so well together, it made us not
to leave the work half- way (peer supporter)
…we even took lots of photos
The community volunteers, they really
embrace us…we support one another in
the work (peer supporter)
I looked forward to the call from the PI
every week – it gave me motivation
(peer supporter)
Regular briefing helped us to keep involved
(steering committee member)
Executing We were of course concerned about the
feasibility of the intervention since we
have not used the DSG platform before.
But we had success with the pilot trial,
so this proved not to be a major issue
(member of project steering group)
The DSGs in the control arm are left out,
but we have understood that they can
get the intervention thereafter
(peer supporter)
Evaluating I am looking forward to the findings of
the study (research nurse)
You need to give us a copy of the results
…(MoH county representative)
We will organize a forum to share the
results with the stakeholders (MoH
national representative)
DSG Diabetes Support Group, DURE Uptake of Retinal Examination in Diabetes study, FGD Focus Group Discussion, KDDA Kenya Defeat Diabetes Association, MoH
Ministry of Health, PI Principal Investigator
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barrier to screening. Another relative disadvantage was
the need for queuing at the eye clinic, especially because
those who attended the diabetes clinic on the same day
had to queue twice. One participant expressed skepticism
about prioritizing screening rather than lifestyle interven-
tions (such as physical exercise).
Outer setting
Stakeholders highlighted the growing health priority
given to diabetes and other non-communicable diseases
within national health policy framework as an import-
ant outer setting construct that increased stakeholder
interest in the implementation of the DURE interven-
tion. The intervention was also perceived to be
responding to patients’ need for a patient-centered ap-
proach to care, in addition to being aligned with the
norms of the health system such as increasing efficiency
and access to services.
The recent implementation of the clinical guidelines for
DR had sensitized the diabetes and eye health workers that
all PLWD need annual screening for DR. Eye care providers
also found the guidelines useful for mobilizing required re-
sources such as mydriatic eye drops. The guidelines were
considered an aid to implementing the intervention.
Disruptions in the sociopolitical environment presented
a potential outer setting constraint. During the study
period, there was a disputed election that was subse-
quently nullified and had to be repeated. It can be challen-
ging to maintain participant attendance to DSG meetings
or to screening during periods of political turmoil. The
peer supporters mitigated this potential disruption
through persuasive communication with participants. The
research team similarly maintained communication with
all the stakeholders to ensure continued engagement, fi-
delity, and availability of screening at the eye clinic.
There were two external outreach eye camps in the
county during the study period. Some participants attended
screening at these camps instead of the eye clinic. This is
because they offered the advantage of proximity, conveni-
ence, and the perception of being a scarce but valuable op-
portunity for screening, which constituted an external
incentive. As they used the same screening guidelines, any
participants screened at the outreach site was taken to have
the outcome of interest.
Inner setting
The implementation climate is a key sub-construct
within the inner setting construct that was found to be
associated with the DURE implementation. Among the
peer supporters, there was tension for change that re-
sulted from the training, since they perceived that
PLWD are vulnerable to vision loss from DR. Similarly,
eye care workers expressed the need to detect and treat
DR in a timely manner, as most patients presented with
advanced DR. The PLWD reported having taken up
screening early in the intervention because the group
talks raised awareness about their vulnerability to DR,
thus raising the relative priority of taking up screening.
Peer supporters found the intervention to have high com-
patibility as it was seen to respond to the tension for change,
and it was designed to fit within the usual support group ac-
tivities. To this extent, the compatibility was a facilitator for
implementation. Participants tended to turn up at the eye
clinic in groups especially early in the trial, and since screen-
ing procedures take time, there was a risk of overloading the
health system. However, we recognized that this potential im-
plementation barrier was foreseeably transient, since the
participants would get individualized appointments for subse-
quent screening. Based on this premise, the eye care workers
supported the implementation, and thus the potential chal-
lenge transitioned to become an enabler. This theme also
emerged in relation to acceptability (above).
The organizational culture of DSGs is another sub-
construct that influenced the implementation. One of the
participants referenced that DSGs are usually receptive for
“new things” especially those that empower the PLWD.
Participants pointed to the culture of self-disclosure,
which was associated with the willingness of participants
to update the peer supporter and DSG members on
whether they had taken up screening. Further, the culture
of collective action led participants in a DSG to team up
and go together for screening. Due to the culture of volun-
teerism, peer supporters were willing to commit time to
deliver the intervention and sometimes to accompany the
participants to the eye clinic. However, a potential threat
to volunteerism was also voiced by peer supporters who
expressed that they could be doing other things (oppor-
tunity cost) and that since their work was effective they
should receive some incentives from the government.
Readiness for implementation was epitomized by the
interest of DSG leadership at national level to begin scale
up of peer-supporter training and to incorporate the
DURE training curriculum in the peer-supporter training
manual. Participants referenced national-level stakeholder
interest to scale up the intervention to other counties. On
the other hand, eye care workers articulated the need to
equip the eye clinic with more staff and technology for
screening.
Participants in the control arm requested for the inter-
vention to be implemented in their own DSGs as they
felt left out. This was already planned to meet the ethical
obligation to ensure that control groups also benefit
from the intervention [18]. This implementation in con-
trol arm DSGs was implemented subsequent to the trial.
A potential barrier in the structural characteristics
construct of the inner setting is the geographical terrain
and distance to the eye clinic for geographically remote
participants—distance, unsuitable transport options,
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cost, and time for travel were noted to be challenges for
participants of some DSGs.
Characteristics of peer supporters
On the sub-construct of knowledge and beliefs about
the intervention, all peer supporters attended the train-
ing and rated it as a very useful learning experience be-
cause they had no previous exposure to eye health. The
training was articulated as a facilitator of implementa-
tion since it created self-efficacy to deliver the interven-
tion and to answer any questions from participants.
Both the training and the task-shifting inherent to the
intervention were valued as sources of personal fulfil-
ment and increased role-recognition by peers and health
workers. However, supporters identified that their con-
tribution in the intervention risked being overlooked or
under-recognized as they had not received formal recog-
nition such as certificates. Providing certificates was a
challenge at this stage because we needed to have the
training curriculum formally adopted before certifica-
tion. Providing certificates may facilitate implementation
in scale up of the intervention, by stemming potential
burnout or turnover of peer supporters.
Regarding individual stage of change, peer supporters
expressed a collective (rather than individual) sense of
accountability to implement the intervention: “we are
the people to make a contribution to reducing the num-
ber of people going blind”. This may relate to the culture
of collective action, a theme already highlighted under
inner setting constructs. Being volunteers, their motiv-
ation came from a sense of altruism, but they were also
motivated by the training and subsequent initial success
of seeing participants attend the screening. The 13/14
peer supporters remained engaged with the trial until
the end, and they reported that the weekly telephone
contact with the principal investigator kept them en-
gaged. Community volunteers were a further source of
motivation, even though they do not have diabetes. This
is because they are also volunteers in the community,
are well versed with the health system and they rein-
forced the key messages.
Cultural adaptation was further highlighted at the peer
supporter level, especially relating to gender and age
norms in the performance of peer support roles. For ex-
ample, a female peer supporter noted that she took on a
smaller proportion of the tasks and left the rest to her
younger male counterpart. However, age and gender were
not sufficient to account for the effectiveness of peer sup-
porters. Participants identified some personal attributes of
peer supporters that influenced them to take up screening.
These included interpersonal skills demonstrated while
delivering the group talk (e.g., using humour, keeping
time), persistence with follow-up, individual reminders
and accompanying participants to the eye clinic.
Process
Collaborating with stakeholders emerged as an import-
ant attribute. DSG leadership at national and county
level were satisfied that they had been involved in the
planning of the implementation, through attending pre-
implementation meetings. They also noted that the com-
munity entry process (through the national, county, and
support group leadership) positively influenced accept-
ability of the intervention.
Continuous engagement was considered critical, in the
form of frequent telephone contact or face-to-face con-
tact with all the stakeholders. Peer supporters found the
training and weekly telephone calls to give them a sense
of identity with the trial. Research assistants valued role
modelling for their tasks, while all stakeholders valued
regular feedback. In the executing sub-construct, the
trial was executed as per the trial protocol. It was not
feasible to mask the intervention arm to the interven-
tion, since the intervention activities within a DSG were
overt. However, we did not find any evidence of contam-
ination between clusters, perhaps because participants
were not privy to the intervention allocation of other
DSGs. Regarding reflecting and evaluating, we regularly
reviewed the progress and quality of implementation
with peer supporter and eye care workers. Peer sup-
porters constantly reflected on their own performance
and gave updates particularly on the reach and fidelity.
All key informants and participants looked forward to
receiving the results of the trial.
Over-arching analysis of the factors influencing
implementation
We found that the intervention was in alignment with
health system priorities and stakeholder interest. All five
constructs of the CFIR impacted the extent to which the
intervention was implemented, and the sub-constructs
within different constructs were inter-related. For ex-
ample, among the participants, tension for change devel-
oped when the intervention raised awareness of the
vulnerability to vision loss from DR. Training of peer sup-
porters enabled them to deliver the intervention, as well
as to develop self-efficacy to increase uptake of screening
among participants. Getting feedback on the number of
people who had attended screening further increased self-
efficacy among peer supporters. Prioritization of diabetes
and implementation of clinical guidelines for DR also cre-
ated tension for change among health workers who con-
ducted the screening. Figure 3 illustrates this example of
inter-relatedness. Most of the factors identified in each of
the constructs were facilitators of implementation, and
were modifiable, which means interventions targeting
these factors can improve implementation during scaling
up.
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Discussion
The DURE study process evaluation provides detailed
information on the implementation outcomes and the
context of implementation to better understand how
the intervention and context interacted. This is the first
trial to increase access to DR screening through peer
support interventions that has also documented the im-
plementation process. The strengths of this study in-
clude the use of a validated theory (CFIR). This theory
focuses on broad constructs that are representative of
the potential influences on the implementation process,
which enhances the generalizability and replicability of
our methods [12]. We collected data from different stake-
holders, which provided an understanding of how differ-
ent stakeholders experienced the intervention and its
implementation strategies. We engaged PLWD who had
gone for screening as well as those who had not to identify
different perspectives on facilitators and enablers for the
intervention. We collected extensive data using mixed-
methods, and we triangulated findings from different
sources for validity and to reduce the potential risk of bias.
The qualitative data were in broad agreement and pro-
vided rich context for the quantitative findings, which en-
hances confidence in the findings.
The trial had success with implementation outcomes,
i.e., acceptability, recruitment and retention, reach, fidel-
ity, and dose. This success resulted from the perception
of stakeholders and that the intervention was beneficial.
The stakeholder interest, the tension for change and the
increasing priority given to diabetes in the national
health policy suggest that this was an opportune time
for the intervention.
Stakeholders identified that the national clinical guide-
lines for DR positively influence the practice and readi-
ness of eye clinics to provide screening. By sensitizing
health workers to the need to screen all PLWD, the
guidelines created tension for change. This in turn
ensured that all who turned up for screening received
the service, as it addressed potential supply-side barriers
to screening. We therefore conclude that health system
strengthening such as the development and implementa-
tion of clinical guidelines was a facilitator for the imple-
mentation of the intervention as well as adoption of
screening behaviour by the participants. Several studies
have found that health system strengthening gives trac-
tion to heath care interventions [18–21].
We observed an early response to the intervention ac-
tivities. The highest attendance at group talks was at the
first group talk. In addition, all participants were referred
to the eye clinic for DR screening at the start of the trial.
Participants who took up screening reported doing so as
soon as they received the group talk and referral, and
other DSG members accompanied them. This may be
related to the influence of the culture of collective action
as well as the effect of the group talk and referral card.
We therefore hypothesise that the first group talk and
the referral are the most essential components of the
intervention. We also hypothesise that these compo-
nents are well aligned to the causes of non-attendance
to screening in this population, which we had found to
be inadequate knowledge of diabetes eye complications
and lack of referral of referral for screening [2].
Among those in the intervention arm who did not take
up screening in the intervention arm, lack of knowledge
was not identified as a barrier, suggesting that the inter-
vention had good reach and had increased awareness even
among those who did not take up screening. At the same
time, participants who did not attend screening still indi-
cated intention to take up screening. These points to the
need to identify the post-awareness/intention barriers
among PLWD. Grimshaw et al. (2014) had a similar find-
ing among physicians who received an educational inter-
vention to increase referrals of PLWD for DR screening
[12]. There were some potential relative disadvantages of
Fig. 3 Inter-relatedness of the CFIR constructs
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the intervention, such as having to queue and pay consult-
ation fee twice if a PLWD was attending both diabetes
and eye clinics. This was foreseeable, given the structure
of the hospital. These individual, social, and organizational
level barriers are consistent with those in the literature
[12, 21–23]. Some hospitals are testing the effectiveness of
conducting DR screening at the diabetes clinic to over-
come this challenge [24]. There is also need to support
geographically remote individuals with logistical and fi-
nancial challenges, such as through multiple access points
for DR screening, closer to home [25].
The role of peer supporters in delivering the interven-
tion was a prominent facilitator. Peer supporters deliv-
ered the health education talks and telephone reminders,
but in addition, they visited participants who were not
reachable on phone, accompanied participants to the eye
clinics, and waited with them. These are roles of peer
supporters that we had envisaged would contribute to
increasing the self-efficacy of participants who took up
screening [3]. This is evidence that the intervention
worked through the anticipated mechanism of the inter-
vention, which strengthens the plausibility of the results
[26]. The peer supporters also identified the training and
task shifting as very valuable, and these were important
enablers for the role of peer supporters. We also found
that community volunteers to be an important enabler
to peer supporter roles, which we had not anticipated.
This is evidence that complex interventions interact with
the context in multiple ways to influence the outcomes.
The intervention was compatible with processes and activ-
ities of both the DSGs and the eye clinics. We noted adapta-
tion to the delivery of the intervention (but not to the
content of the intervention), driven by contextual experience.
Like other investigators of pragmatic public health interven-
tions, we recognized the need for fidelity-adaptation balance,
since they coexist and are both valuable [10, 27]. To mitigate
the risk of intervention drift that may occur with adaptation,
we monitored the level of fidelity, which was maintained. Ra-
ther than threatening fidelity, we found that this adaptation
actually maintained fidelity, because it ensured that those
who could not be reached by phone still got the scheduled
reminders to attend screening.
Our findings highlight that all the constructs of the
CFIR were relevant to the trial, and there were multiple
determinants to implementation. We cannot attribute the
success of implementation exclusively to the characteris-
tics of the intervention, the peer supporters, the DSGs, eye
clinics, the outer setting, or implementation processes.
More likely, it is the combination and interconnectivity of
these constructs working together. This highlights the im-
portance of alignment of interventions to context.
The process evaluation has potential limitations. We did
not conduct evaluation at multiple points in the trial; hence,
we could not capture changes over time. As the study was
conducted in multiple DSGs with different peer supporters,
we cannot account for differences in peer support styles.
The social and health system context of the trial may also
affect the generalizability of its results. The potential for re-
searcher bias by the project investigator undertaking the
qualitative interviews is acknowledged; however, it was
agreed among the project team that she was the most cul-
turally appropriate person to probe about how the context
affected implementation and the mechanisms of impact.
We cannot rule out response bias by social desirability, but
the risk was low, given that this was not a sensitive topic,
and we relied on diverse sources of data.
Conclusion
The intervention was largely implemented as designed, and
achieved high implementation outcomes for acceptability, re-
cruitment, retention, reach, fidelity, and dose. There is high
stakeholder interest to support scale up. The intervention
worked through the expected mechanisms, but was also
aided by unanticipated mechanisms. Health system strength-
ening was a necessary pre-requisite for implementation. We
recommend that future process evaluations are carried out
at multiple points and include a cost analysis.
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Methods that were used to mitigate contamination are summarised in three categories: 
statistical design, trial conduct, and monitoring for contamination. In statistical design, we used 
302 
Additional notes on data collection 
Trial documents such as registers, activity logs, minutes, diaries and field notes provided 
quantitative and qualitative data on field activities. Quantitative data was extracted on an Excel 
template by the study team and used to measure recruitment, reach, dose and fidelity. 
Qualitative data was extracted by two team members independently using thematic analysis 
and provided explanatory information on the quantitative parameters, as well as on adaptation 
and contextual factors. 
Interviews with key informants were conducted by the primary investigator and captured 
through field notes written during the interviews. The data was not audio-recorded as field 
notes were considered sufficient for capturing the information, providing an audit trail and 
were easily accessible to the key informant during the interview for member-checking. 
Multiple coders carried out the analysis as explained in the paper. These factors helped to 
maintain objectivity and transparency, and minimize bias. 
Additional notes on measurement of contamination in the DURE study 
Before the study we identified processes that may lead to contamination. The intervention was 
delivered during DSG meetings. There were two main processes that could lead to 
contamination at DSG meetings. The first process was participants in the control arm attending 
meetings in the intervention arm. This might occur if PLWD in the control arm were visiting in 
the vicinity of an intervention DSG. The second process was peer supporters from the 
intervention arm delivering the intervention in the control arm, if they were responsible for 
more than one DSG. 
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cluster randomisation, where the intervention was delivered within geographically dispersed 
clusters. This minimized the likelihood of members of different DSGs coming into close contact. 
Regarding trial conduct, the recruitment of peer supporters from each DSG ensured that each 
peer supporter was only responsible for delivering the intervention in one DSG. Visiting PLWD 
were not eligible for recruitment into the study. To monitor contamination, participants in all 
trial activities (such as attendance to DSG meetings) were carefully documented in trial 
registries, to identify any movement of participants between DSGs. We did not find evidence of 
contamination.  
We measured self-efficacy in all participants before and after the intervention, as discussed in 
chapter 10. We found that self-efficacy was low in all arms at the start of the study, but 
increased in the intervention arm after the intervention. Self-efficacy remained low in the 
control arm. This indicated that there was no receipt of intervention in the control arm, and 
therefore that there was little evidence of contamination.  During focus group discussions with 
participants and peer supporters at the end of the trial, we also enquired about exposure of 
the control group to the intervention. We had promised the DSG leaders that we would offer 
the intervention to the control arm at the end of the follow-up period. The follow-up period 
was short (180 days) and this may have safeguarded against contamination. 
304 
Chapter 10 
Effectiveness of peer support to increase attendance at DR 
screening - a pragmatic cluster randomized clinical trial 
Outcome evaluation of the DURE trial 
10.1 Overview 
Research paper 1 (chapter 4) provided a conceptual model on how interventions to strengthen 
knowledge, referral and self-efficacy of PLWD can improve uptake of eye examination. In 
settings that have diabetes support groups, innovative use of this resource to influence these 
factors may be effective in enhancing uptake of DRS uptake. 
Research paper 5, which is the study protocol (chapter 7), provided further insights on how 
self-efficacy for taking a retinal examination might improve through peer support in the Uptake 
of Retinal Examination in Diabetes (DURE) study. The previous chapter (chapter 9) reported the 
process evaluation of the trial, which provided evidence that the intervention worked through 
the anticipated mechanism of the intervention. 
This chapter consists of a research paper that describes the main trial results reporting the 
effectiveness of the intervention. The trial is reported in adherence to the Consolidated 
Standards of Reporting Trials (CONSORT) 2010 statement: extensions for cluster trials and for 
pragmatic trials (www.consort-statement.org).  
Research paper 8 (being submitted to Lancet Global Health) includes data on baseline 
characteristics of participants, self-efficacy scores, follow-up, attendance to DRS screening and 
time to screening.  The data on effectiveness of the intervention is stratified by gender, as 
there was evidence of variability of effect between men and women. 
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This study demonstrated a significant early screening response following the intervention, and 
it offers a practical way to increase attendance at DRS screening, particularly in countries 
where DR is often detected late. 
10.2 Research Paper 8  
Lancet Global Health – Licences and Copyright 
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copyright while allowing others to copy, distribute, and make some uses of their work, 
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licences (CC BY or CC BY-NC-ND) depending on whether or not they wish to allow commercial 
reuse of their work and whether or not they wish to allow others to alter their work in the 
course of its reuse. Authors will be asked to sign a licence to permit our publisher, Elsevier, to 
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Diabetic retinopathy (DR) is a common complication of diabetes; it can occur without symptoms, 
so regular screening is essential to avoid vision loss. Access to screening for DR remains limited, 
particularly in low and middle-income countries (LMICs). We assessed whether combining usual 
care in diabetes support groups with a peer-led health education intervention was effective in 
increasing attendance at DR screening. 
Methods  
In a  cluster randomised controlled trial, we randomly assigned 14 diabetes support groups (1:1)  
to receive a peer-led health education intervention (group talks, individual reminders and referral 
for screening) in addition to usual care (intervention group) or to receive usual care only (control 
group). The primary outcomes were proportion of participants who attended DR screening in 
each arm at 6 months, analysed in the intention to treat population.  
[Pan African Clinical Trials Registry number: PACTR201707002430195, registered 15 July 2017]. 
Findings  
Among 734 participants, 54.2% (200/ 369) in the intervention arm and 11.2% (41/365) in the 
control arm attended screening (Odds Ratio [OR] 9.4 95%CI 6.4–13.7; p<0.0001). Gender was an 
effect modifier (Men: OR 4.5 95%CI 2.5-7.1; Women: OR 19.5 95%CI 10.9-34.8, p<0.0001). Among 
those who attended screening, the median time to screening was 11 days (range 1-180) in the 
intervention arm and 90 days (range 1-180) in the control arm, p<0.0001. No unanticipated 
adverse events occurred. 
Interpretation  
This intervention increased attendance at DR screening in people who had not previously 
attended screening.  
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Research in context panel 
Evidence before this study 
Before this trial, we searched in PubMed, the Cochrane Library and trial registries on the 
International Clinical Trials Registry Platform for systematic reviews and randomised controlled 
trials (RCTs) using peer support (emotional, educational, motivational or practical assistance 
provided by non-professionals) to improve diabetes outcomes, including screening for 
retinopathy.  We searched with the terms: “peer support”, “diabetes”, “diabetic retinopathy”, 
“screening” and “retinal examination” for literature published in English by June 1, 2017.  
We found three systematic reviews. Dale et al in 2012 included 14 RCTs and found that peer 
support improved clinical and behavioural outcomes in some adults with diabetes. Fisher et al in 
2017 included 30 studies and found that peer support can reduce HbA1c levels. Gatlin et al in 2017 
included seven studies and found that peer led self-management education can increase diabetes 
knowledge and reduce HbA1c. None of the studies in these reviews included any outcome related 
to diabetic retinopathy screening (DRS) and none of the studies was conducted in LMICs.  We 
searched the reference lists of included studies to identify additional relevant studies, but found 
none.
During our study, Lawrenson et al (2018), published a systematic review in January 2018 reporting 
that interventions targeting patients, health professionals, the healthcare system, or a 
combination of these may be effective in increasing access to DRS.  None of the included studies 
were from LMICs, and none provided evidence on the effect of peer supporter-led interventions. 
Thus, before our study, there was no substantial evidence on whether peer-supporter-led 
interventions can increase attendance to screening in LMICs. 
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Added evidence 
To our knowledge, this is the first published randomised trial to assess the effect of a peer-led 
intervention to increase uptake of DRS among members of diabetes support groups (DSGs). We 
provide evidence that attendance at DRS in similar settings can substantially and rapidly improve 
if peer supporters are empowered to provide an intervention that combines health education and 
referral. This finding is novel, and of considerable potential importance not only because the 
intervention is feasible and acceptable, but also because a mixed-methods process evaluation of 
the trial identified the active ingredients of the intervention. Our findings further add value to the 
existing evidence because the participants were people who had never had DRS hence they are 
the population who need screening most urgently. 
What the whole evidence means 
Increasing attendance to DRS is a key objective of DR screening programs in all countries. Our 
results showed that it is feasible to reach PLWD who have never had screening with a peer 
support intervention that increases initiation of DRS. Many countries may have untapped 
potential for improving health-care access using existing resources such as community groups. 
This highlights the importance of collaboration with DSGs in order to reach this highly vulnerable 
group in the real world settings.  
The findings have important implications for public health programs, particularly in countries 
where DR is often detected late with the risk of resultant visual loss and blindness. In such 
resource-limited settings, DR control programs should give priority to potentially feasible and 
sustainable public health interventions like those suggested in our study. Future studies should 
investigate context-specific costs of the intervention, and whether the intervention leads to 
maintenance of annual DRS over the long term. 
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Background 
Retinal changes due to diabetic retinopathy (DR) were first described by Jaeger in 1856.(1) It is  
estimated that there were 420 million people living with diabetes (PLWD) in 2017, with a third 
having DR.(2) Early detection and treatment are important for preventing vision loss associated 
with DR, therefore regular DR screening (DRS) for all PLWD is recommended.(3)  Low uptake of DRS 
is well documented, particularly in low and middle-income countries (LMICs), where the majority 
of PLWD live. Lack of screening or low uptake contribute to increased risk of vision loss from DR.(4)
Given the need to increase coverage of screening, it is essential that attendance at DRS be 
maximized as far as resources allow. Finding low cost effective interventions that can increase 
uptake of screening in the real world setting is challenging for DR screening programs. Lawrenson 
in 2018, in a systematic review on attendance at DRS, provided evidence that various 
interventions targeting patients, healthcare professionals or the healthcare system are associated 
with meaningful improvements in DRS attendance.(5) However, the authors noted that the 
interventions were ‘black box’ whose active ingredients were not easily identifiable. All the 66 
studies included in this review were conducted in high income countries, hence there is need for 
evidence from LMICs.(5) There is also need for evidence on interventions that are targeted to 
those who need DRS most— those who have never had screening, as they are highly vulnerable to 
vision loss from DR.   
Improving the knowledge of PLWD about eye screening is essential if avoidable vision loss is to be 
prevented.(6) The lack of knowledge of PLWD on diabetes eye health is known to be a modifiable 
predictor of DRS uptake, especially in LMICs.(7, 8) Knowledge can raise PLWD’s perception of 
vulnerability and severity of DR, hence building self-efficacy for adherence to screening 
recommendations.  A recent systematic review of barriers and enablers for DRS reported higher 
odds of uptake of DRS when PLWD were provided health education.(7) The effect of health 
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education interventions led by peers within community-based diabetes support groups (DSGs) on 
attendance at DRS remains equivocal, although peer support is beneficial for other outcomes.(9-11)
The Uptake of Retinal Screening in Diabetes (DURE) trial was a two arm (1:1) pragmatic cluster-
randomized clinical trial (cRCT) designed to test the hypothesis that the proportion of PLWD 
attending DRS would be higher in DSGs with the peer supporter-led intervention than in DSGs 
offering the usual standard of care in DSGs. The mechanism of effect of the intervention was 
predicted to be through increasing the self-efficacy of PLWD to adopt screening behaviour. The 
primary outcome was the proportion attending DRS in either arm during the six-month study 
period. We defined DRS as measurement of visual acuity and a retinal examination through a 
dilated pupil conducted by an eye care worker using either an ophthalmoscope, a slit lamp 
microscope or a retinal camera, which reflects current practice in Kenya.(12)
We chose a cRCT design instead of an individually randomised trial because peer support is 
normally provided at group level in DSGs, and to reduce the effect of intervention contamination, 
since patients in the same DSG often interact with one another. The trial design was guided by the 
United Kingdom’s Medical Research Council framework for developing complex interventions.(13)
Patient representatives were involved in the planning and implementation of the intervention. 
We anticipate that the trial findings will inform future strategies for improving screening services 
and subsequent early detection and treatment of vision threatening DR (VTDR). 
Methods 
Setting 
Kenya is a LMIC, as defined by the World Bank(14), and the prevalence of diabetes is 2% in the 18-
64 years age group.(15) Kirinyaga is a rural county located in central Kenya. Our formative research 
had established that only 12% of PLWD who are already attending diabetes services in Kirinyaga 
had ever taken DRS.(8)  DRS services are available at the county hospital on a walk-in basis, but 
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they are under-utilized. An estimated 25%-30% of PLWD are registered members of DSGs, while 
an additional 20% of PLWD attend DSG meetings occasionally even though they are not members.  
Study design and conduct 
The study protocol was peer-reviewed and a favourable ethics opinion was received from the 
ethics committees of the London School of Hygiene and Tropical Medicine (LSHTM) and the 
African Medical Research Foundation.  The trial was conducted in accordance with the principles 
of the International Conference on Harmonisation of Good Clinical Practice under the oversight of 
the study sponsor, LSHTM. Written informed consent was obtained at the cluster level, while 
participants gave verbal consent to receive the study interventions and follow-up. 
The sample size was estimated using standard formulas for cRCTs recommended by Hayes and 
Bennett.(16) Based on the data from formative research, with 50 PLWD in each DSG and 12% of 
PLWD attending DRS services in the control arm, and using a coefficient of variation of 0.25, 14 
clusters (7 in each arm, Fig 10-1) were required in order to have 80% power to detect a twofold 
increase in uptake in the intervention arm (with statistical significance at the 5% level). 
A research nurse recruited the participants from each group through simple random sampling 
prior to randomization. Table 10-1 shows the eligibility criteria while Fig 10-2 (at the end of the 
chapter) shows the participant flow in the trial.  Computer generated random numbers were 
obtained remotely by a statistician on STATA 15 (StataCorp 2017) and used for allocation of 
clusters to study arm. The allocation sequence was concealed from trial personnel until the 
moment of assignment.   
For each cluster in the intervention arm, two peer supporters (1 male, 1 female) were selected 
according to the exclusion and inclusion criteria and received a two-day training to deliver the 
intervention. The content of the training is described in the trial protocol(17) and summarized in 
Box 1. In addition to usual care at DSGs, the intervention arm had three components: monthly 
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group talks on diabetes eye health, individual referral for DRS using a referral card and monthly 
individual telephone reminders to take DRS. Peer supporters received airtime to facilitate the 
telephone calls, as well as reimbursement for any logistical costs, but no other incentives. 
Research assistants monitored the implementation of the intervention. Self-efficacy to take a 
retinal examination (a participant’s confidence in his ability to obtain a retinal examination, 
despite potential barriers) was assessed at baseline, after the first group talk and at the end of the 
study period, using a structured questionnaire. The primary outcome was attendance at DRS 
within six months. The records at Kerugoya County Hospital eye clinic were monitored daily and 
the identifier cards of participants that attended screening were deposited in a specific container 
by the eye care team. These cards were then collected and given to the outcome assessment 
nurse (not involved in recruitment or follow-up). 
Table 10-1: Eligibility criteria for participants and peer supporters
Criterion Participants Peer supporters
Age > 18 years
Member of a diabetes support group
Will reside in the county for the next 12 months
Has a mobile phone
Willing to participate in the study
Had not had a screening exam in the last 12 months
Has had a screening exam in the preceding 12 months
Willing to be a peer supporter
Willing to commit two days for training
Willing to commit many hours to peer support work
Fluent in Kikuyu or Kiswahili
Already attending DR screening
Already receiving treatment for DR
Has a debilitating illness
KEY Include Exclude Not applicable
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The recruitment nurse, research assistants and the outcome assessor had no training in eye care, 
and were masked to the intervention allocation, to avoid contamination and bias. The eye care 
providers were also masked to the intervention allocation. It was not possible to mask the study 
participants or peer supporters in the intervention arm, because the peer supporters’ activities 
within the DSG were overt. As the primary outcome was assessed from hospital records, we 
concluded that the lack of masking could not incentivise over-reporting or under-reporting in 
either arm. 
Box 1: Trial Interventions
Domain Intervention group Control group 
Usual care Monthly group meetings with 
general diabetes education 
talks, blood sugar and blood 
pressure measurements 
Monthly group meetings with 
general diabetes education 





Two days training following a 
structured curriculum 
regarding diabetes eye 
disease,  retinal screening, 
role of peer-supporters, 
communication and other 
aspects specified in the 
protocol(17)
Group education Monthly group education 
provided by trained peer-
supporters, with structured 
content on diabetic eye 
disease and retinal screening 
as specified in the protocol(17)
Individual participant 
reminders 
Monthly individual telephone 
reminder by peer-supporters 
to participants to take a 
screening exam as specified in 
the protocol(17)
Statistical analysis and reporting  
This study is reported in accordance with the Consolidated Standards of Reporting Trials 
(CONSORT) 2010 statement and its extensions to cluster randomized studies(18) and pragmatic 
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trials(19). The CONSORT flow chart and the checklists are included as appendices. All data analysis 
was carried out using Stata 15 (StataCorp, College Station, Texas, USA 2017) and following a pre-
specified analysis plan (Appendix 9). 
We calculated descriptive statistics for participants’ characteristics and compared the study arms. 
Continuous variables are summarised by mean and standard deviation, SD (if normally 
distributed), or median and inter-quartile range (IQR) if distribution was skewed. Categorical data 
are summarised as frequencies and percentages. We further analysed the intra-DSG correlation 
for these variables, to address a gap found in previous DRS studies.(5)
Our primary analysis was by intent-to-treat population, and we did not conduct interim analyses. 
The primary outcome (attendance at DRS) was binary, and analysed at the participant level as well 
as at cluster level. Tests of crude association with exposure to the intervention and with self-
efficacy scores were performed. The measure of effect is presented as odds ratios (OR) with 95% 
confidence intervals (CI).  
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KEY Kerugoya hospital 
eye clinic 
Control DSGs Intervention DSGs
Fig 10-1: Location of the clusters and the eye clinic within Kirinyaga county 
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We generated Kaplan-Meier survival curves to illustrate the difference in time-to-attendance 
between the two arms. We assessed the difference in time-to-attendance with hazard ratios 
(HRs) estimated by Cox regression. As the assumption for proportional hazards was not met, we 
estimated HRs for narrower time bands, within which the proportional hazard assumption holds. 
We performed logistic regression for bivariate and multivariable analysis, while accounting for 
clustering, to identify which of the independent variables were predictors of attendance to DRS. 
We also constructed nested multivariable logistic models including all potential confounders and 
did not find any evidence of a confounding effect.  
Role of the funding source 
The funder of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The first author had full access to all the data in the study 
and had final responsibility for the decision to submit for publication. 
Results 
Baseline characteristics 
All the 14 DSGs completed the trial. Baseline data was collected for all 734 participants (369 in 
intervention and 365 in control arm). The two arms were balanced for baseline characteristics 
(Table 10-2).  Appendix 8 shows the intra-cluster correlation coefficients (ICC) for the baseline 
anthropometric and clinical characteristics.  The ICC is low for all the variables, indicating minimal 
clustering effect.  
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Follow-up 
Some 4.2% (n=31) participants were lost to follow-up (20/369 in intervention arm and 11/365 in 
control arm).  They were lost to follow up relatively late in the study (median 150 days, inter-
quartile range 96-156 days). The reasons for loss to follow-up were travel (Intervention 7, Control 
2); illness, not related to the intervention (Intervention 2, Control 1); untraceable (Intervention  
11, Control 8). No adverse reactions were reported among the 369 participants who received the  





Age (years)  mean (SD) 59.6  (11.6) 56.5 (11.5)
Gender -Female n (%) 211 (57.8%) 208 (56.4%)
Duration of diabetes years, median (IQR) 4 (1 - 9) 4 (2-8)
Duration of DSG membership
median (IQR) 
2 (1-4) 2 (1-3)
Education (highest level completed) N, %




Employed n (%) 294(80.1%) 297(80.5%)
Known comorbidity with hypertension 
(N, %) 
34 (9.3%) 61(16.5%)
Body Mass Index mean (SD) 28.3 (5.0) 27.9 (5.1)
Waist circumference cm (mean, SD) 89.9 (8.5) 87.2 (9.6)
Random Blood Sugar mmol/l (mean, SD) 8.0 (3.2) 7.9 (3.0)
Systolic blood pressure mmHg (mean, SD) 137.8 (19.4) 134.3 (18.8)
Diastolic blood pressure mmHg (mean, SD) 76.6 (12.3) 77.4 (11)
Self-Efficacy (mean, SD) 13.4/50 (1.2) 13.5/50 (1.2)
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intervention. Participants who attended for retinal examination screening experienced temporary 
blurring of vision due to the effect of mydriatic eye drops, but this was anticipated and explained 
to the participants in advance. All of them described this effect as minor. 
Proportion attending screening
In the intervention arm, 54.2% (200/ 369) and in the control arm 11.2% (41/365) PLWD attended 
DRS. Compared with usual care, the intervention quintupled the number of participants taking 
screening. Overall, participants in the intervention arm had 9.4 times the odds of taking screening 
compared to those in the control arm (Odds Ratio 9.4, 95% CI 6.4–13.7; p<0.0001). Given the 
apparent imbalance between trial arms at baseline in terms of age, education, known comorbidity 
with hypertension and waist circumference, adjusting for these covariates (Odds Ratio 9.4, 95% CI 
6.3 – 14; p<0.0001). 
We obtained similar results in both participant level and cluster level analysis, Fig 10-3 shows the 
attendance by cluster. The influence of clustering on attendance to screening was reflected in an 
ICC of 0.3, (95% CI 0.05-0.54, p<0.0001), meaning that 30% of the variation in attendance to 
screening can be explained by the variation between DSGs. Attendance at DR screening was 
markedly high in two of the intervention DSGs, as compared to the other DSGs. Process 
evaluation (chapter 9) showed that this was due to the exceptional performance of the peer 
supporters in the task of delivering the intervention. 
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Figure 10-3: Proportion of PLWD that attended screening in each cluster 
Although the intervention effect was high in both men and women, there was a more pronounced 
effect in women. The odds of taking screening in women was higher than in men (OR 19.5, 95% CI 
10.9-34.9, p<0.001 compared to OR 4.2 95% CI 2.5-7.1, p<0.001), which was confirmed through 
logistic regression (interaction p<0.0001).  Gender is thus an effect modifier. We did not find 
variability in the pooled effect estimates for other variables, hence there were no strong reason 
to perform subgroup analysis for other variables.   
The scores for self-efficacy to take DRS at baseline did not differ between the two arms (median 
score 13/50, IQ z\d R 12-14 for both arms, p=0.2). After exposure to the first dose of the 
intervention there was strong evidence of a difference in self-efficacy scores, intervention arm 
(median 43/50, IQR 42-45) and control arm (median 14/50, IQR 13-15), p<0.0001) (Fig 10-4). This 
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Fig 10-4 Self-efficacy scores in intervention and control arms
Time to screening 
Trends in attendance to DRS over the study period were consistently higher in the intervention 
arm compared with the control arm, (Fig 10-5 and Table 10-3). However DRS was only taken up by 
54% (200/369) of the intervention arm over the 6 months, of which 183 (50%) had their screening 
within the first 30 days of the trial after the first group talk and referral for screening. This 
indicates that the intervention had an early benefit for DRS attendance, but only an additional 16 
(4%) attended DRS over the next five months of further exposure to the intervention. In the 
control arm, DRS attendance was spread more evenly across the follow-up period at 1-3% of 
control participants/ month. The median time to screening was 11 days (range 1-180) in the 












































Fig 10-5 Kaplan-Meier analysis of time from first group talk to attendance at DRS (A) and in 
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We found strong evidence that the intervention increased uptake of screening. To our knowledge, 
this is the first trial to investigate the effect of peer-led intervention on DR screening rates within 
diabetes support groups in any part of the world. The trial population was homogeneous in that 
they had not previously taken screening, hence they are the group particularly in need of 
screening.(6) The large effect of the intervention is likely to be because the intervention addressed 
known barriers to screening in this community, which are lack of referral and lack of knowledge 
on diabetes eye health.(8) Secondly, the high effect might be because the PLWD in our trial had 
never had screening, and other studies have reported that populations with low screening rates at 
baseline show the largest improvements. 
We found an early response—PLWD exposed to the intervention tended to attend screening right 
after the first group talk and subsequent referral, and further group talks did not tend to increase 
the effect. This important finding has not been reported in the literature. In addition, similar to 
Zhang et al, we observed a ceiling effect, whereby additional reminders did not increase 
attendance at DR screening.(6) Given the relatively low probability of further improvement after 
exposure to the active ingredients, it may be appropriate to limit the intervention to a single 
Table 10-3: Time period of trial in which attendance at DR screening occurred 








Hazard ratio [CI] p value
0 -30 183(49.6%) 4 (1.1%) 63.0 [20.4 - 194.6] <0.001
31-60 14 (3.8%) 7 (1.9%) 4.3 [1.6 - 11.8] <0.001
61-90 2 (0.5%) 10 (2.7%) 0.4 [0.1 - 2.7] <0.001
91-180 1 (0.3%) 20 (5.5%) 0.1 [0.02 - 2.6] <0.001
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group talk and referral, and then repeat the intervention after six months. Additional intervention 
components are likely required to increase uptake among those who did not respond to this 
intervention.  
In this population of African PLWD, diabetes was of short duration on average (median duration 4 
years) and glycemic control at the time of study was poor. The demographic and anthropometric 
characteristics of this group are comparable to the characteristics of the national population 18-
64 years, as described in the Kenya STEPwise survey for risk factors for non-communicable 
disease.(15) The results can be used to improve services in populations with a similar profile. 
We envisaged that the intervention would cause effect by increasing PLWD’s self-efficacy to 
initiate screening and this was confirmed. However, 46% of the PLWD in the intervention arm still 
did not take screening even though the overall self-efficacy in the group increased. This suggests 
that some participants face additional post-self-efficacy barriers that are not addressed by this 
intervention. Similar to other studies, our process evaluation (chapter 9) found that geographical 
barriers (for PLWD living in rural remote areas) as well as direct and indirect costs of screening are 
additional challenges for PLWD.(20) On the other hand, it is also possible that in some individuals 
there is a considerable time lag between improvement in self-efficacy and uptake of screening. 
In the control arm, 11% attended DRS. This might be because all participants were asked if they 
have ever had a DR screening exam in the baseline assessment, which may have encouraged them 
to think about the need for DRS and motivated them to go for screening. Gender was an effect 
modifier with a more pronounced effect in women. This is fortunate, since women are known to 
have a higher burden of VI and lower use of eye care services, as compared to men.(21, 22)
Younger age and higher education were associated with increased odds of attendance to DRS.  
Considering the implications of DR-related vision loss on quality of life, and economic 
consequences such as lost productivity, it is of interest that young PLWD attend screening. In 
contrast, some studies have reported younger age to be associated with poor attendance to 
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screening.(20) There is consensus in most studies that higher education improves access to eye 
care services.(21, 23)
In women, known comorbidity with hypertension and poor control of blood pressure were 
associated with increased odds of attendance to DRS.(2) This is fortunate, since poor blood 
pressure control is a known risk factor for DR, and these women at high risk are more likely to 
attend DRS. However the same effect was not seen in men with hypertension. 
In men, being employed was associated with reduced odds of attendance, perhaps because the 
DSG activities and the screening service are mostly available during regular working hours, when 
they are at work. We did not note a similar association for women, possibly reflecting different 
circumstances around employment. This is an indicator that there are additional barriers for men, 
and it might explain why the intervention effect in men was less pronounced than in women. It 
might be useful to target work spaces with additional interventions for men in employment. 
Two DSGs in the intervention arm had higher performance than other DSGs, due to the high 
performance of peer supporters in their tasks. This shows the need for DR screening programs 
using this intervention to pay attention to the performance of peer supporters, and the factors 
that influence this performance. Peer supporters are volunteers and have different motivators for 
performance. Incentives that are responsive to their needs may sustain high performance.(24)
These incentives may include formal employment with remuneration. However it is unclear 
whether employment would stifle the creativity, flexibility and sense of altruism that underpins 
this performance.(24, 25)  Non-financial incentives including training and recognition through 
provision of badges, t-shirts or bicycles to help with transportation are appreciated by community 
volunteers in Kenya.(26, 27) The right package of incentives that is essential for program 
effectiveness and corresponds to the expectations of peer supporters will need to be determined.  
The strengths of our study are the cluster randomised study design and robust study procedures 
that followed international guidance, with oversight from a registered clinical trials unit. It is a 
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pragmatic study, conducted in real world settings and using peer supporters to deliver the 
intervention, which facilitates sustainability and expansion to larger scale. The choice of 
intervention was based on barriers and enablers identified in literature review and formative 
research.(8) The follow up rate was high, and the primary outcome was measured objectively with 
data for the outcome being available for all participants. The trial steering team included a 
diabetes educator; this expertise is known to be particularly important in health education 
interventions for PLWD.  The trial was also accompanied by a robust theory-driven process 
evaluation, hence it is not a ‘black-box’ intervention.(5, 28)
The trial provides an important example of task shifting to increase screening coverage. The task 
of providing health education on diabetes eye health was shifted from the clinic to the 
community, and from health workers to the peer supporters in DSGs.  In turn the peer supporters 
referred the PLWD to the clinic, thus facilitating DRS. This linkage is important for reaching under-
reached groups with screening interventions. Our study thus contributes to ongoing discussions 
on the role of task shifting in eye health. 
Our study has limitations that also indicate directions for future research. We used a single 
geographic setting so the results may not be widely generalizable. However, they are likely to be 
replicable in LMIC settings with diabetes support groups and poor uptake of DRS. Longer-term 
follow-up studies are needed to determine the sustainability of the effect of peer support on 
attendance to regular annual screening, as opposed to a one-time effect. We did not collect data 
on socioeconomic status and did not measure cost-effectiveness. 
The findings have important implications for clinical and public health policy, particularly in low-
income countries where DR is often detected late. This peer supporter-led intervention may be 
effective in countries with similar health system structures, an opportunistic DR screening model 
and a low attendance to DRS. Many countries have diabetes support groups with peer supporters; 
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innovative use of this resource in enhancing uptake of DRS uptake may be implemented with 
minimum disruption to the existing health system.  
This study may assist health workers understand the relationship between self-efficacy and DRS 
when attending to individual PLWD.(29) Our findings should assist policy makers in developing DRS 
strategies that utilise existing resources to improve coverage of screening. The next step in scaling 
up the intervention in Kenya would be for the Ministry of Health to collaborate with DSGs and 
train peer supporters to deliver the intervention in all 47 counties.  We are presently planning this 
approach, which has stakeholder support.  
Conclusion 
The pragmatic DURE intervention resulted in a positive and early response for attendance at DRS  
offering a practical way to increase screening. The intervention was effective for both men and 
women, although it had a greater impact on women. Further research is needed to assess the 
best timing for repeating the intervention and the cost-effectiveness of this strategy.  
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Fig 10-2 Trial flow chart   
Enrolment We invited 16 clusters to 
participate 





14 clusters were recruited 
for the main trial 
Cluster members assessed 
for eligibility (837) 
86 did not meet eligibility criteria
(48 were not regular members of the 
DSGS, 15 did not have a phone and 
23 will not reside in the county for 
the period of the trial) 





clusters,  369 
participants, 14 peer 
educators  




Intervention Peer educators received 
a 2 day training 
All participants received 
the intervention 
(monthly group talk)  
Those who had not 
attended eye exam 
received a weekly 
individual reminder 
All received usual care
Follow-up 349 participants and 13
peer educators were 
retained over 180-day 
follow-up period.  
20 were lost to follow-
up.  
1 peer educator got a 
job in another county 
and was unavailable day 
72 - 180 
354 participants were retained over 
180-day follow-up period.  






0 participants excluded 
Intention to treat 
analysis 
365 participants included
0 participants excluded 
Intention-to-treat analysis  
                 Figure 10-2: Flow diagram for the trial 
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Table 10-4: Predictors of attendance at DR screening  
Variable  Attended 
screening (241) 







9.4 [6.4 - 13.7] <0.001 
Control 41 324 1 
Intervention 200 169 9.4 [6.4 - 13.7] <0.001 
Age (years)   0.5 [0.4 - 0.7] <0.001 
<45 years 48 45 1 
45-64 years 142 272 0.5 [0.3 - 0.8] 0.002 
>65 years 51 176 0.3 [0.2 - 0.5] <0.001 
Gender 1.18 [0.9 - 1.6] 0.3 
Male 97 218 1.00 
   Female 144 275 1.18 [0.9 - 1.6] 0.3 
Duration since diagnosis of diabetes 1.0 [0.9 - 1.2] 0.9 
<6 years 158 313 1 
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6-9 years 30 78 0.8 [0.5 - 1.2] 0.2 
10-20 years 41 80 1 [0.7 - 1.5] 0.9 
>= 20 years 12 22 1.1 [0.5 - 2.2] 0.8 
Duration of membership to DSG 0.6 [0.5 - 0.9] 0.003 
<3 years 165 287 1 
3-5 years 74 191 0.7 [0.5 - 0.9] 0.02 
>=6 years 2 15 0.2 [0.05 - 1.02] 0.05 
Education 1.5 [1.3 - 1.8[ <0.001 
Did not complete primary 38 154 1 
Primary 116 222  2.1 [1.4 - 3.2] <0.001 
Secondary 64 89  2.9 [1.8 - 4.7] <0.001 
Post-secondary 23 28 3.3 [1.7 - 6.4] <0.001 
Employed 0.8 [0.5 - 1.1] 0.2 
Unemployed 54 89 1 
Employed 187 404 0.8 [0.5 - 1.1] 0.2 
Hypertension 2.0 [1.3-3.1] 0.001 
Previously diagnosed with hypertension 45 50 2.0 [1.3-3.1] 
Not previously diagnosed with 
hypertension 
196 443 1 
Body Mass Index 0.9 [0.8 - 1.1] 0.2 
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Normal 74 131 1 
Increased 167 362 0.8 [0.6 - 1.1] 0.2 
Waist circumference  0.9 [0.7 - 1.3] 0.7 
Normal 109 215 1 
Increased 132 278 0.9 [0.7 - 1.3] 0.7 
Random Blood Sugar 1.01 [0.8 - 1.4] 0.9 
Hypoglycaemia 6 14 1 
Normoglycaemia 129 263 1.14 [0.4 - 3.0] 0.8 
Hyperglycaemia 106 216 1.14 [0.4 - 3.1] 0.9 
Systolic blood pressure at baseline mmHg 0.9 [0.6 - 1.3] 0.5 
Normal 54 101 1 
Elevated 187 392 0.9 [0.6 - 1.3] 0.5 
Diastolic blood pressure at baseline 
mmHg
1.3 [1.0 - 1.8] 0.07 
Normal 143 326 1 
Elevated 98 167 1.3 [1.0 - 1.8] 0.07 
Visual Acuity 1.1 [0.8-1.6] 0.5 
Normal 176 372 1 





















“I fully realize that I have not succeeded in answering all of your questions... Indeed, I feel I 
have not answered any of them completely. The answers I have found only serve to raise a 
whole new set of questions, which only lead to more problems, some of which we weren't 
even aware were problems. To sum it all up... In some ways I feel we are confused as ever, 
but I believe we are confused on a higher level, and about more important things.”   
Mary Ann Raywid, 1928-2010  





Chapter Eleven: Thesis summary 
 
11.0 Overview 
This thesis documents lessons learned regarding the assessment of diabetic 
retinopathy (DR) services in Kenya and interventions to improve access to these 
services. In this chapter, we summarize the PhD narrative, including the overall 
strengths and limitations, highlight the key findings, consider the implications for 
policy, practice, research, and dissemination, and provide recommendations and 
conclusions. 
11.1 The PhD narrative 
The thesis is organized in five sections A-E and 11 chapters.  
Section A provides an overview of the research (Chapter 1) and background 
information from the literature (Chapter 2).  
Section B describes the health system assessment for diabetes and DR in three 
counties of Kenya (Chapter 3 and 4).  
Section C describes the health system strengthening activities, mainly in knowledge 
translation of the evidence to develop clinical guidelines (Chapter 5) and a training 
program to address supply side gaps that hinder availability of DR services in the 
country (Chapter 6).  
Section D describes the clinical trial, whether the DURE intervention increases 
attendance at screening in Kirinyaga county (Chapter 7-10).   
Section E provides a summary discussion for the thesis (Chapter 11). 
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The strength of this research is the progression of thinking from an understanding of 
the global literature on DR services, assessment of the Kenyan health system, 
identification of a critical gap in services, and culminating in the design, 
implementation and evaluation of an intervention to increase access to DR 
screening. This progression of research, where each step informed the next step, 
made it possible to develop a significant knowledge base.   In addition, each of those 
steps was based on a strong theoretical underpinning, which facilitated a deeper 
understanding of the findings.  
The main limitation of the research concerns the generalizability of the findings. The 
findings may apply to the wider Kenyan population and possibly a wider African 
population with similar social, cultural and health system context, and a similar 
patient profile. However, the findings may not be generalizable to other settings.  
11.2 Overview of DR services 
The aim of DR services is to prevent DR-related vision loss. The growing increase in 
prevalence of diabetes in all parts of the world places the spotlight on these services, 
since a third of people living with diabetes (PLWD) at any point will have DR and one 
in 10 will require immediate treatment for vision-threatening DR (VTDR). The 
services encompass a broad approach consisting of: first, prevention of DR through 
metabolic control of diabetes; second, DR screening among PLWD, for early 
detection of DR; third, timely treatment of those with VTDR; and fourth, 
rehabilitation of those with significant sight loss. This comprehensive approach 
includes services provided in the community and in diabetes and eye care clinics, 
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although the extent of integration between these services varies in different parts of 
the world.   
While high-income countries have successful DR programs that provide these 
services, sub-Saharan Africa (SSA) has a high level of unmet need for these services. 
The International Diabetes Federation reports that the projected increase in the 
prevalence of diabetes over the next two decades will be disproportionately 
concentrated in this region.  We can expect a commensurate increase in the need for 
DR services, given that all PLWD are at risk of DR. As DR is asymptomatic until some 
sight is lost, early detection depends on the provision of regular screening for DR for 
all PLWD.  
The first objective was a review of the literature on the epidemiology of both 
diabetes and DR globally and in Africa. In chapter two, the evidence from population-
based studies, clinic-based studies and systematic reviews on the risk factors, 
prevention and treatment of DR was presented. It is notable that globally there is 
plenty of literature on these conditions, but the evidence from Africa is sparse. This 
was not a surprising finding, as this discrepancy is ubiquitous in global health 
research.  
As explained in section 11.5, we did not conduct a systematic review. However, the 
principles of systematic review were applied to ensure robustness and breadth of the 
literature review. The population, intervention, comparator and outcomes (PICO) 
were defined, and the London School of Hygiene and Tropical Medicine provided 
access to a wide range of peer reviewed and grey literature.  This made it possible to 
343 
 
perform a comprehensive and balanced synthesis of the evidence, as reported in 
chapter two. Important gaps were identified in the literature, which would be of 
interest to the academic and policy audience.  
The literature review was useful for identifying the priorities and challenges in DR 
services. One such challenge is screening for DR. There is evidence that DR meets 
established criteria for a screening programme, and that such screening is cost-
effective, at least in high-income settings that have well-established systematic 
screening programs and a higher prevalence of diabetes. A few papers reported that 
DR screening (or opportunistic case detection) in SSA is fragmented. It is not clear 
whether screening is cost-effective in SSA, but a first step would be to investigate this 
in a well-documented project within an African health system.  
Kenya is one of the growing economies in SSA and the geographical context of this 
research, therefore the general health system in Kenya is described in chapter two. 
11.3 DR services in Kenya 
The prevalence of diabetes in Kenya is reported at 2% of the population 18-64 years 
(2015).1 However, there are no population-based data on the prevalence of DR.  The 
number of people requiring DR services can be estimated using existing evidence 
from the global literature, and this has been presented in chapter two in section A. 
Health systems influence the implementation and success of DR programs. Health 
systems research to improve DR services is thus an important area, in order to close 
existing gaps for PLWD.   
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The second objective of the thesis was to conduct a health system assessment. 
Section B describes the health system assessment for diabetes and DR in three 
counties of Kenya, representing rural, urban and semi-urban areas. The assessment 
employed mixed methods (quantitative and qualitative), was guided by the WHO 
health system approach and the tracer condition approach, and obtained patients’ 
perspectives in the health system assessment. The use of these mixed methods and 
approaches provided a more comprehensive understanding of the health system. 
Quantitative methods facilitated the analyses of patient-level predictors of use of DR 
services, such as duration of diabetes. Quantitative methods were also useful for 
identifying groups of PLWD who may be most at risk of not receiving screening 
services (e.g. those without symptoms, or those from a rural county), thereby 
contributing evidence to inform the design of targeted interventions to improve 
uptake in these groups. Barriers to access of services were also identified. 
With qualitative methods (semi-structured interviews with service providers and key 
informants), strengths and weaknesses of the health system could also be explored. 
The use of the tracer approach alongside the WHO health systems approach 
facilitated the link of various health system indicators to the specific outcomes of 
interest in diabetes eye health, as discussed in section B. 
Major gaps were found in the area of awareness and access. There were also gaps in 
availability and affordability of DR services, but the main barriers to entry to DR 
services were lack of awareness and lack of access. Although it is recommended that 
100% of PLWD have an annual screening examination, only 25.6% of PLWD attending 
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diabetes clinics had ever had a DR screening examination in their lifetime, which 
demonstrates a need-demand mismatch (or a screening gap) in DR services. Only 
13.3% had a screening examination in the preceding year as recommended in clinical 
guidelines. This 87% unmet need for screening (screening gap) emerged as the 
priority area for DR interventions, since it is a bottleneck in the continuum of DR 
services. The findings presented in this thesis support the findings of other studies 
that the uptake of DR screening is low in low-resource settings. 
The PLWD in Kirinyaga (a rural county) were the least likely to have had an eye 
examination in the preceding 12 months, with PLWD in Nairobi (urban  county) 
having 2.6 times (95% CI 1.1–7.1) and PLWD in Nakuru (semi-urban county) having 
approximately three times increased uptake (95% CI 1.1–8.0). The main predictors 
for attendance at screening were referral from diabetes services and knowledge of 
diabetes complications. Participants referred for an eye examination had almost 
eight times the odds of having attended an eye examination in the last 12 months 
compared to those who had not been referred (OR 7.9, 95% CI 3.7–16.4, p < 0.001). 
Participants who had a knowledge of diabetes eye complications had four times the 
odds (OR 3.9, 95% CI 1.6–9.1) of attending as compared to those who had no 
knowledge of eye complications. 
The strong association of knowledge of diabetes complications and uptake of 
screening is suggestive of the influence of demand-side barriers to access. Only 
24.4% of participants had ever been referred from the diabetes clinic for a retinal 
examination, which on the other hand reflects a supply-side barrier. Additional 
supply side barriers obtained from qualitative interviews were: the lack of local 
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clinical guidelines for DR; lack of mechanisms to ensure that patients referred for 
screening are not lost in the referral pathway between diabetes and eye care 
services; lack of point of care tools, such as checklists or protocols; lack of systematic 
patient education; and health workforce challenges such as lack of access to 
continuous professional development on DR.  
This study helped to identify important opportunities in the health system. These 
include a high stakeholder interest in strengthening services, well-established 
support groups, a strong non-communicable disease strategy, and strong governance 
structures at national and county level. These strengths and gaps have been 
discussed in detail in section B the thesis. 
In the papers from the health system assessment (research papers 1 and 2), these 
findings have been presented as the basis for exploring an approach to fill the health 
system gaps. Interventions to increase attendance to screening need to address the 
barriers and take the enablers in the health system into account. 
11.4 Health system strengthening 
As screening is the entry to DR services, and attendance at screening is low, our aim 
was to increase attendance to screening. However, it would be unethical and 
unnecessary to increase attendance at screening where existing supply-side barriers 
to DR services translate to the services being unavailable or of sub-optimal quality.  
Therefore there was need for health system strengthening (as a third objective) to 
facilitate the availability of an appropriate standard of care, including screening, 
treatment, referral and follow-up.   
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Stakeholders identified the priorities for health system strengthening at national 
level. The priorities identified were national clinical guidelines and easily accessible 
resources for continuous professional development for health workers. Both of these 
were important opportunities for knowledge translation informed by research 
evidence.  The scientific evidence identified through our literature review and 
stakeholder engagement were useful for translating the evidence into clinical 
guidelines and a training programme that can be accessed easily. 
Although several studies have pointed out the need for health system strengthening 
ahead of intervention research, most of the health system strengthening activities 
reported have not involved knowledge translation and have not been described in 
detail. In addition, there is limited literature on the processes and outputs from these 
health system strengthening activities. In order to address this gap, section C of the 
thesis provides a detailed description of these activities. 
Clinical guidelines are an important governance tool in health systems. There is a 
paucity of literature on how context-relevant guidelines can be developed in Africa, 
despite the potential value of these guidelines.  This study has provided 
methodological contributions on this process and contributed to expanding the 
literature on this subject.   The process and outputs of guideline development are 
described in the research papers 3 and 4. The scope of the guidelines is screening, 
diagnosis, treatment and follow-up for DR. The guidelines have been implemented 
nationally, not just in the study area. An online training course on the control of DR 
has been developed, targeting multidisciplinary teams involved in DR care. The 
development of the course is described in chapter six.  
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The health system strengthening was done with significant input from stakeholders 
in both the diabetes and eye care services. This is important because it facilitates 
ownership and implementation by the stakeholders, as well as capacity building that 
can be applied in the health system. We have described the technical aspects of the 
health system strengthening that could aid replication of these interventions 
elsewhere.  
11.5 Development of an intervention to increase uptake of screening 
The fourth objective of the thesis was to develop an intervention to increase 
attendance at DR screening and to test it in a randomized controlled trial. This study 
involved a community-based intervention relevant for an LMIC setting, where the 
unmet need for DR screening is higher, and hence the intervention had the potential 
for significant health system benefits.  
The intervention in this trial utilizes diabetes support groups (DSGs) and peer-
supporters because they are existing resources in this context, a strength of the 
health system. The process of intervention development has been guided by the 
findings of the health system assessment, stakeholder consultation, review of the 
evidence and by the UK Medical Research Council’s guidance on the development of 
complex interventions.  The intervention fits the criteria for a complex intervention 
because it had several components, required different behaviours by PLWD, peer-
supporters and eye care workers, and required implementation at multiple settings 
at community level and at eye clinics. Multiple stakeholders in diabetes and eye care 
services were involved in intervention development. It was important to combine 
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these approaches, as described in Section D of the thesis, in order to develop an 
intervention that could improve uptake of screening.  The trial protocol for the trial is 
presented as research paper 5.  
Before the trial, the literature on peer-support interventions to improve diabetes 
outcomes as well as the role of peer-support in other chronic conditions was 
reviewed. We did not conduct a systematic review, since previous systematic review 
evidence on peer-support for diabetes was already available and because of time 
limitations. This evidence has been presented in the thesis. The studies included in 
the systematic reviews were mainly conducted in high-income countries, while the 
peer-support models were mainly facility-based and led by health workers. In 
addition, the studies were mostly focused on other outcomes than DR screening.  
11.5.1 Conceptual framework for the intervention 
In developing the conceptual framework for the intervention it was hypothesised 
that a multi-faceted intervention delivered by peer-supporters would create 
awareness in PLWD regarding screening, build self-efficacy, link the PLWD with the 
eye clinic and provide reminders to attend screening. The basic principle behind the 
Self-Efficacy Theory by Albert Bandura is that individuals are more likely to engage in 
activities for which they have high self-efficacy in comparison to those in which they 
have low self-efficacy.2, 3 Self-efficacy has been shown to be a strong and consistent 
predictor of health behaviours such as physical activity. However, self-efficacy is task 
specific, meaning that it is crucial to identify the mechanisms in which self-efficacy is 
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developed for a given behaviour, like attending DR screening.  Self-efficacy had not 
been investigated previously in relation to uptake of DR screening services. 
We developed the conceptual framework deductively using the self-efficacy theory. 
We also considered the barriers to attendance to screening identified by PLWD 
during the health system assessment. Our framework is thus novel and has not been 
validated in other populations. However, it could serve as a starting point for 
replication or expansion in future interventions. 
11.6 Implementation of the intervention 
This research has been conducted in the pragmatic context, which means the results 
are likely to be applicable to everyday practice and are important to policy makers 
looking for scalable interventions to increase access to DR screening in Kenya. The 
clinical trials unit at the London School of Hygiene and Tropical Medicine provided 
oversight of the trial. 
The population included in the research were PLWD who are attending diabetes 
services but have never had eye screening for DR. Although this population is large in 
this context, in future screening programs will need to target a more heterogeneous 
population (PLWD that have previously been screened and those that have never 
been screened) hence these differences would need to be considered. 
11.6.1 Pilot trial 
Two clusters (DSGs) participated in a pilot trial to investigate the feasibility of the 
trial. The criterion for continuation to the main study was the feasibility of 
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recruitment of 50 participants in the trial, 80% monthly follow-up rates for 
individuals and no attrition of clusters. The pilot study met these success criteria, 
indicating that a full trial of the intervention was feasible. The pilot trial also provided 
additional benefits, such as documenting high acceptability and an interim measure 
of the effectiveness of the intervention. The findings of the pilot trial are described in 
research paper 6. The interpretation of these findings was that the full trial was 
feasible and we did not need to change the study procedures. We did not conduct a 
process evaluation for the pilot study, preferring to defer it to the main trial. 
11.6.2 Full trial 
11.6.2.1 Self-efficacy outcomes 
The measurement of self-efficacy is particularly relevant for interventional studies 
aiming to improve specific health behaviours. The majority of studies evaluating the 
effects of interventions on health behaviour rely only on the distal outcome 
measures. The results of research that includes a measure that is proximal to the 
screening behaviour are relevant in that they provide insights on the intervention 
pathway; in this trial, that the intervention increased self-efficacy to take screening in 
the intervention arm. This increase occurred early in the intervention, corresponding 
to the first group talk and referral. Based on the findings of the process evaluation 
(chapter 9), evaluation of self-efficacy and the evaluation of the primary outcome 
(chapter 10), an association between the increase in self-efficacy and attendance at 
screening was inferred. However, some of the PLWD who had high self-efficacy after 
receiving the intervention did not attend screening, suggesting that there are 
additional barriers that were not addressed by the intervention. 
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11.6.2.2 Primary outcome evaluation 
The intervention was highly effective for increasing uptake of DR screening, and this 
effect occurs early in the intervention, followed by a ceiling effect. Further, there was 
strong evidence of effect modification by gender, with women showing a more 
pronounced effect than men for exposure to the intervention and attendance at 
screening. This unusual effect was difficult to explain. However, it suggests that 
gender is a significant determinant of screening behaviour. It also corroborates the 
finding of other researchers that behaviour change and interventions to change 
behaviour are complex.4 
These findings would suggest that the level of awareness of PLWD is a major driver of 
attendance to DRS. The intervention effect was primarily due to the first group talk, 
following which 50% of participants in the intervention arm took up screening. Only a 
further 4% took up screening in the following 5 months (making a total of 54%), 
hence it is clear that further group talks and telephone reminders to take screening 
have limited returns. Although the intervention increased self-efficacy in the 
intervention arm, 46% of participants exposed to the intervention did not go for 
screening over the follow-up period. This suggests that raised self-efficacy is 
necessary but not sufficient, as there are post-self-efficacy barriers to screening. 
We found that 11% of the PLWD in the control arm took screening, which may have 
been because at baseline they were asked whether they had ever taken screening. It 
is worth considering how participation in the research itself (such as responding to 
the baseline questionnaire) may have influenced the results obtained. It is also 
possible that a similar effect may account for part of the response in the intervention 
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arm. This would suggest that the effect size might be smaller in a non-research 
setting. These results of the outcome evaluation are described in the research paper 
8. 
In this study, the primary outcome was the proportion of PLWD who attended DR 
screening by the end of the study period. This is an essential outcome indicator to 
chart progress in DR screening programs, and we have shown that it is possible to 
measure it easily and objectively. This measure also provides important evidence 
related to uptake, access and coverage of DR services. Screening programs in 
resource-restrained settings may benefit from identifying a single measure of 
intervention effect that can be used for monitoring, for which we would recommend 
this outcome. As gender is an effect modifier in this intervention, we would 
recommend that this outcome be routinely analysed by gender. 
There were many additional questions on screening which were not addressed in this 
study. For instance, the cost-effectiveness of screening and the prevalence of DR in 
PLWD were not included as they were beyond the scope of the thesis. However, they 
are important input and impact factors that would further complete the 
understanding of the intervention. Given that screening programs are not uniform 
and they evolve over time, it is not possible to have a universal monitoring tool that 
provides a complete picture of a screening program.  Each program needs to choose 




11.6.3 Process evaluation 
The Consolidated Framework for Implementation Research (CIFR) guided the mixed- 
methods process evaluation of the trial. This framework, linked with principles of 
Implementation Science, was useful in identifying how, why and for whom the 
intervention worked.  The quantitative component enabled the evaluation of 
implementation outcomes, in terms of recruitment, retention, reach, dose and 
fidelity. These important process indicators may be used for monitoring this 
intervention, however their measurement is labour-intensive, requiring lots of 
documentation and time, especially when the intervention is delivered in its current 
form.  The measurement of the indicators is more viable for routine settings, if the 
intervention is limited to just one group talk as we recommend later in this chapter. 
Both quantitative and qualitative components of the process evaluation contributed 
to the investigation of potential influences on attendance at screening. Findings 
generated using different methods could therefore be synthesised, compared, and 
triangulated to increase the validity and facilitate a deeper understanding of how the 
intervention worked. The results indicated that all the elements of the CIFR had an 
influence on how the intervention worked. There was evidence of local adaptation of 
the intervention during implementation, to suit local contexts, which is described in 
research paper 7. 
Participants who took up screening reported doing so soon after receiving the first 
group talk.  This is attributable to the finding that the first group talk addressed the 
main barriers to screening attendance, which were lack of awareness and lack of 
referral. In addition, the influence of the culture of collective action led to the 
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majority of the PLWD attending screening together early in the intervention.  These 
findings provide evidence that the first group talk and the referral are the most 
essential components of the intervention, as mentioned earlier. Research paper 7 
describes these findings in detail. 
11.7 Implications 
 
11.7.1 Implications for research 
Whilst the findings of this research contribute to evidence for improving DR 
screening services in Kenya, they also demonstrate that gaps remain and present 
opportunities for future research. As an example, further longitudinal research to 
enable greater understanding of the effect of the intervention on the future cycles of 
annual DR screening for the participants.   
There is considerable social, cultural, and health system variation in different settings 
and the intervention may work differently in other settings. Further research is 
required to explore the extent to which the peer-led intervention is transferrable for 
use in other contexts and countries. We recommend that research interventions 
should be: preceded by a situation analysis to identify the existing forms of peer-
support; robust in design; comprehensively described and process evaluations 
conducted to gain insights into their mechanism of action. 
Priority research areas in the short-term period are:  
1. How can the ceiling effect of the intervention be broken? 
2. How feasible, cost-effective and sustainable is the scale-up of the 
intervention for the health system? 
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3. What is the long-term effect of the intervention on initiation and 
maintenance of screening for PLWD? 
4. What is the effect of adding further components to the intervention (such as 
photography-based screening in diabetes clinics)? 
5. Why is the intervention effect more pronounced in women? 
11.7.2 Implications for DR programs 
DR programs in Kenya  
Given the implementation of the clinical guidelines that explicitly emphasise annual 
screening for all PLWD, it is anticipated that screening services will be developed and 
become available to all PLWD in all parts of the country.  
This study has introduced a new intervention that is not already part of the existing 
DR program. The findings presented in this thesis suggest that the intervention 
components could feasibly be delivered as they were delivered in this trial, at 
community DSGs with DR screening being provided at the existing eye clinic with the 
required capacity. The intervention is acceptable to the PLWD, the peer-supporters, 
health-care providers and other stakeholders. This trial tested the effectiveness of 
the intervention for PLWD who have never had screening. However, the intervention 
could be offered to all PLWD, as envisaged in the DR guidelines. The intervention 
could be scaled up to other counties in Kenya that have DSGs in the current form and 
services to examine and treat patients with DR, though cost-effectiveness data is 
lacking.   
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The intervention could potentially be modified to just one group talk and referral to 
the eye clinic. The group talk could then be repeated after six months, and 
monitored to see if this repetition will increase uptake of screening. A further group 
talk should also be provided before the next screening cycle, at 12 months. The 
monthly group talks and monthly telephone reminders can be left out, as they did 
not seem to be critical ingredients for the effect of the intervention.  
The ‘bottom-up’ approach to health education in this intervention is advantageous 
because it is delivered to the target audience that may benefit from it. It is a suitable 
model for use with other chronic conditions for which peer groups exist. The training 
curriculum for peer-supporters developed in this study is already being adopted by 
the Kenya Defeat Diabetes Association as part of their peer-support manual. The 
online DR course is already available for use by health workers, and it will continue to 
be available to support lifelong learning within and outside Kenya.  
It is important to note that while this was a pragmatic study, the implementation 
phase required a lot of follow-up by the principal investigator (PI) and regular 
documentation by the peer-supporters. For example, the PI and peer-supporters had 
weekly telephone contact, which would not be considered standard ‘real-world’ 
practice in any context. When the programme is implemented in non-study 
conditions, it will be necessary to see if these roles are required and if so who may be 
suitable to fill them. In Kenya, this might be the focal person for NCDs or the focal 
person for eye care in each county.  Thus during program scale-up it will be 
necessary for further health system strengthening to consider these questions.  In 
addition, there will be a need for continuous engagement of the communities and 
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DSGs.  Although the intervention is a ‘low-hanging fruit’, it is critical for policy makers 
and DR program implementers to invest adequately in the scale-up phase if the 
research finding is to be turned into a practical and effective health service activity.  
DR programs outside Kenya 
The Kenya model of national DR guidelines has already been used to develop the DR 
guidelines in Ghana through the DR Network. The online training program is open to 
participants in all parts of the world. 
In principle, the DSG intervention can be implemented in other contexts that have 
similar DSG and health system structures, after adaptation to account for the local 
context. Funders of international DR programs may therefore wish to invest in such a 
process of adaptation before program implementation. 
11.7.3 Implications for practice 
 
Pocock and Stone5 in their paper ‘The primary outcome is positive —Is that good 
enough?’ recommend that researchers reflect on the following questions to interpret 
whether the evidence from a clinical trial with positive results is sufficient to advance 
clinical practice (Table 11-1).  These questions have provided a useful framework for 






Table 11-1: Is the evidence sufficient? 
1. Does a p value of <0.05 provide strong enough evidence? 
There is very strong evidence of a large intervention effect, which is not 
just based on an interpretation of the statistical significance of the p value  
2. What is the magnitude of the treatment benefit? 
Compared with usual care, the intervention quintupled the number of 
PLWD taking screening. Given that these are PLWD who had never taken 
screening, this effect has important implications for increasing screening 
among this unreached group.  The literature suggests that 10 people need 
to be screened to find one person who requires treatment, however 
further research is needed to investigate if this is true in LMIC settings with 
no or limited previous screening programmes. 
3. Is the primary outcome clinically important (and internally 
consistent)? 
Yes, attendance to screening is important for early detection of DR. 
However, we did not investigate the prevalence of DR among those 
screened. The literature evidence indicates that a third of PLWD have DR 
and one in 10 VTDR.  
4. Are secondary outcomes supportive? 
Yes the secondary outcomes in our study were evaluated in the process 
evaluation, such as implementation outcomes (high acceptability, fidelity, 
reach and dose), and they support the findings of the outcome evaluation. 
5. Are the principal findings consistent across important subgroups? 
360 
 
The intervention effect was high in both men and women. It was markedly 
higher in women. 
6. Is the trial large enough to be convincing? 
Although the sample size was sufficient for our study objectives, we 
recommend replication of the study with larger samples in different LMICs. 
7. Was the trial stopped early?  
No 
8. Do concerns about safety counterbalance positive efficacy?  
No 
9. Is the efficacy–safety balance patient-specific?  
No, this intervention is considered safe for all participants. 
10. Are there flaws in trial design and conduct?  
No the study design and conduct is robust, we have discussed the 
limitations of the study. 
11. Do the findings apply to my patients?  











The findings contained in this thesis have been disseminated, and will further be 
disseminated to a local, national and international audience of PLWD, diabetes 
support groups, health workers, policy-makers, program implementers and 
researchers.   
The findings have been shared in publications, conferences, stakeholders’ feedback 
meetings, peer research meetings, pubic engagement activities, reports to funders, 
and knowledge translation activities. The specific forums where the findings have 
been shared are shown as an appendix.  We have received positive feedback from 
our dissemination. This has prompted us to further reflect on the implications of our 
findings, and on the next steps. Some of the data on secondary outcomes is still 
being analysed and will be disseminated in similar forums. 
11.9 Conclusion 
The overall aim of the PhD study was to assess DR services and provide evidence to 
improve the services. The findings provide new evidence to further the discussion on 
health systems for diabetes and DR and targeted interventions to improve access to 
DR services.  
We have introduced a peer-led health education intervention in community settings 
and showed that it is effective in increasing attendance to screening. The main 
findings show that the intervention had a positive effect on screening attendance. 
The positive results are largely due to the increased awareness resulting from one 




As this is the first study to document the role of peer-led interventions to increase 
attendance at DR screening, the results provide a useful contribution to the 
knowledge base on the use of community resources for DR care in LMICs, which 
often goes undocumented in practice. 
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The Road Not Taken 
 
Two roads diverged in a yellow wood, 




I shall be telling this with a sigh 
Somewhere ages and ages hence: 
Two roads diverged in a wood, and I— 
I took the one less travelled by, 
And that has made all the difference. 
 







Appendix 1 Courses undertaken 
Modules Organizer 
Sept –Dec 2015 
(10 weeks) 
Statistics for Epidemiology LSHTM module
Sept –Dec 2015 
(10 weeks) 
Extended Epidemiology LSHTM module
Sept –Dec 2015 
(10 weeks) 
Principles of Social Research LSHTM module
Sept 2016 
(eight weeks) 
Ophthalmic Epidemiology LSHTM MOOC
June 2018 (one
week) 
Clinical Trials LSHTM short course
May – July 2018 
(eight weeks) 




Diabetic Eye Disease- Strengthening Services LSHTM MOOC
Transferable Skills courses Organiser 
Friday, 02 
October 2015 




Tuesday, 06 Oct 
2015 
An Introduction to Semi Structured Interviews LSHTM
Wednesday, 07 
Oct 2015 





Introduction to Qualitative Analysis LSHTM
Friday,  09 Oct 
2015 
MS Excel 2013: Data Management LSHTM
Wednesday, 14 
Oct 2015 











Oral Presentations: What Makes it Good? LSHTM
Thursday, 05 
Nov 2015 
Research Information Skills 1 LSHTM Library
Friday,  06 Nov 
2015 






MS Excel 2013: Graphs & Charts LSHTM
Friday, 13 Nov 
2015 
Research Information Skills 2 LSHTM Library
Thursday, 26 
Nov 2015 




Friday, 04 Dec 
2015 
Introduction to Data Management in the Social 
Sciences 
LSHTM
Monday,  07 
Dec 2015 
Oral Presentations: What Makes it Good? LSHTM
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Tuesday, 14 Jun 
2016 
Introduction to Working with NVIVO 10 LSHTM
Wednesday, 15 
Jun 2016 
Working with NVIVO 10 LSHTM
Wednesday, 15 
Jun 2016 





Publication Workshop 2: Publication Ethics LSHTM
Thursday, 23 
Mar 2017 
Journal Metrics and the Publishing Landscape –




Friday, 24 Mar 
2017 








Using Social Media for research Bloomsbury Postgraduate 
Network 
Friday, 31 Mar 
2017 
Skills for Conflict Resolution Bloomsbury Postgraduate 
Network 
Monday, 03 Apr 
2017 
Travel Safety and Security LSHTM
Wednesday, 19 
Apr 2017 
Writing up your Research for Publication and 
Social Media 
LSHTM
Monday, 24 Apr 
2017 
Travel Procedures for Students LSHTM
Tuesday, 25 Apr 
2017 





Sexual Aggression: Avoidance and Survival LSHTM
Tuesday 09 
May 2017 
MS Excel 2016: Data Management LSHTM
Thursday, 10 
May 2016 
Social Media for Research LSHTM
Friday 02 Jun 
2017 
MS Excel 2016: Graphs and Charts LSHTM
Tuesday, 13 
June 2017 
Conducting Systematic literature Search LSHTM Library
Wednesday, 21 
June 2017 







Peer Review Elsevier Researcher 
Academy 
Friday, 10 May 
2019 
Improving your Assertiveness LSHTM
Wednesday, 22 
May 2019 
Preparing to Submit Your Thesis LSHTM
Key:  LSHTM-London School of Hygiene and Tropical Medicine; MOOC-Massive Open Online 
Courses; UCL-University College London
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Appendix 2: PhD Timeline 
ACTIVITY 2015 2016 2017 2018 2019 2020
Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1














Appendix 3-DURE Standard Operating Procedures  
Measuring Clinical and Anthropometric parameters 
Weight 
Participant should be weighed in light dress (remove all heavy items of clothing or items in 
pockets before being weighed) and without shoes. 
Ensure the scale reads ‘zero’ before weighing the patient.  
Use the same scale for all participants. 
Record the weight to one decimal place in the enrolment form. 
Inform the participant of the measurement findings 
Height 
Volunteer must remove his/her shoes and hat before having his/her height measured.
Record the height in cm to no decimal places in the enrolment form.  
Inform the participant of the measurement findings 
Waist circumference 
To measure the waist:
• Participant in upright standing position 
• Find the bottom of the ribs and the top of the hips  
• Wrap a soft tape measure around the waist, midway between these points, usually at the 
level of the umbilicus 
• Participant should breathe out naturally before taking the measurement  
• Record the measurement to the nearest 0.5cm on the enrolment form 
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Inform the participant of the measurements
The cutoffs are 94cm and 80cm for men and women respectively (recommended by IDF for sub-
Saharan Africa)* 
*The metabolic syndrome--a new worldwide definition. Alberti KG, Zimmet P, Shaw J, IDF 
Epidemiology Task Force Consensus Group. Lancet. 2005 Sep 24-30; 366(9491):1059-62. 
Blood pressure 
Participant must rest for at least 5 minutes in the seated position before measuring blood 
pressure 
Use a digital device for measuring blood pressure 
Measure blood pressure in the seated position, at the upper arm, using an appropriate size of cuff 
Record the systolic and diastolic blood pressure in the enrolment form 
Inform the participant of the measurement findings 
Patients with blood pressure >140/90mmHg or >90/60mmHg should be referred to the physician 
Random blood sugar 
Participant should be seated
 Check that meter code and test strip code match 
  Apply single use disposable non sterile gloves 
Using the single use lancet, obtain a blood sample from the side of the finger 
Avoid using thumb or index finger  
The finger may bleed without assistance, but may need ‘milking’ gently  
Apply a drop of blood to the strip by holding the patient’s finger to the edge of the strip 
 until the yellow window is completely filled with blood  
Dispose of used lancet into a sharps container 
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Apply digital pressure to stop bleeding
Remove test strip from meter and switch meter off 
Remove gloves and dispose appropriately 
Record the blood sugar on the enrolment form 
If blood sugar is <=4.4mg/dl, give a glucose feed immediately 
Inform the participant of the measurement findings 
Visual acuity 
Snellen chart is placed 6m away at eye level and in good lighting
Test each eye separately, starting with the right eye 
Test visual acuity with glasses if participant uses glasses 
Record the visual acuity on the enrolment form  
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Appendix 4 
CONSORT 2010 checklist of information to include when reporting a pilot or 
feasibility randomized trial 
Item Description Reported on 
page number 
Title  Identification of study as randomised pilot or feasibility 
trial 
1 
Authors  Contact details for the corresponding author 1 
Trial design Description of pilot trial design (e.g. parallel, cluster) 4 and 5 
Methods 
  Participants Eligibility criteria for participants and the settings where 
the pilot trial was conducted 
4 
  Interventions Interventions intended for each group 5 and 6 
  Objective Specific objectives of the pilot trial 3 
  Outcome Prespecified assessment or measurement to address the 
pilot trial objectives
5 
  Randomization How participants were allocated to interventions 5 
  Blinding 
(masking) 
Whether or not participants, care givers, and those 




  Numbers 
randomized 
Number of participants screened and randomised to each 
group for the pilot trial objectives 
8 
  Recruitment Trial status 8 
  Numbers 
analysed 
Number of participants analysed in each group for the 
pilot objectives 
8 
  Outcome Results for the pilot objectives, including any expressions 
of uncertainty 
8 
  Harms Important adverse events or side effects 8 
Conclusions General interpretation of the results of pilot trial and 
their implications for the future definitive trial 
11 
Trial registration Registration number for pilot trial and name of trial 
register 
1 
Funding Source of funding for pilot trial 11 
Citation: Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, et al. CONSORT 2010 
statement: extension to randomised pilot and feasibility trials. BMJ. 2016;355. 
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Appendix 5 
Developing the competences and training content for peer supporter training 
Context: The content of the training is incremental to the existing training manual for peer 
supporters.   
Process 
The following steps were completed: 
1. Identification of a local gap. The health system assessment for diabetes and diabetic 
retinopathy identified that uptake of eye examination in three counties is low. A peer-led 
educational and referral intervention targets to address the demand side barriers to 
uptake of eye examination.  
2. Literature review of peer support. This showed that peer support has been effective in 
contributing to education of PLWD and linkage with health care resources. 
3. A review of the existing peer support training manual has been conducted. We noted that 
it does not have content on diabetes eye health. 
4. Literature review on development of training programs identified the factors associated 
with greater impact of training initiatives to be: alignment to local needs and priorities, 
country ownership of the training program, competency-based training, and a 
sustainability strategy. 
5. Competencies for peer supporters have been developed, based on the literature and the 
identified local need 
6. Assessment of the social accountability of this training.   Social accountability in medical 
education is defined as an education that responds to the requirements and expectations 
of the society. This training has been assessed for relevance, cost-effectiveness, quality 
and equity. 
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a. Relevance: The training is relevant because it addresses a need that has been 
identified in this community. 
b. Cost-effectiveness: The training is cost-effective because it is low cost in terms 
of training resource. It requires only two days and hence it can easily be added 
to the existing training without causing significant disruption to the training 
arrangements during the scale up phase. In addition, if necessary a shorter 
version of the training can also be created.  
c. Quality Assurance: The identification of concise competencies provides a   
consistent standard of knowledge and skill. The training will also consist of 
structured practical sessions and role modelling to aid application of 
knowledge. 
d. Equity: The training contributes to enhancing equity because it empowers 
disadvantaged individuals and groups to obtain the eye examination that they 
require. 
7. Stakeholder consultation: The draft competencies were reviewed by ophthalmologists, 
endocrinologists, physicians, diabetes educators, public eye health specialists and the 
umbrella body for peer supporters (Kenya Defeat Diabetes Association).  
8. The curriculum was presented at a local workshop and a local conference for discussion. 
This was done to foster a sense of ownership among the stakeholders. 
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Appendix 6: CONSORT 2010 checklist for DURE cluster 
randomised trial  
Section/Topic Item 
No 




Title and abstract 
1a Identification as a 
randomised trial in the title 
Identification as a cluster 
randomised trial in the title 
1
1b Structured summary of 
trial design, methods, 
results, and conclusions 
(for specific guidance see 
CONSORT for abstracts)1,2




2a Scientific background and 
explanation of rationale 
Rationale for using a cluster 
design 
5 
2b Specific objectives or 
hypotheses 
Whether objectives pertain to 
the cluster level, the individual 
participant level or both 
5 
Methods 
Trial design 3a Description of trial design 
(such as parallel, factorial) 
including allocation ratio 
Definition of cluster and 
description of how the design 
features apply to the clusters 
5,6
3b Important changes to 
methods after trial 
commencement (such as 
eligibility criteria), with 
reasons 
None
Participants 4a Eligibility criteria for 
participants 
Eligibility criteria for clusters  Table 1
4b Settings and locations 
where the data were 
collected 
6
Interventions 5 The interventions for each 
group with sufficient 
details to allow replication, 
including how and when 
Whether interventions pertain 
to the cluster level, the 




they were actually 
administered 
Outcomes 6a Completely defined pre-
specified primary and 
secondary outcome 
measures, including how 
and when they were 
assessed 
Whether outcome measures 
pertain to the  cluster level, the 
individual participant level or  
both
7
6b Any changes to trial 
outcomes after the trial 
commenced, with reasons 
None
Sample size 7a How sample size was 
determined 
Method of calculation, number 
of clusters(s) (and whether 
equal or unequal cluster sizes 
are assumed), cluster size, a 
coefficient of intracluster 
correlation (ICC or k), and an 
indication of its uncertainty 
6
7b When applicable, 
explanation of any interim 






8a Method used to generate 
the random allocation 
sequence 
6 
8b Type of randomisation; 
details of any restriction 
(such as blocking and block 
size) 
Details of stratification or 





9 Mechanism used to 
implement the random 
allocation sequence (such 
as sequentially numbered 
containers), describing any 




Specification that allocation was 
based on clusters rather than 
individuals and whether 
allocation concealment (if any) 
was at the cluster level, the 
individual participant level or 
both 
6
 Implementation 10 Who generated the 
random allocation 
sequence, who enrolled 
participants, and who 
Replace by 10a, 10b and 10c 
375 
assigned participants to 
interventions 
10a  Who generated the random 
allocation sequence, who 
enrolled clusters, and who 
assigned clusters to 
interventions 
6
10b Mechanism by which individual 
participants were included in 
clusters for the purposes of the 
trial (such as complete 
enumeration, random sampling) 
6
10c  From whom consent was sought 
(representatives of the cluster, 
or individual cluster members, 
or both), and whether consent 
was sought before or after 
randomisation 
6
Blinding 11a If done, who was blinded 
after assignment to 
interventions (for example, 
participants, care 
providers, those assessing 
outcomes) and how 
7
11b If relevant, description of 





12a Statistical methods used to 
compare groups for 
primary and secondary 
outcomes 
How clustering was taken into 
account 
7,8
12b Methods for additional 
analyses, such as subgroup 





(a diagram is 
strongly 
recommended) 
13a For each group, the 
numbers of participants 
who were randomly 
assigned, received 
intended treatment, and 
For each group, the numbers of 
clusters that were randomly 
assigned, received intended 
treatment, and were analysed 
for the primary outcome 
Fig 2
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were analysed for the 
primary outcome 




For each group, losses and 
exclusions for both clusters and 
individual cluster members 
Fig 2
Recruitment 14a Dates defining the periods 
of recruitment and follow-
up 
Period of follow-up  8
14b Why the trial ended or was 
stopped 
N/A
Baseline data 15 A table showing baseline 
demographic and clinical 
characteristics for each 
group 
Baseline characteristics for the 
individual and cluster levels as 




16 For each group, number of 
participants (denominator) 
included in each analysis 
and whether the analysis 
was by original assigned 
groups 
For each group, number of 





17a For each primary and 
secondary outcome, 
results for each group, and 
the estimated effect size 
and its precision (such as 
95% confidence interval) 
Results at the individual or 
cluster level as applicable and a 
coefficient of intracluster 
correlation (ICC or k) for each 
primary outcome 
7,8
17b For binary outcomes, 
presentation of both 
absolute and relative effect 
sizes is recommended 
8
Ancillary analyses 18 Results of any other 
analyses performed, 
including subgroup 





Harms 19 All important harms or 
unintended effects in each 
group (for specific 





Limitations 20 Trial limitations, addressing 
sources of potential bias, 
imprecision, and, if 
relevant, multiplicity of 
analyses 
11
Generalisability 21 Generalisability (external 
validity, applicability) of 
the trial findings 
Generalisability to clusters 
and/or individual participants 
(as relevant) 
11
Interpretation 22 Interpretation consistent 
with results, balancing 
benefits and harms, and 




Registration 23 Registration number and 
name of trial registry 
2
Protocol 24 Where the full trial 
protocol can be accessed, if 
available 
6
Funding 25 Sources of funding and 
other support (such as 
supply of drugs), role of 
funders 
7
* Note: page numbers optional depending on journal requirements 
Full bibliographic 
reference 
Campbell MK, Piaggio G, Elbourne DR, Altman DG; for the 
CONSORT Group. Consort 2010 statement: extension to 
cluster randomised trials. BMJ. 2012;345: e5661. 
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Appendix 7: Checklist of items for reporting pragmatic trials - DURE trial 
Section Item Standard CONSORT description Extension for pragmatic trials
Title and abstract 1 
How participants were allocated to interventions (e.g., 
“random allocation,” “randomised,” or “randomly assigned”) 
Introduction
Background 2 Scientific background and explanation of rationale 
Describe the health or health service problem that 




Eligibility criteria for participants; settings and locations 
where the data were collected 
Eligibility criteria should be explicitly framed to 
show the degree to which they include typical 
participants and/or, where applicable, typical 
providers (e.g., nurses), institutions (e.g., 
hospitals), communities or localities (e.g., towns) 
and settings of care  
Table 1
Interventions 4 
Precise details of the interventions intended for each group 
and how and when they were actually administered 
Describe extra resources added to (or resources 
removed from) usual settings in order to 
implement intervention. Indicate if efforts were 
made to standardise the intervention or if the 
intervention and its delivery were allowed to vary 
between participants, practitioners, or study sites 
Page 6
Describe the comparator in similar detail to the 
intervention 
Page 6, detailed information is provided in the trial 
protocol
Objectives 5 Specific objectives and hypotheses
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Section Item Standard CONSORT description Extension for pragmatic trials
Outcomes 6 
Clearly defined primary and secondary outcome measures 
and, when applicable, any methods used to enhance the 
quality of measurements (e.g., multiple observations, training 
of assessors) 
Explain why the chosen outcomes and, when 
relevant, the length of follow-up are considered 
important to those who will use the results of the 
trial 
Page 5
Sample size 7 
How sample size was determined; explanation of any interim 
analyses and stopping rules when applicable 
If calculated using the smallest difference 
considered important by the target decision maker 
audience (the minimally important difference) 






Method used to generate the random allocation sequence, 






Method used to implement the random allocation sequence 
(e.g., numbered containers or central telephone), clarifying 





Who generated the allocation sequence, who enrolled 
participants, and who assigned participants to their groups 
Blinding (masking) 11 
Whether participants, those administering the interventions, 
and those assessing the outcomes were blinded to group 
assignment 
If blinding was not done, or was not possible, 
explain why 
Page 7
Statistical methods 12 
Statistical methods used to compare groups for primary 
outcomes; methods for additional analyses, such as subgroup 
analyses and adjusted analyses 
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Section Item Standard CONSORT description Extension for pragmatic trials
Results
Participant flow 13 
Flow of participants through each stage (a diagram is strongly 
recommended)—specifically, for each group, report the 
numbers of participants randomly assigned, receiving 
intended treatment, completing the study protocol, and 
analysed for the primary outcome; describe deviations from 
planned study protocol, together with reasons 
The number of participants or units approached to 
take part in the trial, the number which were 
eligible, and reasons for non-participation should 
be reported 
Figure  2
Recruitment 14 Dates defining the periods of recruitment and follow-up
Baseline data 15 
Baseline demographic and clinical characteristics of each 
group 
Numbers analysed 16 
Number of participants (denominator) in each group included 
in each analysis and whether analysis was by “intention-to-
treat”; state the results in absolute numbers when feasible 




For each primary and secondary outcome, a summary of 
results for each group and the estimated effect size and its 
precision (e.g., 95% CI) 
Ancillary analyses 18 
Address multiplicity by reporting any other analyses 
performed, including subgroup analyses and adjusted 
analyses, indicating which are pre-specified and which are 
exploratory 
Adverse events 19 




Interpretation of the results, taking into account study 
hypotheses, sources of potential bias or imprecision, and the 
dangers associated with multiplicity of analyses and 
outcomes 
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Section Item Standard CONSORT description Extension for pragmatic trials
Generalisability 21 Generalisability (external validity) of the trial findings 
Describe key aspects of the setting which 
determined the trial results. Discuss possible 
differences in other settings where clinical 
traditions, health service organisation, staffing, or 
resources may vary from those of the trial. 
This information is published in the process evalu
ation paper. 
Overall evidence 22 
General interpretation of the results in the context of current 
evidence 
1. Campbell MK, Piaggio G, Elbourne DR, Altman DG, for the CONSORT Group. Consort 2010 statement: extension to cluster randomised 
trials 
BMJ. 2012;345 
 2. Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D, for the CONSORT and Pragmatic Trials in 
Healthcare (Practihc) group,  [1]Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ 2008; 337; a2390 
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Appendix 8: Intra-cluster correlation coefficients (ICC) for 
demographic, anthropometric and clinical variables 
Interpretation 
The intra-cluster correlation coefficients for all the variables are very small, thus there is very little 
effect of clustering. This means that clustering did not reduce the power of the study to detect 
true differences between the study arms.  
Variable ICC 95% CI
Education 0.026 0.000 - 0.060
Occupation 0.021 0.000 - 0.081
Duration of diabetes 0.004 0.000 - 0.022
Duration of membership to 
diabetes support group
0.072 0.007 - 0.136
Weight 0.000 0.000 - 0.015
Height 0.003 0.000 - 0.020
Waist circumference 0.112 0.023 - 0.200
Random blood sugar 0.037 0.012 - 0.158
Systolic blood pressure 0.008 0.000 - 0.029
Diastolic blood pressure 0.035 0.000 - 0.075
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Appendix 9 
 DURE Statistical Analysis Plan (SAP)  
Study title Effectiveness of peer support to increase uptake of retinal examination 
for diabetic retinopathy: pragmatic cluster randomized clinical trial in 
Kirinyaga, Kenya 
Acronym DURE
Pan African Clinical 





Author Nyawira Mwangi, supervisors and statisticians listed below















Aim To evaluate, by means of a pragmatic cluster randomized controlled 
trial, the effectiveness of a peer supporter- led community education 
programme in Kirinyaga county, Kenya. 
Hypothesis The proportion of people living with diabetes (PLWD) having a retinal 
examination for DR is higher in diabetes support groups (DSGs) allocated 
to the peer supporter-led educational package than in DSGs randomized 
to the usual standard of care. 
Research questions 1. To what extent can health education delivered by peer 
supporters increase the demand for annual retinal examination 
among PLWD? 
2. What are the contextual factors that determine the 
effectiveness of the intervention? 
Study design Two arm (1:1) pragmatic cluster randomized clinical trial
Level of statistical 
significance 
P<0.05, two-sided
Sample size Based on standard formula for cluster randomized trials by Hayes and 
Bennett 
*There were no previous studies that assessed attendance to diabetic 
retinopathy screening (DRS) in DSGs, and hence there was no published 
literature on intracluster correlation for DRS. 
The health system assessment had shown that only 12.2% of the PLWD 
in Kirinyaga had ever taken a DRS. We based our sample size 
determination on this evidence, as well as on a discussion with experts 
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about what magnitude of effect would be clinically relevant (two-fold 
increase in attendance to DRS) 
Power: 80%, alpha 5%, 50 participants in each group (including 15% loss) 
Pilot study: 2 clusters (DSGs), 50*2=100 participants




Cronbach alpha of 0.70 
Baseline data Demographic, clinical and self-efficacy data
Randomization - Done after recruitment
- Use computer generated random numbers generated on Stata 
15 away from study site by statistician (DM) 
- Block randomization in groups of 4 clusters 
Follow-up trial period Six months
Stopping rules None - no stopping rules for safety, futility, efficacy or lack of power. We 
do not expect to stop early, based on our findings at the pilot trial. 
Population to be 
analysed  
All those who were randomized, by intention to treat analysis
Interim analysis Not planned
Primary Outcome Attendance to DRS, measured at the end of 180 days
Secondary outcomes These will be assessed as a part of the process evaluation at 6 months: 
1. Contextual factors that affect the effectiveness of 
the intervention 
2. Characteristics of peer supporters associated with 
uptake of eye examination 
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Acceptability, recruitment and retention, reach and dose 
delivered/received will be assessed during the process evaluation and 
reported as proportions and percentages 
Timing of data 
analysis 
Data cleansing will be performed upon completion of the 180-day 
follow-up of the last cluster/participant included in the study. The final 
analysis will be conducted thereafter. 
Presentation of 
results  





-We will list general patient characteristics in a baseline characteristics 
table.  
-Data will be presented as mean with standard deviation (SD) when 
normally distributed or as median with interquartile range in case of 
skewed data.  
-Dichotomous and categorical data will be presented in proportions.  
-Normality of the data will be assessed using histograms.  
-Linearity will be assessed using scatter plots.  
-Differences between continuous variables will be assessed using 
Student’s t-tests or Mann-Whitney-U test, depending on normality, 




interpretation of the 
anthropometric, 
clinical and metabolic 
parameters 
-Visual acuity- WHO classification of Visual Impairment
-Blood sugar – reference ranges from the World Health Organization 
-Blood pressure – reference ranges used by the Ministry of Health, 
Kenya: 60-90mmHg diastolic and 90-40mmHg systolic 
-Body Mass Index: standard international categories 
-Waist circumference cut offs used for sub-saharan Africa (80cm in 
women and 94cm in men) 
Reporting primary 
outcome 
Frequencies and percentages of those that attend DRS in each arm will 
be reported 
Relationship between 
primary outcome and 
explanatory variables 
We will conduct a linear regression analysis for continuous variables and 
a logistic regression for dichotomous variables.  
A univariable regression analysis will be conducted on demographic and 
clinical variables against the outcome variable. 
 A univariable regression analysis will be conducted on all variables and 
all variables will be used for inclusion in the multivariable model.  
As there are no previous studies that include these variables into one 
model estimating effect on DRS, we will not include any variable on a 
theory driven basis. We will construct the multivariable model using 
backward stepwise regression by starting with all variables in the model, 
testing the removal of each variable in turn, and deleting variables 
whose loss gives the most statistically insignificant deterioration in the 
fit of the model. This process will be repeated until no further variables 




We will control for Type 1 errors by adjusting our primary outcomes for 
different confounders. 
Subgroup analysis We will conduct analysis for these subgroups as they reflect the 
perspective from which a patient approaches DRS: age, gender, 
education, occupation, current diabetes treatment, comorbidity with 
hypertension, and current challenges with diabetes services 
Survival analysis Analysis of time-to-DRS data will be done (participants will be censored 
at 180-days of follow-up).  
Categorical variables will be analysed using the log-rank test and 
continuous variables will be assessed using a univariable Cox 
proportional hazard regression analysis.  
Analysis of survival data will be presented by Kaplan-Meier survival 
curves when independent variables are dichotomous or categorical.  
A univariable Cox regression analysis will be conducted on clinical and 
demographic variables with 180-day DRS attendance as the dependent 
variable.  
Covariates with a of p < 0.25 in the univariable analysis will be included 
in the multivariable model 
Reporting guidelines CONSORT 2010 statement and its extensions to abstracts, cluster 
randomized clinical trials and pragmatic trials 
Missing data In our pilot trial we collected baseline data and primary outcome data,
and obtained some insight into the likelihood of missing data in our 
main trial.  We expect to have no missing data for the baseline variables. 
For survival data, any participant lost to follow up before DRS is 
considered censored from the last day of follow-up. 
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Statistical software Statistical analyses will be performed using Stata version 15 
(StataCorp, 4905 Lakeway Drive,  College Station, Texas 77845 USA 
http://www.stata.com)                                      
Publication of results We aim to publish three results papers
1. The pilot trial results 
2. The primary outcome 
3. Process evaluation 
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Appendix 10: Research Dissemination 
Category Audience Venue Date  
Research meetings
CEHC/QEDJT meeting London October 2019
ICEH research meeting ICEH May 2019
CEHC/QEDJT research meeting London March 2019
Publications (see papers in thesis) - -
Kenya DR working group Nairobi Diverse dates
Conferences
Ophthalmological Society of Kenya Conference Nairobi, Kenya November 2018
COECSA 2018 Addis Ababa, Ethiopia August 2018
Nordic Ophthalmology Congress Oslo, Norway August, 2018
UNESCO ‘Open Education for a Better World’ Workshop Vipava, Slovenia July, 2018
World Ophthalmology Congress Barcelona, Spain June 2018
Fourth Global Forum on Human Resource for Health Dublin, Ireland November 2017
COECSA 2017 Kampala, Uganda August 2017
COECSA 2016 Naivasha, Kenya August 2016
Public Engagement
World Diabetes Day Nairobi, Kenya Nov, 2017
World Health Day Nairobi, Kenya April 2017
Three Minute thesis competition London May 2017
Three Minute thesis competition London May 2018
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Lay persons visiting LSHTM for public engagement London May 2017
World Diabetes Day Nairobi Nov 2016
Implementation partners
Kenya DR  Stakeholders meeting Nairobi August 2017
Kenya DR Research Group meeting Nairobi February 2018
KDDA strategic planning meeting Embu Sept 2018
KDDA strategic planning meeting Nairobi Sept 2017
Kenya DR Stakeholders meeting Nairobi May 2016
CEHC - Commonwealth Eye Health Consortium
COECSA - College of Ophthalmology of Eastern, Central and Southern Africa 
DR - Diabetic Retinopathy, ICEH-International Centre for Eye Health  
KDDA - Kenya Defeat Diabetes Association  
LSHTM - London School of Hygiene and Tropical Medicine  
QEDJT -Queen Elizabeth Diamond Jubilee Trust 





                                             




Dr Nyawira Mwangi 
LSHTM
25 May 2016 
Dear Nyawira
Study Title: Assessment of health system performance for Diabetes and Diabetic Retinopathy in Kenya in order to recommend and implement a package of interventions to strengthen DR
services’ 
LSHTM Ethics Ref: 10904 
Thank you for responding to the Observational Committee’s request for further information on the above research and submitting revised documentation.
The further information has been considered on behalf of the Committee by the Chair. 
Confirmation of ethical opinion
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above research on the basis described in the application form, protocol and supporting documentation
as revised, subject to the conditions specified below.
Conditions of the favourable opinion
Approval is dependent on local ethical approval having been received, where relevant. 
Approved documents
The final list of documents reviewed and approved by the Committee is as follows:
Document Type File Name Date Version
Protocol /
Proposal
Nyawira_Project_ Proposal_Feb2016 21/02/2016 final
Protocol /
Proposal
Patient interview (Diabetes) 21/02/2016 final
Protocol /
Proposal
Patient interview (DR) 21/02/2016 final
Protocol /
Proposal
Service provider interview (Diabetes) 21/02/2016 final
Protocol /
Proposal
Service provider interview (DR) 21/02/2016 final
Investigator CV CURRICULUM VITAE 21/02/2016 final
Information
Sheet
Consent to Participate in the Study 21/02/2016 final
Information
Sheet
Information sheet for service providers 21/02/2016 final
Investigator CV CV Foster 2015 27/02/2016 final
Investigator CV Covadonga Bascaran CV 2016 01/03/2016 final
Covering Letter Cover letter for clarifications 23/05/2016 1
Information
Sheet
Information sheet Kiswahili 23/05/2016 update
Information
Sheet
Information sheet for participants 23/05/2016 update
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Information
Sheet
Consent to Participate in the Study 23/05/2016 update
Information
Sheet
Consent Form- Kiswahili 23/05/2016 update
Local Approval AMREF Approval letter 23/05/2016 final
Protocol /
Proposal
Semi-structured interview guide for key informants for diabetes services_240516 24/05/2016 updated
Protocol /
Proposal





The Chief Investigator (CI) or delegate is responsible for informing the ethics committee of any subsequent changes to the application.  These must be submitted to the Committee for review
using an Amendment form.  Amendments must not be initiated before receipt of written favourable opinion from the committee.  
The CI or delegate is also required to notify the ethics committee of any protocol violations and/or Suspected Unexpected Serious Adverse Reactions (SUSARs) which occur during the project
by submitting a Serious Adverse Event form. 
At the end of the study, the CI or delegate must notify the committee using an End of Study form. 
All aforementioned forms are available on the ethics online applications website and can only be submitted to the committee via the website at: http://leo.lshtm.ac.uk
Additional information is available at: www.lshtm.ac.uk/ethics
Yours sincerely,
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5 June 2017 
Dear  Dr. Nyawira Mwangi,
Study Title: Diabetic Retinopathy in Kenya: Uptake of Retinal Examination in patients with Diabetes Mellitus (DURE) study 
LSHTM  ethics ref:  11853  
Thank you for your application for the above research, which has now been considered by the Interventions Committee.
Confirmation of ethical opinion
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above research on the basis described in the application form, protocol and supporting
documentation, subject to the conditions specified below.
Conditions of the favourable opinion
Approval is dependent on local ethical approval having been received, where relevant. 
Approved documents
The final list of documents reviewed and approved by the Committee is as follows:
Document Type File Name Date Version
Investigator CV Covadonga Bascaran CV 2016 21/08/2016 1
Investigator CV CV Foster 2015 21/08/2016 1
Investigator CV Nyawira_LSHTM_CV 21/08/2016 1
Protocol /
Proposal
Information sheet for participants 01/11/2016 1
Protocol /
Proposal
Information sheet Kiswahili 01/11/2016 1
Protocol /
Proposal






Recruitment Form 01/11/2016 1
Protocol /
Proposal
OUTCOME EVALUATION FORM 01/11/2016 1
Protocol /
Proposal
TOPIC GUIDE FOR PARTICIPANTS 01/11/2016 1
Protocol /
Proposal










Evaluation of peer supporters training 01/11/2016 1
Advertisements RECRUITMENT PROCEDURE 01/11/2016 1
Safety
Information
SAFETY INFORMATION 01/11/2016 1




Information Sheet Information sheet for team leaders of patient support groups 20/02/2017 final
Information Sheet Consent to Participate in the Study_team lead 20/02/2017 final
Information Sheet Information sheet Kiswahili 20/02/2017 final
Information Sheet Information sheet for participants 20/02/2017 final
Information Sheet Consent to Participate in the Study 20/02/2017 final
Information Sheet Kiswahili_Consent_Form 20/02/2017 final
Local Approval Approval Letter P301-2016 20/02/2017 final
Sponsor Letter QA973_Sponsor confirmation_22.02.17 22/02/2017 final












































Peer Support Training Programme evaluation 24/05/2017 May
2017
Information Sheet Consent to Participate in the Study 24/05/2017 May
2017
Information Sheet Consent form for participants (Kiswahili) 24/05/2017 May
2017
Information Sheet Information sheet for participants 24/05/2017 May
2017
Information Sheet Information sheet for participants (Kiswahili) 24/05/2017 May
2017
Information Sheet Information sheet for team leaders of patient support groups 24/05/2017 May
2017




The Chief Investigator (CI) or delegate is responsible for informing the ethics committee of any subsequent changes to the application.  These must be submitted to the Committee for
review using an Amendment form.  Amendments must not be initiated before receipt of written favourable opinion from the committee.  
The CI or delegate is also required to notify the ethics committee of any protocol violations and/or Suspected Unexpected Serious Adverse Reactions (SUSARs) which occur during the
project by submitting a Serious Adverse Event form. 
An annual report should be submitted to the committee using an Annual Report form on the anniversary of the approval of the study during the lifetime of the study. 
At the end of the study, the CI or delegate must notify the committee using an End of Study form. 
All aforementioned forms are available on the ethics online applications website and can only be submitted to the committee via the website at: http://leo.lshtm.ac.uk
Additional information is available at: www.lshtm.ac.uk/ethics
Page 2 of 3
Yours sincerely,




Page 3 of 3
401 
To the glory of God and for the good 
of our people. 
